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A B S T R A C T
Background
The World Health Organization recommends uncomplicated P. falciparum malaria is treated using Artemisinin-based Combination
Therapy (ACT). This review aims to assist the decision making of malaria control programmes by providing an overview of the relative
benefits and harms of the available options.
Objectives
To compare the effects of ACTs with other available ACT and non-ACT combinations for treating uncomplicated P. falciparummalaria.
Search strategy
We searched the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CEN-
TRAL); MEDLINE; EMBASE; LILACS, and the metaRegister of Controlled Trials (mRCT) to March 2009.
Selection criteria
Randomized head to head trials of ACTs in uncomplicated P. falciparum malaria.
This review is limited to: dihydroartemisinin-piperaquine; artesunate plus mefloquine; artemether-lumefantrine (six doses); artesunate plus
amodiaquine; artesunate plus sulfadoxine-pyrimethamine and amodiaquine plus sulfadoxine-pyrimethamine.
Data collection and analysis
Two authors independently assessed trials for eligibility and risk of bias, and extracted data. We analysed primary outcomes in line
with the WHO ’Protocol for assessing and monitoring antimalarial drug efficacy’ and compared drugs using risk ratios (RR) and 95%
confidence intervals (CI). Secondary outcomes were effects on P. vivax, gametocytes, haemoglobin, and adverse events.
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Main results
Fifty studiesmet the inclusion criteria. All five ACTs achieved PCR adjusted failure rates of < 10%, in line withWHOrecommendations,
at most study sites.
Dihydroartemisinin-piperaquine performedwell compared to the ACTs in current use (PCR adjusted treatment failure versus artesunate
plus mefloquine in Asia; RR 0.39, 95% CI 0.19 to 0.79; three trials, 1062 participants; versus artemether-lumefantrine in Africa; RR
0.39, 95% CI 0.24 to 0.64; three trials, 1136 participants).
ACTs were superior to amodiaquine plus sulfadoxine-pyrimethamine in East Africa (PCR adjusted treatment failure versus artemether-
lumefantrine; RR 0.12, 95% CI 0.06 to 0.24; two trials, 618 participants; versus AS+AQ; RR 0.44, 95% CI 0.22 to 0.89; three trials,
1515 participants).
Dihydroartemisinin-piperaquine (RR 0.32, 95% CI 0.24 to 0.43; four trials, 1442 participants) and artesunate plus mefloquine (RR
0.30, 95% CI 0.21 to 0.41; four trials, 1003 participants) were more effective than artemether-lumefantrine at reducing the incidence
of P.vivax over 42 days follow up.
Authors’ conclusions
Dihydroartemisinin-piperaquine is another effective first-line treatment for P. falciparum malaria.
The performance of the non-ACT (amodiaquine plus sulfadoxine-pyrimethamine) falls below WHO recommendations for first-line
therapy in parts of Africa.
In areas where primaquine is not being used for radical cure of P. vivax, ACTs with long half-lives may provide some benefit.
P L A I N L A N G U A G E S U M M A R Y
Artemisinin-based combination treatments for uncomplicated malaria
Malaria is a major cause of illness and death in many of the world’s poorest countries. It is spread from person to person by the bite
of mosquitoes infected with a microorganism called Plasmodium. The Plasmodium species P. falciparum is the most common cause of
malaria worldwide and causes the majority of deaths. Uncomplicated malaria is the mild form of the disease which, if left untreated,
can progress rapidly to become life threatening. The drugs traditionally used to treat uncomplicated malaria have become ineffective
in many parts of the world due to the development of drug resistance.
The World Health Organization now recommends Artemisinin-based Combination Therapy (ACTs) for treating uncomplicated
malaria. The ACTs combine an artemisinin-derivative (a relatively new group of drugs which are very effective) with another longer-
lasting drug to try and reduce the risk of further resistance developing.
This review summarizes the relative benefits and harms of the four ACTs in common use, one relatively new ACT (dihydroartemisinin
plus piperaquine), and one combination which does not contain an artemisinin derivative but remains in use in some African countries
(amodiaquine plus sulfadoxine-pyrimethamine).
All five ACTs were shown to be highly effective at treating P. falciparum in most places where they have been studied. However, there
were several trials where ACTs had high levels of treatment failure, which emphasises the need to continue tomonitor their performance.
The new ACT, dihydroartemisinin plus piperaquine, was shown to be at least as effective as the ACTs currently in widespread use in
Asia and Africa, and represents another option for malaria treatment.
ACTs were shown to be more effective than amodiaquine plus sulfadoxine-pyrimethamine in countries from East Africa which probably
represents high levels of resistance, to both drugs in this combination, in this region.
The second most common form of malaria, P. vivax, can also be treated with ACTs but requires additional treatment to cure the patient
completely. This is because the P. vivax parasite can lie dormant in the liver for months or years before becoming active again. ACTs
where the partner drug has a long duration of action may help to delay these relapses.
The ACTs seem to be relatively safe with few serious side effects. Minor side effects are more common but can be difficult to distinguish
from the symptoms of malaria itself. Fifty trials were included in this review but did not include the most vulnerable populations;
pregnant women and young infants (age < six months).
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B A C K G R O U N D
Malaria is a disease of global public health importance. Its social
and economic burden is a major obstacle to human development
in many of the world’s poorest countries. In heavily affected coun-
tries, malaria alone accounts for as much as 40% of public health
expenditure, 30% to 50% of hospital admissions, and up to 60%
of outpatient visits (WHO 2007). It has an annual incidence of
approximately 250 million episodes and is the cause of more than
a million deaths, most of them in infants, young children, and
pregnant women (WHO 2008b).
Malaria is transmitted from person to person by the bite of
mosquitoes infectedwith the protozoanparasitePlasmodium. Four
Plasmodium species are capable of causing malaria in humans: P.
falciparum, P. vivax, P. malariae, and P. ovale. Of theseP. falciparum
is responsible for over 90% of cases and almost all of the malaria
deaths worldwide (WHO 2008b). P. vivax is also common and
often presents as a co-infection with P. falciparum in a single illness
(Mayxay 2004). Uncomplicated malaria is the mild form of the
disease which presents as a febrile illness with headache, tiredness,
muscle pains, abdominal pains, rigors (severe shivering), and nau-
sea and vomiting. If left untreatedP. falciparummalaria can rapidly
develop into severe malaria with anaemia (low haemoglobin in
the blood), hypoglycaemia (low blood sugar), renal failure (kid-
ney failure), pulmonary oedema (fluid in the lungs), convulsions
(fitting), coma, and eventually death (WHO 2006). A clinical di-
agnosis of malaria can be confirmed by detection of the malaria
parasite in the patient’s blood. This has traditionally been done by
light microscopy but increasingly rapid diagnostic tests are being
used.
Resistance of P. falciparum to the traditional antimalarial drugs
(such as chloroquine, sulfadoxine-pyrimethamine, amodiaquine,
and mefloquine) is a growing problem and is thought to have
contributed to increased malaria mortality in recent years (WHO
2006). Chloroquine resistance has now been documented in all
regions except Central America and the Caribbean. There is high-
level resistance to sulfadoxine-pyrimethamine throughout South
East Asia and increasingly in Africa. Mefloquine resistance is com-
mon in the border areas of Cambodia, Myanmar, and Thailand,
but uncommon elsewhere. Resistance of P. vivax to sulfadoxine-
pyrimethamine is also increasing, and chloroquine resistance has
been reported in some parts of Asia and Oceania (WHO 2006).
Artemisinin-based antimalarials
Artemisinin and its derivatives (such as artesunate, artemether, and
dihydroartemisinin) are antimalarial drugs with a unique struc-
ture and mode of action. The first published report of clinical tri-
als appeared in the Chinese Medical Journal in 1979 (Qinghaosu
1979). Until recently there had been no reported resistance to the
artemisinin derivatives; however the possibility of emerging resis-
tance, on the Thai-Cambodian border, is currently being investi-
gated (WHO 2008a).
Artemisinin derivatives have been shown to produce faster re-
lief of clinical symptoms and faster clearance of parasites from
the blood than other antimalarial drugs (McIntosh 1999; Adjuik
2004; WHO 2006). When used as monotherapy, the short half-
life of the artemisinin derivatives (and rapid elimination from
the blood) means that patients must take the drug for at least
seven days (Meshnick 1996; Adjuik 2004). Failure to complete the
course, due to the rapid improvement in clinical symptoms, can
lead to high levels of treatment failure even in the absence of drug
resistance. Artemisinin derivatives are therefore usually given with
another longer-acting drug, with a different mode of action, in a
combination known as artemisinin-based combination therapy or
ACT. These combinations can then be taken for shorter durations
than artemisinin alone (White 1999; WHO 2006).
The artemisinin derivatives also reduce the development of game-
tocytes (the sexual form of themalaria parasite that is capable of in-
fecting mosquitoes) and consequently the carriage of gametocytes
in the peripheral blood (Price 1996; Targett 2001). This reduc-
tion in infectivity has the potential to reduce the post-treatment
transmission of malaria (particularly in areas of low or seasonal
transmission), which may have significant public health benefits (
WHO 2006).
Artemisinin and its derivatives are generally reported as being safe
andwell tolerated, and the safety profile of ACTsmay be largely de-
termined by the partner drug (WHO 2006; Nosten 2007). Stud-
ies of artemisinin derivatives in animals have reported significant
neurotoxicity (brain damage), but this has not been seen in hu-
man studies (Price 1999). Animal studies have also shown adverse
effects on the early development of the fetus, but the artemisinin
derivatives have not been fully evaluated during early pregnancy
in humans (Nosten 2007). Other reported adverse events include
gastrointestinal (GI) disturbance (stomach upset), dizziness, tin-
nitus (ringing in the ears), neutropenia (low levels of white blood
cells), elevated liver enzymes (a marker for liver damage), and elec-
trocardiographic (ECG) abnormalities (changes in cardiac con-
duction). Most studies however, have found no evidence of ECG
changes, and only non-significant changes in liver enzymes (WHO
2006; Nosten 2007). The incidence of type 1 hypersensitivity (al-
lergic) reactions is reported to be approximately 1 in 3000 patients
(Nosten 2007).
Assessing antimalarial efficacy
The World Health Organization (WHO) recommends that first-
line antimalarials should have a treatment failure rate of less than
10%, and failure rates higher than this should trigger a change in
treatment policy (WHO2006). Treatment failure can be classified
as:
Early treatment failure:
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• the development of danger signs or severe malaria on days
one, two, three in the presence of parasitaemia;
• parasitaemia on day two higher than on day 0;
• parasitaemia and axillary temperature > 37.5 °C on day
three;
• parasitaemia on day three > 20% of count on day 0.
or late treatment failure:
• development of danger signs, or severe malaria, after day
three with parasitaemia;
• presence of P. falciparum parasitaemia and axillary
temperature > 37.5 °C on or after day four;
• presence of P. falciparum parasitaemia after day seven.
The late reappearance of P. falciparum parasites in the blood can be
due to failure of the drug to completely clear the original parasite
(a recrudescence) or due to a new infection, which is especially
common in areas of high transmission. A molecular genotyping
technique called polymerase chain reaction (PCR) can be used
in clinical trials to distinguish between recrudescence and new
infection, giving a clearer picture of the efficacy of the drug and
its post-treatment prophylactic effect (White 2002; Cattamanchi
2003).
The WHO recommends a minimum follow-up period of 28 days
for antimalarial efficacy trials, but longer periods of follow up
may be required for antimalarials with long elimination half-lives
(White 2002; WHO 2003). This is because treatment failure due
to true recrudescence of malaria parasites may be delayed until
the drug concentration falls below the minimum concentration
required to inhibit parasite multiplication, which may be beyond
28 days. The WHO recommends 42 days follow up for trials
involving lumefantrine and63days for trials ofmefloquine (WHO
2003).
P. vivax malaria
P. vivax differs from P. falciparum in generally producing a milder
illness and in having a liver stage known as a hypnozoite. These
hypnozoites can lie dormant in the liver following an acute infec-
tion and cause spontaneous relapses at later dates.
As P. vivax often co-exists with P. falciparum in a single illness, it
is important to assess the effect of ACTs on the P. vivax parasite
(Mayxay 2004; WHO 2006). ACTs have been shown to clear P.
vivax from the peripheral blood, but they do not have a substantial
effect on the liver stage of the parasite (Pukrittayakamee 2000).
Although ACTs cannot provide a radical cure for P. vivax, their
ability to delay the eventual relapse of P. vivax and provide a pro-
longed malaria free period may produce significant public health
benefits.
It is important to note that when P. vivax parasitaemia occurs fol-
lowing initial treatment, PCR is unable to distinguish a recrudes-
cence of the original infection (due to failure to clear the parasite
from the peripheral blood) from a spontaneous relapse (due to
failure to clear the liver stage) (WHO 2006).
Choice of combination treatment
The WHO now recommends that P. falciparum malaria is al-
ways treated using a combination of two drugs that act at dif-
ferent biochemical sites within the parasite (WHO 2006). If a
parasite mutation producing resistance arises spontaneously dur-
ing treatment, the parasite should then be killed by the partner
drug, thereby reducing or delaying the development of resistance
to the artemisinin derivatives, and increasing the useful lifetime
of the individual drugs (White 1996; White 1999; WHO 2006).
This policy emerged at the time when ACTs were primarily being
considered, but other possibilities such as amodiaquine combined
with sulfadoxine-pyrimethamine (non-ACTs) are also available.
The decision of which ACT to adopt into national malaria control
programmes has been based on a combination of research and
expert opinion. Systematic reviews can contribute to this decision
by providing evidence on the:
• relative effects on cure between combinations;
• absolute cure levels achieved by a drug in a particular region;
• safety and risk of adverse effects of the combination;
• impact on gametocytes;
• impact on haemoglobin levels; and
• relative effects on P. vivax.
Other information that is also important to decision-making in-
clude:
• the appropriateness of the partner drug within a locality,
based on informed judgements related to regional and national
overviews of drug resistance and the intensity of malaria
transmission;
• the simplicity of the treatment regimen (co-formulated
products are generally preferred as they reduce the availability
and use of monotherapy, which may in turn reduce the
development of resistance);
• the cost (since the ACT is likely to represent a large
percentage of the annual health expenditure in highly endemic
countries); and
• other concerns such as fetal toxicity and teratogenicity.
To contribute to informed decision-making, we have examined
the comparative effects of ACTs for which co-formulated products
are currently available or shortly to be made available. We have
included trials that have used co-packaged or loose preparations
of these same ACTs to provide information on relative effects of
the different treatment options. While recent Cochrane Reviews
have synthesized the evidence around individual ACT compar-
isons (Bukirwa 2005; Omari 2005; Bukirwa 2006; Omari 2006),
this review broadens the inclusion criteria and pools the data into
a single Cochrane Review. A comprehensive list of the available
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drugs and the treatment comparisons that have been assessed is
shown in Appendix 1. The data are presented in answer to four
questions:
1. How does dihydroartemisinin-piperaquine (DHA-P)
perform?
2. How does artesunate-mefloquine (AS+MQ) perform?
3. How does artemether-lumefantrine (AL6) perform?
4. How does artesunate plus amodiaquine (AS+AQ) perform?
The comparison drugs were any of the above plus artesunate plus
sulfadoxine-pyrimethamine (AS+SP) and amodiaquine plus sul-
fadoxine-pyrimethamine (AQ+SP).
O B J E C T I V E S
To compare the effects of ACTs with other available ACT and
non-ACT combinations for treating uncomplicated P. falciparum
malaria.
A secondary objective was to explore the effects of the combina-
tions on P. vivax infection.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials. Quasi-randomized studies were ex-
cluded.
Types of participants
Adults and children (including pregnant women and infants) with
symptomatic, microscopically confirmed, uncomplicated P. falci-
parum malaria.
Trials that included participants with P. vivax co-infection and
mono-infection were also eligible.
Types of interventions
Intervention
Three-day course of an ACT (fixed dosed, co-blistered, or indi-
vidually packaged (loose)).
Control
Three-day course
of an alternative ACT or non-artemisinin combination treatment
(amodiaquine plus sulfadoxine-pyrimethamine).
The specific ACTs included are: dihydroartemisinin-piperaquine;
artesunate plus mefloquine; artemether-lumefantrine (six doses);
artesunate plus amodiaquine and artesunate plus sulfadoxine-
pyrimethamine (Appendix 1).
Types of outcome measures
Primary outcomes
Total failure at days 28, 42, and 63; PCR-adjusted and PCR-
unadjusted.
Secondary outcomes
• P. vivax parasitaemia at day 28, 42, or 63 (all participants).
• P. vivax parasitaemia at day 28, 42, or 63 (only participants
with P. vivax at baseline).
• Gametocyte carriage at day 7 or 14 (preference for day 14
in data analysis).
• Gametocyte development (negative at baseline, and positive
at follow up).
• Change in haemoglobin from baseline (minimum 28 day
follow up).
Adverse events
• Deaths occurring during follow up.
• Serious adverse events (life threatening, causing admission
to hospital, or discontinuation of treatment).
• Haematological and biochemical adverse effects (e.g.
neutropenia, liver toxicity).
• Early vomiting.
• Other adverse events.
Search methods for identification of studies
Electronic searches
We searched the following databases using the search terms de-
tailed inAppendix 2: Cochrane InfectiousDiseasesGroup Special-
ized Register (March 2009); Cochrane Central Register of Con-
trolled Trials (CENTRAL) published in The Cochrane Library
(2009, issue 1); MEDLINE (1966 to March 2009); EMBASE
(1974 to March 2009); and LILACS (1982 to March 2009). We
also searched the metaRegister of Controlled Trials (mRCT) us-
ing ’malaria’ and ’arte* OR dihydroarte*’ as search terms (March
2009).
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Searching other resources
We contacted individual researchers working in the field, orga-
nizations including the World Health Organization, and phar-
maceutical companies (Atlantic, Guilin, Holleykin, HolleyPharm,
Mepha, Novartis, Parke-Davis, Pfizer, Sanofi-Aventis, Roche) for
information on unpublished trials (August 2008).
We also checked the reference lists of all trials identified by the
methods described above.
Data collection and analysis
Selection of studies
David Sinclair (DS) and Babalwa Zani (BZ) reviewed the results
of the literature search and obtained full-text copies of all poten-
tially relevant trials. DS scrutinized each trial report for evidence
of multiple publications from the same data set. DS and BZ then
independently assessed each trial for inclusion in this review using
an eligibility form based on the inclusion criteria. We resolved any
disagreements through discussion or, where necessary, by consul-
tation with Paul Garner (PG). If clarification was necessary we
attempted to contact the trial authors for further information. We
have listed the trials that were deemed ineligible and the reasons
for their exclusion in the ’Characteristics of excluded studies’ ta-
ble.
Data extraction and management
DS and BZ independently extracted data using a pre-tested data
extraction form. We extracted data on trial characteristics includ-
ing methods, participants, interventions, and outcomes as well as
data on dose and drug ratios of the combinations.
We extracted the number randomized and the number analysed
in each treatment group for each outcome. We calculated and
reported the loss to follow up in each group.
For dichotomous outcomes, we recorded the number of partici-
pants experiencing the event and the number of participants in
each treatment group. For continuous outcomes, we extracted
the arithmetic means and standard deviations for each treatment
group together with the numbers of participants in each group. If
the data were reported using geometric means, we recorded this
information and extracted standard deviations on the log scale. If
medians were extracted we also extracted ranges.
Primary outcome
The primary analysis drew on the WHO’s protocol for assessing
and monitoring antimalarial drug efficacy (WHO 2003). This
protocol has been used to guide most efficacy trials since its pub-
lication in 2003, even though it was designed to assess the level
of antimalarial resistance in the study area rather than for com-
parative trials. As a consequence a high number of randomized
participants are excluded from the final efficacy outcome as losses
to follow up or voluntary or involuntary withdrawals. For this
reason we conducted a sensitivity analysis which aimed to restore
the integrity of the randomization process (as is usual in trial anal-
ysis) and test the robustness of the results to this methodology.
(For a summary of the methodology and sensitivity analysis see
Appendix 3)
PCR-unadjusted total failure
PCR-unadjusted total failure (P. falciparum) was calculated as the
sum of early treatment failures and late treatment failures (with-
out PCR adjustment). The denominator excludes participants for
whom an outcome was not available (e.g. those who were lost to
follow up, withdrew consent, took other antimalarials, or failed to
complete treatment) and those participants who were found not
to fulfil the inclusion criteria after randomization.
PCR-adjusted total failure
PCR-adjusted total failure (P. falciparum) was calculated as the
sum of early treatment failures, and late treatment failures due
to PCR-confirmed recrudescence. Participants with indeterminate
PCR results, missing PCR results, or PCR-confirmed new infec-
tions were treated as involuntary withdrawals and excluded from
the calculation. Late treatment failures that occurred between days
4 and 14 were assumed to be recrudescences of the original par-
asite without the need for PCR genotyping (unless genotyped in
the trial). The denominator excludes participants for whom an
outcome was not available (e.g. those who were lost to follow up,
withdrew consent, took other antimalarials, or failed to complete
treatment) and those participants who were found not to fulfil the
inclusion criteria after randomization.
These primary outcomes relate solely to failure due to P. falci-
parum. For both PCR-unadjusted and PCR-adjusted total failure,
participants who experienced P. vivax during follow up were re-
tained in the calculation if they were treated with chloroquine and
continued in follow up. As long as they did not go on to develop
P. falciparum parasitaemia they were classified as treatment suc-
cesses. We excluded from the calculation those participants who
experienced P. vivax and were removed from the trial’s follow up
at the time of P. vivax parasitaemia.
It was not always possible to guarantee that individual trials used
the standard WHO definitions. We have accepted the trial au-
thors’ data unless we had specific reason to reclassify an individual
participant or reject the data. Where this has been done we have
stated clearly the reasons for doing so.
Secondary outcomes and adverse events
In a secondary analysiswe examined the effects of ACTsonP. vivax.
We have reported the incidence of P. vivax parasitaemia during
followup at days 28, 42, and 63.Where possible, we have stratified
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this analysis into participants who had P. vivax co-infection at
baseline and those negative for P. vivax at baseline.
Extracting data on gametocyte carriage was difficult due to the
variety ofways that these data are presented in individual papers. In
order to try to present useful data we contacted the lead author of
all trials that reported on gametocytes for additional information
which fitted our specified outcomes.
Haematological outcomes were also presented in a multitude of
ways which prevented meta-analysis. We have therefore presented
these data as a narrative summary with forest plots where possible.
Other secondary outcomes have been presented using forest plots,
tables, or narrative summaries as appropriate.
We extracted the number of serious adverse events and deaths and
have presented these data in a forest plot. We have only included
those trials that specifically report serious adverse events.
Data on early vomiting were extracted as a measure of tolerability
of these combinations, and are presented as a forest plot. Other
adverse events are presented in tables with a narrative summary.
Assessment of risk of bias in included studies
DS and BZ independently assessed the risk of bias for each trial
using ’The Cochrane Collaboration’s tool for assessing the risk of
bias’ (Higgins 2008). Differences of opinion were discussed with
PG. We followed the guidance to assess whether adequate steps
had been taken to reduce the risk of bias across six domains: se-
quence generation; allocation concealment; blinding (of partic-
ipants, personnel, and outcome assessors); incomplete outcome
data; selective outcome reporting; and other sources of bias. We
have categorized these judgments as ’yes’ (low risk of bias), ’no’
(high risk of bias), or ’unclear’. Where our judgement is unclear
we attempted to contact the trial authors for clarification.
This information was used to guide the interpretation of the data
that are presented.
Measures of treatment effect
We analysed the data using ReviewManager 5. Dichotomous data
are presented and combined using risk ratios. For continuous data
summarized by arithmetic means and standard deviations, data
have been combined using mean differences. Risk ratios and mean
differences are accompanied by 95% confidence intervals. Medi-
ans and ranges are only reported in tables.
Dealing with missing data
If data from the trial reports were insufficient, unclear, or missing,
we attempted to contact the trial authors for additional informa-
tion. If we judged the missing data to render the result uninter-
pretable we excluded the data from the meta-analysis and clearly
stated the reason. The potential effects of missing data have been
explored through a series of sensitivity analyses (Appendix 3).
Assessment of heterogeneity
We assessed for heterogeneity amongst trials by inspecting the
forest plots, applying the Chi² test with a 10% level of statistical
significance, and also using the I² statistic with a value of 50%
used to denote moderate levels of heterogeneity.
Data synthesis
The included trials have been given identity codes which include
the first author, the year the study was conducted (not the year
it was published) and the three-letter international country code.
Studies in forest plots are also listed in chronological order (by the
final date of enrolment). We hope this will aid with interpretation
of the review and forest plots.
Treatments have been compared directly using pair-wise compar-
isons. For outcomes that are measured at different time points we
have stratified the analysis by the time point. The primary out-
come analysis is also stratified by geographical region as a crude
marker for differences in transmission and resistance patterns.
Meta-analysis has been performed within geographic regions
where appropriate after assessment and investigation of hetero-
geneity. A random-effects model was used where the Chi² test P
value was less than 0.1 or the I² statistic was greater than 50%.
In addition, Olliaro-Vaillant plots have been used to simultane-
ously display the absolute and relative benefits of individual ACTs
at day 28.
Subgroup analysis and investigation of heterogeneity
We investigated potential sources of heterogeneity through the fol-
lowing subgroup analyses: geographical region, intensity ofmalaria
transmission (low to moderate versus high malaria transmission),
knownparasite resistance, allocation concealment, participant age,
and drug dose (comparing regimens where there are significant
variations in drug dose).
Sensitivity analysis
We conducted a series of sensitivity analyses to investigate the ro-
bustness of the methodology used in the primary analysis. Our
aim was to restore the integrity of the randomization process by
adding excluded groups back into the analysis in a stepwise fash-
ion (see Appendix 3 for details). Where these analyses altered the
direction or significance of the measure of effect the revised results
are presented and discussed.
R E S U L T S
Description of studies
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See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The search was conducted on 12 August 2008 and repeated on 26
March 2009. In total 517 trials were identified. Full text copies
were obtained for 85 trials. Fifty trials are included in this review
and 35 were excluded. A further four trials (Bousema 2004 KEN;
Koram 2003 GHA; Martensson 2003 TZA; Van den Broek 2004
ZAR) were excluded from the primary analysis due to baseline
differences between groups which had the potential to severely
bias the result. These trials were retained for their data on adverse
events.
Included studies
Forty-six of the fifty included trials were conducted between 2003
and 2009.
Thirty-one trialswere conducted inAfrica, 17 inAsia, one in South
America (DHA-P versus AS+MQ) and one in Oceania (DHA-P
versus AL6 versus AS+SP). There is obvious regional variability
in which drugs are being studied. Trials from Asia mainly involve
AS+MQ, AL6 and DHA-P (plus one trial from Indonesia with
AS+AQ). Only two studies from Africa have evaluated AS+MQ.
Pregnant and lactating women were excluded from all trials. The
study population in Asian trials is older, with exclusion of children
aged less than one year. African studies concentrated more on
children and included those as young as six months.
Three trials (Hasugian 2005 IDN; Karunajeewa 2007 PNG;
Ratcliff 2005 IDN) included participants with P. vivax mono-in-
fection at baseline. For our primary analysis we obtained data from
the authors for only those participants who had P. falciparum or
mixed infection (falciparum and vivax) at baseline.
One trial (Dorsey 2006 UGA) had an unusual study design
where participants were followed up for more than one episode
of malaria. For our primary analysis we obtained data from the
authors for first episodes of malaria only.
The characteristics of the included studies are given in the ’
Characteristics of included studies’ table.
Excluded studies
The reasons for exclusion are given in the ’Characteristics of
excluded studies’ table.
The four additional studies excluded from the primary analysis had
different inclusion criteria for different arms of the trial. Children
aged less than one year were excluded from the AL6 treatment arm
and reassigned to either AS+AQ or AS+SP. In these studies this
led to significant baseline differences in age and weight, factors
known to be associated with the outcomes.We explored the effects
of including these trials in the largest meta-analysis (AL6 versus
AS+AQ, Analysis 9.9; Analysis 9.10). Inclusion of the trials with
this bias shifted the results fromnodifference detected to favouring
AL6. In the light of this we decided to exclude all trials that had
systematically reallocated patients after randomization.
Risk of bias in included studies
For a summary of the ’Risk of bias’ assessments please see Figure
1 and Figure 2.
8Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Allocation
Generation of the randomized sequence was judged to be at low
risk of bias for 33 trials, high risk of bias for 1 trial, and 16 trials
were unclear regarding randomization methods.
Allocation concealment was judged to be at low risk of bias in 21
studies, high risk of bias in 19 studies and unclear in 10 studies.
Descriptions which included the following details were accepted
as adequate for concealment: opaque sealed envelopes; sealed se-
quentially numbered envelopes; or third party allocation. For pri-
mary outcomes we conducted a sensitivity analysis including only
the trials with adequate allocation concealment.
Blinding
Of the included trials only 10 were judged to be at low risk of bias
due to adequate blinding. Blinding or quality control of laboratory
staff was conducted in 34 studies. Although this may be reassuring
with regard to parasitological outcomes, secondary outcomes and
particularly adverse event reporting will remain at high risk of bias.
Incomplete outcome data
We have reported the proportion of participants in each treatment
arm for whom an outcome was not available and conducted sen-
sitivity analyses to test the possible effect of these losses. Eight tri-
als were judged to be at high risk of bias due to either moderate
drop-out (> 15%), differential drop-out between groups that had
the potential to alter the result, or participants missing from the
primary analysis who could not be accounted for.
Selective reporting
Due to the varying half-lives of drugs, the choice of which day
to measure outcomes can influence the comparative effects of the
drugs. If a drug with a long half-life (DHA-P or AS+MQ) is com-
pared to a drug with a short half-life (AS+AQ or AS+SP), day 28
outcomes may underestimate PCR adjusted failure with the long
half-life drug. At later time points (day 42 and 63) drugs with long
half-lives are likely to appear superior in preventing new infections
(PCR unadjusted failure) which represents a prophylactic effect.
We have kept this in mind when interpreting the data but did not
judge the trials to be at high risk of bias.
Other potential sources of bias
Pharmaceutical companies provided financial support or study
drugs in 15 trials. Further involvement of the pharmaceutical com-
pany in trial design or reporting is only described in one study (
Djimde 2004 MLI).
Effects of interventions
In April 2009 we conducted the sensitivity analysis as described in
Table 3 to test the robustness of our methodology. In general these
analyses did not substantially change the direction, magnitude, or
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confidence intervals of the estimate of effect. Examples are shown
in Analysis 1.12 and Analysis 1.13. Only sensitivity analyses of
interest remain linked in this review.
Question 1. How does dihydroartemisinin-
piperaquine (DHA-P) perform?
Dosing concerns
Two dosing regimens have been commonly used in clinical trials of
DHA-P. These two regimens give the same total dose, but divided
into three or four doses, given over three days. One trial (Ashley
2004 THA) directly compared the three-dose regimen with the
four-dose regimen and found no difference at any time point (one
trial, 318 participants, Analysis 14.1, Analysis 14.2).
In comparisons comparing DHA-P to AS+MQ, four trials used
the three-dose regimen, three trials used the four-dose regimen and
one trial used both. Stratifying the analysis by dosing regimen did
not reveal any significant differences in efficacy between the two
regimens (Analysis 15.1; Analysis 15.2; Analysis 15.3; Analysis
15.4; Analysis 15.5; Analysis 15.6).
Comparison 1. DHA-P versus artesunate plus mefloquine
We found nine trials which assessed this comparison (eight in Asia
and one in South America). Allocation concealment was assessed
as ’low risk of bias’ in five trials (Ashley 2003a THA; Ashley 2003b
THA;Ashley2004THA;Grande 2005 PER;Mayxay 2004 LAO).
Laboratory staff (outcome assessors) were blinded to treatment
allocation in three trials (Ashley 2003a THA; Ashley 2003b THA;
Ashley 2005 THA), and no other blinding is described.
Total failure
PCR adjusted treatment failure with DHA-P was below 5% in all
nine studies, and with AS+MQ in seven out of nine studies.
At day 63 comparative results were mixed. Trials from Asia
favoured DHA-P (Day 63, three trials, 1182 participants: PCR
unadjusted RR 0.73, 95% CI 0.54 to 0.98, Analysis 1.1; PCR
adjusted RR 0.39, 95% CI 0.19 to 0.79, Analysis 1.2) and the
one trial from South America favoured AS+MQ (one trial, 445
participants: PCR unadjusted RR 6.19, 95% CI 1.40 to 27.35,
Analysis 1.1; PCR adjusted no significant difference, Analysis 1.2).
This difference may reflect the level of mefloquine resistance at
the study sites. The performance of DHA-P in the study in South
America is similar to that in Asia, but the performance of AS+MQ
was much improved with no PCR confirmed recrudescences.
No significant differences were shown at other time points (Day
42, five trials, 1969 participants, Analysis 1.3, Analysis 1.4; Day
28, six trials, 2034 participants, Analysis 1.5, Analysis 1.6).
P. vivax
No significant difference was shown in the incidence of P. vivax
parasitaemia at any time point (Day 63, four trials, 1661 partic-
ipants; Day 42, three trials, 1251 participants; Day 28, one trial,
402 participants; Analysis 1.7). There were no significant differ-
ences in the incidence of P. vivax between groups with or without
P. vivax at baseline.
Gametocytes
The number of participants who developed detectable gameto-
cytes (after being negative at baseline) was low in both groups, but
significantly lower with AS+MQ (three trials, 1234 participants:
RR 3.06, 95% CI 1.13 to 8.33, Analysis 1.8). AS+MQ may also
clear gametocytes quicker than DHA-P but the analysis is con-
founded by differences in gametocyte carriage at baseline (two tri-
als, 1174 participants, Analysis 1.9).
Anaemia
Five trials report on haematological changes. Individual studies
did not show significant differences between groups (see Appendix
5). Two trials (Ashley 2003b THA; Ashley 2004 THA) report
a decrease in haematocrit over the first seven days followed by
recovery in both groups (figures not reported).
Adverse events
No difference has been shown in the frequency of serious adverse
events (seven trials, 2374 participants, Analysis 1.10).
There is some evidence that DHA-P is better tolerated than
AS+MQ. Cental nervous system (CNS) related adverse events (at
least one of sleep disturbance, dizziness, or anxiety) were reported
as more common with AS+MQ in five out of the nine trials.
Five trials also report significantly more nausea and vomiting with
AS+MQ and two trials report more palpitations and dyspnoea.
Abdominal pain and diarrhoea were reported as significantly more
common with DHA-P in one trial each. For a summary of adverse
event findings see Appendix 4.
Early vomiting
Seven trials report some measure of early vomiting (vomiting re-
lated to drug administration) and no difference was shown in any
trial (seven trials, 2473 participants, Analysis 1.11).
Comparison 2. DHA-P versus artemether-lumefantrine (six
doses)
We found six trials (four in Africa, one in Asia and one inOceania)
which assessed this comparison. Allocation concealment was as-
sessed as low risk of bias in four trials (Kamya 2006 UGA; Ratcliff
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2005 IDN; Yeka 2007 UGA; Zongo 2007 BFA). Laboratory staff
were blinded to treatment allocation in five out of six trials.
Total failure
PCR adjusted treatment failure with DHA-P was below 5% in
four out of six studies and with AL6 in two out of six studies.
Of note, one trial from Africa (Kamya 2006 UGA) found PCR
adjusted failure to be > 10% with both combinations.
In trials from Africa DHA-P performed significantly better than
AL6 at day 42 (three trials, 1136 participants: PCR unadjusted
Heterogeneity: Chi² P < 0.0001, I² = 91%, Analysis 2.1; PCR
adjusted RR 0.39, 95% CI 0.24 to 0.64, Analysis 2.2). Although
there is substantial heterogeneity among PCR unadjusted results
the direction of effect is consistently in favour of DHA-P.
In the one trial from Asia both drugs performed well with a non
significant trend towards reduced re-infections with DHA-P (one
trial, 356 participants, Analysis 2.1; Analysis 2.2; Analysis 2.3;
Analysis 2.4).
In Oceania Karunajeewa 2007 PNG showed a reduction in PCR
adjusted treatment failure at day 28with AL6 but this effect was no
longer significant at day 42 (one trial, 356 participants, Analysis
2.1; Analysis 2.2; Analysis 2.3; Analysis 2.4).
P. vivax
Participants treated with DHA-P had significantly fewer episodes
of P. vivax parasitaemia during 42 days follow up (four trials, 1442
participants: RR 0.32, 95% CI 0.24 to 0.43, Analysis 2.5). Of
these four trials only one (Ratcliff 2005 IDN) included partici-
pants with P. vivax co-infection at baseline.
Gametocytes
Four trials reported the development of gametocytes in those nega-
tive at baseline and the results were highly heterogenous and could
not be pooled (four trials, 1203 participants, heterogeneity: Chi²
P = 0.006, I² = 76%, Analysis 2.6). This heterogeneity is consis-
tent with the performance of the two drugs for total failure. In
the two trials from Uganda (Kamya 2006 UGA and Yeka 2007
UGA) DHA-P had significantly fewer treatment failures and was
also significantly better at reducing gametocyte development. In
trials with no difference for treatment failure (Zongo 2007 BFA
and Mens 2007 KEN) there was also no difference in gametocyte
development. Karunajeewa 2007 PNG and Ratcliff 2005 IDN
report no differences in gametocyte carriage between groups but
did not give figures.
Anaemia
Four trials report changes in haemoglobin from baseline to the
last day of follow up (day 28 or 42). There is a non significant
trend towards a benefit with DHA-P but this is unlikely to be of
clinical significance (four trials, 1356 participants, Analysis 2.7).
In addition Karunajeewa 2007 PNG reports that haemoglobin
remained similar in all groups (no figures given).
Adverse events
No significant difference has been shown in the frequency of seri-
ous adverse events (five trials, 2110 participants, Analysis 2.8).
Kamya 2006 UGA and Karunajeewa 2007 PNG report no differ-
ences between groups (two trials, 671 participants). Ratcliff 2005
IDN reports more diarrhoea (P = 0.003) with DHA-P (774 par-
ticipants). Mens 2007 KEN reports more weakness (P = 0.035)
with AL6 (146 participants). Yeka 2007 UGA reports more ab-
dominal pain (P = 0.05) with AL6 (414 participants). Zongo 2007
BFA reports more abdominal pain (P < 0.05) and headache (P
< 0.05) with AL6 (375 participants). For a summary of adverse
event findings see Appendix 4.
Early vomiting
No difference has been shown in the frequency of drug related
vomiting (two trials,1147 participants, Analysis 2.9).
Comparison 3. DHA-P versus artesunate plus amodiaquine
We found two trials (one in Africa and one in Asia) which assessed
this comparison. Allocation concealment was assessed as low risk
of bias in one trial (Hasugian 2005 IDN) and unclear in the other.
In both trials laboratory staff were blinded to treatment allocation,
but other staff and participants were unblinded.
Total failure
PCR adjusted treatment failure with DHA-P was below 5% in
both trials, and below 10% with AS+AQ.
DHA-P performed significantly better thanAS+AQ at day 28 (two
trials, 679 participants: PCR unadjusted RR 0.53, 95% CI 0.35
to 0.81, Analysis 3.1; PCR adjusted RR 0.47, 95% CI 0.23 to
0.94, Analysis 3.2). The one trial that reports outcomes at day 42
(Hasugian 2005 IDN) had high losses to follow up (> 20%) at
this time point (Analysis 3.3; Analysis 3.4).
P. vivax
Hasugian 2005 IDN reports significantly fewer episodes ofP. vivax
parasitaemia with DHA-P by day 42 (one trial, 170 participants:
RR 0.25, 95% CI 0.09 to 0.74, Analysis 3.5).
Gametocytes
Both trials report no significant differences in gametocyte carriage
during follow up (figures not reported).
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Anaemia
Hasugian 2005 IDN found that the prevalence of anaemia at day
seven (P = 0.02) and 28 (P = 0.006) was significantly higher with
AS+AQ (authors own figures); in this trial recurrence of para-
sitaemia with both P. falciparum and P. vivax was higher in the
AS+AQgroup. Karema 2004 RWA found no significant difference
in PCV between groups at days 0 or 14.
Adverse events
Hasugian 2005 IDN reports three serious adverse events with
AS+AQ (two patients with recurrent vomiting on day three, one
patient with bilateral cerebellar signs) (one trial, 334 participants,
Analysis 3.6). Karema 2004 RWA does not comment on serious
adverse events.
Hasugian 2005 IDN reportsmore nausea (P = 0.004), vomiting (P
= 0.02), and anorexia (P = 0.007) with AS+AQ (334 participants).
Karema2004RWA reportsmore vomiting (P=0.007), anorexia (P
= 0.005) and fatigue (P = 0.001) with AS+AQ (504 participants).
For a summary of adverse event findings see Appendix 4.
Early vomiting
Hasugian 2005 IDN foundno significant difference in the number
of participants who vomited at least one dose of medication (one
trial, 334 participants, Analysis 3.7).
Comparison 4. DHA-P versus artesunate plus sulfadoxine-
pyrimethamine
We found one trial (from Oceania) which assessed this compari-
son. No attempt to conceal allocation was described. Laboratory
staff were blinded to treatment allocation.
Total failure
At day 42 PCR adjusted treatment failure was > 10% in both
groups.
There were no significant differences in treatment failure between
the two arms (one trial, 215 participants, Analysis 4.1; Analysis
4.2; Analysis 4.3; Analysis 4.4)
P. vivax
Compared to AS+SP, DHA-P significantly reduced the incidence
of P. vivax parasitaemia by day 42 in participants treated for P.
falciparummono-infection at baseline (one trial, 194 participants:
RR 0.45, 95% CI 0.32 to 0.65, Analysis 4.5), or P. vivax ± P.
falciparum at baseline (one trial, 75 participants: RR 0.46, 95%
CI 0.27 to 0.79, Analysis 4.5).
Gametocytes
No significant differences in gametocyte carriage during follow up
are reported (figures not reported).
Anaemia
Haemoglobin levelswere reported to remain similar in both groups
throughout follow up (figures not reported).
Adverse events
Monitoring for adverse events was undertaken but no differences
between the groups were reported (see Appendix 4).
Early vomiting
Not reported.
Comparison 5. DHA-P versus amodiaquine plus sulfadoxine-
pyrimethamine
We found two trials (both in Africa) which assessed this compari-
son. Allocation concealment was assessed as low risk of bias in one
trial (Zongo 2007 BFA) and unclear in the other. Karema 2004
RWA blinded laboratory staff to treatment allocation. No other
blinding is described.
Total failure
PCR adjusted treatment failure with DHA-P was below 5% in
both trials. In Rwanda, PCR adjusted treatment failure with
AQ+SP was above 10%.
DHA-P performed significantly better than AQ+SP at 28 days
(two trials, 848 participants: PCR unadjusted RR 0.37, 95% CI
0.25 to 0.55, Analysis 5.1; PCR adjusted RR 0.30, 95% CI 0.17
to 0.54, Analysis 5.2). Zongo 2007 BFA did not show a difference
at day 42 with both drugs performing well at this site (one trial,
341 participants, Analysis 5.3; Analysis 5.4).
P. vivax
Not reported.
Gametocytes
Zongo 2007 BFA found no difference in the development of ga-
metocytaemia in participants who did not have detectable gameto-
cytes at baseline (one trial, 367 participants, Analysis 5.5). Karema
2004 RWA reported no significant difference in gametocyte car-
riage during follow up but figures were not reported (one trial,
510 participants).
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Anaemia
Zongo 2007 BFA found no significant difference in haemoglobin
at baseline or at day 42 (1 trial, 371 participants, Analysis 5.6).
Karema 2004 RWA found that the packed cell volume (PCV)
increased from baseline to day 14 in both groups, but at day 14 it
was significantly lower with DHA-P (one trial, 510 participants:
MD -1.10, 95% CI -1.73 to -0.47, Analysis 5.6). This difference
is unlikely to be of clinical significance.
Adverse events
Zongo 2007 BFA reports that there were no serious adverse events
(one trial, 371 participants). Karema 2004 RWA does not com-
ment on serious adverse events.
Zongo 2007 BFA reports more abdominal pain (P < 0.05) and
pruritis (P < 0.05) with AQ+SP (371 participants). Karema 2004
RWA reports more vomiting (P = 0.007), anorexia (P = 0.005),
and fatigue (P = 0.001) with AQ+SP (510 participants). For a
summary of adverse event findings see Appendix 4.
Early vomiting
Zongo 2007 BFA reports on vomiting medication on day 0 (as
an exclusion criteria not an outcome) and there was no difference
between groups (one trial, 383 participants, Analysis 5.7).
Question 2. How does artesunate mefloquine
(AS+MQ) perform?
Dosing concerns
AS+MQ has traditionally been administered using 15 mg/kg
mefloquine on day one and 10 mg/kg on day two. A new fixed-
dose combination of AS+MQ is now available where mefloquine
is given as a once daily dose of 8 mg/kg. One trial (Ashley 2005
THA) has directly compared these two regimens and found no
significant difference (one trial, 423 participants, Analysis 16.1;
Analysis 16.2). In addition five trials used loose tablets to deliver
a once daily dose of mefloquine of 8 mg/kg in combination with
artesunate. In all of these trials the proportion of treatment failures
with the new regimen was below 10% and in three trials below
5% (Analysis 17.1; Analysis 17.2)
Comparison 6. AS+MQ versus artemether-lumefantrine (six
doses)
We found eight trials (six in Asia and two in Africa) which assessed
this comparison. Allocation concealment was assessed as low risk
of bias in two trials (Mayxay 2003 LAO; Sagara 2005b MLI).
Only one trial blinded microscopists to treatment allocation.
Total failure
In all eight trials both combinations performed well with PCR
adjusted treatment failures below 5%.
In Asia, AS+MQ reduced overall treatment failure by day 42 com-
pared to AL6 (four trials, 1000 participants: PCR unadjusted RR
0.53, 95%CI 0.29 to 0.94, Analysis 6.1). For PCR adjusted treat-
ment failure there was substantial heterogeneity (four trials, 904
participants: heterogeneity Chi² P = 0.04, I² = 64%, Analysis 6.2),
which related to one trial (Hutagalung 2002 THA). This trial was
unusual in that P. vivax was very common during follow up and
significantly more common following treatment with AL6. P. vi-
vax was treated with chloroquine and participants continued in
follow up. Therefore significantly more participants in the AL6
group received additional antimalarials which may have affected
the result. Sensitivity analysis removing this trial shifts the result
significantly in favour of AS+MQ.
There were no significant differences in PCR adjusted treatment
failure at day 28 (five trials, 1479 participants, Analysis 6.4). One
trial from Africa (Sagara 2005b MLI) did find a significant re-
duction in re-infections with AS+MQ but this was not repeated
elsewhere (Analysis 6.3).
P. vivax
AS+MQ performed significantly better than AL6 at reducing the
incidence of P. vivax during 42 days of follow up (four trials, 1003
participants: RR 0.30, 95% CI 0.21 to 0.41, Analysis 6.5).
Gametocytes
There is no evidence of an advantage with either drug at reducing
gametocytaemia. There was no significant difference in gameto-
cyte development in those negative at baseline (three trials, 883
participants, Analysis 6.6). Gametocyte carriage was generally low
in the three trials which report it, with a statistically significant
reduction in gametocyte carriage with AS+MQ on day seven, but
not day three or 14 (three trials, 636 participants: Gametocyte
carriage day seven RR 0.35, 95% CI 0.14 to 0.85, Analysis 6.7).
Sagara 2005b MLI reports no differences between groups (no fig-
ures given).
Anaemia
Six trials report some measure of haematological recovery.
Hutagalung 2002 THA found a greater decrease in haematocrit
at day seven with AS+MQ (9.3% AS+MQ versus 6.7% AL6, P
= 0.02; authors own figures). None of the remaining five trials
report a significant difference (see Appendix 5).
Adverse events
No difference has been shown in the frequency of serious adverse
events (seven trials, 1773 participants, Analysis 6.8).
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Three trials report significantly more CNS symptoms with
AS+MQ (dizziness, headache, confusion, or sleep disturbance)
and one reports more with AL6. Gastrointestinal (GI) symptoms
(nausea, vomiting, abdominal pain, or anorexia) were significantly
more common with AS+MQ in four trials. For a summary of ad-
verse events see Appendix 4.
Early vomiting
No difference has been shown in the frequency of early vomiting
(six trials, 1479 participants, Analysis 6.9).
Comparison 7. AS+MQ versus artesunate plus amodiaquine
We only found one trial in Africa (Faye 2003 SEN) which assessed
this comparison. Allocation concealment and blinding were not
described.
Total failure
In the 28 days of this trial, treatment failure was very low in both
groups. It is therefore not possible to draw conclusions on the
benefits of either drug. There were no significant differences in
PCR unadjusted failure (one trial, 493 participants, Analysis 7.1)
and no episodes of PCR confirmed recrudescence.
P. vivax
Not reported.
Gametocytes
Gametocyte carriage was very low in both groups. Gametocytes
were only detectable in three participants in the AS+MQ group
on day three. At baseline, day seven and day 14 gametocytes were
undetectable in all participants.
Anaemia
Twenty-five percent of participants had haemoglobin measured
on days 0 and 14 and no significant differences are reported.
Adverse events
In this trial there were no serious adverse events (one trial, 505
participants) and no differences between groups reported (see
Appendix 4).
Early vomiting
Not reported.
Comparison n/a. AS+MQ versus artesunate plus sulfadoxine-
pyrimethamine
We did not find any trials which assessed this comparison.
Comparison 8. AS+MQ versus amodiaquine plus
sulfadoxine-pyrimethamine
We only found one trial in Africa (Faye 2003 SEN) which assessed
this comparison. Allocation concealment and blinding were not
described.
Total failure
In the 28 days of this trial, treatment failure was very low in both
groups. It is therefore not possible to draw conclusions on the ben-
efits of either drug. There were no differences in PCR unadjusted
failure (one trial, 300 participants, Analysis 8.1) and there were
no episodes of PCR confirmed recrudescence.
P. vivax
Not reported.
Gametocytes
Detectable gametocytaemia was significantly less common with
AS+MQ at days three and seven (Gametocyte carriage day three:
RR0.21, 95%CI 0.06 to 0.70;Gametocyte carriage day seven: RR
0.03, 95% CI 0.00 to 0.47, Analysis 8.3). At day 14 gametocytes
were undetectable in all participants.
Anaemia
Twenty five percent of participants had haemoglobin measured on
days 0 and 14 and no significant differences were reported.
Adverse events
In this trial there were no serious adverse events in either group
(one trial, 306 participants) and no differences between groups
reported (see Appendix 4).
Early vomiting
Not reported.
Question 3. How does artemether-lumefantrine (6
doses) perform?
Dosing concerns
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The six-dose regimen of AL6 has been shown to be superior to
the four-dose regimen (Vugt 1999; Omari 2006). In this review
we have only included the six-dose regimen.
Comparison 9. AL6 versus artesunate plus amodiaquine
We found twelve trials (all in Africa) which assessed this com-
parison. Three of these trials were excluded after sensitivity anal-
ysis due to baseline differences which had the potential to bias
the result in favour of AL6 (Analysis 9.9; Analysis 9.10). Of the
remaining nine trials allocation concealment was assessed as low
risk of bias in five trials (Adjei 2006 GHA; Bukirwa 2005 UGA;
Dorsey 2006 UGA; Kobbe 2007 GHA; Mutabingwa 2004 TZA)
and laboratory staff were blinded to treatment allocation in four
trials.
Total failure
PCR adjusted treatment failure was below 5% for both AL6 and
AS+AQ in six out of eight trials. In two more recent trials (both
from Ghana), PCR adjusted treatment failure for both arms was
above 5% and for AL6 above 10% (Analysis 9.2).
No difference has been shown in PCR adjusted total failure at
day 28, either within individual trials or after pooling (eight trials,
1729 participants, Analysis 9.2). There is substantial heterogene-
ity in PCR unadjusted failure (nine trials, 3021 participants: het-
erogeneity Chi² P < 0.0001, I² = 76%, Analysis 9.1). Subgroup
analysis seems to suggest regional differences, with studies from
East Africa showing benefit with AL6 and recent studies from
West Africa favouring AS+AQ (Analysis 9.1). However, substan-
tial heterogeneity remains, and further subgroup analysis by trial
characteristics and transmission intensity did not expand the in-
terpretation of this heterogeneity.
P. vivax
One trial (Dorsey 2006 UGA) reported on P. vivax but there were
too few patients to draw a conclusion (AL6: 8/202 at baseline and
3/202 during follow up, AS+AQ: No vivax at any time point).
Gametocytes
Bukirwa 2006 found that AL6 significantly reduced the develop-
ment of gametocytaemia in patients who did not have detectable
gametocytes at baseline (one trial, 305 participants: RR 0.34, 95%
CI 0.15 to 0.74, Analysis 9.3). Three trials reporting gametocyte
carriage over 14 days of follow up do not show a clear advantage
with either combination (three trials, 1078 participants, Analysis
9.4).
Anaemia
Four studies reported some measure of haematological recovery
from baseline to day 28 and did not show a difference between the
two combinations (four trials, 2356 participants, Analysis 9.5).
Guthmann 2004 AGO reported the proportion of participants
who were anaemic (Hb < 11 g/dl) at day 0 and 28 and did not
show a difference (one trial, 123 participants, Analysis 9.6). Three
trials (Dorsey 2006 UGA; Faye 2003 SEN; Mutabingwa 2004
TZA) also reported measures of anaemia at day 14 and did not
show a difference.
Adverse events
No difference has been shown in the frequency of serious adverse
events (six trials, 2749 participants, Analysis 9.7).
No important differences in adverse events were reported between
groups. For a summary of adverse events see Appendix 4.
Early vomiting
No difference has been shown in the frequency of early vomiting
(five trials, 1097 participants, Analysis 9.8).
Comparison 10. AL6 versus artesunate plus sulfadoxine-
pyrimethamine
We found four trials (three from Africa and one from Oceania)
which assessed this comparison. Two of these trials were excluded
from the primary analysis due to baseline differences between the
groups (Analysis 10.6; Analysis 10.7). Allocation concealment was
judged to be at high risk of bias in the two remaining trials. Lab-
oratory staff were blinded to treatment allocation in one trial.
Total failure
In Oceania, Karunajeewa 2007 PNG found no difference in
PCR unadjusted failure (one trial, 217 participants, Analysis 10.1;
Analysis 10.3), but did show a significant reduction in PCR ad-
justed treatment failure with AL6 at both day 28 and day 42 (one
trial, 217 participants: Day 42 RR 0.33, 95% CI 0.13 to 0.86,
Analysis 10.2; Day 28 RR 0.28, 95% CI 0.08 to 0.97, Analysis
10.4). PCR adjusted treatment failure with AS+SP was > 20% at
day 42.
In Africa, Mukhtar 2005 SDN found no difference between the
two groups (one trial, 157 participants, Analysis 10.3, Analysis
10.4).
P. vivax
Karunajeewa 2007 PNG found no differences in the incidence
of P. vivax parasitaemia by day 42 in participants treated for P.
falciparummono-infection at baseline (one trial, 196participants),
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or those treated for P. vivax at baseline (one trial, 72 participants,
Analysis 10.5)
Gametocytes
Karunajeewa 2007 PNG reports no differences in gametocyte car-
riage between the two groups during follow up (figures not re-
ported).
Anaemia
Karunajeewa 2007 PNG reports no differences in mean
haemoglobin during follow up (figures not reported).
Adverse events
Two trials report on adverse events and no differences are noted
between the two groups (Karunajeewa 2007 PNG; Van den Broek
2004 ZAR). For a summary of adverse events see Appendix 4.
Early vomiting
Not reported.
Comparison 11. AL6 versus amodiaquine plus sulfadoxine-
pyrimethamine
We found seven trials (all in Africa) which assessed this compari-
son. One trial was excluded from the primary analysis due to base-
line differences between groups. Of the remaining trials allocation
concealment was assessed as low risk of bias in two trials (Dorsey
2006 UGA; Zongo 2007 BFA) and laboratory staff were blinded
to treatment allocation in four trials.
Total failure
PCR adjusted treatment failure with AL6 was below 5% in all six
trials. The performance of AQ+SP was much more variable.
In East Africa, where treatment failure with AQ+SPwas high, AL6
performed markedly better at day 28 (three trials, 1646 partici-
pants: PCR unadjusted RR 0.35, 95% CI 0.30 to 0.41, Analysis
11.1; PCR adjustedRR0.12, 95%CI 0.06 to 0.24, Analysis 11.2).
In contrast, inWest Africa, where AQ+SP performedmuch better,
there were fewer PCR unadjusted treatment failures with AQ+SP
at both day 28 (three trials, 1130 participants: PCRunadjustedRR
2.88, 95% CI 1.86 to 4.47, Analysis 11.1) and day 42 (one trial,
345 participants: PCR unadjusted RR 2.64, 95%CI 1.66 to 4.21,
Analysis 11.3). There were no significant differences between the
two combinations after PCR adjustment (Analysis 11.2; Analysis
11.4).
P. vivax
Only one trial (Dorsey 2006 UGA) reported on P. vivax and there
were too few patients to draw a conclusion (AL6 8/202 at baseline
and 3/202 during follow up, AQ+SP 4/253 at baseline and 0
during follow up).
Gametocytes
The prevalence of gametocyte carriage was significantly lower with
AL6 at day three (three trials, 1331 participants: RR 0.43, 95%
CI 0.25 to 0.75, Analysis 11.5) and day seven (four trials,1538
participants: RR0.32, 95%CI0.18 to 0.54, Analysis 11.5). Zongo
2007 BFA found no significant difference in the development of
gametocytaemia in participants without detectable gametocytes at
baseline (one trial, 371 participants, Analysis 11.6).
Anaemia
Zongo 2005 BFA reports change in haemoglobin from baseline to
day 28; Zongo 2007 BFA reports mean haemoglobin at baseline
and day 42. Neither of these trials showed a clinically significant
difference (two trials, 893 participants, Analysis 11.7). Four other
trials assessed haematological recovery at shorter time points and
did not detect a difference (Dorsey 2006 UGA; Fanello 2004
RWA; Faye 2003 SEN; Mutabingwa 2004 TZA).
Adverse events
No difference has been shown in the frequency of serious adverse
events (five trials, 2684 participants, Analysis 11.8).
Dorsey 2006 UGA reports more anorexia (P < 0.05) and weakness
(P < 0.05) with AQ+SP (455 participants). Two trials report a
significant increase in pruritis (P < 0.05, P < 0.0001) with AQ+SP.
No further differences are noted. For a summary of adverse events
see Appendix 4.
Early vomiting
Two trials report on the number of participants excluded for persis-
tent vomiting on day 0. There were no differences between groups
(two trials, 893 participants, Analysis 11.9).
Question 4. How does artesunate plus amodiaquine
perform?
Comparison 12. AS+AQ versus artesunate plus sulfadoxine-
pyrimethamine
We found seven trials (all in Africa) which assessed this compari-
son. Allocation concealment was judged as low risk of bias in only
one trial (Bonnet 2004 GIN) and unclear in four. Laboratory staff
were blinded to treatment allocation in two trials.
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Total failure
PCR adjusted treatment failures with AS+AQ were < 10% in all
seven trials, and with AS+SP in six out of seven trials.
Overall the number of PCR adjusted failures was low with no sig-
nificant difference between groups (seven trials, 1419 participants,
Analysis 12.2). There was substantial heterogeneity in PCR unad-
justed failure rates between trials (seven trials, 1419 participants:
heterogeneity: Chi² P < 0.00001, I² = 88%, Analysis 12.1). We
attempted to investigate this heterogeneity with subgroup analysis
on geographical region, allocation concealment, drug dose, stated
resistance pattern, and age of participants, with no clear findings.
P. vivax
Not reported.
Gametocytes
Wewere able to combine the results of three trials reporting game-
tocyte carriage on days three, seven and 14 and no difference was
shown at any time point (three trials, 532 participants, Analysis
12.3). The remaining four trials report that there were no differ-
ences in carriage between groups but do not give figures.
Anaemia
Five trials report that levels of anaemia improved following treat-
ment in both groups. Three of these trials did not give figures (
Djimde 2004 MLI; Swarthout 2004 ZAR; Van den Broek 2004
ZAR). Two trials report the proportion of patients with anaemia
at baseline and day 28. The proportion improved in both groups
with no significant differences between the two treatments (two
trials, 452 participants, Analysis 12.4).
Adverse events
No difference has been shown in the frequency of serious adverse
events (four trials, 1108 participants, Analysis 12.5).
Five trials reported on adverse events and no significant differences
between treatments were noted. One trial (Djimde 2004 MLI)
performedhaematological andbiochemical tests ondays 7, 14, and
28 and no significant abnormalities were noted. For a summary
of adverse events see Appendix 4.
Early vomiting
Not reported.
Comparison 13. AS+AQ versus amodiaquine plus
sulfadoxine-pyrimethamine
We found eight trialswhich assessed this comparison (all inAfrica).
Allocation concealment was assessed as low risk of bias in four tri-
als (Dorsey 2006 UGA; Menard 2006 MDG; Mutabingwa 2004
TZA; Staedke 2003 UGA) and unclear in two. Laboratory staff
were unaware of treatment allocation in seven trials.
Total failure
The efficacy of both drugs in these trials was highly variable.
A subgroup analysis demonstrates that it is in East Africa that
AQ+SP is failing as a first-line therapy. Heterogeneity is high, lim-
iting meaningful pooling of data, but trials from East Africa tend
to favour AS+AQ (five trials, 3317 participants, PCR unadjusted
heterogeneity: Chi² P < 0.0001, I² = 91%, Analysis 13.1; three
trials, 1515 participants, PCR adjusted heterogeneity: Chi² P =
0.03, I² = 73%, Analysis 13.2). AQ+SP performed well in Sene-
gal in 2003, Mali in 2006 and Madagascar in 2006. We further
investigated this heterogeneity with subgroup analysis on alloca-
tion concealment, drug dose, stated resistance pattern, and age of
participants, with no clear findings.
P. vivax
Not reported.
Gametocytes
AS+AQ significantly reduced the development of gametocytes in
those negative at baseline (two trials, 1354 participants: RR 0.67,
95% CI 0.54 to 0.82, Analysis 13.3). Six trials measured gameto-
cyte carriage during follow up. Three of these reported that there
were no differences but did not give figures. Of the three trials
which gave figures, only one (Faye 2003 SEN) found that AS+AQ
significantly reduced carriage rates at days three and seven (Analysis
13.4).
Anaemia
All eight trials reported some measure of haematological recovery.
No individual trial has reported a clinically important difference
at day 14 or 28 (see Appendix 5).
Adverse events
No difference has been shown in the frequency of serious adverse
events (seven trials, 4200 participants, Analysis 13.6).
Dorsey 2006 UGA reports more anorexia (P < 0.05) and weak-
ness (P < 0.05) with AQ+SP (485 participants). No differences
are noted in any other trial. Four trials also undertook some bio-
chemical monitoring and no important differences are noted. For
a summary of adverse events see Appendix 4.
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Early vomiting
Not reported.
D I S C U S S I O N
Summary of main results
Efficacy (as measured by total failure)
The WHO has set two standards for antimalarial drugs:
1. that a total failure rate (adjusted for new infections) of >
10% should trigger a change of first-line drug policy; and
2. that a new drug being adopted as policy should have total
failure rates (adjusted for new infections) of < 5%.
This review has demonstrated that:
• In head to head trials the newest ACT, dihydroartemisinin-
piperaquine, achieved the standard of < 5% total failure in 15 out
of the 17 studies it was involved in. DHA-P appears to be at least
as effective as AS+MQ in Asia (eight trials) providing a valuable
alternative to current therapy. In clinical trials in Africa, DHA-P
may be more effective than the current widely used options AL6
(four trials) and AS+AQ (one trial), although these two drugs
continue to perform well in many areas (Figure 3; Figure 4).
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Figure 3. How does Dihydroartemisinin-piperaquine perform? Summary of primary outcome:
Effectiveness: Total Failure (P. falciparum) PCR adjusted.
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Figure 4. Olliaro-Vaillant plot. Day 28 PCR adjusted treatment failure data for trials of DHA-P against all
comparators are presented in this plot.The horizontal red line represents the WHO standard of 10%
treatment failure (PCR corrected). Plots below this line represent trials where DHA-P performed to this
standard.The vertical blue line represents no difference between the two drugs. Plots to the right of this line
represent trials where DHA-P performed better than the comparator drug, and plots to the left represent
trials where the comparator drug performed better than DHA-P.
• AS+MQ has performed well in trials from Asia and South
America, with failure rates consistently low, but has been little
studied in the African context (Figure 5; Figure 6).
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Figure 5. How does Artesunate plus mefloquine perform? Summary of primary outcome: Effectiveness:
Total Failure (P. falciparum) PCR adjusted.
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Figure 6. Olliaro-Vaillant plot. Day 28 PCR adjusted treatment failure data for trials of AS+MQ against all
comparators are presented in this plot.The horizontal red line represents the WHO standard of 10%
treatment failure (PCR corrected). Plots below this line represent trials where AS+MQ performed to this
standard.The vertical blue line represents no difference between the two drugs. Plots to the right of this line
represent trials where AS+MQ performed better than the comparator drug, and plots to the left represent
trials where the comparator drug performed better than AS+MQ.
• AL6 and AS+AQ performed well in almost all studies they
were involved in but Kamya 2006 UGA found failure rates in
excess of 10% with AL6 and Yeka 2004 UGA reported > 10%
failure with AS+AQ (Figure 7; Figure 8; Figure 9; Figure 10).
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Figure 7. How does Artemether-lumefantrine perform? Summary of primary outcome: Effectiveness: Total
Failure (P. falciparum) Day PCR adjusted.
24Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 8. Olliaro-Vaillant plot. Day 28 PCR adjusted treatment failure data for trials of AL6 against all
comparators are presented in this plot.The horizontal red line represents the WHO standard of 10%
treatment failure (PCR corrected). Plots below this line represent trials where AL6 performed to this
standard.The vertical blue line represents no difference between the two drugs. Plots to the right of this line
represent trials where AL6 performed better than the comparator drug, and plots to the left represent trials
where the comparator drug performed better than AL6.
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Figure 9. How does Artesunate plus amodiaquine perform? Summary of primary outcome: Effectiveness:
Total Failure (P. falciparum) PCR adjusted.
26Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 10. Olliaro-Vaillant plot. Day 28 PCR adjusted treatment failure data for trials of AS+AQ against all
comparators are presented in this plot.The horizontal red line represents the WHO standard of 10%
treatment failure (PCR corrected). Plots below this line represent trials where AS+AQ performed to this
standard.The vertical blue line represents no difference between the two drugs. Plots to the right of this line
represent trials where AS+AQ performed better than the comparator drug, and plots to the left represent
trials where the comparator drug performed better than AS+AQ.
• There is very little good quality evidence available
comparing AS+SP to DHA-P, AS+MQ or AL6 but it has
performed well in head to head trials with AS+AQ.
• The performance of the non-ACT AQ+SP (which is only
recommended as an interim measure by the WHO), was
inadequate for first-line use in several countries from East Africa.
It was, however, still performing well in Senegal in 2003 (Faye
2003 SEN), Madagascar in 2006 (Menard 2006 MDG), and
Burkina Faso in 2005 (Zongo 2005 BFA).
Efficacy (P. vivax)
The two drugs with long half-lives (DHA-P and AS+MQ) have
been shown to be superior to AL6 in reducing the incidence of P.
vivax following treatment (for either P. falciparum or P. falciparum/
P. vivax co-infections). DHA-P has also been shown to reduce
the incidence of P. vivax compared to AS+AQ. Five trials have
compared DHA-P and AS+MQ and shown no difference.
There could be some public health benefits to using drugs with
long half-lives in this way, to prolong the malaria free period.
One trial (Hasugian 2005 IDN) demonstrated a reduced risk of
anaemia after treatment with DHA-P. This is likely to be due to
the lower incidence of both P. falciparum re-infections and P. vivax
in this group. As ACTs are ineffective at treating the liver stages
of P. vivax, this effect may be lost as follow up continues as the
majority of P. vivax will eventually relapse.
Prevention of transmission (as measured by
gametocytes)
ACTs may be superior to AQ+SP (the only combination not
containing an artemisinin derivative) in their effect on gameto-
cytes. Gametocyte carriage at days three and sevenwas higher with
AQ+SP compared toAS+MQ(one trial, 306participants, Analysis
8.3) and AL6 (four trials, 1538 participants, Analysis 11.5). Ga-
metocyte development in those negative at baseline was also higher
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with AQ+SP compared to AS+AQ (two trials, 1354 participants,
Analysis 13.3). No difference was shown between AQ+SP and
DHA-P.
Artesunate plus mefloquine seems to be superior to DHA-P in
reducing the carriage of gametocytes and preventing gametocyte
development. This effect may be a result of the relatively low
artemisinin content of this combination. Pharmokinetic data sug-
gest that dihydroartemisinin and artesunate are broadly bioequiv-
alent (Newton 2002) but at current dosing the total dose of di-
hydroartemisinin over three days (6 mg/kg) is only half the total
dose of artesunate (12 mg/kg).
DHA-P did perform well against other combinations, and there is
currently no evidence that it is inferior to AL6, AS+AQ or AQ+SP
in its effect on gametocytes.
It should be noted that there is evidence that even submicroscopic
levels of gametocytes (which are present in a significant number
of patients after treatment) are capable of transmission (Bousema
2004 KEN).
Haematological recovery
Anaemia is a common complication of malaria. Following success-
ful treatment of the parasite, the level of anaemia should improve
gradually over time, provided there is no further re-infection. This
process can be hastened by supplementation with oral iron ther-
apy.
In this review, where measures of haematological recovery were
reported, there is no evidence of clinically important differences
between the different ACTs.
Harms (as measured by adverse events)
The general lack of standardization in recording and reporting of
adverse events unfortunately precludes the use of meta-analysis to
analyse safety data. In addition, very few of the included trials in-
volved adequate blinding to prevent bias in adverse event report-
ing. Although serious adverse events seem to be uncommon, very
few trials undertook the biochemical or haematological monitor-
ing necessary to detect neutropenia or hepatotoxicity which have
been previously reported.
DHA-P seems to have a favourable profile in comparison to the
other drugs. In the 17 trials involving DHA-P, results are inconsis-
tent, but individual trials have shown reduced incidence of vom-
iting, anorexia, abdominal pain, fatigue, and pruritis compared
to AQ+SP, vomiting, anorexia, and fatigue compared to AS+AQ,
abdominal pain and headache compared to AL6 and sleep dis-
turbance, dizziness, anxiety, nausea and vomiting compared to
AS+MQ.
AS+MQ seems to cause more sleep disturbance and dizziness than
DHA-P and AL6. Overall there are also probably more gastroin-
testinal symptoms with AS+MQ.
Combinations including amodiaquine do seem to cause more gas-
trointestinal upset when compared to DHA-P but there is no con-
vincing evidence of increased vomiting compared to AL6.
No clinically severe alterations in biochemical tests were noted in
any of these trials.
AS+MQ tolerability in African children
There has been concern regarding the tolerability of AS+MQ
in African children (WHO 2006). This concern was raised by
Slutsker 1990 in a trial of mefloquine monotherapy in children
aged three months to five years. They found vomiting rates of
16/56 (29%) with a single dose of 25 mg/kg and 26/65 (40%)
with15 mg/kg; 13% and 8% were unable to tolerate a second
dose respectively. Three important details from this trial should
be noted: i) there was no comparison with an alternative therapy,
ii) the one-off dose was higher than in current regimens, and iii)
the mean age of children was 13 months which is considerably
younger than most trials of mefloquine in Asia.
In this review, we found two head to head trials of AS+MQ in
Africa. Both of these studies excluded children aged < one year
but vomiting was noted to be more common with AS+MQ in one
of these trials (Sagara 2005b MLI). There are, in addition, several
published single-arm or excluded trials of AS+MQ use in Africa (
Massougbodji 2002; Agomo 2008; Sagara 2008), but again these
do not include the very young children as included in Slutsker
1990. It is therefore not possible with current evidence to say
whether this poor tolerance is a consistent finding, whether it is
substantially different from other available ACTs or whether the
new regime of mefloquine 8 mg/kg/day is better tolerated.
Overall completeness and applicability of
evidence
Due to the changing patterns of resistance, summary statistics
should be interpreted with caution as the effectiveness of these
combinations is likely to vary from place to place, and to change
with time.
Evidence is generally lacking on the safety and efficacy of these
combinations in very young children (< six months) and in preg-
nant and lactating women who were excluded from all of the in-
cluded trials.
In addition to the ACTs presented here, two further combina-
tions (dihydroartemisinin plus naphthoquine and artesunate plus
sulfamethoxypyrazine-pyrimethamine) are beginning to appear in
the published literature and the market place, and these will be
added to future updates of this review.
Quality of the evidence
The quality of the evidence has been assessed using the GRADE
process (Guyatt 2008) and the results presented in the ’Summary
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of findings tables’. For these tables we asked the following ques-
tions:
1) Is dihydroartemsinin-piperaquine a suitable
alternative to the currently recommended ACTs?
There is high quality evidence that DHA-P is at least as effective
(at reducing PCR corrected treatment failure) as AS+MQ in Asia,
and AL6 in Africa, and moderate quality evidence that DHA-P is
at least as effective as AS+AQ (Appendix 6).
2) Does amodiaquine plus sulfadoxine-pyrimethamine
remain a valid alternative to ACTs?
The performance of AQ+SP is highly variable and so it is difficult
to make general statements on relative effects. There is moderate
quality evidence that AQ+SP is inferior to DHA-P and AL6 in
East Africa and very low quality evidence that it is also inferior to
AS+AQ (Appendix 6).
3) Does artesunate plus sulfadoxine-pyrimethamine remain a valid
alternative to other ACTs?
There is no good quality evidence comparing AS+SP to DHA-P,
AS+MQor AL6. In trials comparing AS+SP to AS+AQboth drugs
performed well and no clear difference was shown (Appendix 6).
4) Is artesunate plus mefloquine a valid alternative to the currently
used ACTs in Africa?
AS+MQ generally performed well in trials in Asia against DHA-
P and AL6 (Appendix 6). The direct evidence from Africa versus
AS+AQandAQ+SP is of lowquality (Summary of findings table 7;
Summary of findings table 8). The high performance of AS+MQ
is likely to be maintained in Africa where resistance to mefloquine
is low.
For the comparison artemether-lumefantrine versus artesunate
plus amodiaquine see Appendix 6.
Potential biases in the review process
Data extraction was unblinded. All included trials are published;
we were unable to obtain further unpublished data from pharma-
ceutical companies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
All five ACTs performed adequately, to be used as first-line ther-
apies, in most sites where they were studied, however there are
examples of failure rates above 10% with all combinations, em-
phasizing the need for continued monitoring and evaluation.
There is now a growing weight of evidence available to justify
the use of dihydroartemisinin-piperaquine as a first-line treatment
option for P. falciparum malaria.
There is evidence that the non-artemisinin combination AQ+SP
is failing in parts of East Africa where DHA-P, AL6, and AS+AQ
have been shown to be superior. There is also evidence that ACTs
have a superior effect on gametocytes that may be of public health
benefit particularly in low transmission settings.
The ACTs appear to be effective in treating the blood stage of
P. vivax. There may also be some benefit in using drugs with
long half-lives to delay spontaneous relapses. This prophylactic
effect needs to be balanced with the theoretical risk of promoting
the development of drug resistance. Additionally, in areas where
primaquine is being used to provide a radical cure this effect may
not be be of clinical significance.
Evidence of the safety of artemisinins is accumulating. Serious
adverse events with these drugs appear to be rare. However, these
trials are not powered to detect rare but clinically important events
and so it is imperative that active monitoring continues.
Implications for research
There are several new ACT combinations in development which
are likely to become commercially available in the next few years.
Policy makers therefore have a greater range of potential products.
In these circumstances, improved information on comparative ef-
ficacy, adverse events, and tolerability is invaluable for informed
decision making.
Many trials are using relatively standardized primary outcomes. A
move towards standardized approaches tomeasuring and reporting
secondary outcomes, and adverse events, would greatly improve
comparability between trials and meta-analysis.
In the absence of mefloquine resistance, AS+MQ is likely to be
highly effective in African countries but concerns regarding poor
tolerability in young infants have restricted its use in this setting.
There is in fact little evidence on the use of any of the ACTs in
this age group, and head to head randomized trials are necessary
to clarify or refute the specific concerns regarding AS+MQ and to
provide more general guidance on the choice and use of ACTs in
infants.
Further research is needed to clarify the role of specific ACTs in
the treatment of P. vivax. It remains unclear as to whether a long
acting ACT offers individual or public health benefits compared
to standard treatments for radical cure.
The most vulnerable populations (pregnant women and very
young infants) were excluded from all trials, and represent a criti-
cal gap in current knowledge.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adjei 2006 GHA
Methods Trial design: A single blind randomized controlled trial
Follow up: Clinical and laboratory assessment on days 0, 1, 2, 3, 7, 14, 28 and then
monthly for 1 year
Adverse event monitoring: Assessed at each visit up to 1 year using open questions about
side effects, behavioural and developmental concerns. Neurological examination at each
visit. Audiometry assessment on days 0, 3, 7, 28, and 1 year. WBC, aminotransferase
and total bilirubin at days 0, 3, 7, 14, and 28.
Participants Number: 227 randomized
Inclusion criteria: Age 6 months to 14 yrs, axillary temp > 37.5 ºC, signs and symptoms
of uncomplicated malaria, P. falciparummono-infection 2000 to 200,000/µl, willingness
to comply with the follow up, informed consent
Exclusion criteria: Signs or symptoms of severe malaria, chronic malnutrition or other
severe disease, known intolerance or allergy to study meds, reported treatment with any
of the study drugs during preceding month
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• 5 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
2. Artesunate plus amodiaquine, loose combination (Plasmotrim: Mepha, Camoquine:
Pfizer)
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg once daily for 3 days
Only the first dose each day was supervized
Outcomes 1. ACPR at day 28, PCR adjusted and PCR unadjusted
2. Adverse events including neurological, biochemical, and audiological events
Not included in this review:
1. Fever clearance
2. Parasite clearance
3. Further episodes of symptomatic malaria in 1 year
Notes Country: Ghana
Setting: Urban primary health facilities
Transmission: Not described
Resistance: AQ
Dates: Oct 2004 to Dec 2006
Funding: Danish Council for Development Research, Global Fund for AIDS, TB and
Malaria through the National Malaria Control Programme
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Adjei 2006 GHA (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’A computer generated randomisation
scheme was prepared in advance’
Allocation concealment? Yes ’Allocated treatments were kept in sealed
opaque envelopes’
Blinding?
All outcomes
Yes ’All study personnel (except project nurses)
were unaware of the assigned treatments’
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up in both groups
(7.2% AL6 vs 7.8% AS+AQ)
Free of selective reporting? Yes All WHO outcomes reported. The WHO
recommends 42 days followup in studies of
AL6.Day 28 outcomesmay under estimate
treatment failure with AL6.
Free of other bias? Yes No other sources of bias identified
Ashley 2003a THA
Methods Trial design: A 3-arm randomized controlled trial
Follow up: All patients admitted to hospital for 28 days, oral temperature taken every 6
hours, parasite counts 12-hourly until negative then daily for 28 days
Adverse event monitoring: Adverse events defined as signs or symptoms that occurred
or became more severe after treatment started. All patients had full blood counts, urea,
electrolytes, creatinine, and liver function tests at days 0 and 7.
Participants Number: 134 randomized into included treatment arms
Inclusion criteria: Age > 14 yrs, weight > 40 kg, symptoms of malaria, P. falciparum
parasitaemia, informed consent
Exclusion criteria: Pregnancy or lactation, signs or symptoms of severe malaria, > 4% of
red blood cells parasitized, contraindication to mefloquine, treatment with mefloquine
in the previous 60 days, sulphonamides or 4-aminoquinolones present in urine on ad-
mission
Interventions 1. Dihydroartemisinin-piperaquine, fixed dose combination (Artekin: Holleykin)
• Total dose: 6 mg/kg DHA and 48 mg/kg P in 4 divided doses at 0, 8, 24 and 48
hours
2. Artesunate plusmefloquine, loose combination (Artesunate:Guilin,Mequin: Atlantic)
• AS 4 mg/kg once daily for 3 days
• MQ 8 mg/kg once daily for 3 days
All doses supervized
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Ashley 2003a THA (Continued)
Outcomes 1. Cure rate at day 28, all reappearances of parasites presumed to be recrudescences
as patients hospitalized for duration
2. Adverse events
Not included in this review:
1. Fever clearance time
2. Parasite clearance time
Notes Country: Thailand
Setting: Bangkok Hospital for Tropical Diseases
Transmission: Low transmission
Resistance: Multiple-drug resistance
Dates: Jul 2002 to Apr 2003
Funding: Mahidol University, Tak Malaria Initiative Project, supported by Bill and
Melinda Gates Foundation, Wellcome Trust of Great Britain
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’The randomisation was computer gener-
ated (STATA; version 7; Statacorp)’. Ran-
domized in blocks of 6
Allocation concealment? Yes ’The treatment allocation was concealed
in sealed envelopes labelled with the study
code’
Blinding?
All outcomes
No ’Laboratory staff reading the blood smears
had no knowledge of the treatment re-
ceived’. No other blinding described
Incomplete outcome data addressed?
All outcomes
Yes Similar loss to follow up in all groups
(10.6% DHA-P vs 11.9% AS+MQ)
Free of selective reporting? Yes TheWHO recommends 63 days follow up
in studies of AS+MQ. Day 28 outcomes
are likely to underestimate treatment fail-
ure with AS+MQ and DHA-P.
Free of other bias? Yes No other sources of bias identified
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Ashley 2003b THA
Methods Trial design: A randomized controlled trial
Follow up: Temperature and blood smears daily until clearance of fever and parasites,
then weekly attendance until day 63
Adverse event monitoring: Adverse events defined as signs or symptoms that occurred
or became more severe after treatment started. A subset of 55 patients in the DHA-P
group had full blood counts, urea, electrolyte, creatinine and liver function tests at days
0 and 7. 32 patients from the DHA-P group also had ECG monitoring before and after
treatment.
Participants Number: 355 randomized into included treatment arms
Inclusion criteria: Age 1 to 65 yrs, symptomatic P. falciparum parasitaemia, informed
consent
Exclusion criteria: Pregnancy or lactation, signs or symptoms of severe malaria, > 4% of
red blood cells parasitized, contraindication to mefloquine, treatment with mefloquine
in the previous 60 days
Interventions 1. Dihydroartemisinin-piperaquine, fixed dose combination (Artekin: Holleykin)
• Total dose: 6 mg/kg DHA and 48 mg/kg P in 4 divided doses at 0, 8, 24, and 48
hours
2. Artesunate plusmefloquine, loose combination (Artesunate:Guilin,Mequin: Atlantic)
• AS 4 mg/kg once daily for 3 days
• MQ 8 mg/kg once daily for 3 days
All doses supervized
Outcomes 1. Cure rate at day 63, PCR adjusted and unadjusted
2. P. vivax during follow up, and mean time to reappearance
3. Gametocyte development during follow up
4. Mean haematocrit at days 0 and 7
5. Adverse events
Not included in this review:
1. Fever clearance time
2. Parasite clearance time
Notes Country: Thailand
Setting: 4 clinics on the Thai-Myanmar border
Transmission: Unstable low and seasonal transmission
Resistance: Multiple-drug resistance
Dates: Jul 2002 to Apr 2003
Funding: Wellcome Trust of Great Britain
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’The randomisation was computer gener-
ated (STATA; version 7; Statacorp)’. Ran-
domized in blocks of 9.
40Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ashley 2003b THA (Continued)
Allocation concealment? Yes ’The treatment allocation was concealed
in sealed envelopes labelled with the study
code’
Blinding?
All outcomes
No ’Laboratory staff reading the blood smears
had no knowledge of the treatment re-
ceived’. No other blinding described.
Incomplete outcome data addressed?
All outcomes
Yes Similar losses to follow up in all groups
(12.8% DHA-P vs 13.6% AS+MQ)
Free of selective reporting? Yes All WHO outcomes reported
Free of other bias? Yes No other sources of bias identified
Ashley 2004 THA
Methods Trial design: A 3-arm randomized controlled trial
Followup:Temperature andblood smears daily until clearance of fever andparasites, then
weekly attendance for examination, symptom enquiry, malaria smear and haematocrit
until day 63
Adverse event monitoring: Adverse events defined as signs or symptoms that occurred
or became more severe after treatment started. Symptoms were screened at each visit
Participants Number: 499 randomized
Inclusion criteria: Age 1 to 65 yrs, symptomatic P. falciparum mono-infection or mixed
infections, informed consent
Exclusion criteria: Pregnancy or lactation, signs or symptoms of severe malaria, > 4% of
red blood cells parasitized, treatment with mefloquine in the previous 60 days
Interventions 1. Dihydroartemisinin-piperaquine, fixed dose combination (Artekin: Holleykin)
• Total dose: 6.4 mg/kg DHA and 51.2 mg/kg P in 4 divided doses at 0, 8, 24, and
48 hours
2. Dihydroartemisinin-piperaquine, fixed dose combination (Artekin: Holleykin)
• Total dose: 6.4 mg/kg DHA and 51.2 mg/kg P in 3 divided doses at 0, 24, and 48
hours
3. Artesunate plusmefloquine, loose combination (Artesunate:Guilin,Mequin: Atlantic)
• AS 4 mg/kg once daily for 3 days
• MQ 8 mg/kg once daily for 3 days
All doses supervized
Outcomes 1. Cure rate at days 63, 42, and 28, PCR adjusted and unadjusted
2. P. vivax during follow up, and median time to reappearance
3. Gametocyte development during follow up
4. Mean haematocrit during follow up
5. Adverse events
Not included in this review:
1. Fever clearance
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Ashley 2004 THA (Continued)
2. Parasite clearance
Notes Country: Thailand
Setting: 4 clinics on the Thai-Myanmar border
Transmission: Unstable low and seasonal transmission
Resistance: Multiple-drug resistance
Dates: Apr 2003 to Apr 2004
Funding: Medicines for Malaria Venture, Wellcome Trust of Great Britain
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’The randomisation list was generated us-
ing STATA; version 7 (Stata)’. Randomized
in blocks of 9.
Allocation concealment? Yes ’The treatment allocation was concealed
in sealed envelopes labelled with the study
code’
Blinding?
All outcomes
No ’Laboratory staff reading the blood smears
had no knowledge of the treatment re-
ceived’. No other blinding described.
Incomplete outcome data addressed?
All outcomes
Yes Losses to follow up were low in all groups
(4.2% DHA-P vs 4.8% AS+MQ)
Free of selective reporting? Yes All WHO outcomes reported. 2 patients
were considered to be early treatment fail-
ures by the reviewers and reclassified as
such. This was not clearly stated in the pa-
per.
Free of other bias? Yes No other sources of bias identified
Ashley 2005 THA
Methods Trial design: An open label randomized controlled trial
Follow up: Temperature and blood smears daily until clearance of fever and parasites,
then weekly attendance for clinical examination, symptom enquiry, malaria smear, and
haematocrit until day 63
Adverse event monitoring: Adverse events were actively screened at each visit. Adverse
events were defined as signs or symptoms that occurred or became more severe after
treatment started.
Participants Number: 500 randomized
Inclusion criteria: Age 6 months to 65 yrs, weight > 5 kg, symptomatic P. falciparum
mono-infection or mixed infections, informed consent
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Ashley 2005 THA (Continued)
Exclusion criteria: Pregnancy or lactation, signs or symptoms of severe malaria, > 4%
of red blood cells parasitized, treatment with mefloquine in the previous 60 days, con-
traindication to mefloquine
Interventions 1. Artesunate plus mefloquine, fixed-dose combination, adult tablets 100 mg/220 mg,
paediatric tablets 25 mg/55 mg (Far-Manguinhos)
• 5 to 8 kg 1 paediatric tablet per day
• 9 to 17 kg 2 paediatric tablets per day
• 18 to 29 kg 1 adult tablet per day
• > 30 kg 2 adult tablets per day
2. Artesunate plus mefloquine, loose combination, (Arsumax: Sanofi-Synthelabo, Lar-
iam: Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 15 mg/kg on day 1 and 10 mg/kg on day 2
All doses supervized
Outcomes 1. Cure rate at day 63, PCR adjusted and unadjusted
2. P. vivax during follow up, and median time to reappearance
3. Gametocyte development during follow up
4. Mean haematocrit during follow up
5. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
Notes Country: Thailand
Setting: 6 clinics on the Thai-Myanmar border
Transmission: Unstable low and seasonal transmission
Resistance: Multiple-drug resistance
Dates: Nov 2004 to Jun 2005
Funding: DNDi, European Union International Co-operation programme, Médecins
sans Frontières, WHO/TDR, Wellcome Trust of Great Britain
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Randomised in blocks of 10 by a statisti-
cian using a computer-generated randomi-
sation’
Allocation concealment? Yes ’The treatment allocation was concealed in
numbered, sealed envelopes...opened only
after enrolment in the study’
Blinding?
All outcomes
No An open label study. ’50% of enrolment
slides, 10% of follow up slides and all slides
reported as showing recrudescence were
subjected to a second blind reading’
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Ashley 2005 THA (Continued)
Incomplete outcome data addressed?
All outcomes
No Losses to follow-up are moderate (15.5%
FDC vs 15.3% loose). Reasons are not
clearly stated and some losses may repre-
sent early treatment failures.
Free of selective reporting? Yes All WHO outcomes reported
Free of other bias? Yes No other sources of bias identified
Bonnet 2004 GIN
Methods Trial design: A randomized controlled trial
Follow up: Clinical and parasitological assessment on days 0, 1, 2, 3, 7, 14, 21 and 28.
Gametocyte carriage measured at day 0 and 28. PCR genotyping on all reappearances
after day 9.
Adverse event monitoring: None described
Participants Number: 220 randomized
Inclusion criteria: Age 6 to 59 months, axillary temp > 37.5 ºC, P. falciparum mono-
infection 2000 to 200,000/µl
Exclusion criteria: Signs of severity or severe malaria, severe anaemia (Hb < 5 g/dl),
severe malnutrition, concomitant febrile condition with the potential to confound study
outcome, history of allergic reaction to the study drugs
Interventions 1. Artesunate plus amodiaquine, loose combination (Arsumax: Guilin, Camoquin:
Parke-Davis)
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg once daily for 3 days
2. Artesunate plus sulfadoxine-pyrimethamine, loose combination, (Arsumax: Guilin,
Fansidar: Roche)
• AS 4 mg/kg once daily for 3 days
• SP 25/1.25 mg/kg as a single dose
All doses supervized
Outcomes 1. ACPR at day 28, PCR adjusted and unadjusted
2. Gametocyte carriage at baseline and day 28
Notes Country: Guinea
Setting: Outpatient department
Transmission: Perennial seasonal malaria with increased transmission between June and
October
Resistance: CQ, AQ and SP resistance
Dates: Jun 2004 to Sept 2004
Funding: Médecins sans Frontières
Risk of bias
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Bonnet 2004 GIN (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes ’A randomization list with a block size
of 20 was electronically generated by the
methodological center (Epicentre, Paris)’
Allocation concealment? Yes ’Sealed opaque envelopes corresponding to
each inclusion number, and containing the
name of the allocated treatment regimen,
were prepared before the study started.’ (
Additional information from authors)
Blinding?
All outcomes
No No comment on blinding. A random sam-
ple of 92 slides were cross-checked by an
independent technician.
Incomplete outcome data addressed?
All outcomes
Yes Low loss to follow up in both groups (2.7%
AS+AQ vs 3.6% AS+SP)
Free of selective reporting? Yes All WHO outcomes reported
Free of other bias? Yes No other sources of bias identified
Bousema 2004 KEN
Methods Trial design: A 3-arm, single blind (outcome assessors)randomized controlled trial
Follow up: Days 0, 1, 2, 3, 7, 14, and 28 or any other day they became ill
Adverse event monitoring: None described
Participants Number: 376 randomized to included treatment arms
Inclusion criteria: Age 6months to 10 yrs, temp > 37.5 ºC or history of fever,P. falciparum
mono-infection > 500/µl. Additionally for AL group: weight > 10 kg and living < 5 km
from the clinic.
Exclusion criteria: Signs of severe malaria, inability to take meds orally, evidence of
chronic disease or an acute infection other thanmalaria, known hypersensitivity to any of
the study drugs, reported treatment with antimalarials in the previous 2 weeks, resident
outside of study area
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• 1/2 tablet per 5 kg bodyweight twice daily for 3 days
2. Artesunate plus sulfadoxine-pyrimethamine, loose combination (Arsumax: Sanofi-
Aventis, Fansidar: Roche)
• AS 4 mg/kg once daily for 3 days
• SP 25/1.25 mg/kg as a single dose
3. Amodiaquine plus sulfadoxine-pyrimethamine, loose combination (Camoquine:
Pfizer, Fansidar: Roche)
• AQ 10 mg/kg once daily for 3 days
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• SP 25/1.25 mg/kg as a single dose
All doses supervized and given with a fatty meal
Outcomes 1. Adequate clinical response at day 28, PCR adjusted and unadjusted (excluded
from primary analysis)
Not included in the review:
1. Gametocytes carriage at days 0 and 7
2. Assessment of infectiousness of participants
Notes Country: Kenya
Setting: Rural clinic
Transmission: High and perennial
Resistance: Not reported
Dates: Oct to Dec in 2003 and 2004
Funding: Foundation for the Advancement of Tropical Research, Netherlands Organi-
zation for Scientif Research, Ter Meulen Fund
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Childrenwere divided in age strata and ran-
domized to different treatment regimens
using Excel generated randomization ta-
bles. Serious flaws in randomization.
Allocation concealment? No None described
Blinding?
All outcomes
Yes ’Other than those administering the med-
ication, all staff engaged in the trial were
blinded to allocation’
Incomplete outcome data addressed?
All outcomes
No Losses to follow up were different between
groups with no losses in the AL group (0%
AL6vs 8.0%AS+SP vs 9.4%AQ+SP).This
is likely to be related to the different inclu-
sion criteria for AL6.
Free of selective reporting? Yes TheWHO recommends 42 days follow up
in studies of AL6. Day 28 outcomes may
underestimate treatment failure with AL6.
Free of other bias? No Due to differing inclusion criteria for the 3
arms children in the AL6 group were older,
heavier and had higher Hb levels at base-
line. This may improve outcome in this
group and consequently the AL6 arm was
excluded from this review.
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Bukirwa 2005 UGA
Methods Trial design: A single blind randomized controlled trial
Follow up: Days 0, 1, 2, 3, 7, 14, and 28 or any other day they became ill, for a
standardized history, examination and malaria film. Haemoglobin measurement day
0, 28 or day of failure. Participants with Hb < 10 g/dl given ferrous sulphate and
antihelminthic treatment.
Adverse event monitoring: Assessed at each follow-up visit, an adverse event defined as
any untoward medical occurrence
Participants Number: 419 randomized
Inclusion criteria: Age 1 to 10 yrs, axillary temp > 37.5 ºC or history of fever in previous
24 hrs, P. falciparum mono-infection 2000 to 200,000/µl, informed consent
Exclusion criteria: Danger signs or evidence of severe malaria, evidence of a concomitant
febrile illness, repeated vomiting of first dose of medication, history of serious side effects
to study drugs
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• 10 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
2. Artesunate plus amodiaquine, loose combination (Arsumax: Sanofi-Aventis, Camo-
quin: Parke-Davis)
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg on days 0 & 1 and 5 mg/kg on day 2
• Plus placebos in the evening for 3 days
All doses supervized
Outcomes 1. Risk of recurrent parasitaemia and recurrent symptomatic malaria at day 28, PCR
adjusted and unadjusted
2. Gametocytes during follow up
3. Mean change in haemoglobin from baseline to last day of follow up
4. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
Notes Country: Uganda
Setting: Rural health centre
Transmission: High transmission, holoendemic with peaks following 2 rainy seasons
Resistance: CQ and SP resistance
Dates: Dec 2004 to July 2005.
Funding: Centers for Disease Control and Prevention, Association of Schools of Public
Health, DfID
Risk of bias
Item Authors’ judgement Description
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Bukirwa 2005 UGA (Continued)
Adequate sequence generation? Yes ’An off-site investigator prepared com-
puter-generated age-stratified randomisa-
tion codes’
Allocation concealment? Yes ’The randomisation list was secured in a
locked cabinet accessible only by the study
nurse. Participants were enrolled by study
physicians and treatments were assigned by
the study nurse’
Blinding?
All outcomes
Yes ’Only the study nurse was aware of treat-
ment assignments. All other study person-
nel including study physicians and labora-
tory personnel involved in assessing out-
comes were blinded’
Incomplete outcome data addressed?
All outcomes
Yes Participants were excluded before enrol-
ment only by predefined criteria. Losses to
follow up after enrolment were low (1%
AL6 vs 1.5% AS+AQ)
Free of selective reporting? Yes TheWHO recommends 42 days follow up
in studies of AL6. Day 28 outcomes may
under estimate treatment failure with AL6.
Free of other bias? Yes No other sources of bias identified
Djimde 2004 MLI
Methods Trial design: A single blind (outcome assessors)randomized controlled trial
Follow up: Days 0, 1, 2, 3, 7, 14, 21, and 28 or any other day they became ill, for a
clinical assessment and malaria film
Adverse event monitoring: Haemoglobin, glucose, complete blood count, liver enzymes,
and creatinine were measured on days 0, 7, 14, and 28
Participants Number: 502 randomized to included treatment arms
Inclusion criteria: Age > 6months, weight > 5 kg, axillary temp > 37.5 ºC, uncomplicated
malaria of any species 2000 to 200,000/µl, able to tolerate oral treatment, resident of
study area for entire period of follow up, informed consent
Exclusion criteria: Pregnancy, symptoms of severe malaria, allergy to a study drug, doc-
umented consumption of 1 of the study drugs in the previous 7 days
Interventions 1. Artesunate plus amodiaquine, fixed dose combination, 50/153 mg tablets (Arsucam:
Sanofi-Aventis)
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg once daily for 3 days
2. Artesunate plus sulfadoxine-pyrimethamine, loose combination (Arsumax: Sanofi-
Aventis, Fansidar: Roche)
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Djimde 2004 MLI (Continued)
• AS 4 mg/kg once daily for 3 days
• Plus half a tablet of SP (500/25mg tablets) per 10 kg as a single dose
All doses supervized
Outcomes 1. ACPR at day 28, PCR adjusted and unadjusted
2. Treatment outcome in non-falciparum species
3. Gametocyte carriage during follow up
4. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
Notes Country: Mali
Setting: A village
Transmission: Hyperendemic with seasonal peaks
Resistance: CQ and SP resistance
Dates: Dec 2002 to Oct 2004
Funding: Access to Medicines, Sanofi-Aventis and the International Atomic Energy
Agency
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Enrolled patients were randomly assigned
to treatment groups’. No further details.
Allocation concealment? Unclear ’The randomisation list was concealed to
clinicians’. No further details.
Blinding?
All outcomes
Unclear Described as single blind, although details
not given
Incomplete outcome data addressed?
All outcomes
No In the day 28 efficacy analysis 13 patients
in the AS+AQ group and 9 in the AS+SP
group are unaccounted for
Free of selective reporting? Yes All WHO outcomes reported
Free of other bias? No ’The study sponsor was involved in the pro-
tocol development and reporting of severe
adverse events’
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Dorsey 2006 UGA
Methods Trial design: A 3-arm, single blind (outcome assessors)randomized controlled trial. An
unusual design where participants were randomized to a treatment and followed up
through however many episodes of malaria happened to occur during the time period.
Follow up: Days 0, 1, 2, 3, 7, 14, and 28 or any other day they became ill, for a
standardized history, examination and malaria film. Anthelminthics, iron sulphate, and
vitamin A were prescribed as per IMCI guidelines.
Participants with P. vivax during follow up were censored on day of occurrence
Adverse event monitoring: Assessed at each follow-up visit, an adverse event defined as
any untoward medical occurrence. Complete blood count and alanine aminotransferase
on day 0 and 14.
Participants Number: 329 children randomized to a treatment group
Inclusion criteria: Age 1 to 10 yrs, weight >10 kg, agreement to remain in Kampala,
agreement to attend the study clinic for any febrile illness, agreement to avoidmedications
outside of the study, informed consent
Exclusion criteria: Known adverse reactions to study meds, severe malnutrition, known
serious chronic disease, life threatening lab results on screening
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets
• 5 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
2. Artesunate plus amodiaquine, loose combination
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg on days 0 and 1 and 5 mg/kg on day 2
• Plus placebo in the evenings
3. Amodiaquine plus sulfadoxine-pyrimethamine, loose combination
• AQ 10 mg/kg on days 0 and 1 and 5 mg/kg on day 2
• SP 25/1.25 mg/kg on day 1
• Plus placebo in the evenings
Only the first dose was supervized each day
Outcomes 1. Risk of treatment failure at day 28, PCR adjusted and unadjusted
2. Recurrent malaria caused by non-falciparum species
3. Gametocyte carriage by day of follow up
4. Mean change in haemoglobin from baseline to day 14
5. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
Notes Country: Uganda
Setting: Urban clinic
Transmission: Mesoendemic with peaks during the 2 rainy seasons
Resistance: CQ, AQ and SP resistance
Dates: Nov 2004 to June 2006
Funding: National Institutes of Health, Doris Duke Charitable Foundation
Risk of bias
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Item Authors’ judgement Description
Adequate sequence generation? Yes ’A randomisation list was computer gener-
ated with variable blocks of 3, 6, and 9 by
an off-site investigator’
Allocation concealment? Yes ’Sequentially numbered, sealed envelopes
containing the treatment group assign-
ments were prepared from the randomisa-
tion list’
Blinding?
All outcomes
Yes ’All study personnel involved in outcome
assessment were blinded to treatment allo-
cation’
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up in all groups and
reasons given (2.9% AL6 vs 5.4% AS+AQ
vs 5.4% AQ+SP)
Free of selective reporting? Yes TheWHOrecommends 42 days follow-up
in studies of AL6. Day 28 outcomes may
underestimate the failure rate with AL6.
Free of other bias? Yes No other sources of bias identified
Falade 2005 NGA
Methods Trial design: An open-label randomized controlled trial
Follow up: Examination and malaria film on days 0 to 7, 14, 21, and 28. Participants
were admitted to hospital for the first 3 days then seen at days 7, 14, 21, and 28.
Adverse event monitoring: Assessed at each visit by examination and questioning about
the progress of presenting symptoms and new symptoms. FBC,WBC, and liver enzymes
on days 0, 7, and 28. An adverse event defined as not present at enrolment but occurring
during follow up.
Participants Number: 132 participants randomized
Inclusion criteria: Age 6 months to 10 yrs, axillary temp > 37.5 ºC, signs and symptoms
of malaria, P. falciparummono-infection 2000 to 200,000/µl, willingness to comply with
the protocol, informed consent
Exclusion criteria: Signs of severe and complicated malaria or other febrile illness, severe
malnutrition, history of hypersensitivity to any of the study drugs
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• 5 to 15 kg 1 tablet twice daily for 3 days
• 15 to 25 kg 2 tablets twice daily for 3 days
• 25 to 35 kg 3 tablets twice daily for 3 days
2. Artesunate plus amodiaquine, loose combination (Arsumax: Sanofi-Synthelabo,
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Falade 2005 NGA (Continued)
Camoquine: Pfizer)
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg once daily for 3 days
All doses supervized and given with food, fruit drink, or dissolved in water
Outcomes 1. ACPR at day 28, PCR adjusted and unadjusted
2. Haematocrit on days 0, 7, and 28
3. Adverse events, including mean WBC and liver enzymes
Not included in the review:
1. Fever clearance time
2. Parasite clearance time
Notes Country: Nigeria
Setting: General Outpatient Department of University College Hospital
Transmission: Intense and occurs all year round
Resistance: CQ and SP
Dates: Aug 2004 to Aug 2005
Funding: Study meds were supplied by Novartis, Sanofi-Sycitilabo and Pfizer
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’A pregenerated randomisation table’
Allocation concealment? No None described
Blinding?
All outcomes
No An open label trial. No comment on blind-
ing of lab staff
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up in both groups
(7.5% AL6 vs 6.0% AS+AQ)
Free of selective reporting? Yes All WHO outcomes reported. The WHO
recommends 42 days followup in studies of
AL6.Day 28 outcomesmay under estimate
treatment failure with AL6.
Free of other bias? Yes No other sources of bias identified
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Methods Trial design: An open-label randomized controlled trial
Follow up: Participants were admitted to hospital for the first 3 days then seen at days
7, 14, 21, and 28. At each visit history, clinical signs and symptoms, temperature and
malaria film. PCV and WBC were recorded on days 0 and 14.
Adverse event monitoring: All adverse events were recorded on the clinical record form
and a causality assessment was made
Participants Number: 500 randomized
Inclusion criteria: Age 12 to 59 months, weight >10 kg, axillary temp > 37.5 ºC or
history of fever in the previous 24 hrs, P. falciparum mono-infection 2000 to 200,000/
µl, informed consent
Exclusion criteria: Severe malaria, concomitant illness or underlying disease, known
allergy to the study drugs, a clear history of adequate antimalarial treatment in the
previous 72 hrs
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets
• < 15 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
2. Amodiaquine plus sulfadoxine-pyrimethamine, loose combination
• AQ 10 mg/kg once daily for 3 days
• SP 25/1.25 mg/kg on day 0
All doses supervized
Outcomes 1. ACPR at day 28, PCR adjusted and unadjusted
2. Gametocyte carriage during follow up
3. Mean PCV at days 0 and 14
4. Adverse events, including mean WBC at days 0 and 14
Not included in the review:
1. Fever clearance
2. Parasite clearance
Notes Country: Rwanda
Setting: Rural health clinics
Transmission: Variable
Resistance: Not described
Dates: July 2004 to Dec 2004
Funding: Belgian Development Co-operation (DGIS) and the Prince Leopold Institute
of Tropical Medicine
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Randomly allocated in blocks of 20...ac-
cording to a randomization list prepared in
Belgium’
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Allocation concealment? Unclear ’Allocation of treatment was concealed
from both the doctor and the patient, until
final recruitment of the patient’. Method
not described.
Blinding?
All outcomes
No An open-label trial. ’Laboratory techni-
cians reading malaria slides did not know
the treatment received by individual pa-
tients’
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up (2% AL6 vs 0.8%
AQ+SP)
Free of selective reporting? Yes TheWHO recommends 42 days follow up
in studies of AL6. Day 28 outcomes may
overestimate the efficacy of AL6.
Free of other bias? Yes No other sources of bias identified
Faye 2003 SEN
Methods Trial design: A 5-arm, open-label randomized controlled trial
Follow up: Days 0, 1, 2, 7, 14, 21, and 28 for a clinical examination and malaria film
Adverse event monitoring: All side effects were monitored actively and passively during
the study. 25% randomly selected for blood counts, liver, and renal function tests at days
0, 14, and 28.
Participants Number: 815 randomized into included treatment arms
Inclusion criteria: ’as per WHO 2002 protocol’
Exclusion criteria: ’as per WHO 2002 protocol’
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• Twice daily dosing for 3 days
• Exact dosing regimen not specified
2. Artesunate plus mefloquine, co-blistered (Artequine: Mepha)
• Adults: AS 200 mg/day plus MQ 250 mg/day for 3 days
• Children: AS 100 mg/day plus MQ 125 mg/day for 3 days
3. Artesunate plus amodiaquine, co-blistered (Arsucam: Sanofi-Aventis)
• AS 4 mg/kg/day for 3 days
• AQ 10 mg/kg/day for 3 days
4. Amodiaquine plus sufadoxine-pyrimethamine (Pharmacie Nationale
d’Approvisionnement d Senegal)
• AQ 10 mg/kg/day for 3 days
• Plus half a tablet of SP per 10 kg as a single dose
All doses supervized
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Outcomes 1. Day 28 ACPR PCR adjusted and unadjusted
2. Gametocyte carriage at days 0, 7, 14, 28
3. Anaemia (Hb < 12) days 0, 14
4. Adverse events
Notes Country: Senegal
Setting: Healthcare centres
Transmission: Moderate with a peak in the rainy season
Resistance: High levels of chloroquine resistance
Dates: The transmission periods of 2002 and 2003
Funding: Study drugs supplied by Sanofi-Aventis, Mepha, and Novartis
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not described. Only described as ’random-
ized’
Allocation concealment? No None described
Blinding?
All outcomes
No An open label trial. No comment on blind-
ing of lab staff
Incomplete outcome data addressed?
All outcomes
Yes Losses to followupwere not reported in the
original paper and figures were only given
as percentages.Unpublisheddata reveal loss
to follow up as low in all groups (3.1%
AS+AQ, 0.7% AS+MQ, 1.3% AL6, 3.1%
AQ+SP).
Free of selective reporting? Yes The WHO recommend 42 days follow up
for studies involving AL6 and 63 days for
AS+MQ. Day 28 outcomes may under-
estimate treatment failure with AL6 and
AS+MQ.
Free of other bias? Yes No other sources of bias identified
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Grande 2005 PER
Methods Trial design: An open-label randomized controlled trial
Follow up: Days 0, 1, 2, 3, 7, 14, 21, 28, 35, 42, 49, 56, and 63 or any other day they
became ill, for a clinical assessment and malaria film. PCV measurement day 0, 7, 14
and 63. P. vivax treated with CQ.
Adverse event monitoring: Assessed at each follow-up visit, an adverse event defined as
any unfavourable and unintended sign, symptom or disease temporally associated with
the drug administered. Complete blood count, liver, and renal function tests at days 0
and 7.
Participants Number: 522 randomized
Inclusion criteria: Age 5 to 60 yrs, fever > 37.5 ºC or history of fever in the previous 24
hours, P. falciparum mono-infection 1000 to 200,000/µl
Exclusion criteria: Pregnancy or lactation, severe malaria, any concomitant illness or
underlying disease, contraindication to any of the trial drugs, history of treatment with
mefloquine in the previous 60 days or chloroquine, primaquine or quinine in previous
14 days
Interventions 1. Dihydroartemisinin-piperaquine, fixed dose combination (Artekin: Holleykin)
• Total dose: 6.3 mg/kg DHA and 50.4 mg/kg PQP in 3 divided doses, given once
daily for 3 days
2. Artesunate plusmefloquine, loose combination (Artesunate: Guilin, Lariam:Hoffman
La-Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 8 mg/kg once daily for 3 days
All doses supervized
Outcomes 1. Day 63 cure rate PCR adjusted and unadjusted
2. P. vivax during follow up
3. Gametocyte prevalence at day 0, 7, 14, 21 and 28
4. Gametocyte development during follow up
5. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
Notes Country: Peru
Setting: 9 rural health posts
Transmission: Low malaria transmission
Resistance: High CQ and SP resistance
Dates: July 2003 to July 2005
Funding: Directorate-General for Development and Cooperation of the Belgian Gov-
ernment
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Randomized in blocks of 10’. No further
details given.
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Allocation concealment? Yes ’Sealed opaque envelopes were opened only
after the final decision to recruit the patient
had been made’
Blinding?
All outcomes
No An open-label trial. No comment on blind-
ing of laboratory staff.
Incomplete outcome data addressed?
All outcomes
Yes Similar loss to follow up in both groups
(8.7% DHA-P vs 5.9% AS+MQ)
Free of selective reporting? Yes All WHO outcomes reported
Free of other bias? Yes No other sources of bias identified
Guthmann 2003 AGO
Methods Trial design: An open label randomized controlled trial
Follow up: Reassessed clinically and parasitologically on days 0, 3, 7, 14, 21, and 28.
Gametocytes were measured at each visit. Haemoglobin was measured at days 0 and 28.
Adverse event monitoring: None described
Participants Number: 187 randomized into included treatment arms
Inclusion criteria: Age 6 to 59 months, weight > 5 kg, axillary temp > 37.5 ºC or history
of fever in the previous 24 hours, P. falciparum mono-infection 2000 to 100,000/µl,
living within 1 hours walk of the clinic, informed consent
Exclusion criteria: Signs of severity or severe malaria, severe anaemia (Hb < 5 g/dl),
severe malnutrition, any concomitant febrile condition with the potential to confound
the study outcome, history of allergic reaction to the study drug, reported intake of a
full course of antimalarials in the previous 7 days
Interventions 1. Artesunate plus amodiaquine, loose combination (Arsumax: Sanofi-Aventis, Camo-
quin: Parke-Davis)
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg/day for 3 days
2. Artesunate plus sulfadoxine-pyrimethamine, loose combination (Arsumax: Sanofi-
Aventis, Fansidar: Roche)
• AS 4 mg/kg once daily for 3 days
• SP 25/1.25 mg/kg as a single dose
All doses supervized
Outcomes 1. Failure at day 28 PCR adjusted
2. Prevalence of anaemia at days 0 and 28
3. Gametocyte carriage at day 28
Notes Country: Angola
Setting: Hospital outpatient dept., health centre, 3 health posts and 1 maternal and child
health centre
Transmission: Mesoendemic with stable and seasonal transmission with a peak from
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September to April
Resistance: CQ and SP resistance
Dates: March 2003 to July 2003
Funding: Médecins sans Frontières
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Randomly allocated in blocks of 20’. Due
to technical problems randomization only
started after the first 30 patients had been
enrolled.
Allocation concealment? No ’Without a concealment procedure’
Blinding?
All outcomes
No No comment on blinding. External qual-
ity control on a random sample of malaria
films was conducted.
Incomplete outcome data addressed?
All outcomes
No 3 times as many withdrawals in AS+AQ
group vs AS+SP (12% vs 4%). Reasons for
this disparity are not given.
Free of selective reporting? Yes Only PCR adjusted results given, PCR un-
adjusted is unpublished data
Free of other bias? Yes No other sources of bias identified
Guthmann 2004 AGO
Methods Trial design: A randomized controlled trial
Follow up: Days 0, 1, 2, 3, 7, 14, 21, and 28, for a clinical assessment and malaria film.
Haemoglobin and gametocyte measurement on days 0 and 28.
Adverse event monitoring: Not described
Participants Number: 137 randomized
Inclusion criteria: Age 6 to 59months, confirmed clinical P. falciparummalaria, informed
consent
Exclusion criteria: As per WHO 2003 protocol
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• Twice daily for 3 days as per manufacturers guidance
2. Artesunate plus amodiaquine, loose combination (Arsumax: Sanofi-Aventis, Camo-
quin: Parke-Davis)
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg once daily for 3 days
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All doses supervized
Outcomes 1. Recurrent parasitaemia at day 28, PCR adjusted and unadjusted
2. Prevalence of anaemia at days 0 and 28
3. Early vomiting
Not included in the review:
1. Gametocytes on days 0 and 28
Notes Country: Angola
Setting: Health centre
Transmission: High transmission, mesoendemic
Resistance: CQ and SP resistance
Dates: Apr 2004 to Jul 2004
Funding: Médecins sans Frontières, The American Society of Tropical Medicine and
Hygiene (ASTMH) and the American Committee on Clinical Tropical Medicine
and Travelers’ Health (ACCTMTH)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as ’randomized’ but no other de-
tails
Allocation concealment? No None described
Blinding?
All outcomes
No Blinding not mentioned. 100 malaria films
were checkedby an independent laboratory
Incomplete outcome data addressed?
All outcomes
Yes Losses to follow up low in both groups
(6.2% AL6 vs 7.2% AS+AQ)
Free of selective reporting? Yes TheWHO recommends 42 days follow up
in studies of AL6. Day 28 outcomes may
under estimate treatment failure with AL6.
Free of other bias? Yes No other sources of bias identified
Hamour 2003 SDN
Methods Trial design: An open label randomized controlled trial
Follow up: Reassessed clinically and parasitologically on days 0, 1, 2, 3, 7, 14, 21, and
28
Adverse event monitoring: Not described
Participants Number: 161 randomized
Inclusion criteria: Age 6 to 59 months, weight > 5 kg, axillary temp > 37.5 ºC, P.
falciparum mono-infection 2000 to 200,000/µml, informed consent
Exclusion criteria: Signs of severe malaria, concomitant febrile conditions except mild
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viral upper respiratory tract infections, hypersensitivity to study drugs
Interventions 1. Artesunate plus sulphadoxine-pyrimethamine, loose combination (Arsumax: Sanofi-
Aventis, Fansidar: Roche)
• AS 4 mg/kg once daily for 3 days
• SP 25/1.25 mg/kg as a single dose
2. Artesunate plus amodiaquine, loose combination (Arsumax: Sanofi-Aventis, Camo-
quin: Parke-Davis)
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg once daily for 3 days
All doses supervized
Outcomes 1. ACPR at day 28, PCR adjusted and unadjusted
2. Gametocyte carriage on days 0, 14, and 28
3. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
Notes Country: Sudan
Setting: Rural health care centre
Transmission: Markedly seasonal
Resistance: CQ resistance
Dates: Sept 2003 to Nov 2003
Funding: Médecins sans Frontières
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Randomized by sealed envelopes’. No fur-
ther details given.
Allocation concealment? Unclear ’Sealed envelopes’. No further details.
Blinding?
All outcomes
No An open-label trial. No comment on blind-
ing of laboratory staff to allocation, but
slides read independently with external
quality control.
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up in both groups
(2.5% AS+SP vs 0% AS+AQ). A large
number of PCR samples were indetermi-
nate but equally distributed across groups.
Free of selective reporting? Yes All WHO outcomes reported
Free of other bias? Yes No other sources of bias identified
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Hasugian 2005 IDN
Methods Trial design: An open label randomized controlled trial
Follow up: Daily until fever and parasites cleared then weekly until day 42, for a physical
examination, a symptom questionnaire and malaria film. Haemoglobin measured on
days 0, 7, and 28.
Adverse event monitoring: Assessed at each follow-up visit
Participants Number: 340 randomized
Inclusion criteria: Age > 1 yr, weight > 5 kg, slide confirmed malaria (P. falciparum, P.
vivax or both), fever or history of fever in the preceding 48 hours
Exclusion criteria: Pregnancy or lactation, danger signs or signs of severe malaria, > 4%
red blood cells parasitized, concomitant disease that required hospital admission
Interventions 1. Dihydroartemisinin-piperaquine, fixed dose combination (Artekin: Holley)
• Total dose: 6.75 mg/kg DHA and 54 mg/kg PQP in 3 divided doses given once
daily for 3 days
2. Artesunate plus amodiaquine, loose combination (Arsumax:Guilin, Flavoquine: Aven-
tis)
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg once daily for 3 days
All doses supervized
Outcomes 1. Parasitological failure on days 42 and 28, PCR adjusted and unadjusted
2. Parasitological failure with P. vivax on days 42 and 28
3. Gametocyte carriage after treatment
4. Anaemia at day 0, 7, 28
5. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
Notes Country: Indonesia
Setting: Rural clinics
Transmission: Unstable
Resistance: Chloroquine and SP resistance
Dates: Jul 2005 to Dec 2005
Funding: Wellcome Trust - National Health and Medical Research Council
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’A randomisation list was generated in
blocks of 20 by an independent statistician’
Allocation concealment? Yes ’Treatment allocation concealed in an
opaque, sealed envelope that was opened
once the patient had been enrolled’
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Hasugian 2005 IDN (Continued)
Blinding?
All outcomes
No An open-label trial. ’All slides were read by
a certifiedmicroscopist who was blinded to
treatment allocation’.
Incomplete outcome data addressed?
All outcomes
No The primary outcomedata are unpublished
data including only participants with P. fal-
ciparum mono or co-infection at baseline.
High losses to follow up in both groups
at day 42 (21% DHA-P vs 24.5 % AL6),
moderate at day 28 (16.6%DHA-P vs 18.8
% AL6).
Free of selective reporting? Yes All WHO outcomes reported. Day 42
outcomes may underestimate failure with
DHA-P due to its long half-life.
Free of other bias? Yes No other sources of bias identified
Hutagalung 2002 THA
Methods Trial design: An open-label randomized controlled trial
Follow up: Examination and malaria film daily until fever and parasites cleared then
weekly to day 42 or any other day they became unwell
P. vivax during follow up was treated with CQ and continued in follow up
Adverse event monitoring: At each visit a questionnaire on adverse events was completed
Participants Number: 490 randomized
Inclusion criteria: Weight > 10 kg, slide confirmed P. falciparum, informed consent
Exclusion criteria: Pregnancy, clinical or laboratory signs of severe illness and/or severe
and complicated malaria severe malaria, treatment with mefloquine in previous 63 days
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• < 15 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
• Plus glass of chocolate milk with each dose
2. Artesunate plus mefloquine, loose combination (Artesunate: Guilan, Lariam: Hoff-
man-La Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 15 mg/kg on day 1 and 10 mg/kg on day 2
All doses supervized
Outcomes 1. Cure rates at days 42 and 28, PCR adjusted and unadjusted
2. P. vivax parasitaemia during follow up
3. Gametocyte development
4. Mean decrease in HCT by day 7
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Hutagalung 2002 THA (Continued)
5. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
3. Gametocyte clearance
Notes Country: Thailand
Setting: Malaria clinics of the Shoklo Malaria Research Unit
Transmission: Low and unstable
Resistance: Multiple-drug resistance
Dates: July 2001 to June 2002
Funding: Wellcome Trust of Great Britain
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Computerized randomisation was in
blocks of ten’
Allocation concealment? No None described
Blinding?
All outcomes
No An open label trial. No comment on blind-
ing of laboratory staff.
Incomplete outcome data addressed?
All outcomes
Yes Losses to follow up balanced and low in
both groups (8% AL6 vs 7% AS+MQ)
Free of selective reporting? Yes TheWHO recommends 63 days follow up
in studies of AS+MQ. Day 42 outcomes
may under estimate treatment failure with
AS+MQ.
Free of other bias? Yes No other sources of bias identified
Janssens 2003 KHM
Methods Trial design: An open label randomized controlled trial
Follow up: Monitored daily until fever and parasites cleared then weekly to day 63.
Temperature, symptom questionnaire, malaria film, and haematocrit at each visit.
Adverse event monitoring: An adverse event defined as any new sign or symptom ap-
pearing after treatment started. At each visit a symptom questionnaire was completed.
Participants Number: 464 randomized
Inclusion criteria: Age > 1 yr, axillary temp > 37.5 ºC or history of fever, signs and
symptoms of uncomplicated malaria, P. falciparum mono or mixed infections, written
informed consent
Exclusion criteria: Pregnancy or lactation, signs or symptoms of severe malaria, > 4% red
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blood cells parasitized, a history of convulsions or neuropsychiatric disorder, treatment
with mefloquine in the past 60 days
Interventions 1. Dihydroartemisinin-piperaquine, fixed dose combination, 40 mg/320 mg tablets
(Artekin: Holleykin)
• Adult total dose: 6 mg/kg DHA and 48 mg/kg P in 4 divided doses, given at 0, 8,
24, and 48 hours
• Children total dose: 6.4 mg/kg DHA + 51.2 mg/kg P in 4 divided doses, given at
0, 8, 24, 48 hours
2. Artesunate plus mefloquine, loose combination (Artesunate: Guilin, Mefloquine:
Mepha)
• Adults: 100 mg AS plus 500 mg MQ twice daily on day 0, then 200 mg AS once
daily on day 1 and day 2
• Children: AS 4 mg/kg once daily for 3 days plus 25 mg/kg MQ split into 2 doses
on day 0
All doses supervized
Outcomes 1. Cure rate at days 63, 42, and 28, PCR adjusted and unadjusted
2. P. vivax parasitaemia during follow up
3. Mean haematocrit at day 0 and 63
4. Adverse effects
Not included in the review:
1. Fever clearance
2. Parasite clearance
Notes Country: Cambodia
Setting: Rural health centres and outreach malaria clinics
Transmission: Low and seasonal
Resistance: Multiple-drug resistance
Dates: Oct 2002 to March 2003
Funding: Médecins sans Frontières
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Computer generated randomisation
(STATA version 8, Statacorp)’
Allocation concealment? Unclear ’Treatment allocations were concealed in
sealed envelopes’. No further details.
Blinding?
All outcomes
No An open-label trial. No comment on blind-
ing of laboratory staff.
Incomplete outcome data addressed?
All outcomes
Yes Losses to follow up balanced and low
in both groups (9.3% DHA-P vs 10%
AS+MQ)
64Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Janssens 2003 KHM (Continued)
Free of selective reporting? Yes All WHO outcomes reported
Free of other bias? Yes No other sources of bias identified
Kamya 2006 UGA
Methods Trial design: A single blind (outcome assessors)randomized controlled trial
Follow up: Standardized history and examination and malaria film on days 0, 1, 2,
3, 7, 14, 21, 28, 35, 42 and any other day they felt unwell. Haemoglobin measured
at day 0 and day 42 or day of failure. Anaemia was treated with ferrous sulphate and
anthelminthics according to IMCI guidelines.
Adverse event monitoring: Assessed for any new or worsening event at each visit. An
adverse event defined as any untoward medical occurrence, irrespective of its suspected
relationship to the study medications.
Participants Number: 509 randomized
Inclusion criteria: Age 6 m to 10 yrs, weight > 5 kg, axillary temp > 37.5 ºC or history of
fever in the past 24 hours, P. falciparum mono-infection 2000 to 200,000/µl, informed
consent
Exclusion criteria: Danger signs or signs of severe malaria, evidence of concomitant
febrile illness, history of serious side effects to study medication
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• 5 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
2. Dihydroartemisinin-piperaquine, fixed dose combination, 40 mg/320 mg tablets (
Duocotexin: HolleyPharm)
• Total dose: DHA 6.4 mg/kg + P 51.2 mg/kg in 3 divided doses, given once daily
for 3 days
• Plus placebo tablet in the evening to simulate twice daily dosing
All doses supervized. All participants received a glass of milk after each dose
Outcomes 1. Risk of treatment failure at day 42, PCR adjusted and unadjusted
2. Non falciparum species during follow up
3. Gametocyte development during follow up
4. Mean increase in haemoglobin at last day of follow up
5. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
Notes Country: Uganda
Setting: Rural health centre
Transmission: Perennial holoendemic malaria with very high transmission intensity
Resistance: Not reported
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Kamya 2006 UGA (Continued)
Dates: Mar 2006 to July 2006
Funding:USCentres forDisease Control,MalariaConsortiumDrugman,DFID,DHA-
P supplied by HolleyPharm
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’A randomisation list was computer gener-
ated by an off-site investigator’
Allocation concealment? Yes ’Sequentially numbered, sealed envelopes
containing the treatment group assign-
ments were prepared from the randomisa-
tion list’
Blinding?
All outcomes
Yes ’Study physicians and laboratory person-
nel involved in assessing outcomes were
blinded to treatment assignments’
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up in both groups
(0.9%AL6 vs 0.9%DHA-P). A large num-
ber of participants were excluded after ran-
domization for failing tomeet the entry cri-
teria.
Free of selective reporting? Yes All WHO outcomes reported. Day 42
outcomes may underestimate failure with
DHA-P due to its long half-life.
Free of other bias? Yes No other sources of bias identified
Karema 2004 RWA
Methods Trial design: A 3-arm open label randomized controlled trial
Follow up: History, clinical signs and symptoms, and malaria film on days 0, 1, 2, 3, 7,
14, 21, and 28 and any other day they felt unwell. PCV measured at days 0 and 14.
Adverse eventmonitoring: An adverse event defined as any unfavourable and unintended
sign associated temporally with the use of the drug administered. Differential WBC
count (and liver function tests at 1 site only) assessed at days 0 and 14.
Participants Number: 762 randomized
Inclusion criteria: Age 12 to 59 months, weight > 10 kg, axillary temp > 37.5 ºC or
history of fever in the preceding 24 hrs, P. falciparummono-infection 2000 to 200,000/
µl
Exclusion criteria: Severe malaria, any other concomitant illness or underlying disease,
known allergy to study drugs, clear history of adequate antimalarial treatment in the
previous 72 hours, PCV < 15%
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Karema 2004 RWA (Continued)
Interventions 1. Dihydroartemisinin-piperaquine, fixed dose combination, 40 mg/320 mg tablets
(Artekin: Holleypharm)
• Total dose: DHA 4.8 to 9.3 mg/kg + P 38.4 to 73.8 mg/kg in 3 divided doses,
given once daily for 3 days
2. Artesunate plus amodiaquine, loose combination (Arsumax: Sanofi)
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg once daily for 3 days
3. Amodiaquine plus sulfadoxine-pyrimethamine, loose combination.
• AQ 10 mg/kg once daily for 3 days
• SP 25/1.25 mg/kg once on the first day
All doses supervized
Outcomes 1. ACPR at day 28, PCR adjusted and unadjusted
2. Gametocyte prevalence during follow up
3. Mean PCV at baseline and day 14
4. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
Notes Country: Rwanda
Setting: Peri-urban and rural health centres
Transmission: Not reported
Resistance: Not reported
Dates: Oct 2003 to Apr 2004
Funding: Belgian Development Co-operation in collaboration with the Prince Leopold
Institute of Tropical Medicine. DHA-P provided by Holleypharm
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Randomly allocated in blocks of 15’,
computer generated sequence (information
from author)
Allocation concealment? Unclear ’Allocation of treatment was concealed un-
til final recruitment’. No further details
Blinding?
All outcomes
No An open-label trial. ’Laboratory techni-
cians reading malaria slides did not know
the treatment received’
Incomplete outcome data addressed?
All outcomes
Yes Very low losses to follow up in all groups
(0.8% DHA-P vs 0.4% AS+AQ vs 1.2%
AQ+SP)
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Free of selective reporting? Yes All WHO outcomes reported. Day 28
outcomes may underestimate failure with
DHA-P due to its long half-life.
Free of other bias? Yes No other sources of bias identified
Karunajeewa 2007 PNG
Methods Trial design: A 4-arm open label randomized controlled trial
Follow up: Standardized follow up including temperature and malaria film on days 0, 1,
2, 3, 7, 14, 28, and 42. Drug levels assayed on day 7.
Adverse event monitoring: None described
Participants Number: 372 randomized to included treatment arms
Inclusion criteria: Age 0.5 to 5 years, axillary temp > 37.5 ºC or history of fever in the
preceding 24 hrs, > 1000/µl asexual P. falciparum or > 250/µl asexual P. vivax, P. ovale or
P. malariae, informed consent
Exclusion criteria: Features of severe malaria, evidence of another infection or coexisting
condition including malnutrition, intake of study drug in previous 14 days
Interventions 1. Artesunate plus sulfadoxine-pyrimethamine, loose combination (Sanofi-Aventis,
Roche)
• AS 4 mg/kg once daily for 3 days
• SP 25/1.25 mg/kg once on the first day
2.Dihydroartemisinin-piperaquine, fixed dose combination, 40mg/320mg tablets (Bei-
jing Holley-Cotec)
• DHA 2.5 mg/kg once daily for 3 days
• P 20 mg/kg once daily for 3 days
3. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Novartis),
given with milk
• A 1.7 mg/kg twice daily for 3 days
• L 10 mg/kg twice daily for 3 day
All doses supervized except the evening dose of AL6
Outcomes 1. ACPR (P. falciparum) at days 28 and 42, PCR adjusted and unadjusted
2. ACPR (P. vivax) at day 42
3. Gametocyte prevalence during follow up
4. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
3. Drug levels day 7
Notes Country: Papua New Guinea
Setting: Health centres
Transmission: Holoendemic
Resistance: CQ and SP
Dates: Apr 2005 to Jul 2007
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Karunajeewa 2007 PNG (Continued)
Funding: WHOWestern Pacific Region, Rotary against Malaria in Papua New Guinea,
National Health and Medical Research Council of Australia
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Computer-generated randomised assign-
ment with blocks of 24 for each site’
Allocation concealment? No Not described
Blinding?
All outcomes
No An open label trial. Microscopists were un-
aware of treatment assignments.
Incomplete outcome data addressed?
All outcomes
Yes Moderate losses to follow up in all groups
(11.5%AS+SP vs 13.0%DHA-P vs 14.2%
AL6)
Free of selective reporting? Yes All WHO outcomes reported. Day 42
outcomes may underestimate failure with
DHA-P due to its long half-life.
Free of other bias? Yes No other sources of bias identified
Kayentao 2006 MLI
Methods Trial design: An open label 3-arm randomized controlled trial
Follow up: Assessment and malaria film on days 0, 1, 2, 7, 14, and 28. Haemoglobin on
days 0, 14, 28 or day of failure.
Adverse event monitoring: None described
Participants Number: 397 randomized
Inclusion criteria: Age 6 to 59 months, axillary temp > 37.5 ºC, P. falciparum mono-
infection of 2000 to 200,000/µl, informed consent
Exclusion criteria: Danger signs, evidence of another febrile illness, haemoglobin < 5
g/dl
Interventions 1. Artesunate plus amodiaquine, loose combination
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg once daily for 3 days
2. Artesunate plus sulfadoxine-pyrimethamine, loose combination
• AS 4 mg/kg once daily for 3 days
• SP 25/1.25 mg/kg once on the first day
3. Amodiaquine plus sulfadoxine-pyrimethamine, loose combination
• AQ 10 mg/kg once daily for 3 days
• SP 25/1.25 mg/kg once on the first day
All doses supervized
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Kayentao 2006 MLI (Continued)
Outcomes 1. ACPR at days 28, PCR adjusted and unadjusted
2. Mean haemoglobin at days 14 and 28
3. Gametocyte carriage during follow up
Not included in this review:
1. Proportion with fever days 0, 1, 2, 3
2. Proportion parasitaemic days 0, 1, 2, 3
Notes Country: Mali
Setting: Rural health centre
Transmission: Seasonal with peak in October
Resistance: CQ
Dates: Jul 2005 to Jan 2006
Funding:USCenters forDisease Control and Prevention,Malaria and ResearchTraining
Center, University of Bamako
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Block randomisation (block size of 20)’.
No further details.
Allocation concealment? No None described
Blinding?
All outcomes
No Described as ’open-label’. Patients were not
informed of the drug received but no place-
bos were used. Microscopists were unaware
of treatment allocation.
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up in all groups (1.5%
AS+AQ vs 1.5% AS+SP vs 1.5% AQ+SP)
Free of selective reporting? Yes All WHO outcomes reported
Free of other bias? Yes No other sources of bias identified
Kobbe 2007 GHA
Methods Trial design: An open label randomized controlled trial
Follow up: Standardized history and examination, malaria film and haemoglobin on
days 0, 3, 7, 14, and 28 and any other day they felt unwell
Adverse event monitoring: ’The comparative tolerability was assessed by the risk of oc-
currence of an adverse event’. For each adverse event causality was assessed as recom-
mended by the WHO.
Participants Number: 246 randomized
Inclusion criteria: Age 6 to 59 months, axillary temp > 37.5 ºC or history of fever in the
preceding 24 hrs, P. falciparum mono-infection 2000 to 200,000/µl, informed consent
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Kobbe 2007 GHA (Continued)
Exclusion criteria: Danger signs or signs of severe malaria, any other severe underlying
disease, severe malnutrition, antibiotics or adequate antimalarials in the previous 7 days,
a history of hypersensitivity to study drugs, unable to tolerate oral treatment
Interventions 1. Artesunate plus amodiaquine, co-blister combination 50 mg AS/153 mg AQ, (Arsu-
cam: Sanofi-Aventis)
• 5 to 10 kg AS 1/2 tablet + AQ 1/2 tablet once daily for 3 days
• 10 to 21 kg AS 1 tablet + AQ 1 tablet once daily for 3 days
• 21 to 40 kg AS 2 tablets + AQ 2 tablets once daily for 3 days
2. Artemether-lumefantrine, fixed dose combination 20/120 mg (Coartem: Novartis)
• 5 to 15 kg 1 tablet twice daily for 3 days
• 15 to 25 kg 2 tablets twice daily for 3 days
• 25 to 35 kg 3 tablets twice daily for 3 days
All doses supervized
Outcomes 1. ACPR at day 28, PCR adjusted and unadjusted
2. Haematological recovery at day 28
3. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
3. Parental acceptance of drug therapy
Notes Country: Ghana
Setting: District Hospital
Transmission: Holoendemic with seasonal peaks
Resistance: CQ
Dates: Oct 2006 to Sept 2007
Funding: Vereinigung der Freunde des Tropeninstituts Hamburg E.V., German Aca-
demic Exchange Service. Drugs supplied free of charge by Novartis and Sanofi-Aventis
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Computer generated list with randomisa-
tion in blocks of ten’
Allocation concealment? Yes ’Children received the first dose of the in-
dividually allocated treatment (in sealed,
numbered, opaque envelopes)’
Blinding?
All outcomes
No An open label trial. 10% of malaria slides
were cross-checked by a blinded micro-
scopist.
Incomplete outcome data addressed?
All outcomes
No Moderate losses to followup in both groups
(14% AL6 vs 16% AS+AQ)
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Free of selective reporting? Yes All WHO outcomes reported
Free of other bias? Yes No other sources of bias identified
Koram 2003 GHA
Methods Trial design: A 4-arm, open-label randomized controlled trial
Follow up: Examination, symptoms recorded, temperature and pulse and malaria film
on days 0, 1, 2, 3, 7, 14, 21 and 28 and any other day they felt unwell. Full blood count
and haemoglobin measured at days 14 and 28.
Adverse event monitoring: None
Participants Number: 105 randomized into included treatment arms
Inclusion criteria: Age 6 to 59 months, signs and symptoms of uncomplicated malaria
including axillary temp > 37.5 ºC, P. falciparummono-infection of 2000 to 200,000/µl,
informed consent
Exclusion criteria: Signs and symptoms of severe malaria, other diseases requiring drugs
with antimalarial or antihistaminic activities, Hb < 5 g/dl
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• Twice daily for 3 days based on weight
2. Artesunate plus amodiaquine, loose combination
• AS 4 mg/kg/day for 3 days
• AQ 10 mg/kg on days 0 and 1 and 5 mg/kg on day 2
All doses supervized
Outcomes 1. ACPR at day 28, PCR adjusted and unadjusted (excluded from primary analysis
due to baseline differences)
2. Gametocyte carriage on days 0, 7, and 14
3. Mean haemoglobin on days 0, 14, and 28
Not included in the review:
1. Fever clearance time
2. Parasite clearance time
Notes Country: Ghana
Setting: Hohoe District Hospital and Navrongo War Memorial Hospital
Transmission: High transmission and markedly seasonal
Resistance: CQ and SP resistance
Dates: June 2003 to Aug 2003
Funding: Multilateral Initiative on Malaria, UNICEF/UNDP/World Bank/WHO Spe-
cial Program for Research & Training in Tropical Diseases
Risk of bias
Item Authors’ judgement Description
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Adequate sequence generation? Yes ’Computer generated random list based on
a simple random selection procedure’
Allocation concealment? No None described
Blinding?
All outcomes
No An open-label trial. No comment on blind-
ing of laboratory staff
Incomplete outcome data addressed?
All outcomes
No ’Patients who showed signs/symptoms of
severe malaria, had serious adverse events
or required blood transfusion were with-
drawn from the study’. These events after
enrolment would represent treatment fail-
ure and should not be withdrawn.
Free of selective reporting? Yes TheWHO recommends 42 days follow up
in studies of AL6. Day 28 outcomes may
under estimate treatment failure with AL6.
Free of other bias? No Participants in the AL6 group were signif-
icantly older and had a higher Hb at base-
line. This is due to differing inclusion cri-
teria for the 2 groups and is likely to affect
the result.
Lefevre 1999 THA
Methods Trial design: An open-label clinical and pharmacokinetic randomized controlled trial
Follow up: Monitored 3 times daily until parasites and fever cleared. Then follow up at
days 1, 2, 3, 7, 14, 21, and 28 for temp and malaria film.
P. vivax during follow up was treated with CQ and primaquine and continued in follow
up
Adverse event monitoring: Assessed at each visit. ECG monitoring and laboratory tests
(including FBC liver and renal function tests) at baseline and each day of follow up.
Participants Number: 219 randomized
Inclusion criteria: Age > 12 yrs, weight > 35 kg, microscopically confirmed P. falciparum,
informed consent
Exclusion criteria: Signs or symptoms of severe malaria, heart disease or significant ECG
abnormalities, psychiatric disorders, severe renal or hepatic impairment, history of drug
hypersensitivity or allergy
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• 4 tablets twice daily for 3 days
2. Artesunate plus mefloquine, loose combination (Artesunate: Guilan, Lariam: Hoff-
man-La Roche)
• AS 4 mg/kg once daily for 3 days
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• MQ 15 mg/kg on day 1 and 10 mg/kg on day 2
All doses supervized
Outcomes 1. Cure rate at day 28 PCR adjusted and unadjusted
2. P. vivax parasitaemia during follow up
3. Gametocyte development
4. Mean Hb at days 0 and 28
5. Adverse events
Not included in the review:
1. Fever clearance time
2. Parasite clearance time
Notes Country: Thailand
Setting: Bangkok Hospital for Tropical Diseases
Transmission: Low transmission
Resistance: Multiple-drug resistance
Dates: Sept 1998 to Jan 1999
Funding: Novartis Pharma AG
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Randomized in a ratio of 3:1’. No further
details given.
Allocation concealment? No None described
Blinding?
All outcomes
No An open-label trial. No comment on blind-
ing of laboratory staff
Incomplete outcome data addressed?
All outcomes
Yes Losses to follow up were low and propor-
tional in the 2 groups (5.4% AL6 vs 3.6%
AS+MQ)
Free of selective reporting? Yes The WHO recommends 42 days follow
up in studies of AL6 and 63 days with
AS+MQ. Day 28 outcomes may overesti-
mate the efficacy of AL6 and AS+MQ.
Free of other bias? No It is stated that participants whose condi-
tion deteriorated were to be excluded from
the trial. There is no flow chart so it is
unclear how many participants this repre-
sented, andwhether these should have been
classified as early treatment failures.
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Martensson 2003 TZA
Methods Trial design: A randomized controlled trial
Follow up: Clinical assessment, malaria film, and haemoglobin measurement on days 0,
1, 2, 3, 7, 14, 21, 28, 35, and 42
Adverse event monitoring: Possible adverse events recorded at each visit. Differential
white cell counts at days 0, 3, 7, 14, 21, and 28. An adverse event was defined as any
undesirable medical occurrence regardless of wether it was related to the treatments.
Participants Number: 408 randomized
Inclusion criteria: Age 6 to 59 months and weight > 6 kg for AS+AQ group, 9 to 59
months and > 9 kg for AL6 group, axillary temp > 37.5 ºC or history of fever in previous
24 hrs, P. falciparum parasitaemia 2000 to 200,000/µl
Exclusion criteria: Symptoms and signs of severe malaria, any danger sign, serious un-
derlying disease, Hb < 5 g/dl, known allergy to study drugs
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• 9 to 15 kg 1 tablet twice daily for 3 days
• 15 to 25 kg 2 tablets twice daily for 3 days
2. Artesunate plus amodiaquine, loose combination (Plasmotrim: Mepha, Flavoquin:
Roussel)
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg once daily for 3 days
All doses supervized
Outcomes 1. Cure rate at days 28 and 42, PCR adjusted and unadjusted (excluded from
primary analysis due to baseline differences)
2. Gametocyte carriage on days 0 and 7
3. Mean haemoglobin on days 0 and 42
4. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
Notes Country: Zanzibar, Tanzania
Setting: Outpatient departments in densely populated rural areas
Transmission: Holoendemic
Resistance: Not reported
Dates: Nov 2002 to Feb 2003
Funding: UNDP/World Bank/WHO Special Program for Research & Training in Trop-
ical Diseases, SwedishDevelopment Co-operation AgencyDepartment for ResearchCo-
operation, European 5th Framework Project
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as ’randomized’ but no details
given
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Allocation concealment? No None described
Blinding?
All outcomes
No No blinding is described. 10% of malaria
films were cross-checked by an indepen-
daent examiner in a central laboratory
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up (1.5% AL6 vs 1%
AS+AQ)
Free of selective reporting? Yes All WHO outcomes reported
Free of other bias? No Due to different inclusion criteria for the 2
groups, participants in the AL6 groupwere,
on average, older and heavier at baseline
Mayxay 2003 LAO
Methods Trial design: A 3-arm, open label randomized controlled trial
Follow up: Temperature was measured every 6 hours and patient reviewed daily until
fever and parasites cleared then weekly until day 42 or any time they felt unwell. At each
visit a malaria film and haematocrit measurement was taken.
Adverse event monitoring: Potential side effects were recorded at each visit
Participants Number: 220 randomized into included treatment arms
Inclusion criteria: Age > 1 yr, axillary temp > 37.5 ºC or history of fever in previous 3
days, P. falciparum parasitaemia 5000 to 200,000/µl, likely to stay in hospital until fever
cleared and complete 42 days follow up, informed consent
Exclusion criteria: Pregnancy or lactation, signs of severe malaria, history of allergy or
contraindication to the study drugs, a full course of antimalarials in the previous 3 days
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• < 15 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
• Advised to take with fatty food
2. Artesunate plus mefloquine, loose combination (artesunate: Guilan, Lariam: Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 15 mg/kg on day 1 and 10 mg/kg on day 2
All doses supervized
Outcomes 1. Cure rates at day 42, PCR adjusted and unadjusted
2. P. vivax parasitaemia during follow up
3. Gametocyte development
4. Mean haematocrit after treatment
5. Adverse events
Not included in the review:
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Mayxay 2003 LAO (Continued)
1. Fever clearance time
2. Parasite clearance time
Notes Country: Lao People’s Democratic Republic
Setting: District clinic
Transmission: Not stated
Resistance: CQ and SP resistance
Dates: June to Oct in 2002 and 2003
Funding: Wellcome Trust of Great Britain
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Randomized in blocks of 15’. No further
details given.
Allocation concealment? Yes ’The treatment choice was kept in a sealed
opaque envelope that was opened only after
the decision to recruit had been made’
Blinding?
All outcomes
No An open label trial. No comment on blind-
ing of laboratory staff.
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up in both groups
(2.7% AL6 vs 1.8% AS+MQ)
Free of selective reporting? Yes TheWHO recommends 63 days follow up
in studies of AS+MQ. Day 42 outcomes
may underestimate treatment failure with
AS+MQ.
Free of other bias? Yes No other sources of bias identified
Mayxay 2004 LAO
Methods Trial design: An open label randomized controlled trial
Follow up: Temperature was measured every 6 hours and patient reviewed daily until
fever and parasites cleared then weekly until day 42 or anytime they felt unwell. At each
visit a malaria film and haematocrit measurement was taken.
Adverse event monitoring: Potential adverse events were recorded at each visit
Participants Number: 220 randomized
Inclusion criteria: Age > 1 year, axillary temp > 37.5 ºC or history of fever in the previous
3 days, P. falciparum mono-infection 1000 to 200,00/µl, were likely to stay in hospital
until parasite clearance and complete 42 days follow up, informed consent
Exclusion criteria: Pregnancy or lactation, signs of severe malaria, antimalarials in the
previous 3 days, contraindications to the study drugs
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Mayxay 2004 LAO (Continued)
Interventions 1. Dihydroartemisinin-piperaquine, fixed dose combination, 40 mg/320 mg tablets
(Artekin: Holleykin)
• Total dose: DHA 6.3 mg/kg + P 50.4 mg/kg in 3 divided doses, given once daily
for 3 days
2. Artesunate plus mefloquine, loose combination (Artesunate: Guilin, Lariam: Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 15 mg base/kg on day 1 and 10 mg base/kg on day 2
All doses supervized
Outcomes 1. Cure rate at day 42, PCR adjusted and unadjusted
2. P. vivax during follow up
3. Adverse events
Not included in the review:
1. Fever clearance time
2. Parasite clearance time
3. Gametocyte carriage after treatment
Notes Country: Lao People’s Democratic Republic (Laos)
Setting: District clinic
Transmission: Not reported
Resistance: Not reported
Dates: May 2004 to Sept 2004
Funding: Western Pacific Regional office of WHO, Wellcome Trust of Great Britain,
Artekin provided by Holleykin Pharmaceuticals
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Randomized in blocks of 10’. No further
details given.
Allocation concealment? Yes ’The treatment choice was kept in a sealed
opaque envelope, which was opened only
after the decision to recruit’
Blinding?
All outcomes
No An open-label trial. No comment on blind-
ing of laboratory staff.
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up in both groups
(3.6% DHA-P vs 1.8% AS+MQ)
Free of selective reporting? Yes TheWHO recommends 63 days follow up
in studies of AS+MQ. Day 42 outcomes
are likely to overestimate the efficacy of the
2 drugs.
Free of other bias? Yes No other sources of bias identified
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Menard 2006 MDG
Methods Trial design: A 5-arm single blind (outcome assessors)randomized controlled trial
Follow up: Patients returned for malaria films on days 0, 1, 2, 3, 7, 14, 21, 28, and any
other day they felt ill. Haemoglobin was assessed on days 0 and 28.
Adverse event monitoring: Not described
Participants Number: 166 randomized to included treatment arms
Inclusion criteria: Age 6 months to 15 yrs, weight > 5 kg, axillary temp > 37.5 ºC, P.
falciparum mono-infection 1000 to 200,000/µl, informed consent
Exclusion criteria: Danger signs, severe or complicated malaria, febrile conditions other
than malaria, severe malnutrition, severe anaemia (Hb < 5 g/dl), development of con-
comitant disease which could interfere with study outcome, known hypersensitivity to
the study drugs, repeated vomiting of the first dose
Interventions 1. Artesunate plus amodiaquine
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg once daily for 3 days
2. Amodiaquine plus sulfadoxine-pyrimethamine, loose combination
• AQ 10 mg/kg once daily for 3 days
• SP 25/1.25 mg/kg once on the first day
All doses supervized
Outcomes 1. ACPR at day 28, PCR adjusted and unadjusted
2. Gametocyte carriage at days 0, 7, 14, 21, and 28
3. Mean increase in haemoglobin by day 28
4. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
Notes Country: Madagascar
Setting: Primary health centres
Transmission: Low and predominantly seasonal
Resistance: CQ resistance
Dates: Feb 2006 to June 2006
Funding: Natixis, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the
IAEA project
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Randomization was in blocks of 5’. Draw-
ing numbered papers from a box (addi-
tional detail from author).
Allocation concealment? Yes ’Treatment regimens were allocated by an
independent individual not involved in the
analysis of the study’
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Menard 2006 MDG (Continued)
Blinding?
All outcomes
Yes ’All other study personnel were blinded
to the treatment assignments, and patients
not informed of their treatment regimen’
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up in both groups
(8.4% AS+AQ vs 4.8% AQ+SP)
Free of selective reporting? Yes All WHO outcomes reported
Free of other bias? Yes No other sources of bias identified
Mens 2007 KEN
Methods Trial design: An open label randomized controlled trial
Follow up: Malaria film and haemoglobin level on days 0, 1, 2, 3, 7, 14, and 28, plus
QT-NASBA for detection of sub-microscopic gametocytaemia
Adverse event monitoring: Adverse events were recorded at each visit in the case record
form. An adverse event defined as any unfavourable and unintended sign.
Participants Number: 146 randomized
Inclusion criteria: Age 6 months to 12 years, axillary temp > 37.5 ºC or history of fever,
P. falciparum mono-infection 1000 to 200,000/µl, informed consent
Exclusion criteria: Severe malaria, any other underlying illness
Interventions 1. Dihydroartemisinin-piperaquine, fixed dose combination, 20 mg/160 mg tablets (
Sigma-Tau)
• 4 to 7 kg 1/2 tablet once daily for 3 days
• 7 to 13 kg 1 tablet once daily for 3 days
• 13 to 24 kg 2 tablets once daily for 3 days
• 24 to 35 kg 4 tablets once daily for 3 days
2. Artemether-lumefantrine, fixed dose combination, 20/120 mg tablets (Novartis)
• 5 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
All doses supervized and given with a glass of milk
Outcomes 1. Recurrent parasitaemia at day 28, PCR adjusted and unadjusted
2. Gametocyte prevalence during follow up
3. Mean haemoglobin at day 28
4. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
Notes Country: Kenya
Setting: Health centre
Transmission: High transmission
Resistance: Not reported
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Mens 2007 KEN (Continued)
Dates: Apr 2007 to July 2007
Funding: The Knowledge and Innovation Fund, Koninklijk Instituut voor de Tropen/
Royal Tropical Institute. DHA-P provided free of charge by Sigma-Tau.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’A computer generated randomisation list’
Allocation concealment? No None described
Blinding?
All outcomes
No Microscopists were blinded to treatment al-
location. No other blinding described.
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up in both groups
(8.2% DHA-P vs 8.2% AL6)
Free of selective reporting? Yes TheWHO recommends 42 days follow up
in studies of AL6. Day 28 outcomes may
underestimate treatment failure with AL6
and DHA-P.
Free of other bias? Yes No other sources of bias identified
Mukhtar 2005 SDN
Methods Trial design: A randomized controlled trial
Follow up: On days 0, 1, 2, 3, 7, 14, 21, and 28. A malaria film taken at each visit
Adverse event monitoring: None described
Participants Number: 160 randomized
Inclusion criteria: All age groups, as per WHO protocol 2003
Exclusion criteria: As per WHO protocol 2003
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• Dosing details not given
2. Artesunate plus sulfadoxine-pyrimethamine, loose combination
• Dosing details not given
Only first dose of each day was supervized
Outcomes 1. ACPR at day 28, PCR adjusted and unadjusted
Notes Country: Sudan
Setting: 3 villages in eastern Sudan
Transmission: Low endemicity
Resistance: CQ and SP resistance
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Mukhtar 2005 SDN (Continued)
Dates: Oct to Dec in 2004 and 2005
Funding: National Centre for Research, drugs provided by Novartis, Amipharma and
the national Malaria Control Programme
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’A simple random technique of a hat draw’
Allocation concealment? No None described
Blinding?
All outcomes
No No details of blinding given. Malaria films
were read by 2 independent microscopists.
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up in both groups (0%
AL6 vs 3.8% AS+SP)
Free of selective reporting? Yes TheWHO recommends 42 days follow up
in studies of AL6. Day 28 outcomes may
under estimate the failure rate of AL6.
Free of other bias? No In general details of the trial were limited.
Very few baseline data given and no detail
on drug regimens.
Mutabingwa 2004 TZA
Methods Trial design: A 4-arm, randomized controlled trial
Follow up: Participants were assessed clinically and by malaria film on days 0, 14, and
28 or any other day they were unwell
Adverse event monitoring: Parents or guardians were asked to report on side effects,
tolerability, and usefulness of the treatment
Participants Number: 1541 randomized into included treatment arms
Inclusion criteria: Age 4 to 59 months, symptoms suggestive of malaria, P. falciparum >
2000/µl, able to take oral meds, able to attend clinic for follow up, informed consent
Exclusion criteria: Mixed infections, severe or complicated malaria, concomitant disease
masking assessment of the response to treatment, intake of antimalarials other than CQ
within the past 7 days, known hypersensitivity to any of the study drugs
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• 10 to 15 kg 1 tablet twice daily for 3 days
• 15 to 25 kg 2 tablets twice daily for 3 days
• 25 to 35 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
2. Artesunate plus amodiaquine, co-blistered/loose (Sanofi)
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Mutabingwa 2004 TZA (Continued)
• AS 4 mg/kg/day for 3 days
• AQ 10 mg/kg on days 0 and 1 and 5 mg/kg on day 2
3. Amodiaquine plus sulfadoxine-pyrimethamine, loose combination (Sanofi, Roche)
• AQ 10 mg/kg on days 0 and 1 and 5 mg/kg on day 2
• SP 25/1.25 mg/kg on day 0
All doses unsupervized
Outcomes 1. Parasitological failure at day 28 PCR unadjusted
2. Mean change in haemoglobin from baseline day 14
3. Adverse events
Not included in the review:
1. PCR corrected data (only conducted for 1 year of the trial and we were unable to
adequately extract attrition data)
2. Gametocytes during follow up (no baseline data)
Notes Country: Tanzania
Setting: Maternal and child health clinic
Transmission: Very high
Resistance: High level CQ and SP resistance
Dates: Sept 2002 to Oct 2004
Funding: GatesMalaria Partnership. AS+AQ donated by Sanofi. AL6 donated byWHO
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Randomization was done by computer
(Stata Version 6), with blocks of variable
sizes’
Allocation concealment? Yes ’Treatment allocations were put into
opaque, sealed and countersigned, sequen-
tially numbered envelopes’
Blinding?
All outcomes
No Malaria films were read by 2 different lab-
oratories unaware of treatment allocation.
No other blinding is reported.
Incomplete outcome data addressed?
All outcomes
Yes Losses to follow up were low in all groups
(6.5% AL6 vs 8.3% AS+AQ vs 8.7%
AQ+SP)
Free of selective reporting? No No baseline data is given on gametocytes.
PCR data is only given for 1 year of the
trial. It is not possible to calculate attrition
for this period.
Free of other bias? Yes No other sources of bias identified
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Owusu-Agyei 2006 GHA
Methods Trial design: A 3-arm, randomized controlled trial
Follow up: Participants were assessed for adverse events and by malaria film on days 0,
2, 3, 7, 14, and 28 or any other day they were unwell. Haemoglobin measured on days
1, 2, 3, 7, and 28. Anaemia was treated with iron according to national guidelines
Adverse event monitoring: Field workers visited their homes to solicit adverse events on
days 0, 2, 3, 7, 14, and 28
Participants Number: 355 randomized into included treatment arms
Inclusion criteria: Age 6 months to 10 yrs, weight > 5 kg, axillary temp > 37.5 ºC or
history of fever, parasitaemia 2000 to 200,000/µl, informed consent
Exclusion criteria: Danger signs, signs of severe malaria, concomitant febrile illness, Hb
< 7 g/dl
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• Details not given
2. Artesunate plus amodiaquine, co-blistered (Arsucam: Sanofi-Aventis)
• Details not given
All doses supervized for 3 days
Outcomes 1. Parasitological and clinical failure at day 28, PCR unadjusted and PCR adjusted
2. Gametocytaemia at day 7
3. Haemoglobin at day 28
4. Adverse events
Notes Country: Ghana
Setting: District hospital
Transmission: Perennial, high with a peak July to August
Resistance: Not stated
Dates: June 2005 to May 2006
Funding: Gates Malaria Partnership of the London School of Hygiene and Tropical
Medicine
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Randomization was done using Microsoft
Excel 2003 randomisation generator’
Allocation concealment? No None described
Blinding?
All outcomes
No An open label trial. No comment on blind-
ing of lab staff.
Incomplete outcome data addressed?
All outcomes
Yes Moderate losses to follow up but similar in
both groups (14% AL6 vs 15% AS+AQ)
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Owusu-Agyei 2006 GHA (Continued)
Free of selective reporting? Yes AllWHOoutcomes reported. Biochemical
monitoring is stated although this outcome
is not reported
Free of other bias? Yes No other sources of bias identified
Ratcliff 2005 IDN
Methods Trial design: An open-label randomized controlled trial
Follow up: A symptom questionnaire, physical examination, malaria film and
haemoglobin measurement daily until fever and parasites cleared then weekly to day 42
Adverse event monitoring: A symptom questionnaire at each visit
Participants Number: 774 randomized
Inclusion criteria: Weight >10 kg, fever or a history of fever in the preceding 48 hours,
slide confirmed malaria (P. falciparum, P. vivax or mixed infections)
Exclusion criteria: Pregnancy or lactation, danger signs or signs of severity, parasitaemia
> 4%, concomitant disease requiring hospital admission
Interventions 1. Dihydroartemisinin-piperaquine, fixed dose combination, 40 mg/320 mg tablets
(Artekin: Holleykin)
• Total dose: DHA 6.75 mg/kg + P 54 mg/kg in 3 divided doses, given once daily
for 3 days
2. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• 10 to 15 kg 1 tablet twice daily for 3 days
• 15 to 25 kg 2 tablets twice daily for 3 days
• 25 to 35 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
Only the first dose of each day was supervized. All participants advised to take each dose
with a biscuit or milk.
Outcomes 1. Parasitological failure at days 42 and 28, PCR adjusted and unadjusted
2. P. vivax during follow up
3. Gametocyte carriage after treatment
4. Anaemia during follow up
5. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
Notes Country: Indonesia
Setting: Rural outpatient clinics
Transmission: Unstable
Resistance: Multiple-drug resistance
Dates: Jul 2004 to Jun 2005
Funding: Wellcome Trust UK and National Health and Medical Research Council Aus-
tralia
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Ratcliff 2005 IDN (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’A randomisation list was generated in
blocks of 20 patients by an independent
statistician’
Allocation concealment? Yes ’With each treatment allocation concealed
in an opaque sealed envelope’. No further
details given.
Blinding?
All outcomes
No An open label trial. The microscopists were
blinded to treatment allocation.
Incomplete outcome data addressed?
All outcomes
No The primary outcomedata are unpublished
data including only participants with P.
falciparum mono or co-infection at base-
line. Losses to follow up were high in both
groups at day 42 (28.4%DHA-P vs 25.6%
AL6) and moderate at day 28 (19% DHA-
P vs 17.6% AL6).
Free of selective reporting? Yes All WHO outcomes reported. Day 42
outcomes may underestimate failure with
DHA-P due to its long half-life.
Free of other bias? Yes No other sources of bias identified
Sagara 2005b MLI
Methods Trial design: An open label randomized controlled trial
Follow up: Examination and malaria film on days 0, 1, 2, 3, 7, 14, 21, 28, and any day
they felt unwell. Haemoglobin on days 0, 14, and 28.
Adverse event monitoring: CBC, ALT, and creatinine on 20% of participants on days 0
and 14
Participants Number: 470 randomized
Inclusion criteria: Age > 1 yr, weight >10 kg, axillary temperature > 37.5 ºC, P.falciparum
mono-infection 2000 to 200,000, resident at study site, able to take oral medication,
informed consent
Exclusion criteria: Pregnancy, severe malaria, a serious underlying disease, an allergy to
1 or more study drugs, use of study drugs within 28 days
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• 5 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
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Sagara 2005b MLI (Continued)
• 25 to 34 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
2. Artesunate plus mefloquine, co-blistered (Artequin: Mepha)
• 10 to 14 kg AS 4 mg/kg and MQ 5 mg/kg once daily for 3 days
• 15 to 30 kg AS 100 mg and MQ 150 mg once daily for 3 days
• > 31 kg AS 200 mg and MQ 250 mg once daily for 3 days
All doses supervized
Outcomes 1. ACPR at day 28, PCR adjusted and unadjusted
2. Gametocyte carriage
3. Prevalence of anaemia on days 0, 28
4. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
Notes Country: Mali
Setting: Peri-urban
Transmission: Hyperendemic with highly seasonal transmission
Resistance: Not stated
Dates: Aug 2004 to Feb 2005
Funding: Pharmatech Inc (also donated AS+MQ), and Mepha Ltd.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’A bloc randomisation code with treatment
arm was computer generated by the study
statistician’
Allocation concealment? Yes ’Study codes were sealed in individual
opaque and sequentially numbered en-
velopes’
Blinding?
All outcomes
No An open label trial. Microscopists were
blinded to the treatment arm.
Incomplete outcome data addressed?
All outcomes
Yes Losses to followupwere low in both groups
(2.1% AS+MQ vs 1.7% AL6)
Free of selective reporting? Yes The WHO recommends 42 days follow
up in studies of AL6 and 63 days with
AS+MQ. Day 28 outcomes may overesti-
mate the efficacy of AL6 and AS+MQ.
Free of other bias? Yes No other sources of bias identified
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Smithuis 2004 MMR
Methods Trial design: A 4-arm open-label randomized controlled trial
Follow up: A symptom questionnaire, malaria film, and gametocyte count on days 0, 1,
2, 3, 7, 14, 21, 28, 35, and 42. Haemoglobin was measured on days 0 and 28.
Adverse event monitoring: A symptom questionnaire at each visit
Participants Number: 652 randomized
Inclusion criteria: Age > 1 year, axillary temperature > 37.5 ºC or history of fever in
the previous 48 hrs, P. falciparum mono-infection 500 to 100,000 parasites/µl or co-
infection with P. vivax, informed consent
Exclusion criteria: Pregnancy, signs of severe malaria, signs or symptoms of other diseases,
history of taking mefloquine in the previous 2 months or any other antimalarial in the
previous 48 hrs, history of psychiatric disease
Interventions 1. Dihydroartemisinin-piperaquine, fixed dose combination, 40 mg/320 mg tablets
(Artekin: Holleykin)
• Total dose: DHA 6.3 mg/kg + P 50.4 mg/kg in 3 divided doses, given once daily
for 3 days
• Supervized
2. Dihydroartemisinin-piperaquine, fixed dose combination, 40 mg/320 mg tablets
(Artekin: Holleykin)
• Total dose: DHA 6.3 mg/kg + P 50.4 mg/kg in 3 divided doses, given once daily
for 3 days
• Unsupervized
3. Artesunate plusmefloquine, loose combination (artesunate:Guilin, Lariam:Hoffman-
La Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 25 mg base/kg as a single dose on day 0
• Supervized
4. Artesunate plusmefloquine, loose combination (artesunate:Guilin, Lariam:Hoffman-
La Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 25 mg base/kg as a single dose on day 0
• Unsupervized
Outcomes 1. Failure Rate at days 42 and 28, 42 PCR unadjusted and PCR adjusted
2. P. vivax during follow up and median time to appearance
3. Gametocyte carriage at days 0, 7, 14, 21, and 28
4. Mean change in haemoglobin from day 0 to day 28
5. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
3. New gametocyte appearance at day 7 and day 14
Notes Country: Myanmar
Setting: Rural village tracts
Transmission: Seasonal with peaks in the monsoon season Nov to Jan and sometimes in
the early monsoon, May to June
Resistance: Very high rates of CQ and SP resistance
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Smithuis 2004 MMR (Continued)
Dates: Nov 2003 to Feb 2004
Funding: Médecins sans Frontières (Holland)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Unmarked and sealed envelopes, contain-
ing the treatment allocation were drawn
from a box
Allocation concealment? Unclear ’Unmarked and sealed envelopes’. No fur-
ther details given.
Blinding?
All outcomes
No An open label trial. No comment on blind-
ing of laboratory staff.
Incomplete outcome data addressed?
All outcomes
Yes Very low losses to follow up in both groups
Free of selective reporting? Yes TheWHO recommends 63 days follow up
in studies of AS+MQ. Day 42 outcomes
are likely to overestimate the efficacy of the
2 drugs.
Free of other bias? Yes No other sources of bias identified
Staedke 2003 UGA
Methods Trial design: An open label randomized controlled trial
Follow up: A standardized history and examination and malaria film on days 1, 2, 3, 7,
14, 21, and 28 or other times if they were unwell. Haemoglobin was measured on days
0, 7, and 28.
Adverse event monitoring: Assessed at each visit. Neurological assessment on days 0, 7,
14, and 28. Complete blood count, creatinine, and alanine transferase on days 0, 7, and
28.
Participants Number: 278 randomized into included treatment arms
Inclusion criteria: Age 6months to 10 yrs, tympanic temp > 38.0 ºC or febrile symptoms
in previous 48 hrs, P. falciparum mono-infection 500 to 200,000/µl, willingness to
participate in 28 day follow up, informed consent
Exclusion criteria: Danger signs, severe malaria, alternative diagnosis for febrile illness,
antifolate use in the previous 4 weeks, history of serious side effects to any of the study
drugs, severe anaemia (Hb < 5 g/dl)
Interventions 1. Amodiaquine plus sulfadoxine-pyrimethamine, loose combination
• AQ 10 mg/kg on days 0 and 1 and 5 mg/kg on day 2
• SP 25/1.25 mg/kg once on day 0
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Staedke 2003 UGA (Continued)
2. Artesunate plus amodiaquine
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg on days 0 and 1 and 5 mg/kg on day 2
All doses supervized. Meds crushed and mixed with chocolate to mask the colour and
taste.
Outcomes 1. Risk of treatment failure at day 28, PCR unadjusted
2. Gametocytes during follow up
3. Anaemia during follow up
4. Adverse events
Not included in the review:
1. Risk of treatment failure at day 28, PCR adjusted (only late clinical failures
underwent PCR testing)
2. Fever clearance
3. Parasite clearance
Notes Country: Uganda
Setting: Urban hospital
Transmission: Mesoendemic with peaks in the 2 rainy seasons
Resistance: CQ and SP resistance
Dates: Aug 2002 to July 2003
Funding: NIH and the Fogarty International Centre/NIH
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’An off-site investigator generated random-
ization codes with a computer for two age
groups using variable blocking’
Allocation concealment? Yes ’Sequentially numbered sealed envelopes
containing the treatment group assign-
ments were prepared from the randomiza-
tion lists’
Blinding?
All outcomes
Yes ’All study personnel (excluding study
nurse), including the doctors, were un-
aware of the treatment assignments’
Incomplete outcome data addressed?
All outcomes
Yes Losses to followupwere low in both groups
(3% AS+AQ vs 3.7% AQ+SP)
Free of selective reporting? Yes We were unable to use PCR adjusted data
as PCR was only performed on late clinical
failures, not on late parasitological failures
Free of other bias? Yes No other sources of bias identified
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Stohrer 2003 LAO
Methods Trial design: An open label randomized controlled trial
Follow up: A history, axillary temperature and malaria film on days 0, 1, 2, 3, 7, 14, 21,
28, and 42 or other times if they were unwell. Haemoglobin was measured on days 0
and 28
Participants experiencing P. vivax during follow up were withdrawn
Adverse event monitoring: Treatment emergent symptoms and signs were recorded on
days 0 to 3
Participants Number: 108 randomized
Inclusion criteria: Weight > 10 kg, axillary temperature > 37.5 ºC, P. falciparum mono-
infection 1000 to 100,000/µl, ability to attend follow up, informed consent
Exclusion criteria: Pregnancy or lactation, signs of severe or complicated malaria, severe
malnutrition, febrile diseases other than malaria, history of hypersensitivity reaction to
any of the study drugs
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• 10 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
2, Artesunate plus mefloquine, loose combination (Plasmotrim: Mepha, Mephaquine:
Mepha)
• AS 4 mg/kg once daily for 3 days
• MQ 15 mg/kg on day 1 and 10 mg/kg on day 2
All doses supervized
Outcomes 1. ACPR at day 42, PCR adjusted and unadjusted
2. P. vivax parasitaemia during follow up
3. Gametocyte carriage at day 7
4. Adverse events
Not included in the review:
1. Parasite clearance
Notes Country: Lao People’s Democratic Republic
Setting: Hospital and community based
Transmission: Perennial with peaks during the rainy season May to Oct
Resistance: CQ and SP resistance
Dates: Oct to Dec 2003
Funding: USAID, mefloquine and artesunate donated by Mepha, Wellcome Trust of
Great Britain
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Envelope randomisation’ in blocks of var-
ious sizes, no further details given
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Stohrer 2003 LAO (Continued)
Allocation concealment? Unclear ’A sealed envelope was opened which as-
signed patients to one of the two treatment
arms’. No further details given.
Blinding?
All outcomes
No An open label trial. No comment on blind-
ing of laboratory staff, quality control was
conducted by rechecking malaria films by
expert microscopists.
Incomplete outcome data addressed?
All outcomes
Yes Disproportionate losses to follow up
(11.3% AL6 vs 3.6% AS+MQ) but un-
likely to have affected the overall result
Free of selective reporting? Yes TheWHO recommends 63 days follow up
in studies of AS+MQ. Day 42 outcomes
may overestimate the efficacy of AS+MQ.
Free of other bias? Yes No other sources of bias identified
Swarthout 2004 ZAR
Methods Trial design: An open label randomized controlled trial
Follow up: Examination and malaria film on days 0, 1, 2, 3, 7, 14, 21, and 28, or other
times if they were unwell
Adverse event monitoring: Parents and guardians were asked about tolerability and po-
tential side effects of the drugs
Participants Number: 180 randomized
Inclusion criteria: Age 6 to 59 months, symptoms suggestive of malaria, P. falciparum
mono-infection 2000 to 200,000/µl, able to take the study drugs orally, able to attend
follow up, informed consent
Exclusion criteria: Severe or complicated malaria, concomitant disease that could mask
response to antimalarial treatment, known hypersensitivity to any of the study drugs
Interventions 1. Artesunate plus amodiaquine
• No dosing details given
2. Artesunate plus sulfadoxine-pyrimethamine
• No dosing details given
All doses supervized
Outcomes 1. Failure rate at day 28, PCR adjusted and unadjusted
2. Gametocytaemia during follow up
3. The percentage of participants with mild and moderate anaemia during follow up
4. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
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Swarthout 2004 ZAR (Continued)
Notes Country: Democratic Republic of Congo
Setting: Small town health centre
Transmission: Highly endemic and seasonal with peaks in the rainy seasons; March to
May and September to November
Resistance: CQ and SP resistance
Dates:April 2004 to May 2004
Funding: Médecins sans Frontières (Holland) and ECHO
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Randomization in blocks of 12 was per-
formed by computer before the study
started’
Allocation concealment? Unclear ’A sealed envelope containing the treat-
ment allocation...was opened only after in-
formed consent had been obtained’
Blinding?
All outcomes
No ’Neither patients nor clinicians were
blinded to the treatment given, micro-
scopists unaware of treatment allocation
read all slides’
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up in both groups
(7.8% AS+AQ vs 10% AS+SP)
Free of selective reporting? Yes All WHO outcomes reported
Free of other bias? Yes No other sources of bias identified
Tangpukdee 2005 THA
Methods Trial design: An open label randomized controlled trial
Follow up: The patients were admitted to hospital for 28 days. Clinical evaluation and
parasite counts were performed 12-hourly until parasites cleared then daily for 28 days.
Adverse event monitoring: Assessed daily using non-suggestive questioning. Side effects
were defined as signs and symptoms which occurred or became more severe after treat-
ment started. Routine haematology, biochemistry, and urinalysis were conducted and
baseline and weekly during follow up.
Participants Number: 180 randomized
Inclusion criteria: Age >14 years, weight > 40 kg, P. falciparum on blood smear, ability
to take oral medicines, agree to stay in hospital for 28 days, informed consent
Exclusion criteria: Pregnancy or lactation, severe malaria, severe vomiting, concomi-
tant systemic diseases, other antimalarials in the previous 14 days or the presence of
sulphonamides or 4-aminoquinolones in the urine
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Tangpukdee 2005 THA (Continued)
Interventions 1. Dihydroartemisinin-piperaquine, fixed dose combination, 40 mg/320 mg tablets
(Artekin: Holleykin)
• Total dose: DHA 6 mg/kg + P 45 mg/kg in 3 divided doses, given once daily for 3
days
2. Artesunate plus mefloquine, loose combination
• AS 4 mg/kg once daily for 3 days
• MQ 8 mg/kg once daily for 3 days
All doses supervized
Outcomes 1. Cure rate at day 28. PCR analysis not performed as all patients hospitalised for
duration of follow up, so all recurrent parasitaemias presumed to be recrudescence
2. Adverse events
Not included in the review:
1. Fever clearance time
2. Parasite clearance time
Notes Country: Thailand
Setting: Bangkok Hospital for Tropical Diseases
Transmission: Low
Resistance: Multiple-drug resistance
Dates: Not given
Funding: Mahidol University Research Grant, Artekin supplied by Holleykin Pharma-
ceuticals
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Randomly treated at a ratio of 1:2’. No
further details given.
Allocation concealment? No None described
Blinding?
All outcomes
No An open label trial. No comment on blind-
ing of laboratory staff.
Incomplete outcome data addressed?
All outcomes
Yes Losses to follow up were low and similar
between groups (10.8% DHA-P vs 10%
AS+MQ)
Free of selective reporting? Yes Day 28 outcomes may overestimate the ef-
ficacy of drugs with long half-lives such as
AS+MQ and DHA-P
Free of other bias? Yes No other sources of bias identified
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Tran 2002 VNM
Methods Trial design: An open label randomized controlled trial
Follow up: Malaria film on days 0, 2, and 7. Participants followed up to day 56 but
further details not described
Adverse event monitoring: Not described
Participants Number: 243 randomized to included treatment arms
Inclusion criteria: Age > 2 yrs, microscopically confirmed uncomplicated P. falciparum
malaria
Exclusion criteria: Pregnancy, evidence of organ dysfunction, unable to tolerate oral
medication, unable to return for follow up, resident in Dac O for > 2 years
Interventions 1. Dihydroartemisinin-piperaquine, fixed dose combination, 40 mg/320 mg tablets
(Artekin: Holleykin)
• Adults: 2 tablets at 0, 6, 24, and 48 hrs
• Children < 15 yrs: 1 tablet at 0, 6, 24, and 48 hrs
2. Artesunate plusmefloquine, loose combination (artesunate:Guilin, Lariam:Hoffman-
La Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 25 mg base/kg as 2 divided doses 6 hours apart on day 3
Outcomes 1. Parasitological failure at days 42 and 28, PCR adjusted and unadjusted
2. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
Notes Country: Vietnam
Setting: Health station
Transmission: Low and seasonal
Resistance: Multiple-drug resistance
Dates: Nov 2001 to Mar 2002
Funding: Wellcome Trust of Great Britain
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Patients were randomly allocated one of
three treatments in a ratio of 2:2:1’. No
further details given.
Allocation concealment? Unclear ’Drugs were kept in identically numbered
opaque envelopes’. No further details.
Blinding?
All outcomes
No An open label trial. No comment on blind-
ing of laboratory staff.
Incomplete outcome data addressed?
All outcomes
Yes ’There were no losses to follow-up’
95Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tran 2002 VNM (Continued)
Free of selective reporting? Unclear It is unclear from the paper whether it is
only clinical failure that is being reported
Free of other bias? Yes No other sources of bias identified
Van den Broek 2003a BGD
Methods Trial design: A 3-arm, open label randomized controlled trial
Follow up: Clinical assessment and malaria film on days 0, 1, 2, 3, 7, 14, 21, 28, 35,
and 42 and any other day when feeling ill
P. vivax or P. malariae during follow up were treated with CQ and continued in follow
up
Adverse event monitoring: Possible side effects assessed at each visit
Participants Number: 242 randomized to included treatment arms
Inclusion criteria: Age > 1 yr, history of fever, P. falciparum mono-infection 1000 to
100,000/µl, informed consent
Exclusion criteria: Pregnancy, signs of severe malaria, signs of another febrile illness or
severe illness requiring treatment, Hb < 6 g/dl
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• 2 doses per day for 3 days according to weight (no further details).
• Taken with 250 ml of sweetened milk
2. Artesunate plus mefloquine, loose combination
• AS 4 mg/kg once daily for 3 days
• MQ 15 mg/kg on day 0 and 10 mg/kg on day 1
All doses supervized
Outcomes 1. ACPR at day 42, PCR adjusted and unadjusted
2. P. vivax parasitaemia during follow up
3. Gametocyte prevalence at days 0, 3, 7, and 14
4. Adverse events
Notes Country: Bangladesh
Setting: Outpatient clinics
Transmission: High endemicity with a clear seasonal pattern
Resistance: Multiple-drug resistance
Dates: May 2003 to Sept 2003
Funding: Médecins sans Frontières (Holland)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Randomisation was done in blocks of 30
by drawing a card from a box’
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Van den Broek 2003a BGD (Continued)
Allocation concealment? No ’Treatment allocation was done by drawing
a card from a box containing three types of
cards coding for treatments’
Blinding?
All outcomes
No An open label trial. No comment on blind-
ing of laboratory staff. 10% of slides were
cross-checked.
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up (1.6%AL6 vs 5.8%
AS+MQ)
Free of selective reporting? Yes TheWHO recommends 63 days follow up
in studies of AS+MQ. Day 42 outcomes
may underestimate treatment failure with
AS+MQ.
Free of other bias? Yes No other sources of bias identified
Van den Broek 2004 ZAR
Methods Trial design: A 3-arm, open label randomized controlled trial
Follow up: Clinical assessment and malaria film on days 0, 1, 2, 3, 7, 14, 21, and 28.
Haemoglobin measured at days 0, 14, and 28
Adverse event monitoring: Possible side effects as passively reported to the examiner were
recorded at each visit
Participants Number: 298 randomized
Inclusion criteria: Age 6 to 59 months, weight > 5 kg for AS+AQ and AS+SP groups and
> 10 kg for AL6, fever > 37.5 ºC or history of fever in the previous 24 hrs, P. falciparum
mono-infection 2000 to 200,000/µl, lives within 2 hours walking distance, informed
consent
Exclusion criteria: Signs of severe or complicated malaria, any danger sign, a serious
concomitant illness, malnutrition, known hypersensitivity to the study drugs
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• Twice daily for 3 days, weight based as per manufacturers guidance
• Given with fatty food or a glass of milk
2. Artesunate plus amodiaquine, loose combination (Arsumax: Sanofi-Aventis, Camo-
quin: Parke-Davis)
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg once daily for 3 days
3. Artesunate plus sulphadoxine-pyrimethamine, loose combination (Arsumax: Sanofi-
Aventis, Fansidar: La Roche)
• AS 4 mg/kg once daily for 3 days
• SP 25/1.25 mg/kg on day 1
All doses supervized
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Van den Broek 2004 ZAR (Continued)
Outcomes 1. Recurrent parasitaemia at day 28, PCR adjusted and unadjusted
2. Gametocyte carriage at days 0 and 28
3. Changes in haemoglobin during follow up
4. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
Notes Country: Republic of Congo
Setting: Health centre
Transmission: Holoendemic with a peak in the rainy seasons
Resistance: CQ, SP, and AQ resistance
Dates: May 2004 to Oct 2004
Funding: Médecins sans Frontières (Holland)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Randomized to the three treatments by a
randomnumber list’ (information fromau-
thor)
Allocation concealment? No Allocation was not concealed (information
from author)
Blinding?
All outcomes
No An open label trial. 10% of malaria films
were cross-checkedby external laboratories.
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up in all groups (5.7%
AL6 vs 4% AS+AQ vs 6.6% AS+SP). A
significant number of PCR samples were
indeterminate or missing which may affect
the result.
Free of selective reporting? Yes TheWHO recommends 42 days follow up
in studies of AL6. Day 28 outcomes may
underestimate the failure rate with AL6.
Free of other bias? No Due to differing inclusion criteria for the 3
arms children in the AL6 group were older,
heavier and had higher Hb levels at base-
line. This may improve outcome in this
group and consequently the AL6 arm was
excluded from this review.
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Van Vugt 1998 THA
Methods Trial design: An open-label randomized controlled trial
Follow up: Examination and malaria film daily until fever and parasites cleared then
weekly to day 28
Adverse event monitoring: A questionnaire for adverse effects was completed at each
visit. Full neurological examination on days 0, 3, 7, and 28. Complete haematology and
biochemistry (at 1 centre) on days 0, 3, 7, and 28.
Participants Number: 200 randomized
Inclusion criteria: Age > 2 yrs, P. falciparum parasitaemia > 500/µl, informed consent
Exclusion criteria: Pregnancy or lactation, severe or complicated malaria
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• < 15 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
2. Artesunate plus mefloquine, loose combination (artesunate: Guilan, Lariam: Hoff-
man-La Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 15 mg/kg on day 1 and 10 mg/kg on day 2
All doses supervized
Outcomes 1. Cure rate at day 28, PCR adjusted and unadjusted
2. Anaemia (haematocrit < 30%) on days 0, 3, and 28
3. Adverse events
Not included in the review:
1. Fever clearance time
2. Parasite clearance time
3. Gametocyte clearance during first 3 days
Notes Country: Thailand
Setting: Bangkok Hospital for Tropical Diseases and an outpatient clinic
Transmission: Not reported
Resistance: Multiple-drug resistance
Dates: Nov 1997 to Mar 1998
Funding: Wellcome Trust of Great Britain, Novartis
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Using a 3:1 randomization scheme’. No
further details given.
Allocation concealment? Unclear ’The allocationwas in sealed envelopes’.No
further details given.
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Van Vugt 1998 THA (Continued)
Blinding?
All outcomes
No An open label trial. No other comment on
blinding.
Incomplete outcome data addressed?
All outcomes
Yes Different losses to follow up in each group
(11% AL6 vs 6% AS+MQ) but unlikely to
affect the overall result
Free of selective reporting? Yes TheWHO recommends 63 days follow up
in studies of AS+MQ, and 42 days with
AL6. Day 28 outcomes may underestimate
treatment failure with both drugs.
Free of other bias? Yes No other sources of bias identified
Yeka 2004 UGA
Methods Trial design: A 3-arm single blind randomized controlled trial
Follow up: Malaria film on days 0, 1, 2, 3, 7, 14, 21, 28 and any other day they were
unwell. Haemoglobin on days 0 and 28 or the day of failure.
Adverse event monitoring: Not described
Participants Number: 1537 randomized to included treatment arms
Inclusion criteria: Age > 6 months, axillary temp > 37.5 ºC or history of fever in the
previous 24 hours, P. falciparummono-infection 2000 to 200,000/µl, informed consent
Exclusion criteria: Pregnancy, danger signs, signs of severe malaria, concomitant febrile
illness, history of treatment with an antifolate or amodiaquine during the previous week,
history of serious side effects to the study meds
Interventions 1. Amodiaquine plus sulfadoxine-pyrimethamine, loose combination
• AQ 10 mg/kg on days 0 and 1 and 5 mg/kg on day 2
• SP 25/1.25 mg/kg once on day 0, plus placebo on days 1 and 2
2. Artesunate plus amodiaquine
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg on days 0 and 1 and 5 mg/kg on day 2
All doses supervized
Outcomes 1. Risk of recurrent infection at day 28, PCR adjusted and unadjusted
2. Gametocytes during follow up
3. Mean increase in haemoglobin
4. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
Notes Country: Uganda
Setting: District health centres
Transmission: 4 sites with medium-high to high endemicity
Resistance: CQ and SP resistance
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Yeka 2004 UGA (Continued)
Dates: Nov 2002 to May 2004
Funding: CDC/Association of Schools of PublicHealth co-operative agreement,Malaria
Surveillance and Control in Uganda, DfID
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Randomisation codes were computer gen-
erated’
Allocation concealment? No Not described
Blinding?
All outcomes
Yes ’All other study personnel (except study
nurse) were blinded to the treatment as-
signments and participants were not in-
formed of their treatment regimen’
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up in both groups
(3.4% AS+AQ vs 4.0% AQ+SP). High
transmission with very high reinfection
rates results in very high exclusions from
primary analysis.
Free of selective reporting? Yes Outcomes only presented as percentages.
Additional data gained from authors.
Free of other bias? Yes No other sources of bias identified
Yeka 2007 UGA
Methods Trial design: A single blind randomized controlled trial
Follow up: Standardized history, physical exam, and malaria film on days 0, 1, 2, 3, 7,
14, 21, 28, 35, and 42 and any other day they were unwell. Haemoglobin on days 0 and
42 or the day of failure. Anaemia was treated with ferrous sulphate and antihelminthics
according to IMCI guidelines.
Adverse event monitoring: Assessed at each visit including neurological examination.
Adverse events described as any untoward medical occurrence.
Participants Number: 461 randomized
Inclusion criteria: Age 6 months to 10 yrs, weight > 5 kg, axillary temp > 37.5 ºC or
history of fever in the previous 24 hours, P. falciparummono-infection 2000 to 200,000/
µl, informed consent
Exclusion criteria: Danger signs or evidence of severe malaria, concomitant febrile illness,
history of serious side effects to the study meds
Interventions 1. Dihydroartemisinin-piperaquine, fixed dose combination, 40 mg/320 mg tablets (
Duocotexin: HolleyPharm)
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Yeka 2007 UGA (Continued)
• Total dose: DHA 6.4 mg/kg + P 51.2 mg/kg in 3 divided doses, given once daily
for 3 days
• Plus placebo in the evenings to simulate twice daily dosing
2. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• 5 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
All doses supervized and given with a glass of milk
Outcomes 1. ACPR at day 42, PCR adjusted and unadjusted
2. Gametocytes development during follow up
3. Mean increase in haemoglobin at last day of follow up
4. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
Notes Country: Uganda
Setting: Health centre
Transmission: Moderate transmission
Resistance: Not stated
Dates: Aug 2006 to Apr 2007
Funding: CDC, DfID, DHA-P supplied by Holleypharm, AL6 supplied by Uganda
Ministry of Health
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’A randomisation list was computer gener-
ated by an off-site investigator’
Allocation concealment? Yes ’Sealed opaque envelopes containing the
study number and assigned treatment were
secured in a locked cabinet’
Blinding?
All outcomes
Yes ’Only the study nurse was aware of as-
signments. All other study personnel were
blinded. Patients were not informed of
their treatment regimen’.
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up in both groups
(1.4% DHA-P vs 1.5% AL6)
Free of selective reporting? Yes AllWHO outcomes reported. Day 42 out-
comesmay underestimate treatment failure
with DHA-P due to its long half-life.
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Yeka 2007 UGA (Continued)
Free of other bias? Yes No other sources of bias identified
Zongo 2005 BFA
Methods Trial design: A randomized controlled trial
Follow up: A standardized history, examination, and malaria film on days 0, 1, 2, 3, 7,
14, 21, 28, or any other day they felt unwell. Haemoglobin measured on days 0 and 28
or day of clinical failure. Children with Hb < 10 g/dl were treated with ferrous sulphate
and antihelminthic treatment.
Adverse event monitoring: Assessed at each visit
Participants Number: 580 randomized
Inclusion criteria: Age > 6 months, weight > 5 kg, axillary temp > 37.5 ºC or history of
fever in the last 24 hours, P. falciparum mono-infection 2000-200,000/µl, the ability to
participate in 28 days follow up, informed consent
Exclusion criteria: Danger signs or signs of severe malaria, history of serious adverse
effects related to study meds, evidence of concomitant febrile illness, antimalarial use
other than chloroquine in previous 2 weeks, haemoglobin < 5 g/dl
Interventions 1. Artemether-Lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• 5 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
2. Amodiaquine plus sulfadoxine-pyrimethamine, loose combination (Amodiaquine:
Aventis, Fansidar: Roche)
• AQ 10 mg/kg on days 0 and 1 and 5 mg/kg on day 2
• SP 25/1.25 mg/kg on day 0
Placebos were used to simulate equal numbers of pills. All doses supervized.
Outcomes 1. Recurrent parasitaemia at day 28, PCR adjusted and unadjusted
2. Gametocyte carriage assessed weekly
3. Changes in haemoglobin during follow up
4. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
Notes Country: Burkina Faso
Setting: Urban health centres
Transmission: Holoendemic with transmission peaks during the rainy season
Resistance: Not stated
Dates: Aug 2005 to Dec 2005
Funding: Fogarty International Centre of theNational Institutes of Health, International
Atomic Energy Agency, National Budget of the Institut de Recherche en Sciences de la
Sante
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Zongo 2005 BFA (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Computer-generated randomisation lists’
Allocation concealment? No None described
Blinding?
All outcomes
Yes ’Investigators responsible for classification
of treatment outcomes were unaware of
treatment assignment’. Placebos were used
and participants not informed of alloca-
tion.
Incomplete outcome data addressed?
All outcomes
Yes Mildly disparate losses to follow up (6.1%
AL6 vs 10.4% AQ+SP), unlikely to have
affected overall result
Free of selective reporting? Yes TheWHO recommends 42 days follow up
in studies of AL6. Day 28 outcomes may
under estimate treatment failure with AL6
and DHA-P.
Free of other bias? Yes No other sources of bias identified
Zongo 2007 BFA
Methods Trial design: A 3-arm randomized controlled trial
Follow up: A standardized history, examination, and malaria film on days 0, 1, 2, 3,
7, 14, 21, 28, 35, and 42. Haemoglobin measured on days 0 and 42 or day of clinical
failure. ChildrenwithHb<10 g/dl were treatedwith ferrous sulphate and antihelminthic
treatment.
Adverse event monitoring: Assessed at each visit. Adverse events defined as untoward
medical occurrences.
Participants Number: 580 randomized
Inclusion criteria: Age > 6 months, weight > 5 kg, axillary temp > 37.5 ºC or history of
fever in the last 24 hours, P. falciparum mono-infection 2000 to 200,000/µl, the ability
to participate in 42 days follow up, informed consent
Exclusion criteria: Danger signs or signs of severe malaria, history of serious adverse
effects related to study meds, evidence of concomitant febrile illness, antimalarial use
other than chloroquine in previous 2 weeks, haemoglobin < 5 g/dl
Interventions 1. Dihydroartemisinin-piperaquine, fixed dose combination, 40 mg/320 mg tablets (
Duocotexin: HolleyPharm)
• Total dose: DHA 6.4 mg/kg + PQP 51.2 mg/kg in 3 divided doses, given once
daily for 3 days
2. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
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Zongo 2007 BFA (Continued)
Novartis)
• 5 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
3. Amodiaquine plus sulfadoxine-pyrimethamine, loose combination (Flavoquine: Aven-
tis, Fansidar: Roche)
• AQ 10 mg/kg once daily on days 0 and 1, then 5 mg/kg once on day 2
• SP 25/1.25 mg/kg on day 0
All doses supervized
Outcomes 1. Risk of treatment failure at days 42 and 28, PCR adjusted and unadjusted
2. Gametocyte development during follow up
3. Hemoglobin (mean g/dl) on day 0 and last day of follow up
4. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
Notes Country: Burkino Faso
Setting: Health dispensaries
Transmission: Holoendemic, transmission principally in the rainy season May to Oct
Resistance: Not reported
Dates: Not reported
Funding: Doris Duke Charitable Foundation, Holley Cotec Pharmaceuticals, Interna-
tional Atomic Energy Agency, National Budget of the Institut de Recherche en Sciences
de la Sante
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Randomly assigned on the basis of a com-
puter-generated code provided by an off-
site investigator’
Allocation concealment? Yes ’Referred for treatment allocation by a
study nurse not involved in enrolment or
assessment of treatment outcomes’
Blinding?
All outcomes
No ’The study was not blinded’
Incomplete outcome data addressed?
All outcomes
Yes Low losses to follow up in all groups (8%
DHA-P vs 6.4% AL6 vs 8.2% AQ+SP)
Free of selective reporting? Yes AllWHO outcomes reported. Day 42 out-
comesmay underestimate treatment failure
with DHA-P due to its long half-life.
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Zongo 2007 BFA (Continued)
Free of other bias? Yes No other sources of bias identified
A = artemether
ACPR = adequate clinical and parasitological response
AL = artemether-lumefantrine
AL6 = artemether-lumefantrine (six doses)
AQ = amodiaquine
AS = artesunate
CQ = chloroquine
DFID = Department for International Development (UK)
DHA-P = dihydroartemisinin-piperaquine
FBC = full blood count
HCT = haematocrit
L = lumefantrine
m = months
MQ = mefloquine
PCR = polymerase chain reaction
PCV = packed cell volume
SP = sulfadoxine-pyrimethamine
vs = versus
WBC = white blood cell
yrs = years
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Characteristics of excluded studies [ordered by study ID]
Abacassamo 2002 MOZ Only 21 days follow up
Abuaku 2005 Conference presentation of Koram 2003 GHA
Adjei 2005 Conference presentation of Adjei 2006 GHA
Bell 2008 Comparison not relevant to this review: artesunate plus sulfadoxine-pyrimethamine vs amodiaquine plus
sulfadoxine-pyrimethamine
Blair 2006 Duration of follow up in the group given amodiaquine plus sulfadoxine-pyrimethamine was only 21 days.
The randomization procedure is also unclear.
Denis 2006 Not randomized
Dorsey 2002 Comparison not relevant to this review: artesunate plus sulfadoxine-pyrimethamine vs amodiaquine plus
sulfadoxine-pyrimethamine
Dorsey-G 2003 A paper based on the trial reported in Dorsey 2002. Contains no new efficacy data.
Fofana 2005 Conference presentation of Djimde 2004 MLI
Ibrahium 2007 Quasi-randomized
Jiao 1997 Comparison not relevant to this review: benflumetol vs artesunate plus benflumetol
Kabanywanyi 2007 Not randomized. Participants were randomized to monotherapy or artemether-lumefantrine at 1 site and
monotherapy or artesunate plus amodiaquine at a second site. This does not allow a proper randomized
comparison of AL6 vs AS+AQ.
Massougbodji 2005 Comparison not relevant to this review: trial of 2 different regimens of artesunate plus mefloquine
Meremikwu 2004 NGA Only 14 days follow up
Mockenhaupt 2005 Comparison not relevant to this review: artesunate plus sulfadoxine-pyrimethamine vs amodiaquine plus
sulfadoxine-pyrimethamine
Mohamed 2006 Not randomized. Participants at 1 centre received artemether-lumafantrine, participants at a second centre
received artesunate plus sulfadoxine-pyrimethamine.
Mulenga 2006 Comparison not relevant to this review: artemether-lumefantrine vs sulfadoxine-pyrimethamine
Ndayiragije 2004 Follow up only 14 days. Differences between groups at baseline. Not randomized.
Ndiaye 2005 Conference presentation of Faye 2003 SEN
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(Continued)
Obonyo 2007 A meta-analysis of trials included in this review
Okell 2008 A meta-analysis of 6 trials. All trials relevant to this review are included.
Piola 2005 Comparison not relevant to this review: artemether-lumefantrine supervized vs unsupervized
Rwagacondo 2003 Comparison not relevant to this review: artesunate plus sulfadoxine-pyrimethamine vs amodiaquine plus
sulfadoxine-pyrimethamine
Sagara 2006 Comparison not relevant to this review: artesunate plus sulphamethoxypyrazine-pyrimethamine vs
artemether lumefantrine
Sowunmi 2007a Reports the same trial as Sowunmi 2007b. No new efficacy data.
Sowunmi 2007b Comparison not relevant to this review: artemether-lumefantrine vs amodiaquine-sulphalene-
pyrimethamine
Tall 2005 A conference presentation of Tall 2007
Tall 2007 Quasi-randomized
Thapa 2007 Quasi-randomized. Comparison not relevant to this review: artemether-lumefantrine vs sulfadoxine-
pyrimethamine.
Tranh 2009 Quasi-randomized
van den Broek 2005b Quasi-randomized
van Vugt 1998 Comparison not relevant to this review: artemether-lumefantrine (4 doses) vs artesunate plus mefloquine
Vugt 1999 Comparison not relevant to this review: artemether-lumefantrine (4 doses) vs 2 different 6-dose regimens
of artemether-lumefantrine
Wilairatana 2002 Comparison not relevant to this review: Artecom (dihydroartemisinin-piperaquine -trimethoprim)vs arte-
sunate mefloquine
Wiseman 2006 A cost-effectiveness analysis based on the findings of Mutabingwa 2005. Contains no new efficacy data.
AL6 = artemether-lumefantrine (six doses)
AQ = amodiaquine
AS = artesunate
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D A T A A N D A N A L Y S E S
Comparison 1. Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure (P. falciparum) Day
63 PCR unadjusted
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Asia 3 1182 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.54, 0.98]
1.2 South America 1 445 Risk Ratio (M-H, Fixed, 95% CI) 6.19 [1.40, 27.35]
2 Total Failure (P. falciparum) Day
63 PCR adjusted
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Asia 3 1062 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.19, 0.79]
2.2 South America 1 435 Risk Ratio (M-H, Fixed, 95% CI) 9.55 [0.52, 176.35]
3 Total Failure (P. falciparum) Day
42 PCR unadjusted
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Asia 5 1969 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.46, 1.69]
4 Total Failure (P. falciparum) Day
42 PCR adjusted
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Asia 5 1898 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.30, 1.39]
5 Total Failure (P. falciparum) Day
28 PCR unadjusted
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Asia 6 2034 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.22, 6.42]
6 Total Failure (P. falciparum) Day
28 PCR adjusted
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Asia 6 2020 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.31, 1.56]
7 P. vivax parasitaemia 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Mixed P. falciparum and
vivax infection at baseline
5 2248 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.63, 1.12]
7.2 Total P. vivax parasitaemia
by day 28
1 402 Risk Ratio (M-H, Fixed, 95% CI) 7.43 [0.39, 142.89]
7.3 Total P. vivax parasitaemia
by day 42
3 1251 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.57, 1.11]
7.4 Total P. vivax parasitaemia
by day 63
4 1661 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.91, 1.34]
7.5 P. vivax parasitaemia by
day 63 in those negative at
baseline
3 1172 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.95, 1.56]
7.6 P. vivax parasitaemia by
day 63 in those positive at
baseline
2 79 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.57, 1.65]
8 Gametocyte development (in
those negative at baseline)
3 1234 Risk Ratio (M-H, Fixed, 95% CI) 3.06 [1.13, 8.33]
9 Gametocytaemia carriage 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Gametocyte carriage day 0 2 1174 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.66, 1.73]
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9.2 Gametocyte carriage day 7 2 1152 Risk Ratio (M-H, Random, 95% CI) 2.00 [1.54, 2.58]
9.3 Gametocyte carriage day
14
2 1142 Risk Ratio (M-H, Random, 95% CI) 5.14 [3.17, 8.33]
9.4 Gametocyte carriage day
21
2 1123 Risk Ratio (M-H, Random, 95% CI) 7.23 [0.10, 519.79]
9.5 Gametocyte carriage day
28
2 1124 Risk Ratio (M-H, Random, 95% CI) 9.68 [1.23, 75.98]
10 Serious adverse events
(including deaths)
7 2374 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.38, 2.15]
11 Early vomiting 7 2473 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.69, 1.16]
12 Sensitivity analysis: Total
Failure Day 63 PCR unadjusted
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 Total Failure (P.
falciparum) Day 63 PCR
unadjusted
4 1627 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.52, 1.70]
12.2 Total Failure Day 63
PCR unadjusted (losses to
follow up included as failures)
4 1801 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.65, 1.38]
12.3 Total Failure Day 63
PCR unadjusted (losses to
follow up included as successes)
4 1801 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.52, 1.68]
13 Sensitivity analysis: Total
Failure Day 63 PCR adjusted
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
13.1 Total Failure (P.
falciparum) Day 63 PCR
adjusted
4 1497 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.17, 1.83]
13.2 Total Failure Day 63
PCR adjusted (indeterminate
PCR included as failures)
4 1508 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.32, 1.39]
13.3 Total Failure Day 63
PCR adjusted (new infections
included as successes)
4 1627 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.34, 1.35]
13.4 Total Failure Day 63
PCR adjusted (losses to follow
up included as failures)
4 1801 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.67, 1.30]
13.5 Total Failure Day 63
PCR adjusted (losses to follow
up included as successes)
4 1801 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.34, 1.33]
Comparison 2. Dihydroartemisinin-piperaquine vs Artemether-lumefantrine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure (P. falciparum) Day
42 PCR unadjusted
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Africa 3 1136 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.20, 0.95]
1.2 Asia 1 356 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.35, 1.05]
1.3 Oceania 1 216 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.76, 1.50]
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2 Total Failure (P. falciparum) Day
42 PCR adjusted
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Africa 3 869 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.24, 0.64]
2.2 Asia 1 317 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.16, 3.76]
2.3 Oceania 1 151 Risk Ratio (M-H, Fixed, 95% CI) 2.31 [0.85, 6.23]
3 Total Failure (P. falciparum) Day
28 PCR unadjusted
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Africa 2 484 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.05, 0.32]
3.2 Asia 1 451 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.17, 1.12]
3.3 Oceania 1 224 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.75, 2.15]
4 Total Failure (P. falciparum) Day
28 PCR adjusted
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Africa 2 453 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.17, 1.99]
4.2 Asia 1 436 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.13, 6.36]
4.3 Oceania 1 193 Risk Ratio (M-H, Fixed, 95% CI) 3.63 [1.04, 12.60]
5 P. vivax parasitaemia 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Mixed P. falciparum and
vivax infection at baseline
4 1608 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.73, 1.42]
5.2 P. vivax parasitaemia by
D28
1 473 Risk Ratio (M-H, Fixed, 95% CI) 0.05 [0.01, 0.36]
5.3 P. vivax parasitaemia by
D42
4 1442 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.24, 0.43]
6 Gametocyte development (in
those negative at baseline)
4 1203 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.35, 2.59]
7 Anaemia 4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Mean haemoglobin (g/dl)
at baseline
4 1356 Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.27, 0.13]
7.2 Mean haemoglobin (g/dl)
at day 28
1 134 Mean Difference (IV, Fixed, 95% CI) 0.36 [-0.03, 0.75]
7.3 Mean haemoglobin (g/dl)
at day 42
1 375 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.02, 0.62]
7.4 Mean change in
haemoglobin (g/dl) from
baseline to Day 42
2 835 Mean Difference (IV, Fixed, 95% CI) 0.26 [0.00, 0.51]
8 Serious adverse events (including
deaths)
5 2110 Risk Ratio (M-H, Fixed, 95% CI) 1.71 [0.66, 4.46]
9 Early vomiting 2 1147 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [0.68, 2.78]
Comparison 3. Dihydroartemisinin-piperaquine vs Artesunate plus amodiaquine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure (P. falciparum) Day
28 PCR unadjusted
2 679 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.35, 0.81]
1.1 Africa 1 501 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.34, 0.85]
1.2 Asia 1 178 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.17, 1.42]
2 Total Failure (P. falciparum) Day
28 PCR adjusted
2 629 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.23, 0.94]
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2.1 Africa 1 458 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.27, 1.27]
2.2 Asia 1 171 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.02, 1.22]
3 Total Failure (P. falciparum) Day
42 PCR unadjusted
1 152 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.10, 0.72]
3.1 Asia 1 152 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.10, 0.72]
4 Total Failure (P. falciparum) Day
42 PCR adjusted
1 141 Risk Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 0.81]
4.1 Asia 1 141 Risk Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 0.81]
5 P. vivax parasitaemia 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Mixed P. falciparum and
vivax infection at baseline
1 220 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.67, 2.29]
5.2 P. vivax parasitaemia by
day 28
1 181 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.04, 4.90]
5.3 P. vivax parasitaemia by
day 42
1 170 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.09, 0.74]
6 Serious adverse events (including
deaths)
1 334 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.71]
7 Early vomiting 1 334 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.22, 1.30]
Comparison 4. Dihydroartemisinin-piperaquine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure (P. falciparum) Day
42 PCR unadjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Oceania 1 215 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.74, 1.45]
2 Total Failure (P. falciparum) Day
42 PCR adjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Oceania 1 161 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.39, 1.51]
3 Total Failure (P. falciparum) Day
28 PCR unadjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Oceania 1 223 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.62, 1.64]
4 Total Failure (P. falciparum) Day
28 PCR adjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Oceania 1 195 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.46, 2.22]
5 P. vivax parasitaemia by day 42 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Participants with P.
falciparum mono-infection at
baseline
1 194 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.32, 0.65]
5.2 Participants with P. vivax
± P. falciparum at baseline
1 75 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.27, 0.79]
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Comparison 5. Dihydroartemisinin-piperaquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure (P. falciparum) Day
28 PCR unadjusted
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Africa 2 848 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.25, 0.55]
2 Total Failure (P. falciparum) Day
28 PCR adjusted
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Africa 2 802 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.17, 0.54]
3 Total Failure (P. falciparum) Day
42 PCR unadjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Africa 1 341 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.33, 1.24]
4 Total Failure (P. falciparum) Day
42 PCR adjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Africa 1 319 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.16, 1.83]
5 Gametocyte development 1 367 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.27, 1.79]
6 Anaemia 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 Mean haemoglobin (g/dl)
at baseline
1 371 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.68, 0.28]
6.2 Mean haemoglobin (g/dl)
at day 42 or last day of follow
up
1 371 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.51, 0.11]
6.3 Mean packed cell volume
at baseline
1 510 Mean Difference (IV, Fixed, 95% CI) Not estimable
6.4 Mean packed cell volume
at day 14
1 510 Mean Difference (IV, Fixed, 95% CI) -1.10 [-1.73, -0.47]
7 Early vomiting 1 383 Risk Ratio (M-H, Fixed, 95% CI) 3.34 [0.70, 15.87]
Comparison 6. Artesunate plus mefloquine vs Artemether-lumefantrine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure (P. falciparum) Day
42 PCR unadjusted
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Asia 4 1000 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.29, 0.94]
2 Total Failure (P. falciparum) Day
42 PCR adjusted
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Asia 4 904 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.05, 2.84]
3 Total Failure (P. falciparum) Day
28 PCR unadjusted
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Africa 2 752 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.48, 0.89]
3.2 Asia 3 854 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.41, 1.58]
4 Total Failure (P. falciparum) Day
28 PCR adjusted
5 1479 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.63, 2.50]
4.1 Africa 2 643 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.41, 2.85]
113Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
4.2 Asia 3 836 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [0.53, 3.86]
5 P. vivax parasitaemia 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Mixed P. falciparum and
vivax infection at baseline
5 1279 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.57, 3.00]
5.2 P. vivax parasitaemia by
day 28
1 208 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.01, 3.88]
5.3 P. vivax parasitaemia by
day 42
4 1003 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.21, 0.41]
6 Gametocyte development (in
those negative at baseline)
3 883 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.54, 3.28]
7 Gametocyte carriage 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Gametocyte carriage day 0 1 294 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 2.10]
7.2 Gametocyte carriage day 3 2 536 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.21, 1.48]
7.3 Gametocyte carriage day 7 3 636 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.14, 0.85]
7.4 Gametocyte carriage day
14
2 536 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.08, 2.10]
8 Serious adverse events (including
deaths)
7 1773 Risk Ratio (M-H, Fixed, 95% CI) 2.96 [0.64, 13.76]
9 Early vomiting 6 1479 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.55, 2.08]
Comparison 7. Artesunate plus mefloquine vs Artesunate plus amodiaquine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure (P. falciparum) Day
28 PCR unadjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Africa 1 493 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.12, 2.46]
2 Total Failure (P. falciparum) Day
28 PCR adjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Africa 1 482 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3 Gametocyte carriage 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Gametocyte carriage day 0 1 505 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3.2 Gametocyte carriage day 3 1 505 Risk Ratio (M-H, Fixed, 95% CI) 17.31 [0.90, 332.99]
3.3 Gametocyte carriage day 7 1 505 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3.4 Gametocyte carriage day
14
1 505 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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Comparison 8. Artesunate plus mefloquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure (P. falciparum) Day
28 PCR unadjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Africa 1 300 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.15, 7.59]
2 Total Failure (P. falciparum) Day
28 PCR adjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Africa 1 296 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3 Gametocyte carriage 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Gametocyte carriage day 0 1 306 Risk Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 1.81]
3.2 Gametocyte carriage day 3 1 306 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.06, 0.70]
3.3 Gametocyte carriage day 7 1 306 Risk Ratio (M-H, Fixed, 95% CI) 0.03 [0.00, 0.47]
3.4 Gametocyte carriage day
14
1 306 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 9. Artemether-lumefantrine vs Artesunate plus amodiaquine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure (P. falciparum) Day
28 PCR unadjusted
9 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 East Africa 3 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.2 West Africa 5 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.3 South/Central Africa 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2 Total Failure (P. falciparum) Day
28 PCR adjusted
8 1729 Risk Ratio (M-H, Fixed, 95% CI) 1.65 [0.95, 2.87]
2.1 East Africa 2 365 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.15, 4.59]
2.2 West Africa 5 1245 Risk Ratio (M-H, Fixed, 95% CI) 1.81 [1.00, 3.26]
2.3 South/Central Africa 1 119 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3 Gametocyte development 1 305 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.15, 0.74]
4 Gametocyte carriage 3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Gametocyte carriage day 0 3 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4.2 Gametocyte carriage day 3 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4.3 Gametocyte carriage day 7 3 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4.4 Gametocyte carriage day
14
2 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5 Anaemia 5 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Mean haemoglobin (g/dl)
at baseline
4 Mean Difference (IV, Fixed, 95% CI) Not estimable
5.2 Mean haemoglobin (g/dl)
at Day 28
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
5.3 Mean change in
haemoglobin (g/dl) from
baseline to Day 28
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
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5.4 Mean haematocrit at
baseline
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
5.5 Mean haematocrit at Day
28
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
6 Proportion anaemic
(Haemoglobin < 11 g/dl)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 At baseline 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6.2 At day 28 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7 Serious adverse events (including
deaths)
6 2749 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.59, 2.08]
8 Early vomiting 5 1097 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.59, 1.31]
9 Sensitivity analysis: Total Failure
Day 28 PCR unadjusted
12 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Total Failure (P.
falciparum) Day 28 PCR
unadjusted
9 3021 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.60, 1.27]
9.2 Total Failure Day 28 PCR
unadjusted (trials with baseline
differences included)
12 3719 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.49, 0.97]
9.3 Total Failure Day 28 PCR
unadjusted (losses to follow up
included as failures)
9 3230 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.62, 1.06]
9.4 Total Failure Day 28 PCR
unadjusted (losses to follow up
included as successes)
9 3230 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.61, 1.30]
10 Sensitivity analysis: Total
Failure Day 28 PCR adjusted
11 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Total Failure (P.
falciparum) Day 28 PCR
adjusted
8 1729 Risk Ratio (M-H, Fixed, 95% CI) 1.65 [0.95, 2.87]
10.2 Total Failure Day 28
PCR adjusted (trials with
baseline differences included)
11 2311 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.69, 1.67]
10.3 Total Failure Day 28
PCR adjusted (indeterminate
PCR included as failures)
8 1747 Risk Ratio (M-H, Fixed, 95% CI) 1.72 [1.06, 2.78]
10.4 Total Failure Day 28
PCR adjusted (new infections
included as successes)
8 2064 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [1.06, 2.75]
10.5 Total Failure Day 28
PCR adjusted (losses to follow
up included as failures)
8 2196 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.78, 1.31]
10.6 Total Failure Day 28
PCR adjusted (losses to follow
up included as successes)
8 2196 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [1.08, 2.83]
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Comparison 10. Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure (P. falciparum) Day
42 PCR unadjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Oceania 1 217 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.68, 1.36]
2 Total Failure (P. falciparum) Day
42 PCR adjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Oceania 1 158 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.13, 0.86]
3 Total Failure (P. falciparum) Day
28 PCR unadjusted
2 382 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.48, 1.16]
3.1 Africa 1 157 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.28, 1.48]
3.2 Oceania 1 225 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.47, 1.34]
4 Total Failure (P. falciparum) Day
28 PCR adjusted
2 345 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.25, 1.13]
4.1 Africa 1 151 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.34, 2.47]
4.2 Oceania 1 194 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.08, 0.97]
5 P. vivax parasitaemia 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 P. vivax parasitaemia by
day 42 (P. vivax ± P. falciparum
at baseline)
1 72 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.76, 1.43]
5.2 P. vivax parasitaemia by
day 42 (P. falciparum mono-
infection at baseline)
1 196 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.87, 1.35]
6 Sensitivity analysis Total Failure
Day 28 PCR unadjusted
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Total Failure (P. falciparum
) Day 28 PCR unadjusted
2 382 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.48, 1.16]
6.2 Total Failure Day 28 PCR
unadjusted (trials with baseline
differences included)
4 802 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.39, 0.79]
6.3 Total Failure Day 28 PCR
unadjusted (losses to follow up
included as failures)
2 409 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.57, 1.17]
6.4 Total Failure Day 28 PCR
unadjusted (losses to follow up
included as successes)
2 409 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.47, 1.15]
7 Sensitivity analysis: Total Failure
Day 28 PCR adjusted
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Total Failure (P. falciparum
) Day 28 PCR adjusted
2 345 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.25, 1.13]
7.2 Total Failure Day 28 PCR
adjusted (trials with baseline
differences included)
4 718 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.17, 0.66]
7.3 Total Failure Day 28 PCR
adjusted (indeterminate PCR
included as failures)
2 349 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.29, 1.16]
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7.4 Total Failure Day 28
PCR adjusted (new infections
included as successes)
2 382 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.29, 1.17]
7.5 Total Failure Day 28 PCR
adjusted (losses to follow up
included as failures)
2 409 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.48, 1.23]
7.6 Total Failure Day 28 PCR
adjusted (losses to follow up
included as successes)
2 409 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.30, 1.17]
Comparison 11. Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure (P. falciparum) Day
28 PCR unadjusted
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 East Africa 3 1646 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.30, 0.41]
1.2 West Africa 3 1130 Risk Ratio (M-H, Fixed, 95% CI) 2.88 [1.86, 4.47]
2 Total Failure (P. falciparum) Day
28 PCR adjusted
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 East Africa 2 618 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.06, 0.24]
2.2 West Africa 3 1051 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [0.55, 3.47]
3 Total Failure (P. falciparum) Day
42 PCR unadjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 West Africa 1 345 Risk Ratio (M-H, Fixed, 95% CI) 2.64 [1.66, 4.21]
4 Total Failure (P. falciparum) Day
42 PCR adjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 West Africa 1 284 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.44, 3.38]
5 Gametocyte carriage 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Gametocyte carriage day 0 4 1545 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.51, 1.39]
5.2 Gametocyte carriage day 3 3 1331 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.25, 0.75]
5.3 Gametocyte carriage day 7 4 1538 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.18, 0.54]
5.4 Gametocyte carriage day
14
4 1536 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.21, 1.01]
6 Gametocyte development (in
those negative at baseline)
1 371 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.08, 1.04]
7 Anaemia 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Mean haemoglobin (g/dl)
at baseline
2 Mean Difference (IV, Fixed, 95% CI) Not estimable
7.2 Mean change in
haemoglobin (g/dl) from
baseline to Day 28
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
7.3 Mean haemoglobin (g/dl)
at Day 42 or last day of follow
up.
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
8 Serious adverse events (including
deaths)
5 2684 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.56, 2.08]
9 Early vomiting 2 893 Risk Ratio (M-H, Fixed, 95% CI) 1.42 [0.54, 3.68]
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Comparison 12. Artesunate plus amodiaquine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure (P. falciparum) Day
28 PCR unadjusted
7 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Africa 7 Risk Ratio (M-H, Random, 95% CI) Not estimable
2 Total Failure (P. falciparum) Day
28 PCR adjusted
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Africa 7 1419 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.37, 1.08]
3 Gametocyte carriage 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Gametocyte carriage day 0 3 532 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.60, 1.32]
3.2 Gametocyte carriage day 3 2 363 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.67, 1.25]
3.3 Gametocyte carriage day 7 2 363 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.64, 1.61]
3.4 Gametocyte carriage day
14
3 520 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.32, 3.73]
4 Proportion of participants with
anaemia
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 At baseline 2 452 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.83, 1.00]
4.2 At Day 28 2 429 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.79, 1.14]
5 Serious adverse events (including
deaths)
4 1108 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.14, 7.02]
Comparison 13. Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure (P. falciparum) Day
28 PCR unadjusted
8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 East Africa 5 3317 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.51, 1.01]
1.2 West Africa 2 766 Risk Ratio (M-H, Random, 95% CI) 6.57 [0.68, 63.26]
1.3 Other 1 155 Risk Ratio (M-H, Random, 95% CI) 3.12 [1.05, 9.25]
2 Total Failure (P. falciparum) Day
28 PCR adjusted
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 East Africa 3 1515 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.22, 0.89]
2.2 West Africa 2 701 Risk Ratio (M-H, Random, 95% CI) 9.72 [1.19, 79.26]
2.3 Other 1 148 Risk Ratio (M-H, Random, 95% CI) 2.23 [0.58, 8.58]
3 Gametocyte development 2 1354 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.54, 0.82]
4 Gametocyte carriage 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Gametocyte carriage day 0 3 909 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.13, 3.59]
4.2 Gametocyte carriage day 3 1 521 Risk Ratio (M-H, Random, 95% CI) Not estimable
4.3 Gametocyte carriage day 7 3 897 Risk Ratio (M-H, Random, 95% CI) 0.25 [0.02, 2.69]
4.4 Gametocyte carriage day
14
3 894 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.16, 2.02]
5 Anaemia 4 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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5.1 Mean haemoglobin (g/dl)
at baseline
4 Mean Difference (IV, Fixed, 95% CI) Not estimable
5.2 Mean change in
haemoglobin (g/dl) from
baseline to day 14
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
5.3 Mean change in
haemoglobin (g/dl) from
baseline to Day 28
2 Mean Difference (IV, Fixed, 95% CI) Not estimable
5.4 Mean haemoglobin (g/dl)
at Day 28
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
6 Serious adverse events (including
deaths)
7 4200 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.36, 1.03]
Comparison 14. Dihydroartemisinin-piperaquine dose analysis: 3 dose vs 4 dose regimen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure PCR unadjusted 1 318 Risk Ratio (M-H, Fixed, 95% CI) 1.72 [0.84, 3.53]
1.1 Day 63 1 318 Risk Ratio (M-H, Fixed, 95% CI) 1.72 [0.84, 3.53]
2 Total Failure PCR adjusted 1 292 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.05, 6.09]
2.1 Day 63 1 292 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.05, 6.09]
Comparison 15. Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus mefloquine)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure Day 63 PCR
unadjusted
4 1784 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.49, 1.38]
1.1 DHA-P 4 doses 3 1019 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.59, 1.10]
1.2 DHA-P 3 doses 2 765 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.09, 22.81]
2 Total Failure Day 63 PCR
adjusted
4 1634 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.18, 1.31]
2.1 DHA-P 4 doses 3 908 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.17, 1.04]
2.2 DHA-P 3 doses 2 726 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.03, 48.28]
3 Total Failure Day 42 PCR
unadjusted
5 2126 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.43, 1.35]
3.1 DHA-P 4 doses 3 957 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.50, 1.28]
3.2 DHA-P 3 doses 3 1169 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.20, 3.81]
4 Total Failure Day 42 PCR
adjusted
5 2043 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.20, 1.91]
4.1 DHA-P 4 doses 3 903 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.14, 2.82]
4.2 DHA-P 3 doses 3 1140 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.08, 5.87]
5 Total Failure Day 28 PCR
unadjusted
6 2191 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.20, 2.65]
5.1 DHA-P 4 doses 4 1075 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.10, 3.14]
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5.2 DHA-P 3 doses 3 1116 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.09, 18.93]
6 Total Failure Day 28 PCR
adjusted
6 2171 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.19, 2.86]
6.1 DHA-P 4 doses 4 1067 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.10, 6.11]
6.2 DHA-P 3 doses 3 1104 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.08, 7.82]
Comparison 16. Artesunate Mefloquine dose analysis: FDC versus split dose regimen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure Day 63 PCR
unadjusted
1 423 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.68, 1.27]
2 Total Failure Day 63 PCR
adjusted
1 342 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.34, 1.28]
Comparison 17. Artesunate plus mefloquine dose analysis (versus Dihydroartemisinin-piperaquine)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure Day 63 PCR
adjusted
3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Total Failure Day 28 PCR
adjusted
2 279 Risk Ratio (M-H, Fixed, 95% CI) 2.16 [0.23, 19.88]
Comparison 18. How does Dihydroartemisinin-piperaquine perform?
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Effectiveness: Total Failure (P.
falciparum) PCR adjusted
11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Day 63: DHA-P vs
Artesunate plus mefloquine
4 1497 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.17, 1.83]
1.2 Day 42: DHA-P vs
Artemether-lumefantrine
5 1337 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.29, 1.30]
1.3 Day 28: DHA-P vs
Artesunate plus amodiaquine
2 629 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.13, 1.35]
1.4 Day 42: DHA-P vs
Artesunate plus sulfadoxine-
pyrimethamine
1 161 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.39, 1.51]
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1.5 Day 28: DHA-P vs
Amodiaquine plus sulfadoxine-
pyrimethamine
2 802 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.16, 0.64]
Comparison 19. How does Artesunate plus mefloquine perform?
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Effectiveness: Total Failure (P.
falciparum) PCR adjusted
9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Day 63: AS+MQ
vs Dihydroartemisinin-
piperaquine
4 1497 Risk Ratio (M-H, Random, 95% CI) 1.77 [0.55, 5.72]
1.2 Day 42: AS+MQ vs
Artemether-lumefantrine
4 904 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.05, 2.84]
1.3 Day 28: AS+MQ vs
Artesunate plus amodiaquine
1 482 Risk Ratio (M-H, Random, 95% CI) Not estimable
1.4 Day 28: AS+MQ vs
Artesunate plus sulfadoxine-
pyrimethamine
0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
1.5 Day 28: AS+MQ vs
Amodiaquine plus sulfadoxine-
pyrimethamine
1 296 Risk Ratio (M-H, Random, 95% CI) Not estimable
Comparison 20. How does Artemether-lumefantrine perform?
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Effectiveness: Total Failure (P.
falciparum) Day PCR adjusted
19 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Day 42: AL vs
Dihydroartemisinin-
piperaquine
5 1337 Risk Ratio (M-H, Random, 95% CI) 1.61 [0.77, 3.39]
1.2 Day 42: AL vs Artesunate
plus mefloquine
4 904 Risk Ratio (M-H, Random, 95% CI) 2.66 [0.35, 20.09]
1.3 Day 28: AL vs Artesunate
plus amodiaquine
8 1729 Risk Ratio (M-H, Random, 95% CI) 1.71 [0.97, 3.02]
1.4 Day 42: AL vs
Artesunate plus sulfadoxine-
pyrimethamine
1 158 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.13, 0.86]
1.5 Day 28: AL vs
Amodiaquine plus sulfadoxine-
pyrimethamine
5 1669 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.08, 2.11]
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Comparison 21. How does Artesunate plus amodiaquine perform?
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Effectiveness: Total Failure (P.
falciparum) PCR adjusted
19 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Day 28: AS+AQ
vs Dihydroartemisinin-
piperaquine
2 629 Risk Ratio (M-H, Random, 95% CI) 2.36 [0.74, 7.54]
1.2 Day 28: AS+AQ vs
Artesunate plus mefloquine
1 482 Risk Ratio (M-H, Random, 95% CI) Not estimable
1.3 Day 28: AS+AQ vs
Artemether-lumefantrine
8 1729 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.33, 1.03]
1.4 Day 28: AS+AQ vs
Artesunate plus sulfadoxine-
pyrimethamine
7 1419 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.34, 1.45]
1.5 Day 28: AS+AQ vs
Amodiaquine plus sulfadoxine-
pyrimethamine
6 2364 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.33, 1.63]
Analysis 1.1. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 1
Total Failure (P. falciparum) Day 63 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine
Outcome: 1 Total Failure (P. falciparum) Day 63 PCR unadjusted
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Asia
Ashley 2003b THA 26/154 29/151 33.7 % 0.88 [ 0.54, 1.42 ]
Janssens 2003 KHM 18/195 22/207 24.6 % 0.87 [ 0.48, 1.57 ]
Ashley 2004 THA 29/318 27/157 41.7 % 0.53 [ 0.33, 0.86 ]
Subtotal (95% CI) 667 515 100.0 % 0.73 [ 0.54, 0.98 ]
Total events: 73 (DHA-P), 78 (AS+MQ)
Heterogeneity: Chi2 = 2.56, df = 2 (P = 0.28); I2 =22%
Test for overall effect: Z = 2.09 (P = 0.037)
2 South America
Grande 2005 PER 12/219 2/226 100.0 % 6.19 [ 1.40, 27.35 ]
0.01 0.1 1 10 100
Favours DHA-P Favours AS+MQ
(Continued . . . )
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(. . . Continued)
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 219 226 100.0 % 6.19 [ 1.40, 27.35 ]
Total events: 12 (DHA-P), 2 (AS+MQ)
Heterogeneity: not applicable
Test for overall effect: Z = 2.41 (P = 0.016)
0.01 0.1 1 10 100
Favours DHA-P Favours AS+MQ
Analysis 1.2. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 2
Total Failure (P. falciparum) Day 63 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine
Outcome: 2 Total Failure (P. falciparum) Day 63 PCR adjusted
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Asia
Ashley 2003b THA 3/131 9/131 38.4 % 0.33 [ 0.09, 1.20 ]
Janssens 2003 KHM 4/181 5/190 20.8 % 0.84 [ 0.23, 3.08 ]
Ashley 2004 THA 3/292 7/137 40.7 % 0.20 [ 0.05, 0.77 ]
Subtotal (95% CI) 604 458 100.0 % 0.39 [ 0.19, 0.79 ]
Total events: 10 (DHA-P), 21 (AS+MQ)
Heterogeneity: Chi2 = 2.34, df = 2 (P = 0.31); I2 =15%
Test for overall effect: Z = 2.58 (P = 0.0099)
2 South America
Grande 2005 PER 4/211 0/224 100.0 % 9.55 [ 0.52, 176.35 ]
Subtotal (95% CI) 211 224 100.0 % 9.55 [ 0.52, 176.35 ]
Total events: 4 (DHA-P), 0 (AS+MQ)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
0.005 0.1 1 10 200
Favours DHA-P Favours AS+MQ
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Analysis 1.3. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 3
Total Failure (P. falciparum) Day 42 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine
Outcome: 3 Total Failure (P. falciparum) Day 42 PCR unadjusted
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Asia
Tran 2002 VNM 16/166 7/77 24.2 % 1.06 [ 0.45, 2.47 ]
Janssens 2003 KHM 9/195 9/207 22.9 % 1.06 [ 0.43, 2.62 ]
Mayxay 2004 LAO 4/106 5/108 15.7 % 0.82 [ 0.23, 2.95 ]
Smithuis 2004 MMR 6/319 1/316 7.7 % 5.94 [ 0.72, 49.09 ]
Ashley 2004 THA 16/318 19/157 29.5 % 0.42 [ 0.22, 0.79 ]
0.01 0.1 1 10 100
Favours DHA-P Favours AS+MQ
Analysis 1.4. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 4
Total Failure (P. falciparum) Day 42 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine
Outcome: 4 Total Failure (P. falciparum) Day 42 PCR adjusted
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Asia
Tran 2002 VNM 2/152 1/71 9.5 % 0.93 [ 0.09, 10.13 ]
Janssens 2003 KHM 3/189 2/200 13.6 % 1.59 [ 0.27, 9.39 ]
Smithuis 2004 MMR 2/315 0/315 3.5 % 5.00 [ 0.24, 103.73 ]
Ashley 2004 THA 2/304 7/145 66.4 % 0.14 [ 0.03, 0.65 ]
Mayxay 2004 LAO 1/103 1/104 7.0 % 1.01 [ 0.06, 15.93 ]
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Analysis 1.5. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 5
Total Failure (P. falciparum) Day 28 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine
Outcome: 5 Total Failure (P. falciparum) Day 28 PCR unadjusted
Study or subgroup DHA-P AS+MQ Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Asia
Tran 2002 VNM 0/166 0/77 0.0 [ 0.0, 0.0 ]
Janssens 2003 KHM 2/195 2/207 1.06 [ 0.15, 7.46 ]
Ashley 2003a THA 1/59 0/59 3.00 [ 0.12, 72.18 ]
Ashley 2004 THA 5/318 13/157 0.19 [ 0.07, 0.52 ]
Smithuis 2004 MMR 6/319 0/316 12.88 [ 0.73, 227.64 ]
Tangpukdee 2005 THA 1/107 0/54 1.53 [ 0.06, 36.89 ]
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Analysis 1.6. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 6
Total Failure (P. falciparum) Day 28 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine
Outcome: 6 Total Failure (P. falciparum) Day 28 PCR adjusted
Study or subgroup DHA-P AS+MQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Asia
Tran 2002 VNM 0/166 0/77 0.0 [ 0.0, 0.0 ]
Janssens 2003 KHM 2/195 1/206 2.11 [ 0.19, 23.11 ]
Ashley 2003a THA 1/59 0/59 3.00 [ 0.12, 72.18 ]
Ashley 2004 THA 2/315 7/151 0.14 [ 0.03, 0.65 ]
Smithuis 2004 MMR 2/315 0/316 5.02 [ 0.24, 104.06 ]
Tangpukdee 2005 THA 1/107 0/54 1.53 [ 0.06, 36.89 ]
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Analysis 1.7. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 7 P.
vivax parasitaemia.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine
Outcome: 7 P. vivax parasitaemia
Study or subgroup DHA-P AS+MQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mixed P. falciparum and vivax infection at baseline
Ashley 2003b THA 13/179 19/176 0.67 [ 0.34, 1.32 ]
Smithuis 2004 MMR 40/327 47/325 0.85 [ 0.57, 1.25 ]
Ashley 2004 THA 31/333 16/166 0.97 [ 0.54, 1.71 ]
Mayxay 2004 LAO 0/110 0/110 0.0 [ 0.0, 0.0 ]
Grande 2005 PER 0/262 0/260 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1211 1037 0.84 [ 0.63, 1.12 ]
Total events: 84 (DHA-P), 82 (AS+MQ)
Heterogeneity: Chi2 = 0.65, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
2 Total P. vivax parasitaemia by day 28
Janssens 2003 KHM 3/195 0/207 7.43 [ 0.39, 142.89 ]
Subtotal (95% CI) 195 207 7.43 [ 0.39, 142.89 ]
Total events: 3 (DHA-P), 0 (AS+MQ)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
3 Total P. vivax parasitaemia by day 42
Janssens 2003 KHM 10/195 9/207 1.18 [ 0.49, 2.84 ]
Smithuis 2004 MMR 40/319 57/316 0.70 [ 0.48, 1.01 ]
Mayxay 2004 LAO 3/106 1/108 3.06 [ 0.32, 28.92 ]
Subtotal (95% CI) 620 631 0.79 [ 0.57, 1.11 ]
Total events: 53 (DHA-P), 67 (AS+MQ)
Heterogeneity: Chi2 = 2.65, df = 2 (P = 0.27); I2 =24%
Test for overall effect: Z = 1.35 (P = 0.18)
4 Total P. vivax parasitaemia by day 63
Janssens 2003 KHM 39/195 47/207 0.88 [ 0.60, 1.28 ]
Ashley 2003b THA 52/156 42/152 1.21 [ 0.86, 1.69 ]
Ashley 2004 THA 89/319 38/166 1.22 [ 0.88, 1.70 ]
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(. . . Continued)
Study or subgroup DHA-P AS+MQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Grande 2005 PER 11/230 10/236 1.13 [ 0.49, 2.61 ]
Subtotal (95% CI) 900 761 1.11 [ 0.91, 1.34 ]
Total events: 191 (DHA-P), 137 (AS+MQ)
Heterogeneity: Chi2 = 1.99, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
5 P. vivax parasitaemia by day 63 in those negative at baseline
Ashley 2003b THA 48/143 36/133 1.24 [ 0.86, 1.78 ]
Ashley 2004 THA 74/288 30/142 1.22 [ 0.84, 1.77 ]
Grande 2005 PER 11/230 10/236 1.13 [ 0.49, 2.61 ]
Subtotal (95% CI) 661 511 1.22 [ 0.95, 1.56 ]
Total events: 133 (DHA-P), 76 (AS+MQ)
Heterogeneity: Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
6 P. vivax parasitaemia by day 63 in those positive at baseline
Ashley 2003b THA 4/13 6/19 0.97 [ 0.34, 2.78 ]
Ashley 2004 THA 15/31 8/16 0.97 [ 0.53, 1.78 ]
Subtotal (95% CI) 44 35 0.97 [ 0.57, 1.65 ]
Total events: 19 (DHA-P), 14 (AS+MQ)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
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Analysis 1.8. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 8
Gametocyte development (in those negative at baseline).
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine
Outcome: 8 Gametocyte development (in those negative at baseline)
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ashley 2003b THA 3/168 2/163 37.4 % 1.46 [ 0.25, 8.60 ]
Ashley 2004 THA 9/310 1/153 24.6 % 4.44 [ 0.57, 34.74 ]
Grande 2005 PER 8/227 2/213 38.0 % 3.75 [ 0.81, 17.48 ]
Total (95% CI) 705 529 100.0 % 3.06 [ 1.13, 8.33 ]
Total events: 20 (DHA-P), 5 (AS+MQ)
Heterogeneity: Chi2 = 0.87, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.19 (P = 0.028)
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Analysis 1.9. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 9
Gametocytaemia carriage.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine
Outcome: 9 Gametocytaemia carriage
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Gametocyte carriage day 0
Smithuis 2004 MMR 137/327 103/325 52.3 % 1.32 [ 1.08, 1.62 ]
Grande 2005 PER 35/262 43/260 47.7 % 0.81 [ 0.54, 1.22 ]
Subtotal (95% CI) 589 585 100.0 % 1.07 [ 0.66, 1.73 ]
Total events: 172 (DHA-P), 146 (AS+MQ)
Heterogeneity: Tau2 = 0.10; Chi2 = 4.48, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 0.27 (P = 0.79)
2 Gametocyte carriage day 7
Smithuis 2004 MMR 118/322 58/318 58.3 % 2.01 [ 1.53, 2.64 ]
Grande 2005 PER 17/256 9/256 41.7 % 1.89 [ 0.86, 4.16 ]
Subtotal (95% CI) 578 574 100.0 % 2.00 [ 1.54, 2.58 ]
Total events: 135 (DHA-P), 67 (AS+MQ)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 5.24 (P < 0.00001)
3 Gametocyte carriage day 14
Smithuis 2004 MMR 84/318 17/318 78.0 % 4.94 [ 3.00, 8.13 ]
Grande 2005 PER 10/253 1/253 22.0 % 10.00 [ 1.29, 77.54 ]
Subtotal (95% CI) 571 571 100.0 % 5.14 [ 3.17, 8.33 ]
Total events: 94 (DHA-P), 18 (AS+MQ)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 6.64 (P < 0.00001)
4 Gametocyte carriage day 21
Smithuis 2004 MMR 26/316 0/310 49.6 % 52.00 [ 3.18, 849.49 ]
Grande 2005 PER 1/247 1/250 50.4 % 1.01 [ 0.06, 16.09 ]
Subtotal (95% CI) 563 560 100.0 % 7.23 [ 0.10, 519.79 ]
Total events: 27 (DHA-P), 1 (AS+MQ)
Heterogeneity: Tau2 = 7.51; Chi2 = 4.73, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.91 (P = 0.36)
5 Gametocyte carriage day 28
Smithuis 2004 MMR 6/318 0/314 51.3 % 12.84 [ 0.73, 226.91 ]
Grande 2005 PER 3/243 0/249 48.7 % 7.17 [ 0.37, 138.12 ]
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(. . . Continued)
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Subtotal (95% CI) 561 563 100.0 % 9.68 [ 1.23, 75.98 ]
Total events: 9 (DHA-P), 0 (AS+MQ)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.16 (P = 0.031)
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Analysis 1.10. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 10
Serious adverse events (including deaths).
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine
Outcome: 10 Serious adverse events (including deaths)
Study or subgroup DHA-P AS+MQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ashley 2003a THA 0/67 0/67 0.0 [ 0.0, 0.0 ]
Janssens 2003 KHM 0/228 0/236 0.0 [ 0.0, 0.0 ]
Ashley 2003b THA 1/179 0/176 2.95 [ 0.12, 71.93 ]
Mayxay 2004 LAO 0/110 1/110 0.33 [ 0.01, 8.09 ]
Ashley 2004 THA 11/333 4/166 1.37 [ 0.44, 4.24 ]
Grande 2005 PER 0/262 3/260 0.14 [ 0.01, 2.73 ]
Tangpukdee 2005 THA 0/120 0/60 0.0 [ 0.0, 0.0 ]
Total (95% CI) 1299 1075 0.90 [ 0.38, 2.15 ]
Total events: 12 (DHA-P), 8 (AS+MQ)
Heterogeneity: Chi2 = 2.93, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
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Analysis 1.11. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 11
Early vomiting.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine
Outcome: 11 Early vomiting
Study or subgroup DHA-P AS+MQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Janssens 2003 KHM 56/228 67/236 0.87 [ 0.64, 1.17 ]
Ashley 2003a THA 0/67 0/67 0.0 [ 0.0, 0.0 ]
Ashley 2003b THA 9/179 5/177 1.78 [ 0.61, 5.21 ]
Smithuis 2004 MMR 8/156 10/162 0.83 [ 0.34, 2.05 ]
Ashley 2004 THA 8/333 6/166 0.66 [ 0.23, 1.88 ]
Grande 2005 PER 10/262 11/260 0.90 [ 0.39, 2.09 ]
Tangpukdee 2005 THA 0/120 0/60 0.0 [ 0.0, 0.0 ]
Total (95% CI) 1345 1128 0.90 [ 0.69, 1.16 ]
Total events: 91 (DHA-P), 99 (AS+MQ)
Heterogeneity: Chi2 = 1.96, df = 4 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
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Analysis 1.12. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 12
Sensitivity analysis: Total Failure Day 63 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine
Outcome: 12 Sensitivity analysis: Total Failure Day 63 PCR unadjusted
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Total Failure (P. falciparum) Day 63 PCR unadjusted
Ashley 2003b THA 26/154 29/151 32.2 % 0.88 [ 0.54, 1.42 ]
Janssens 2003 KHM 18/195 22/207 27.5 % 0.87 [ 0.48, 1.57 ]
Ashley 2004 THA 29/318 27/157 31.8 % 0.53 [ 0.33, 0.86 ]
Grande 2005 PER 12/219 2/226 8.5 % 6.19 [ 1.40, 27.35 ]
Subtotal (95% CI) 886 741 100.0 % 0.94 [ 0.52, 1.70 ]
Total events: 85 (DHA-P), 80 (AS+MQ)
Heterogeneity: Tau2 = 0.24; Chi2 = 10.50, df = 3 (P = 0.01); I2 =71%
Test for overall effect: Z = 0.21 (P = 0.83)
2 Total Failure Day 63 PCR unadjusted (losses to follow up included as failures)
Ashley 2003b THA 51/179 54/176 27.1 % 0.93 [ 0.67, 1.28 ]
Janssens 2003 KHM 38/215 45/230 25.0 % 0.90 [ 0.61, 1.33 ]
Ashley 2004 THA 43/332 36/166 24.6 % 0.60 [ 0.40, 0.89 ]
Grande 2005 PER 45/252 27/251 23.3 % 1.66 [ 1.06, 2.59 ]
Subtotal (95% CI) 978 823 100.0 % 0.95 [ 0.65, 1.38 ]
Total events: 177 (DHA-P), 162 (AS+MQ)
Heterogeneity: Tau2 = 0.11; Chi2 = 11.26, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 0.29 (P = 0.77)
3 Total Failure Day 63 PCR unadjusted (losses to follow up included as successes)
Ashley 2003b THA 26/179 29/176 32.0 % 0.88 [ 0.54, 1.43 ]
Janssens 2003 KHM 18/215 22/230 27.6 % 0.88 [ 0.48, 1.59 ]
Ashley 2004 THA 29/332 27/166 31.9 % 0.54 [ 0.33, 0.88 ]
Grande 2005 PER 12/252 2/251 8.5 % 5.98 [ 1.35, 26.43 ]
Subtotal (95% CI) 978 823 100.0 % 0.94 [ 0.52, 1.68 ]
Total events: 85 (DHA-P), 80 (AS+MQ)
Heterogeneity: Tau2 = 0.23; Chi2 = 10.06, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 0.22 (P = 0.82)
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Analysis 1.13. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 13
Sensitivity analysis: Total Failure Day 63 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine
Outcome: 13 Sensitivity analysis: Total Failure Day 63 PCR adjusted
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Total Failure (P. falciparum) Day 63 PCR adjusted
Ashley 2003b THA 3/131 9/131 31.7 % 0.33 [ 0.09, 1.20 ]
Janssens 2003 KHM 4/181 5/190 31.2 % 0.84 [ 0.23, 3.08 ]
Ashley 2004 THA 3/292 7/137 29.7 % 0.20 [ 0.05, 0.77 ]
Grande 2005 PER 4/211 0/224 7.4 % 9.55 [ 0.52, 176.35 ]
Subtotal (95% CI) 815 682 100.0 % 0.57 [ 0.17, 1.83 ]
Total events: 14 (DHA-P), 21 (AS+MQ)
Heterogeneity: Tau2 = 0.78; Chi2 = 6.94, df = 3 (P = 0.07); I2 =57%
Test for overall effect: Z = 0.95 (P = 0.34)
2 Total Failure Day 63 PCR adjusted (indeterminate PCR included as failures)
Ashley 2003b THA 7/135 10/132 36.1 % 0.68 [ 0.27, 1.74 ]
Janssens 2003 KHM 4/181 6/191 23.7 % 0.70 [ 0.20, 2.45 ]
Ashley 2004 THA 6/295 8/138 31.2 % 0.35 [ 0.12, 0.99 ]
Grande 2005 PER 4/211 1/225 9.0 % 4.27 [ 0.48, 37.86 ]
Subtotal (95% CI) 822 686 100.0 % 0.67 [ 0.32, 1.39 ]
Total events: 21 (DHA-P), 25 (AS+MQ)
Heterogeneity: Tau2 = 0.17; Chi2 = 4.28, df = 3 (P = 0.23); I2 =30%
Test for overall effect: Z = 1.08 (P = 0.28)
3 Total Failure Day 63 PCR adjusted (new infections included as successes)
Ashley 2003b THA 7/154 10/151 36.0 % 0.69 [ 0.27, 1.76 ]
Janssens 2003 KHM 4/195 6/207 23.7 % 0.71 [ 0.20, 2.47 ]
Ashley 2004 THA 6/318 8/157 31.2 % 0.37 [ 0.13, 1.05 ]
Grande 2005 PER 4/219 1/226 9.1 % 4.13 [ 0.47, 36.64 ]
Subtotal (95% CI) 886 741 100.0 % 0.67 [ 0.34, 1.35 ]
Total events: 21 (DHA-P), 25 (AS+MQ)
Heterogeneity: Tau2 = 0.12; Chi2 = 3.96, df = 3 (P = 0.27); I2 =24%
Test for overall effect: Z = 1.11 (P = 0.27)
4 Total Failure Day 63 PCR adjusted (losses to follow up included as failures)
Ashley 2003b THA 32/179 35/176 27.8 % 0.90 [ 0.58, 1.38 ]
Janssens 2003 KHM 24/215 29/230 24.9 % 0.89 [ 0.53, 1.47 ]
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(. . . Continued)
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Ashley 2004 THA 20/332 17/166 21.0 % 0.59 [ 0.32, 1.09 ]
Grande 2005 PER 37/252 26/251 26.3 % 1.42 [ 0.89, 2.27 ]
Subtotal (95% CI) 978 823 100.0 % 0.93 [ 0.67, 1.30 ]
Total events: 113 (DHA-P), 107 (AS+MQ)
Heterogeneity: Tau2 = 0.05; Chi2 = 5.22, df = 3 (P = 0.16); I2 =43%
Test for overall effect: Z = 0.41 (P = 0.68)
5 Total Failure Day 63 PCR adjusted (losses to follow up included as successes)
Ashley 2003b THA 7/179 10/176 35.9 % 0.69 [ 0.27, 1.77 ]
Janssens 2003 KHM 4/215 6/230 23.7 % 0.71 [ 0.20, 2.49 ]
Ashley 2004 THA 6/332 8/166 31.3 % 0.38 [ 0.13, 1.06 ]
Grande 2005 PER 4/252 1/251 9.1 % 3.98 [ 0.45, 35.40 ]
Subtotal (95% CI) 978 823 100.0 % 0.67 [ 0.34, 1.33 ]
Total events: 21 (DHA-P), 25 (AS+MQ)
Heterogeneity: Tau2 = 0.10; Chi2 = 3.80, df = 3 (P = 0.28); I2 =21%
Test for overall effect: Z = 1.14 (P = 0.25)
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Analysis 2.1. Comparison 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine, Outcome 1 Total
Failure (P. falciparum) Day 42 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine
Outcome: 1 Total Failure (P. falciparum) Day 42 PCR unadjusted
Study or subgroup DHA-P AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Africa
Kamya 2006 UGA 90/207 108/197 38.4 % 0.79 [ 0.65, 0.97 ]
Zongo 2007 BFA 13/172 55/176 29.5 % 0.24 [ 0.14, 0.43 ]
Yeka 2007 UGA 21/207 46/177 32.0 % 0.39 [ 0.24, 0.63 ]
Subtotal (95% CI) 586 550 100.0 % 0.44 [ 0.20, 0.95 ]
Total events: 124 (DHA-P), 209 (AL6)
Heterogeneity: Tau2 = 0.42; Chi2 = 22.19, df = 2 (P = 0.00002); I2 =91%
Test for overall effect: Z = 2.10 (P = 0.036)
2 Asia
Ratcliff 2005 IDN 19/195 26/161 100.0 % 0.60 [ 0.35, 1.05 ]
Subtotal (95% CI) 195 161 100.0 % 0.60 [ 0.35, 1.05 ]
Total events: 19 (DHA-P), 26 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.074)
3 Oceania
Karunajeewa 2007 PNG 42/107 40/109 100.0 % 1.07 [ 0.76, 1.50 ]
Subtotal (95% CI) 107 109 100.0 % 1.07 [ 0.76, 1.50 ]
Total events: 42 (DHA-P), 40 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
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Analysis 2.2. Comparison 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine, Outcome 2 Total
Failure (P. falciparum) Day 42 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine
Outcome: 2 Total Failure (P. falciparum) Day 42 PCR adjusted
Study or subgroup DHA-P AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Kamya 2006 UGA 13/130 28/117 60.4 % 0.42 [ 0.23, 0.77 ]
Yeka 2007 UGA 4/190 10/141 23.5 % 0.30 [ 0.10, 0.93 ]
Zongo 2007 BFA 4/163 7/128 16.1 % 0.45 [ 0.13, 1.50 ]
Subtotal (95% CI) 483 386 100.0 % 0.39 [ 0.24, 0.64 ]
Total events: 21 (DHA-P), 45 (AL6)
Heterogeneity: Chi2 = 0.32, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 3.72 (P = 0.00020)
2 Asia
Ratcliff 2005 IDN 3/179 3/138 100.0 % 0.77 [ 0.16, 3.76 ]
Subtotal (95% CI) 179 138 100.0 % 0.77 [ 0.16, 3.76 ]
Total events: 3 (DHA-P), 3 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
3 Oceania
Karunajeewa 2007 PNG 12/77 5/74 100.0 % 2.31 [ 0.85, 6.23 ]
Subtotal (95% CI) 77 74 100.0 % 2.31 [ 0.85, 6.23 ]
Total events: 12 (DHA-P), 5 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
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Analysis 2.3. Comparison 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine, Outcome 3 Total
Failure (P. falciparum) Day 28 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine
Outcome: 3 Total Failure (P. falciparum) Day 28 PCR unadjusted
Study or subgroup DHA-P AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Zongo 2007 BFA 4/172 36/178 95.9 % 0.11 [ 0.04, 0.32 ]
Mens 2007 KEN 0/67 1/67 4.1 % 0.33 [ 0.01, 8.04 ]
Subtotal (95% CI) 239 245 100.0 % 0.12 [ 0.05, 0.32 ]
Total events: 4 (DHA-P), 37 (AL6)
Heterogeneity: Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 4.27 (P = 0.000020)
2 Asia
Ratcliff 2005 IDN 6/233 13/218 100.0 % 0.43 [ 0.17, 1.12 ]
Subtotal (95% CI) 233 218 100.0 % 0.43 [ 0.17, 1.12 ]
Total events: 6 (DHA-P), 13 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.083)
3 Oceania
Karunajeewa 2007 PNG 25/111 20/113 100.0 % 1.27 [ 0.75, 2.15 ]
Subtotal (95% CI) 111 113 100.0 % 1.27 [ 0.75, 2.15 ]
Total events: 25 (DHA-P), 20 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
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Analysis 2.4. Comparison 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine, Outcome 4 Total
Failure (P. falciparum) Day 28 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine
Outcome: 4 Total Failure (P. falciparum) Day 28 PCR adjusted
Study or subgroup DHA-P AL6 Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Zongo 2007 BFA 4/172 6/148 0.57 [ 0.17, 1.99 ]
Mens 2007 KEN 0/67 0/66 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 239 214 0.57 [ 0.17, 1.99 ]
Total events: 4 (DHA-P), 6 (AL6)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.38)
2 Asia
Ratcliff 2005 IDN 2/229 2/207 0.90 [ 0.13, 6.36 ]
Subtotal (95% CI) 229 207 0.90 [ 0.13, 6.36 ]
Total events: 2 (DHA-P), 2 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
3 Oceania
Karunajeewa 2007 PNG 11/97 3/96 3.63 [ 1.04, 12.60 ]
Subtotal (95% CI) 97 96 3.63 [ 1.04, 12.60 ]
Total events: 11 (DHA-P), 3 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.042)
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Analysis 2.5. Comparison 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine, Outcome 5 P.
vivax parasitaemia.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine
Outcome: 5 P. vivax parasitaemia
Study or subgroup DHA-P AL6 Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mixed P. falciparum and vivax infection at baseline
Ratcliff 2005 IDN 57/289 56/290 1.02 [ 0.73, 1.42 ]
Kamya 2006 UGA 0/211 0/210 0.0 [ 0.0, 0.0 ]
Karunajeewa 2007 PNG 0/100 0/94 0.0 [ 0.0, 0.0 ]
Yeka 2007 UGA 0/215 0/199 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 815 793 1.02 [ 0.73, 1.42 ]
Total events: 57 (DHA-P), 56 (AL6)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
2 P. vivax parasitaemia by D28
Ratcliff 2005 IDN 1/234 21/239 0.05 [ 0.01, 0.36 ]
Subtotal (95% CI) 234 239 0.05 [ 0.01, 0.36 ]
Total events: 1 (DHA-P), 21 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 2.97 (P = 0.0030)
3 P. vivax parasitaemia by D42
Ratcliff 2005 IDN 12/207 55/216 0.23 [ 0.13, 0.41 ]
Kamya 2006 UGA 2/209 11/208 0.18 [ 0.04, 0.81 ]
Yeka 2007 UGA 5/212 19/196 0.24 [ 0.09, 0.64 ]
Karunajeewa 2007 PNG 27/100 56/94 0.45 [ 0.32, 0.65 ]
Subtotal (95% CI) 728 714 0.32 [ 0.24, 0.43 ]
Total events: 46 (DHA-P), 141 (AL6)
Heterogeneity: Chi2 = 5.73, df = 3 (P = 0.13); I2 =48%
Test for overall effect: Z = 7.55 (P < 0.00001)
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Analysis 2.6. Comparison 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine, Outcome 6
Gametocyte development (in those negative at baseline).
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine
Outcome: 6 Gametocyte development (in those negative at baseline)
Study or subgroup DHA-P AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Kamya 2006 UGA 9/170 18/156 28.2 % 0.46 [ 0.21, 0.99 ]
Yeka 2007 UGA 9/201 21/179 28.4 % 0.38 [ 0.18, 0.81 ]
Zongo 2007 BFA 7/184 3/188 21.1 % 2.38 [ 0.63, 9.08 ]
Mens 2007 KEN 10/64 3/61 22.3 % 3.18 [ 0.92, 11.00 ]
Total (95% CI) 619 584 100.0 % 0.95 [ 0.35, 2.59 ]
Total events: 35 (DHA-P), 45 (AL6)
Heterogeneity: Tau2 = 0.78; Chi2 = 12.61, df = 3 (P = 0.01); I2 =76%
Test for overall effect: Z = 0.10 (P = 0.92)
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Analysis 2.7. Comparison 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine, Outcome 7
Anaemia.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine
Outcome: 7 Anaemia
Study or subgroup DHA-P AL6 Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean haemoglobin (g/dl) at baseline
Kamya 2006 UGA 211 9.5 (1.9) 210 9.7 (1.8) 31.3 % -0.20 [ -0.55, 0.15 ]
Zongo 2007 BFA 187 10.1 (2.4) 188 10.2 (2) 19.6 % -0.10 [ -0.55, 0.35 ]
Mens 2007 KEN 73 6.33 (1.29) 73 6.28 (1.27) 22.7 % 0.05 [ -0.37, 0.47 ]
Yeka 2007 UGA 215 9.9 (2.1) 199 9.9 (1.9) 26.4 % 0.0 [ -0.39, 0.39 ]
Subtotal (95% CI) 686 670 100.0 % -0.07 [ -0.27, 0.13 ]
Heterogeneity: Chi2 = 0.98, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
2 Mean haemoglobin (g/dl) at day 28
Mens 2007 KEN 67 7.15 (1.07) 67 6.79 (1.24) 100.0 % 0.36 [ -0.03, 0.75 ]
Subtotal (95% CI) 67 67 100.0 % 0.36 [ -0.03, 0.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.072)
3 Mean haemoglobin (g/dl) at day 42
Zongo 2007 BFA 187 11.6 (1.6) 188 11.3 (1.6) 100.0 % 0.30 [ -0.02, 0.62 ]
Subtotal (95% CI) 187 188 100.0 % 0.30 [ -0.02, 0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
4 Mean change in haemoglobin (g/dl) from baseline to Day 42
Kamya 2006 UGA 211 1.9 (1.8) 210 1.5 (1.8) 53.3 % 0.40 [ 0.06, 0.74 ]
Yeka 2007 UGA 215 1.75 (1.8) 199 1.66 (2) 46.7 % 0.09 [ -0.28, 0.46 ]
Subtotal (95% CI) 426 409 100.0 % 0.26 [ 0.00, 0.51 ]
Heterogeneity: Chi2 = 1.46, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 1.99 (P = 0.046)
Test for subgroup differences: Chi2 = 7.29, df = 3 (P = 0.06), I2 =59%
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Analysis 2.8. Comparison 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine, Outcome 8
Serious adverse events (including deaths).
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine
Outcome: 8 Serious adverse events (including deaths)
Study or subgroup DHA-P AL6 Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ratcliff 2005 IDN 1/379 2/375 0.49 [ 0.05, 5.43 ]
Kamya 2006 UGA 4/211 2/210 1.99 [ 0.37, 10.75 ]
Yeka 2007 UGA 5/215 2/199 2.31 [ 0.45, 11.79 ]
Zongo 2007 BFA 0/187 0/188 0.0 [ 0.0, 0.0 ]
Mens 2007 KEN 1/73 0/73 3.00 [ 0.12, 72.45 ]
Total (95% CI) 1065 1045 1.71 [ 0.66, 4.46 ]
Total events: 11 (DHA-P), 6 (AL6)
Heterogeneity: Chi2 = 1.31, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
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Analysis 2.9. Comparison 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine, Outcome 9 Early
vomiting.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine
Outcome: 9 Early vomiting
Study or subgroup DHA-P AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ratcliff 2005 IDN 11/379 10/375 77.1 % 1.09 [ 0.47, 2.53 ]
Zongo 2007 BFA 7/196 3/197 22.9 % 2.35 [ 0.62, 8.94 ]
Total (95% CI) 575 572 100.0 % 1.38 [ 0.68, 2.78 ]
Total events: 18 (DHA-P), 13 (AL6)
Heterogeneity: Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
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Analysis 3.1. Comparison 3 Dihydroartemisinin-piperaquine vs Artesunate plus amodiaquine, Outcome 1
Total Failure (P. falciparum) Day 28 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 3 Dihydroartemisinin-piperaquine vs Artesunate plus amodiaquine
Outcome: 1 Total Failure (P. falciparum) Day 28 PCR unadjusted
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Karema 2004 RWA 24/250 45/251 82.5 % 0.54 [ 0.34, 0.85 ]
Subtotal (95% CI) 250 251 82.5 % 0.54 [ 0.34, 0.85 ]
Total events: 24 (DHA-P), 45 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 2.64 (P = 0.0082)
2 Asia
Hasugian 2005 IDN 5/94 9/84 17.5 % 0.50 [ 0.17, 1.42 ]
Subtotal (95% CI) 94 84 17.5 % 0.50 [ 0.17, 1.42 ]
Total events: 5 (DHA-P), 9 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Total (95% CI) 344 335 100.0 % 0.53 [ 0.35, 0.81 ]
Total events: 29 (DHA-P), 54 (AS+AQ)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.95 (P = 0.0032)
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Analysis 3.2. Comparison 3 Dihydroartemisinin-piperaquine vs Artesunate plus amodiaquine, Outcome 2
Total Failure (P. falciparum) Day 28 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 3 Dihydroartemisinin-piperaquine vs Artesunate plus amodiaquine
Outcome: 2 Total Failure (P. falciparum) Day 28 PCR adjusted
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Karema 2004 RWA 10/236 16/222 72.3 % 0.59 [ 0.27, 1.27 ]
Subtotal (95% CI) 236 222 72.3 % 0.59 [ 0.27, 1.27 ]
Total events: 10 (DHA-P), 16 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
2 Asia
Hasugian 2005 IDN 1/90 6/81 27.7 % 0.15 [ 0.02, 1.22 ]
Subtotal (95% CI) 90 81 27.7 % 0.15 [ 0.02, 1.22 ]
Total events: 1 (DHA-P), 6 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.076)
Total (95% CI) 326 303 100.0 % 0.47 [ 0.23, 0.94 ]
Total events: 11 (DHA-P), 22 (AS+AQ)
Heterogeneity: Chi2 = 1.47, df = 1 (P = 0.22); I2 =32%
Test for overall effect: Z = 2.12 (P = 0.034)
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Analysis 3.3. Comparison 3 Dihydroartemisinin-piperaquine vs Artesunate plus amodiaquine, Outcome 3
Total Failure (P. falciparum) Day 42 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 3 Dihydroartemisinin-piperaquine vs Artesunate plus amodiaquine
Outcome: 3 Total Failure (P. falciparum) Day 42 PCR unadjusted
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Asia
Hasugian 2005 IDN 5/86 14/66 100.0 % 0.27 [ 0.10, 0.72 ]
Total (95% CI) 86 66 100.0 % 0.27 [ 0.10, 0.72 ]
Total events: 5 (DHA-P), 14 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0089)
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Analysis 3.4. Comparison 3 Dihydroartemisinin-piperaquine vs Artesunate plus amodiaquine, Outcome 4
Total Failure (P. falciparum) Day 42 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 3 Dihydroartemisinin-piperaquine vs Artesunate plus amodiaquine
Outcome: 4 Total Failure (P. falciparum) Day 42 PCR adjusted
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Asia
Hasugian 2005 IDN 1/82 7/59 100.0 % 0.10 [ 0.01, 0.81 ]
Total (95% CI) 82 59 100.0 % 0.10 [ 0.01, 0.81 ]
Total events: 1 (DHA-P), 7 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.031)
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Analysis 3.5. Comparison 3 Dihydroartemisinin-piperaquine vs Artesunate plus amodiaquine, Outcome 5 P.
vivax parasitaemia.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 3 Dihydroartemisinin-piperaquine vs Artesunate plus amodiaquine
Outcome: 5 P. vivax parasitaemia
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mixed P. falciparum and vivax infection at baseline
Hasugian 2005 IDN 20/114 15/106 100.0 % 1.24 [ 0.67, 2.29 ]
Subtotal (95% CI) 114 106 100.0 % 1.24 [ 0.67, 2.29 ]
Total events: 20 (DHA-P), 15 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
2 P. vivax parasitaemia by day 28
Hasugian 2005 IDN 1/95 2/86 100.0 % 0.45 [ 0.04, 4.90 ]
Subtotal (95% CI) 95 86 100.0 % 0.45 [ 0.04, 4.90 ]
Total events: 1 (DHA-P), 2 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
3 P. vivax parasitaemia by day 42
Hasugian 2005 IDN 4/90 14/80 100.0 % 0.25 [ 0.09, 0.74 ]
Subtotal (95% CI) 90 80 100.0 % 0.25 [ 0.09, 0.74 ]
Total events: 4 (DHA-P), 14 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 2.51 (P = 0.012)
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Analysis 3.6. Comparison 3 Dihydroartemisinin-piperaquine vs Artesunate plus amodiaquine, Outcome 6
Serious adverse events (including deaths).
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 3 Dihydroartemisinin-piperaquine vs Artesunate plus amodiaquine
Outcome: 6 Serious adverse events (including deaths)
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hasugian 2005 IDN 0/168 3/166 100.0 % 0.14 [ 0.01, 2.71 ]
Total (95% CI) 168 166 100.0 % 0.14 [ 0.01, 2.71 ]
Total events: 0 (DHA-P), 3 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
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Analysis 3.7. Comparison 3 Dihydroartemisinin-piperaquine vs Artesunate plus amodiaquine, Outcome 7
Early vomiting.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 3 Dihydroartemisinin-piperaquine vs Artesunate plus amodiaquine
Outcome: 7 Early vomiting
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hasugian 2005 IDN 7/168 13/166 100.0 % 0.53 [ 0.22, 1.30 ]
Total (95% CI) 168 166 100.0 % 0.53 [ 0.22, 1.30 ]
Total events: 7 (DHA-P), 13 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
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Analysis 4.1. Comparison 4 Dihydroartemisinin-piperaquine vs Artesunate plus sulfadoxine-
pyrimethamine, Outcome 1 Total Failure (P. falciparum) Day 42 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 4 Dihydroartemisinin-piperaquine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome: 1 Total Failure (P. falciparum) Day 42 PCR unadjusted
Study or subgroup DHA-P AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oceania
Karunajeewa 2007 PNG 42/107 41/108 100.0 % 1.03 [ 0.74, 1.45 ]
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Analysis 4.2. Comparison 4 Dihydroartemisinin-piperaquine vs Artesunate plus sulfadoxine-
pyrimethamine, Outcome 2 Total Failure (P. falciparum) Day 42 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 4 Dihydroartemisinin-piperaquine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome: 2 Total Failure (P. falciparum) Day 42 PCR adjusted
Study or subgroup DHA-P AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oceania
Karunajeewa 2007 PNG 12/77 17/84 100.0 % 0.77 [ 0.39, 1.51 ]
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Analysis 4.3. Comparison 4 Dihydroartemisinin-piperaquine vs Artesunate plus sulfadoxine-
pyrimethamine, Outcome 3 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 4 Dihydroartemisinin-piperaquine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome: 3 Total Failure (P. falciparum) Day 28 PCR unadjusted
Study or subgroup DHA-P AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oceania
Karunajeewa 2007 PNG 25/111 25/112 100.0 % 1.01 [ 0.62, 1.64 ]
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Analysis 4.4. Comparison 4 Dihydroartemisinin-piperaquine vs Artesunate plus sulfadoxine-
pyrimethamine, Outcome 4 Total Failure (P. falciparum) Day 28 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 4 Dihydroartemisinin-piperaquine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome: 4 Total Failure (P. falciparum) Day 28 PCR adjusted
Study or subgroup DHA-P AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oceania
Karunajeewa 2007 PNG 11/97 11/98 100.0 % 1.01 [ 0.46, 2.22 ]
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Analysis 4.5. Comparison 4 Dihydroartemisinin-piperaquine vs Artesunate plus sulfadoxine-
pyrimethamine, Outcome 5 P. vivax parasitaemia by day 42.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 4 Dihydroartemisinin-piperaquine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome: 5 P. vivax parasitaemia by day 42
Study or subgroup DHA-P AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with P. falciparum mono-infection at baseline
Karunajeewa 2007 PNG 27/100 56/94 100.0 % 0.45 [ 0.32, 0.65 ]
Subtotal (95% CI) 100 94 100.0 % 0.45 [ 0.32, 0.65 ]
Total events: 27 (DHA-P), 56 (AS+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 4.28 (P = 0.000019)
2 Participants with P. vivax P. falciparum at baseline
Karunajeewa 2007 PNG 11/36 26/39 100.0 % 0.46 [ 0.27, 0.79 ]
Subtotal (95% CI) 36 39 100.0 % 0.46 [ 0.27, 0.79 ]
Total events: 11 (DHA-P), 26 (AS+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 2.83 (P = 0.0046)
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Analysis 5.1. Comparison 5 Dihydroartemisinin-piperaquine vs Amodiaquine plus sulfadoxine-
pyrimethamine, Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 5 Dihydroartemisinin-piperaquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 1 Total Failure (P. falciparum) Day 28 PCR unadjusted
Study or subgroup DHA-P AQ+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Karema 2004 RWA 24/250 66/255 85.6 % 0.37 [ 0.24, 0.57 ]
Zongo 2007 BFA 4/172 11/171 14.4 % 0.36 [ 0.12, 1.11 ]
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Analysis 5.2. Comparison 5 Dihydroartemisinin-piperaquine vs Amodiaquine plus sulfadoxine-
pyrimethamine, Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 5 Dihydroartemisinin-piperaquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 2 Total Failure (P. falciparum) Day 28 PCR adjusted
Study or subgroup DHA-P AQ+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Karema 2004 RWA 10/236 38/227 84.5 % 0.25 [ 0.13, 0.50 ]
Zongo 2007 BFA 4/172 7/167 15.5 % 0.55 [ 0.17, 1.86 ]
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Analysis 5.3. Comparison 5 Dihydroartemisinin-piperaquine vs Amodiaquine plus sulfadoxine-
pyrimethamine, Outcome 3 Total Failure (P. falciparum) Day 42 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 5 Dihydroartemisinin-piperaquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 3 Total Failure (P. falciparum) Day 42 PCR unadjusted
Study or subgroup DHA-P AQ+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Zongo 2007 BFA 13/172 20/169 100.0 % 0.64 [ 0.33, 1.24 ]
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Analysis 5.4. Comparison 5 Dihydroartemisinin-piperaquine vs Amodiaquine plus sulfadoxine-
pyrimethamine, Outcome 4 Total Failure (P. falciparum) Day 42 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 5 Dihydroartemisinin-piperaquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 4 Total Failure (P. falciparum) Day 42 PCR adjusted
Study or subgroup DHA-P AQ+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Zongo 2007 BFA 4/163 7/156 100.0 % 0.55 [ 0.16, 1.83 ]
0.01 0.1 1 10 100
Favours DHA-P Favours AQ+SP
Analysis 5.5. Comparison 5 Dihydroartemisinin-piperaquine vs Amodiaquine plus sulfadoxine-
pyrimethamine, Outcome 5 Gametocyte development.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 5 Dihydroartemisinin-piperaquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 5 Gametocyte development
Study or subgroup DHA-P AQ+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zongo 2007 BFA 7/184 10/183 100.0 % 0.70 [ 0.27, 1.79 ]
Total (95% CI) 184 183 100.0 % 0.70 [ 0.27, 1.79 ]
Total events: 7 (DHA-P), 10 (AQ+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
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Analysis 5.6. Comparison 5 Dihydroartemisinin-piperaquine vs Amodiaquine plus sulfadoxine-
pyrimethamine, Outcome 6 Anaemia.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 5 Dihydroartemisinin-piperaquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 6 Anaemia
Study or subgroup DHA-P AQ+SP Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean haemoglobin (g/dl) at baseline
Zongo 2007 BFA 187 10.1 (2.4) 184 10.3 (2.3) 100.0 % -0.20 [ -0.68, 0.28 ]
Subtotal (95% CI) 187 184 100.0 % -0.20 [ -0.68, 0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
2 Mean haemoglobin (g/dl) at day 42 or last day of follow up
Zongo 2007 BFA 187 11.6 (1.6) 184 11.8 (1.4) 100.0 % -0.20 [ -0.51, 0.11 ]
Subtotal (95% CI) 187 184 100.0 % -0.20 [ -0.51, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
3 Mean packed cell volume at baseline
Karema 2004 RWA 252 31.5 (4.9) 258 31.5 (5.3) 100.0 % 0.0 [ -0.89, 0.89 ]
Subtotal (95% CI) 252 258 100.0 % 0.0 [ -0.89, 0.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Mean packed cell volume at day 14
Karema 2004 RWA 252 33.4 (3.6) 258 34.5 (3.7) 100.0 % -1.10 [ -1.73, -0.47 ]
Subtotal (95% CI) 252 258 100.0 % -1.10 [ -1.73, -0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.40 (P = 0.00067)
Test for subgroup differences: Chi2 = 7.14, df = 3 (P = 0.07), I2 =58%
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Analysis 5.7. Comparison 5 Dihydroartemisinin-piperaquine vs Amodiaquine plus sulfadoxine-
pyrimethamine, Outcome 7 Early vomiting.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 5 Dihydroartemisinin-piperaquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 7 Early vomiting
Study or subgroup DHA-P AQ+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zongo 2007 BFA 7/196 2/187 100.0 % 3.34 [ 0.70, 15.87 ]
Total (95% CI) 196 187 100.0 % 3.34 [ 0.70, 15.87 ]
Total events: 7 (DHA-P), 2 (AQ+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
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Analysis 6.1. Comparison 6 Artesunate plus mefloquine vs Artemether-lumefantrine, Outcome 1 Total
Failure (P. falciparum) Day 42 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 6 Artesunate plus mefloquine vs Artemether-lumefantrine
Outcome: 1 Total Failure (P. falciparum) Day 42 PCR unadjusted
Study or subgroup AS+MQ AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Asia
Hutagalung 2002 THA 24/227 27/225 35.1 % 0.88 [ 0.52, 1.48 ]
Stohrer 2003 LAO 8/53 13/47 25.7 % 0.55 [ 0.25, 1.20 ]
Mayxay 2003 LAO 2/108 14/107 12.0 % 0.14 [ 0.03, 0.61 ]
Van den Broek 2003a BGD 9/114 20/119 27.1 % 0.47 [ 0.22, 0.99 ]
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Analysis 6.2. Comparison 6 Artesunate plus mefloquine vs Artemether-lumefantrine, Outcome 2 Total
Failure (P. falciparum) Day 42 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 6 Artesunate plus mefloquine vs Artemether-lumefantrine
Outcome: 2 Total Failure (P. falciparum) Day 42 PCR adjusted
Study or subgroup AS+MQ AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Asia
Hutagalung 2002 THA 9/212 3/201 34.7 % 2.84 [ 0.78, 10.36 ]
Van den Broek 2003a BGD 0/105 3/102 21.7 % 0.14 [ 0.01, 2.65 ]
Stohrer 2003 LAO 0/45 3/37 21.9 % 0.12 [ 0.01, 2.21 ]
Mayxay 2003 LAO 0/106 3/96 21.7 % 0.13 [ 0.01, 2.48 ]
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Analysis 6.3. Comparison 6 Artesunate plus mefloquine vs Artemether-lumefantrine, Outcome 3 Total
Failure (P. falciparum) Day 28 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 6 Artesunate plus mefloquine vs Artemether-lumefantrine
Outcome: 3 Total Failure (P. falciparum) Day 28 PCR unadjusted
Study or subgroup AS+MQ AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Faye 2003 SEN 2/144 0/147 0.6 % 5.10 [ 0.25, 105.39 ]
Sagara 2005b MLI 47/230 76/231 99.4 % 0.62 [ 0.45, 0.85 ]
Subtotal (95% CI) 374 378 100.0 % 0.65 [ 0.48, 0.89 ]
Total events: 49 (AS+MQ), 76 (AL6)
Heterogeneity: Chi2 = 1.86, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 2.72 (P = 0.0066)
2 Asia
Van Vugt 1998 THA 0/47 4/134 12.3 % 0.31 [ 0.02, 5.70 ]
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(. . . Continued)
Study or subgroup AS+MQ AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lefevre 1999 THA 0/53 7/155 20.0 % 0.19 [ 0.01, 3.32 ]
Hutagalung 2002 THA 14/233 13/232 67.7 % 1.07 [ 0.52, 2.23 ]
Subtotal (95% CI) 333 521 100.0 % 0.80 [ 0.41, 1.58 ]
Total events: 14 (AS+MQ), 24 (AL6)
Heterogeneity: Chi2 = 1.97, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
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Analysis 6.4. Comparison 6 Artesunate plus mefloquine vs Artemether-lumefantrine, Outcome 4 Total
Failure (P. falciparum) Day 28 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 6 Artesunate plus mefloquine vs Artemether-lumefantrine
Outcome: 4 Total Failure (P. falciparum) Day 28 PCR adjusted
Study or subgroup AS+MQ AL6 Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Faye 2003 SEN 0/142 0/147 0.0 [ 0.0, 0.0 ]
Sagara 2005b MLI 9/192 7/162 1.08 [ 0.41, 2.85 ]
Subtotal (95% CI) 334 309 1.08 [ 0.41, 2.85 ]
Total events: 9 (AS+MQ), 7 (AL6)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
2 Asia
Van Vugt 1998 THA 0/47 3/133 0.40 [ 0.02, 7.58 ]
Lefevre 1999 THA 0/53 6/154 0.22 [ 0.01, 3.85 ]
Hutagalung 2002 THA 9/228 2/221 4.36 [ 0.95, 19.96 ]
Subtotal (95% CI) 328 508 1.43 [ 0.53, 3.86 ]
Total events: 9 (AS+MQ), 11 (AL6)
Heterogeneity: Chi2 = 4.43, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 662 817 1.25 [ 0.63, 2.50 ]
Total events: 18 (AS+MQ), 18 (AL6)
Heterogeneity: Chi2 = 4.67, df = 3 (P = 0.20); I2 =36%
Test for overall effect: Z = 0.64 (P = 0.52)
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Analysis 6.5. Comparison 6 Artesunate plus mefloquine vs Artemether-lumefantrine, Outcome 5 P. vivax
parasitaemia.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 6 Artesunate plus mefloquine vs Artemether-lumefantrine
Outcome: 5 P. vivax parasitaemia
Study or subgroup AS+MQ AL6 Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mixed P. falciparum and vivax infection at baseline
Lefevre 1999 THA 7/55 16/164 1.30 [ 0.57, 3.00 ]
Hutagalung 2002 THA 0/245 0/245 0.0 [ 0.0, 0.0 ]
Van den Broek 2003a BGD 0/121 0/121 0.0 [ 0.0, 0.0 ]
Stohrer 2003 LAO 0/55 0/53 0.0 [ 0.0, 0.0 ]
Mayxay 2003 LAO 0/110 0/110 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 586 693 1.30 [ 0.57, 3.00 ]
Total events: 7 (AS+MQ), 16 (AL6)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.53)
2 P. vivax parasitaemia by day 28
Lefevre 1999 THA 0/53 6/155 0.22 [ 0.01, 3.88 ]
Subtotal (95% CI) 53 155 0.22 [ 0.01, 3.88 ]
Total events: 0 (AS+MQ), 6 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
3 P. vivax parasitaemia by day 42
Hutagalung 2002 THA 29/227 90/225 0.32 [ 0.22, 0.47 ]
Mayxay 2003 LAO 0/108 5/107 0.09 [ 0.01, 1.61 ]
Van den Broek 2003a BGD 6/114 26/119 0.24 [ 0.10, 0.56 ]
Stohrer 2003 LAO 1/54 2/49 0.45 [ 0.04, 4.85 ]
Subtotal (95% CI) 503 500 0.30 [ 0.21, 0.41 ]
Total events: 36 (AS+MQ), 123 (AL6)
Heterogeneity: Chi2 = 1.17, df = 3 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 7.07 (P < 0.00001)
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Analysis 6.6. Comparison 6 Artesunate plus mefloquine vs Artemether-lumefantrine, Outcome 6
Gametocyte development (in those negative at baseline).
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 6 Artesunate plus mefloquine vs Artemether-lumefantrine
Outcome: 6 Gametocyte development (in those negative at baseline)
Study or subgroup AS+MQ AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lefevre 1999 THA 2/45 1/138 6.6 % 6.13 [ 0.57, 66.06 ]
Hutagalung 2002 THA 3/240 3/241 39.9 % 1.00 [ 0.20, 4.93 ]
Mayxay 2003 LAO 4/110 4/109 53.5 % 0.99 [ 0.25, 3.86 ]
Total (95% CI) 395 488 100.0 % 1.33 [ 0.54, 3.28 ]
Total events: 9 (AS+MQ), 8 (AL6)
Heterogeneity: Chi2 = 1.89, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 6.7. Comparison 6 Artesunate plus mefloquine vs Artemether-lumefantrine, Outcome 7
Gametocyte carriage.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 6 Artesunate plus mefloquine vs Artemether-lumefantrine
Outcome: 7 Gametocyte carriage
Study or subgroup AS+MQ AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gametocyte carriage day 0
Faye 2003 SEN 0/145 4/149 100.0 % 0.11 [ 0.01, 2.10 ]
Subtotal (95% CI) 145 149 100.0 % 0.11 [ 0.01, 2.10 ]
Total events: 0 (AS+MQ), 4 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
2 Gametocyte carriage day 3
Faye 2003 SEN 3/145 9/149 81.6 % 0.34 [ 0.09, 1.24 ]
Van den Broek 2003a BGD 3/121 2/121 18.4 % 1.50 [ 0.26, 8.82 ]
Subtotal (95% CI) 266 270 100.0 % 0.56 [ 0.21, 1.48 ]
Total events: 6 (AS+MQ), 11 (AL6)
Heterogeneity: Chi2 = 1.75, df = 1 (P = 0.19); I2 =43%
Test for overall effect: Z = 1.17 (P = 0.24)
3 Gametocyte carriage day 7
Stohrer 2003 LAO 5/53 6/47 35.9 % 0.74 [ 0.24, 2.26 ]
Van den Broek 2003a BGD 1/121 2/121 11.3 % 0.50 [ 0.05, 5.44 ]
Faye 2003 SEN 0/145 9/149 52.9 % 0.05 [ 0.00, 0.92 ]
Subtotal (95% CI) 319 317 100.0 % 0.35 [ 0.14, 0.85 ]
Total events: 6 (AS+MQ), 17 (AL6)
Heterogeneity: Chi2 = 3.46, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 2.31 (P = 0.021)
4 Gametocyte carriage day 14
Faye 2003 SEN 0/145 4/149 89.9 % 0.11 [ 0.01, 2.10 ]
Van den Broek 2003a BGD 1/121 0/121 10.1 % 3.00 [ 0.12, 72.92 ]
Subtotal (95% CI) 266 270 100.0 % 0.41 [ 0.08, 2.10 ]
Total events: 1 (AS+MQ), 4 (AL6)
Heterogeneity: Chi2 = 2.24, df = 1 (P = 0.13); I2 =55%
Test for overall effect: Z = 1.08 (P = 0.28)
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Analysis 6.8. Comparison 6 Artesunate plus mefloquine vs Artemether-lumefantrine, Outcome 8 Serious
adverse events (including deaths).
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 6 Artesunate plus mefloquine vs Artemether-lumefantrine
Outcome: 8 Serious adverse events (including deaths)
Study or subgroup AS+MQ AL6 Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Van Vugt 1998 THA 1/50 1/150 3.00 [ 0.19, 47.08 ]
Lefevre 1999 THA 0/55 0/164 0.0 [ 0.0, 0.0 ]
Hutagalung 2002 THA 0/245 0/245 0.0 [ 0.0, 0.0 ]
Stohrer 2003 LAO 1/55 1/53 0.96 [ 0.06, 15.01 ]
Mayxay 2003 LAO 3/110 0/110 7.00 [ 0.37, 133.94 ]
Van den Broek 2003a BGD 0/121 0/121 0.0 [ 0.0, 0.0 ]
Faye 2003 SEN 0/145 0/149 0.0 [ 0.0, 0.0 ]
Total (95% CI) 781 992 2.96 [ 0.64, 13.76 ]
Total events: 5 (AS+MQ), 2 (AL6)
Heterogeneity: Chi2 = 0.97, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.17)
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Analysis 6.9. Comparison 6 Artesunate plus mefloquine vs Artemether-lumefantrine, Outcome 9 Early
vomiting.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 6 Artesunate plus mefloquine vs Artemether-lumefantrine
Outcome: 9 Early vomiting
Study or subgroup AS+MQ AL6 Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Van Vugt 1998 THA 5/50 4/150 3.75 [ 1.05, 13.42 ]
Lefevre 1999 THA 1/55 2/164 1.49 [ 0.14, 16.12 ]
Hutagalung 2002 THA 2/245 5/245 0.40 [ 0.08, 2.04 ]
Mayxay 2003 LAO 3/110 6/110 0.50 [ 0.13, 1.95 ]
Stohrer 2003 LAO 0/55 0/53 0.0 [ 0.0, 0.0 ]
Van den Broek 2003a BGD 1/121 0/121 3.00 [ 0.12, 72.92 ]
Total (95% CI) 636 843 1.07 [ 0.55, 2.08 ]
Total events: 12 (AS+MQ), 17 (AL6)
Heterogeneity: Chi2 = 6.79, df = 4 (P = 0.15); I2 =41%
Test for overall effect: Z = 0.19 (P = 0.85)
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Analysis 7.1. Comparison 7 Artesunate plus mefloquine vs Artesunate plus amodiaquine, Outcome 1 Total
Failure (P. falciparum) Day 28 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 7 Artesunate plus mefloquine vs Artesunate plus amodiaquine
Outcome: 1 Total Failure (P. falciparum) Day 28 PCR unadjusted
Study or subgroup AS+MQ AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Faye 2003 SEN 2/144 9/349 100.0 % 0.54 [ 0.12, 2.46 ]
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Analysis 7.2. Comparison 7 Artesunate plus mefloquine vs Artesunate plus amodiaquine, Outcome 2 Total
Failure (P. falciparum) Day 28 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 7 Artesunate plus mefloquine vs Artesunate plus amodiaquine
Outcome: 2 Total Failure (P. falciparum) Day 28 PCR adjusted
Study or subgroup AS+MQ AS+AQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Faye 2003 SEN 0/142 0/340 0.0 [ 0.0, 0.0 ]
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Analysis 7.3. Comparison 7 Artesunate plus mefloquine vs Artesunate plus amodiaquine, Outcome 3
Gametocyte carriage.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 7 Artesunate plus mefloquine vs Artesunate plus amodiaquine
Outcome: 3 Gametocyte carriage
Study or subgroup AS+MQ AS+AQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gametocyte carriage day 0
Faye 2003 SEN 0/145 0/360 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 145 360 0.0 [ 0.0, 0.0 ]
Total events: 0 (AS+MQ), 0 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 Gametocyte carriage day 3
Faye 2003 SEN 3/145 0/360 17.31 [ 0.90, 332.99 ]
Subtotal (95% CI) 145 360 17.31 [ 0.90, 332.99 ]
Total events: 3 (AS+MQ), 0 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
3 Gametocyte carriage day 7
Faye 2003 SEN 0/145 0/360 0.0 [ 0.0, 0.0 ]
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(. . . Continued)
Study or subgroup AS+MQ AS+AQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 145 360 0.0 [ 0.0, 0.0 ]
Total events: 0 (AS+MQ), 0 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
4 Gametocyte carriage day 14
Faye 2003 SEN 0/145 0/360 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 145 360 0.0 [ 0.0, 0.0 ]
Total events: 0 (AS+MQ), 0 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 8.1. Comparison 8 Artesunate plus mefloquine vs Amodiaquine plus sulfadoxine-pyrimethamine,
Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 8 Artesunate plus mefloquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 1 Total Failure (P. falciparum) Day 28 PCR unadjusted
Study or subgroup AS+MQ AQ+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Faye 2003 SEN 2/144 2/156 100.0 % 1.08 [ 0.15, 7.59 ]
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Analysis 8.2. Comparison 8 Artesunate plus mefloquine vs Amodiaquine plus sulfadoxine-pyrimethamine,
Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 8 Artesunate plus mefloquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 2 Total Failure (P. falciparum) Day 28 PCR adjusted
Study or subgroup AS+MQ AQ+SP Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Faye 2003 SEN 0/142 0/154 0.0 [ 0.0, 0.0 ]
0.02 0.1 1 10 50
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Analysis 8.3. Comparison 8 Artesunate plus mefloquine vs Amodiaquine plus sulfadoxine-pyrimethamine,
Outcome 3 Gametocyte carriage.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 8 Artesunate plus mefloquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 3 Gametocyte carriage
Study or subgroup AS+MQ AQ+SP Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gametocyte carriage day 0
Faye 2003 SEN 0/145 5/161 0.10 [ 0.01, 1.81 ]
Subtotal (95% CI) 145 161 0.10 [ 0.01, 1.81 ]
Total events: 0 (AS+MQ), 5 (AQ+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
2 Gametocyte carriage day 3
Faye 2003 SEN 3/145 16/161 0.21 [ 0.06, 0.70 ]
Subtotal (95% CI) 145 161 0.21 [ 0.06, 0.70 ]
Total events: 3 (AS+MQ), 16 (AQ+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 2.54 (P = 0.011)
3 Gametocyte carriage day 7
Faye 2003 SEN 0/145 19/161 0.03 [ 0.00, 0.47 ]
0.005 0.1 1 10 200
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(. . . Continued)
Study or subgroup AS+MQ AQ+SP Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 145 161 0.03 [ 0.00, 0.47 ]
Total events: 0 (AS+MQ), 19 (AQ+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 2.49 (P = 0.013)
4 Gametocyte carriage day 14
Faye 2003 SEN 0/145 0/161 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 145 161 0.0 [ 0.0, 0.0 ]
Total events: 0 (AS+MQ), 0 (AQ+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.005 0.1 1 10 200
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Analysis 9.1. Comparison 9 Artemether-lumefantrine vs Artesunate plus amodiaquine, Outcome 1 Total
Failure (P. falciparum) Day 28 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 9 Artemether-lumefantrine vs Artesunate plus amodiaquine
Outcome: 1 Total Failure (P. falciparum) Day 28 PCR unadjusted
Study or subgroup AL6 AS+AQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 East Africa
Mutabingwa 2004 TZA 103/485 193/472 0.52 [ 0.42, 0.64 ]
Bukirwa 2005 UGA 102/202 133/201 0.76 [ 0.64, 0.90 ]
Dorsey 2006 UGA 5/100 7/105 0.75 [ 0.25, 2.29 ]
2 West Africa
Faye 2003 SEN 0/147 9/349 0.12 [ 0.01, 2.12 ]
Falade 2005 NGA 3/62 5/61 0.59 [ 0.15, 2.36 ]
Adjei 2006 GHA 6/103 5/107 1.25 [ 0.39, 3.96 ]
Owusu-Agyei 2006 GHA 42/152 22/151 1.90 [ 1.19, 3.02 ]
Kobbe 2007 GHA 23/103 15/96 1.43 [ 0.79, 2.57 ]
3 South/Central Africa
Guthmann 2004 AGO 2/61 4/64 0.52 [ 0.10, 2.76 ]
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Analysis 9.2. Comparison 9 Artemether-lumefantrine vs Artesunate plus amodiaquine, Outcome 2 Total
Failure (P. falciparum) Day 28 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 9 Artemether-lumefantrine vs Artesunate plus amodiaquine
Outcome: 2 Total Failure (P. falciparum) Day 28 PCR adjusted
Study or subgroup AL6 AS+AQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 East Africa
Bukirwa 2005 UGA 2/102 0/68 3.35 [ 0.16, 68.71 ]
Dorsey 2006 UGA 0/95 2/100 0.21 [ 0.01, 4.33 ]
Subtotal (95% CI) 197 168 0.83 [ 0.15, 4.59 ]
Total events: 2 (AL6), 2 (AS+AQ)
Heterogeneity: Chi2 = 1.61, df = 1 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.21 (P = 0.83)
2 West Africa
Faye 2003 SEN 0/147 0/340 0.0 [ 0.0, 0.0 ]
Falade 2005 NGA 0/59 0/56 0.0 [ 0.0, 0.0 ]
Owusu-Agyei 2006 GHA 12/122 7/136 1.91 [ 0.78, 4.70 ]
Adjei 2006 GHA 4/101 2/104 2.06 [ 0.39, 11.00 ]
Kobbe 2007 GHA 12/92 7/88 1.64 [ 0.68, 3.97 ]
Subtotal (95% CI) 521 724 1.81 [ 1.00, 3.26 ]
Total events: 28 (AL6), 16 (AS+AQ)
Heterogeneity: Chi2 = 0.08, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.96 (P = 0.050)
3 South/Central Africa
Guthmann 2004 AGO 0/59 0/60 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 59 60 0.0 [ 0.0, 0.0 ]
Total events: 0 (AL6), 0 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 777 952 1.65 [ 0.95, 2.87 ]
Total events: 30 (AL6), 18 (AS+AQ)
Heterogeneity: Chi2 = 2.16, df = 4 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.077)
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Analysis 9.3. Comparison 9 Artemether-lumefantrine vs Artesunate plus amodiaquine, Outcome 3
Gametocyte development.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 9 Artemether-lumefantrine vs Artesunate plus amodiaquine
Outcome: 3 Gametocyte development
Study or subgroup AL6 AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bukirwa 2005 UGA 8/162 21/143 100.0 % 0.34 [ 0.15, 0.74 ]
Total (95% CI) 162 143 100.0 % 0.34 [ 0.15, 0.74 ]
Total events: 8 (AL6), 21 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 2.73 (P = 0.0063)
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Analysis 9.4. Comparison 9 Artemether-lumefantrine vs Artesunate plus amodiaquine, Outcome 4
Gametocyte carriage.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 9 Artemether-lumefantrine vs Artesunate plus amodiaquine
Outcome: 4 Gametocyte carriage
Study or subgroup AL6 AS+AQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gametocyte carriage day 0
Faye 2003 SEN 4/149 0/360 21.66 [ 1.17, 399.81 ]
Owusu-Agyei 2006 GHA 11/177 10/178 1.11 [ 0.48, 2.54 ]
Dorsey 2006 UGA 11/103 16/111 0.74 [ 0.36, 1.52 ]
2 Gametocyte carriage day 3
Faye 2003 SEN 9/149 0/360 45.73 [ 2.68, 780.64 ]
3 Gametocyte carriage day 7
Faye 2003 SEN 9/149 0/360 45.73 [ 2.68, 780.64 ]
Dorsey 2006 UGA 5/102 11/111 0.49 [ 0.18, 1.38 ]
Owusu-Agyei 2006 GHA 0/152 3/151 0.14 [ 0.01, 2.72 ]
0.001 0.01 0.1 1 10 100 1000
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Study or subgroup AL6 AS+AQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
4 Gametocyte carriage day 14
Faye 2003 SEN 4/149 0/360 21.66 [ 1.17, 399.81 ]
Dorsey 2006 UGA 2/100 7/109 0.31 [ 0.07, 1.46 ]
0.001 0.01 0.1 1 10 100 1000
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Analysis 9.5. Comparison 9 Artemether-lumefantrine vs Artesunate plus amodiaquine, Outcome 5
Anaemia.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 9 Artemether-lumefantrine vs Artesunate plus amodiaquine
Outcome: 5 Anaemia
Study or subgroup AL6 AS+AQ Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean haemoglobin (g/dl) at baseline
Bukirwa 2005 UGA 202 10.3 (1.73) 201 10.3 (1.74) 0.0 [ -0.34, 0.34 ]
Dorsey 2006 UGA 202 11.5 (1.2) 232 11.5 (1.4) 0.0 [ -0.24, 0.24 ]
Owusu-Agyei 2006 GHA 152 9.2 (1.4) 151 9 (1.3) 0.20 [ -0.10, 0.50 ]
Kobbe 2007 GHA 123 9.6 (1.7) 123 9.9 (1.9) -0.30 [ -0.75, 0.15 ]
2 Mean haemoglobin (g/dl) at Day 28
Owusu-Agyei 2006 GHA 152 10 (1.6) 151 9.9 (1.7) 0.10 [ -0.27, 0.47 ]
3 Mean change in haemoglobin (g/dl) from baseline to Day 28
Bukirwa 2005 UGA 202 1.39 (1.76) 201 1.35 (1.71) 0.04 [ -0.30, 0.38 ]
4 Mean haematocrit at baseline
Falade 2005 NGA 66 30 (5.05) 66 30.4 (4.79) -0.40 [ -2.08, 1.28 ]
5 Mean haematocrit at Day 28
Falade 2005 NGA 66 33.4 (3.45) 66 33 (3.79) 0.40 [ -0.84, 1.64 ]
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Analysis 9.6. Comparison 9 Artemether-lumefantrine vs Artesunate plus amodiaquine, Outcome 6
Proportion anaemic (Haemoglobin < 11 g/dl).
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 9 Artemether-lumefantrine vs Artesunate plus amodiaquine
Outcome: 6 Proportion anaemic (Haemoglobin < 11 g/dl)
Study or subgroup AL6 AS+AQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At baseline
Guthmann 2004 AGO 33/61 34/64 1.02 [ 0.73, 1.41 ]
2 At day 28
Guthmann 2004 AGO 8/60 10/63 0.84 [ 0.36, 1.98 ]
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Analysis 9.7. Comparison 9 Artemether-lumefantrine vs Artesunate plus amodiaquine, Outcome 7 Serious
adverse events (including deaths).
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 9 Artemether-lumefantrine vs Artesunate plus amodiaquine
Outcome: 7 Serious adverse events (including deaths)
Study or subgroup AL6 AS+AQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Faye 2003 SEN 0/149 0/360 0.0 [ 0.0, 0.0 ]
Mutabingwa 2004 TZA 1/519 0/515 2.98 [ 0.12, 72.91 ]
Falade 2005 NGA 0/66 0/66 0.0 [ 0.0, 0.0 ]
Bukirwa 2005 UGA 1/202 1/201 1.00 [ 0.06, 15.80 ]
Dorsey 2006 UGA 14/202 15/232 1.07 [ 0.53, 2.17 ]
Kobbe 2007 GHA 2/120 2/117 0.98 [ 0.14, 6.81 ]
Total (95% CI) 1258 1491 1.11 [ 0.59, 2.08 ]
Total events: 18 (AL6), 18 (AS+AQ)
Heterogeneity: Chi2 = 0.40, df = 3 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
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Analysis 9.8. Comparison 9 Artemether-lumefantrine vs Artesunate plus amodiaquine, Outcome 8 Early
vomiting.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 9 Artemether-lumefantrine vs Artesunate plus amodiaquine
Outcome: 8 Early vomiting
Study or subgroup AL6 AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Guthmann 2004 AGO 1/68 2/69 4.3 % 0.51 [ 0.05, 5.47 ]
Falade 2005 NGA 4/66 5/66 10.9 % 0.80 [ 0.22, 2.85 ]
Owusu-Agyei 2006 GHA 22/177 22/178 47.8 % 1.01 [ 0.58, 1.75 ]
Adjei 2006 GHA 2/111 2/116 4.3 % 1.05 [ 0.15, 7.29 ]
Kobbe 2007 GHA 11/123 15/123 32.7 % 0.73 [ 0.35, 1.53 ]
Total (95% CI) 545 552 100.0 % 0.87 [ 0.59, 1.31 ]
Total events: 40 (AL6), 46 (AS+AQ)
Heterogeneity: Chi2 = 0.72, df = 4 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
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Analysis 9.9. Comparison 9 Artemether-lumefantrine vs Artesunate plus amodiaquine, Outcome 9
Sensitivity analysis: Total Failure Day 28 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 9 Artemether-lumefantrine vs Artesunate plus amodiaquine
Outcome: 9 Sensitivity analysis: Total Failure Day 28 PCR unadjusted
Study or subgroup AL6 AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Total Failure (P. falciparum) Day 28 PCR unadjusted
Faye 2003 SEN 0/147 9/349 1.2 % 0.12 [ 0.01, 2.12 ]
Mutabingwa 2004 TZA 103/485 193/472 23.5 % 0.52 [ 0.42, 0.64 ]
Guthmann 2004 AGO 2/61 4/64 3.3 % 0.52 [ 0.10, 2.76 ]
Bukirwa 2005 UGA 102/202 133/201 24.2 % 0.76 [ 0.64, 0.90 ]
Falade 2005 NGA 3/62 5/61 4.5 % 0.59 [ 0.15, 2.36 ]
Owusu-Agyei 2006 GHA 42/152 22/151 16.9 % 1.90 [ 1.19, 3.02 ]
Dorsey 2006 UGA 5/100 7/105 6.4 % 0.75 [ 0.25, 2.29 ]
Adjei 2006 GHA 6/103 5/107 6.0 % 1.25 [ 0.39, 3.96 ]
Kobbe 2007 GHA 23/103 15/96 14.0 % 1.43 [ 0.79, 2.57 ]
Subtotal (95% CI) 1415 1606 100.0 % 0.88 [ 0.60, 1.27 ]
Total events: 286 (AL6), 393 (AS+AQ)
Heterogeneity: Tau2 = 0.16; Chi2 = 34.92, df = 8 (P = 0.00003); I2 =77%
Test for overall effect: Z = 0.70 (P = 0.49)
2 Total Failure Day 28 PCR unadjusted (trials with baseline differences included)
Faye 2003 SEN 0/147 9/349 0.9 % 0.12 [ 0.01, 2.12 ]
Martensson 2003 TZA 14/197 57/206 10.6 % 0.26 [ 0.15, 0.45 ]
Koram 2003 GHA 8/47 13/51 7.4 % 0.67 [ 0.30, 1.47 ]
Van den Broek 2004 ZAR 13/100 31/97 10.1 % 0.41 [ 0.23, 0.73 ]
Mutabingwa 2004 TZA 103/485 193/472 16.9 % 0.52 [ 0.42, 0.64 ]
Guthmann 2004 AGO 2/61 4/64 2.4 % 0.52 [ 0.10, 2.76 ]
Falade 2005 NGA 3/62 5/61 3.2 % 0.59 [ 0.15, 2.36 ]
Bukirwa 2005 UGA 102/202 133/201 17.4 % 0.76 [ 0.64, 0.90 ]
Owusu-Agyei 2006 GHA 42/152 22/151 12.1 % 1.90 [ 1.19, 3.02 ]
Adjei 2006 GHA 6/103 5/107 4.3 % 1.25 [ 0.39, 3.96 ]
Dorsey 2006 UGA 5/100 7/105 4.6 % 0.75 [ 0.25, 2.29 ]
Kobbe 2007 GHA 23/103 15/96 10.0 % 1.43 [ 0.79, 2.57 ]
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Study or subgroup AL6 AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Subtotal (95% CI) 1759 1960 100.0 % 0.69 [ 0.49, 0.97 ]
Total events: 321 (AL6), 494 (AS+AQ)
Heterogeneity: Tau2 = 0.20; Chi2 = 51.61, df = 11 (P<0.00001); I2 =79%
Test for overall effect: Z = 2.13 (P = 0.033)
3 Total Failure Day 28 PCR unadjusted (losses to follow up included as failures)
Faye 2003 SEN 2/149 20/360 3.3 % 0.24 [ 0.06, 1.02 ]
Guthmann 2004 AGO 6/65 9/69 6.0 % 0.71 [ 0.27, 1.88 ]
Mutabingwa 2004 TZA 137/519 236/515 18.8 % 0.58 [ 0.49, 0.68 ]
Bukirwa 2005 UGA 104/204 136/204 18.8 % 0.76 [ 0.65, 0.90 ]
Falade 2005 NGA 7/66 10/66 6.7 % 0.70 [ 0.28, 1.73 ]
Adjei 2006 GHA 14/111 14/116 9.2 % 1.05 [ 0.52, 2.09 ]
Dorsey 2006 UGA 8/103 13/111 7.4 % 0.66 [ 0.29, 1.53 ]
Owusu-Agyei 2006 GHA 67/177 49/178 16.4 % 1.38 [ 1.01, 1.86 ]
Kobbe 2007 GHA 29/109 27/108 13.4 % 1.06 [ 0.68, 1.67 ]
Subtotal (95% CI) 1503 1727 100.0 % 0.81 [ 0.62, 1.06 ]
Total events: 374 (AL6), 514 (AS+AQ)
Heterogeneity: Tau2 = 0.09; Chi2 = 30.11, df = 8 (P = 0.00020); I2 =73%
Test for overall effect: Z = 1.51 (P = 0.13)
4 Total Failure Day 28 PCR unadjusted (losses to follow up included as successes)
Faye 2003 SEN 0/149 9/360 1.2 % 0.13 [ 0.01, 2.16 ]
Mutabingwa 2004 TZA 103/519 193/515 23.5 % 0.53 [ 0.43, 0.65 ]
Guthmann 2004 AGO 2/65 4/69 3.3 % 0.53 [ 0.10, 2.80 ]
Bukirwa 2005 UGA 102/204 133/204 24.2 % 0.77 [ 0.65, 0.91 ]
Falade 2005 NGA 3/66 5/66 4.5 % 0.60 [ 0.15, 2.41 ]
Dorsey 2006 UGA 5/103 7/111 6.4 % 0.77 [ 0.25, 2.35 ]
Adjei 2006 GHA 6/111 5/116 6.0 % 1.25 [ 0.39, 3.99 ]
Owusu-Agyei 2006 GHA 42/177 22/178 16.8 % 1.92 [ 1.20, 3.08 ]
Kobbe 2007 GHA 23/109 15/108 13.9 % 1.52 [ 0.84, 2.75 ]
Subtotal (95% CI) 1503 1727 100.0 % 0.89 [ 0.61, 1.30 ]
Total events: 286 (AL6), 393 (AS+AQ)
Heterogeneity: Tau2 = 0.16; Chi2 = 34.16, df = 8 (P = 0.00004); I2 =77%
Test for overall effect: Z = 0.60 (P = 0.55)
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Analysis 9.10. Comparison 9 Artemether-lumefantrine vs Artesunate plus amodiaquine, Outcome 10
Sensitivity analysis: Total Failure Day 28 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 9 Artemether-lumefantrine vs Artesunate plus amodiaquine
Outcome: 10 Sensitivity analysis: Total Failure Day 28 PCR adjusted
Study or subgroup AL6 AS+AQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Total Failure (P. falciparum) Day 28 PCR adjusted
Faye 2003 SEN 0/147 0/340 0.0 [ 0.0, 0.0 ]
Guthmann 2004 AGO 0/59 0/60 0.0 [ 0.0, 0.0 ]
Falade 2005 NGA 0/59 0/56 0.0 [ 0.0, 0.0 ]
Bukirwa 2005 UGA 2/102 0/68 3.35 [ 0.16, 68.71 ]
Owusu-Agyei 2006 GHA 12/122 7/136 1.91 [ 0.78, 4.70 ]
Dorsey 2006 UGA 0/95 2/100 0.21 [ 0.01, 4.33 ]
Adjei 2006 GHA 4/101 2/104 2.06 [ 0.39, 11.00 ]
Kobbe 2007 GHA 12/92 7/88 1.64 [ 0.68, 3.97 ]
Subtotal (95% CI) 777 952 1.65 [ 0.95, 2.87 ]
Total events: 30 (AL6), 18 (AS+AQ)
Heterogeneity: Chi2 = 2.16, df = 4 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.077)
2 Total Failure Day 28 PCR adjusted (trials with baseline differences included)
Faye 2003 SEN 0/147 0/340 0.0 [ 0.0, 0.0 ]
Martensson 2003 TZA 5/188 13/162 0.33 [ 0.12, 0.91 ]
Koram 2003 GHA 1/40 0/38 2.85 [ 0.12, 67.97 ]
Guthmann 2004 AGO 0/59 0/60 0.0 [ 0.0, 0.0 ]
Van den Broek 2004 ZAR 0/87 1/67 0.26 [ 0.01, 6.22 ]
Bukirwa 2005 UGA 2/102 0/68 3.35 [ 0.16, 68.71 ]
Falade 2005 NGA 0/59 0/56 0.0 [ 0.0, 0.0 ]
Adjei 2006 GHA 4/101 2/104 2.06 [ 0.39, 11.00 ]
Dorsey 2006 UGA 0/95 2/100 0.21 [ 0.01, 4.33 ]
Owusu-Agyei 2006 GHA 12/122 7/136 1.91 [ 0.78, 4.70 ]
Kobbe 2007 GHA 12/92 7/88 1.64 [ 0.68, 3.97 ]
Subtotal (95% CI) 1092 1219 1.07 [ 0.69, 1.67 ]
Total events: 36 (AL6), 32 (AS+AQ)
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Study or subgroup AL6 AS+AQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 11.04, df = 7 (P = 0.14); I2 =37%
Test for overall effect: Z = 0.31 (P = 0.76)
3 Total Failure Day 28 PCR adjusted (indeterminate PCR included as failures)
Faye 2003 SEN 0/147 0/340 0.0 [ 0.0, 0.0 ]
Guthmann 2004 AGO 0/59 0/60 0.0 [ 0.0, 0.0 ]
Falade 2005 NGA 0/59 0/56 0.0 [ 0.0, 0.0 ]
Bukirwa 2005 UGA 5/105 1/69 3.29 [ 0.39, 27.52 ]
Dorsey 2006 UGA 0/95 3/101 0.15 [ 0.01, 2.90 ]
Owusu-Agyei 2006 GHA 21/131 10/139 2.23 [ 1.09, 4.55 ]
Adjei 2006 GHA 4/101 2/104 2.06 [ 0.39, 11.00 ]
Kobbe 2007 GHA 12/92 8/89 1.45 [ 0.62, 3.38 ]
Subtotal (95% CI) 789 958 1.72 [ 1.06, 2.78 ]
Total events: 42 (AL6), 24 (AS+AQ)
Heterogeneity: Chi2 = 3.66, df = 4 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.027)
4 Total Failure Day 28 PCR adjusted (new infections included as successes)
Faye 2003 SEN 0/147 0/349 0.0 [ 0.0, 0.0 ]
Guthmann 2004 AGO 0/61 0/64 0.0 [ 0.0, 0.0 ]
Falade 2005 NGA 0/62 0/61 0.0 [ 0.0, 0.0 ]
Bukirwa 2005 UGA 5/202 1/201 4.98 [ 0.59, 42.21 ]
Dorsey 2006 UGA 0/100 3/105 0.15 [ 0.01, 2.87 ]
Adjei 2006 GHA 4/103 2/107 2.08 [ 0.39, 11.10 ]
Owusu-Agyei 2006 GHA 21/152 10/151 2.09 [ 1.02, 4.28 ]
Kobbe 2007 GHA 12/103 8/96 1.40 [ 0.60, 3.27 ]
Subtotal (95% CI) 930 1134 1.70 [ 1.06, 2.75 ]
Total events: 42 (AL6), 24 (AS+AQ)
Heterogeneity: Chi2 = 4.14, df = 4 (P = 0.39); I2 =3%
Test for overall effect: Z = 2.18 (P = 0.029)
5 Total Failure Day 28 PCR adjusted (losses to follow up included as failures)
Faye 2003 SEN 2/149 11/360 0.44 [ 0.10, 1.96 ]
Guthmann 2004 AGO 4/65 5/69 0.85 [ 0.24, 3.03 ]
Falade 2005 NGA 4/66 5/66 0.80 [ 0.22, 2.85 ]
Bukirwa 2005 UGA 7/204 4/204 1.75 [ 0.52, 5.89 ]
Adjei 2006 GHA 12/111 11/116 1.14 [ 0.52, 2.48 ]
Owusu-Agyei 2006 GHA 46/177 37/178 1.25 [ 0.86, 1.83 ]
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Study or subgroup AL6 AS+AQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dorsey 2006 UGA 3/103 9/111 0.36 [ 0.10, 1.29 ]
Kobbe 2007 GHA 18/109 20/108 0.89 [ 0.50, 1.59 ]
Subtotal (95% CI) 984 1212 1.01 [ 0.78, 1.31 ]
Total events: 96 (AL6), 102 (AS+AQ)
Heterogeneity: Chi2 = 6.19, df = 7 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
6 Total Failure Day 28 PCR adjusted (losses to follow up included as successes)
Faye 2003 SEN 0/149 0/360 0.0 [ 0.0, 0.0 ]
Guthmann 2004 AGO 0/65 0/69 0.0 [ 0.0, 0.0 ]
Falade 2005 NGA 0/66 0/66 0.0 [ 0.0, 0.0 ]
Bukirwa 2005 UGA 5/204 1/204 5.00 [ 0.59, 42.42 ]
Owusu-Agyei 2006 GHA 21/177 10/178 2.11 [ 1.02, 4.35 ]
Dorsey 2006 UGA 0/103 3/111 0.15 [ 0.01, 2.94 ]
Adjei 2006 GHA 4/111 2/116 2.09 [ 0.39, 11.18 ]
Kobbe 2007 GHA 12/109 8/108 1.49 [ 0.63, 3.49 ]
Subtotal (95% CI) 984 1212 1.75 [ 1.08, 2.83 ]
Total events: 42 (AL6), 24 (AS+AQ)
Heterogeneity: Chi2 = 3.98, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.28 (P = 0.023)
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Analysis 10.1. Comparison 10 Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine,
Outcome 1 Total Failure (P. falciparum) Day 42 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 10 Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome: 1 Total Failure (P. falciparum) Day 42 PCR unadjusted
Study or subgroup AL6 AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oceania
Karunajeewa 2007 PNG 40/109 41/108 100.0 % 0.97 [ 0.68, 1.36 ]
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Analysis 10.2. Comparison 10 Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine,
Outcome 2 Total Failure (P. falciparum) Day 42 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 10 Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome: 2 Total Failure (P. falciparum) Day 42 PCR adjusted
Study or subgroup AL6 AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oceania
Karunajeewa 2007 PNG 5/74 17/84 100.0 % 0.33 [ 0.13, 0.86 ]
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Analysis 10.3. Comparison 10 Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine,
Outcome 3 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 10 Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome: 3 Total Failure (P. falciparum) Day 28 PCR unadjusted
Study or subgroup AL6 AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Mukhtar 2005 SDN 8/80 12/77 32.8 % 0.64 [ 0.28, 1.48 ]
Subtotal (95% CI) 80 77 32.8 % 0.64 [ 0.28, 1.48 ]
Total events: 8 (AL6), 12 (AS+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
2 Oceania
Karunajeewa 2007 PNG 20/113 25/112 67.2 % 0.79 [ 0.47, 1.34 ]
Subtotal (95% CI) 113 112 67.2 % 0.79 [ 0.47, 1.34 ]
Total events: 20 (AL6), 25 (AS+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Total (95% CI) 193 189 100.0 % 0.74 [ 0.48, 1.16 ]
Total events: 28 (AL6), 37 (AS+SP)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
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Analysis 10.4. Comparison 10 Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine,
Outcome 4 Total Failure (P. falciparum) Day 28 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 10 Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome: 4 Total Failure (P. falciparum) Day 28 PCR adjusted
Study or subgroup AL6 AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Mukhtar 2005 SDN 7/79 7/72 40.2 % 0.91 [ 0.34, 2.47 ]
Subtotal (95% CI) 79 72 40.2 % 0.91 [ 0.34, 2.47 ]
Total events: 7 (AL6), 7 (AS+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
2 Oceania
Karunajeewa 2007 PNG 3/96 11/98 59.8 % 0.28 [ 0.08, 0.97 ]
Subtotal (95% CI) 96 98 59.8 % 0.28 [ 0.08, 0.97 ]
Total events: 3 (AL6), 11 (AS+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.044)
Total (95% CI) 175 170 100.0 % 0.53 [ 0.25, 1.13 ]
Total events: 10 (AL6), 18 (AS+SP)
Heterogeneity: Chi2 = 2.16, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 1.64 (P = 0.10)
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Analysis 10.5. Comparison 10 Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine,
Outcome 5 P. vivax parasitaemia.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 10 Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome: 5 P. vivax parasitaemia
Study or subgroup AL6 AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 P. vivax parasitaemia by day 42 (P. vivax P. falciparum at baseline)
Karunajeewa 2007 PNG 23/33 26/39 100.0 % 1.05 [ 0.76, 1.43 ]
Subtotal (95% CI) 33 39 100.0 % 1.05 [ 0.76, 1.43 ]
Total events: 23 (AL6), 26 (AS+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
2 P. vivax parasitaemia by day 42 (P. falciparum mono-infection at baseline)
Karunajeewa 2007 PNG 66/102 56/94 100.0 % 1.09 [ 0.87, 1.35 ]
Subtotal (95% CI) 102 94 100.0 % 1.09 [ 0.87, 1.35 ]
Total events: 66 (AL6), 56 (AS+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
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Analysis 10.6. Comparison 10 Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine,
Outcome 6 Sensitivity analysis Total Failure Day 28 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 10 Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome: 6 Sensitivity analysis Total Failure Day 28 PCR unadjusted
Study or subgroup AL6 AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Total Failure (P. falciparum) Day 28 PCR unadjusted
Mukhtar 2005 SDN 8/80 12/77 32.8 % 0.64 [ 0.28, 1.48 ]
Karunajeewa 2007 PNG 20/113 25/112 67.2 % 0.79 [ 0.47, 1.34 ]
Subtotal (95% CI) 193 189 100.0 % 0.74 [ 0.48, 1.16 ]
Total events: 28 (AL6), 37 (AS+SP)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
2 Total Failure Day 28 PCR unadjusted (trials with baseline differences included)
Bousema 2004 KEN 3/75 29/160 23.6 % 0.22 [ 0.07, 0.70 ]
Van den Broek 2004 ZAR 13/100 21/85 28.9 % 0.53 [ 0.28, 0.99 ]
Mukhtar 2005 SDN 8/80 12/77 15.6 % 0.64 [ 0.28, 1.48 ]
Karunajeewa 2007 PNG 20/113 25/112 32.0 % 0.79 [ 0.47, 1.34 ]
Subtotal (95% CI) 368 434 100.0 % 0.56 [ 0.39, 0.79 ]
Total events: 44 (AL6), 87 (AS+SP)
Heterogeneity: Chi2 = 4.33, df = 3 (P = 0.23); I2 =31%
Test for overall effect: Z = 3.30 (P = 0.00097)
3 Total Failure Day 28 PCR unadjusted (losses to follow up included as failures)
Mukhtar 2005 SDN 8/80 15/80 29.6 % 0.53 [ 0.24, 1.19 ]
Karunajeewa 2007 PNG 34/127 35/122 70.4 % 0.93 [ 0.62, 1.39 ]
Subtotal (95% CI) 207 202 100.0 % 0.81 [ 0.57, 1.17 ]
Total events: 42 (AL6), 50 (AS+SP)
Heterogeneity: Chi2 = 1.52, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 1.12 (P = 0.26)
4 Total Failure Day 28 PCR unadjusted (losses to follow up included as successes)
Mukhtar 2005 SDN 8/80 12/80 32.0 % 0.67 [ 0.29, 1.54 ]
Karunajeewa 2007 PNG 20/127 25/122 68.0 % 0.77 [ 0.45, 1.31 ]
Subtotal (95% CI) 207 202 100.0 % 0.74 [ 0.47, 1.15 ]
Total events: 28 (AL6), 37 (AS+SP)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
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Analysis 10.7. Comparison 10 Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine,
Outcome 7 Sensitivity analysis: Total Failure Day 28 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 10 Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome: 7 Sensitivity analysis: Total Failure Day 28 PCR adjusted
Study or subgroup AL6 AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Total Failure (P. falciparum) Day 28 PCR adjusted
Mukhtar 2005 SDN 7/79 7/72 40.2 % 0.91 [ 0.34, 2.47 ]
Karunajeewa 2007 PNG 3/96 11/98 59.8 % 0.28 [ 0.08, 0.97 ]
Subtotal (95% CI) 175 170 100.0 % 0.53 [ 0.25, 1.13 ]
Total events: 10 (AL6), 18 (AS+SP)
Heterogeneity: Chi2 = 2.16, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 1.64 (P = 0.10)
2 Total Failure Day 28 PCR adjusted (trials with baseline differences included)
Bousema 2004 KEN 1/73 11/142 22.0 % 0.18 [ 0.02, 1.34 ]
Van den Broek 2004 ZAR 0/87 7/71 24.3 % 0.05 [ 0.00, 0.94 ]
Mukhtar 2005 SDN 7/79 7/72 21.6 % 0.91 [ 0.34, 2.47 ]
Karunajeewa 2007 PNG 3/96 11/98 32.1 % 0.28 [ 0.08, 0.97 ]
Subtotal (95% CI) 335 383 100.0 % 0.34 [ 0.17, 0.66 ]
Total events: 11 (AL6), 36 (AS+SP)
Heterogeneity: Chi2 = 5.86, df = 3 (P = 0.12); I2 =49%
Test for overall effect: Z = 3.21 (P = 0.0013)
3 Total Failure Day 28 PCR adjusted (indeterminate PCR included as failures)
Mukhtar 2005 SDN 7/79 7/72 36.3 % 0.91 [ 0.34, 2.47 ]
Karunajeewa 2007 PNG 5/98 13/100 63.7 % 0.39 [ 0.15, 1.06 ]
Subtotal (95% CI) 177 172 100.0 % 0.58 [ 0.29, 1.16 ]
Total events: 12 (AL6), 20 (AS+SP)
Heterogeneity: Chi2 = 1.38, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 1.54 (P = 0.12)
4 Total Failure Day 28 PCR adjusted (new infections included as successes)
Mukhtar 2005 SDN 7/80 7/77 35.3 % 0.96 [ 0.35, 2.62 ]
Karunajeewa 2007 PNG 5/113 13/112 64.7 % 0.38 [ 0.14, 1.03 ]
Subtotal (95% CI) 193 189 100.0 % 0.59 [ 0.29, 1.17 ]
Total events: 12 (AL6), 20 (AS+SP)
Heterogeneity: Chi2 = 1.66, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 1.52 (P = 0.13)
5 Total Failure Day 28 PCR adjusted (losses to follow up included as failures)
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Study or subgroup AL6 AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mukhtar 2005 SDN 7/80 10/80 29.9 % 0.70 [ 0.28, 1.75 ]
Karunajeewa 2007 PNG 19/127 23/122 70.1 % 0.79 [ 0.46, 1.38 ]
Subtotal (95% CI) 207 202 100.0 % 0.77 [ 0.48, 1.23 ]
Total events: 26 (AL6), 33 (AS+SP)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
6 Total Failure Day 28 PCR adjusted (losses to follow up included as successes)
Mukhtar 2005 SDN 7/80 7/80 34.5 % 1.00 [ 0.37, 2.72 ]
Karunajeewa 2007 PNG 5/127 13/122 65.5 % 0.37 [ 0.14, 1.01 ]
Subtotal (95% CI) 207 202 100.0 % 0.59 [ 0.30, 1.17 ]
Total events: 12 (AL6), 20 (AS+SP)
Heterogeneity: Chi2 = 1.91, df = 1 (P = 0.17); I2 =48%
Test for overall effect: Z = 1.52 (P = 0.13)
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Analysis 11.1. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine,
Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 1 Total Failure (P. falciparum) Day 28 PCR unadjusted
Study or subgroup AL6 AQ+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 East Africa
Fanello 2004 RWA 36/246 89/247 22.1 % 0.41 [ 0.29, 0.57 ]
Mutabingwa 2004 TZA 103/485 282/463 71.8 % 0.35 [ 0.29, 0.42 ]
Dorsey 2006 UGA 5/100 25/105 6.1 % 0.21 [ 0.08, 0.53 ]
Subtotal (95% CI) 831 815 100.0 % 0.35 [ 0.30, 0.41 ]
Total events: 144 (AL6), 396 (AQ+SP)
Heterogeneity: Chi2 = 1.88, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 12.61 (P < 0.00001)
2 West Africa
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Study or subgroup AL6 AQ+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Faye 2003 SEN 0/147 2/156 9.7 % 0.21 [ 0.01, 4.38 ]
Zongo 2005 BFA 37/245 11/233 45.2 % 3.20 [ 1.67, 6.12 ]
Zongo 2007 BFA 36/178 11/171 45.0 % 3.14 [ 1.65, 5.97 ]
Subtotal (95% CI) 570 560 100.0 % 2.88 [ 1.86, 4.47 ]
Total events: 73 (AL6), 24 (AQ+SP)
Heterogeneity: Chi2 = 3.02, df = 2 (P = 0.22); I2 =34%
Test for overall effect: Z = 4.72 (P < 0.00001)
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Analysis 11.2. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine,
Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 2 Total Failure (P. falciparum) Day 28 PCR adjusted
Study or subgroup AL6 AQ+SP Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 East Africa
Fanello 2004 RWA 8/218 51/209 0.15 [ 0.07, 0.31 ]
Dorsey 2006 UGA 0/95 16/96 0.03 [ 0.00, 0.50 ]
Subtotal (95% CI) 313 305 0.12 [ 0.06, 0.24 ]
Total events: 8 (AL6), 67 (AQ+SP)
Heterogeneity: Chi2 = 1.27, df = 1 (P = 0.26); I2 =21%
Test for overall effect: Z = 5.93 (P < 0.00001)
2 West Africa
Faye 2003 SEN 0/147 0/154 0.0 [ 0.0, 0.0 ]
Zongo 2005 BFA 4/212 1/223 4.21 [ 0.47, 37.34 ]
Zongo 2007 BFA 6/148 7/167 0.97 [ 0.33, 2.81 ]
Subtotal (95% CI) 507 544 1.39 [ 0.55, 3.47 ]
Total events: 10 (AL6), 8 (AQ+SP)
Heterogeneity: Chi2 = 1.43, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 0.70 (P = 0.49)
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Analysis 11.3. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine,
Outcome 3 Total Failure (P. falciparum) Day 42 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 3 Total Failure (P. falciparum) Day 42 PCR unadjusted
Study or subgroup AL6 AQ+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 West Africa
Zongo 2007 BFA 55/176 20/169 100.0 % 2.64 [ 1.66, 4.21 ]
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Analysis 11.4. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine,
Outcome 4 Total Failure (P. falciparum) Day 42 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 4 Total Failure (P. falciparum) Day 42 PCR adjusted
Study or subgroup AL6 AQ+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 West Africa
Zongo 2007 BFA 7/128 7/156 100.0 % 1.22 [ 0.44, 3.38 ]
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Analysis 11.5. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine,
Outcome 5 Gametocyte carriage.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 5 Gametocyte carriage
Study or subgroup AL6 AQ+SP Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gametocyte carriage day 0
Faye 2003 SEN 4/149 5/161 0.86 [ 0.24, 3.16 ]
Fanello 2004 RWA 10/251 14/249 0.71 [ 0.32, 1.56 ]
Zongo 2005 BFA 0/261 0/260 0.0 [ 0.0, 0.0 ]
Dorsey 2006 UGA 11/103 12/111 0.99 [ 0.46, 2.14 ]
Subtotal (95% CI) 764 781 0.84 [ 0.51, 1.39 ]
Total events: 25 (AL6), 31 (AQ+SP)
Heterogeneity: Chi2 = 0.35, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
2 Gametocyte carriage day 3
Faye 2003 SEN 9/149 16/161 0.61 [ 0.28, 1.33 ]
Fanello 2004 RWA 7/251 20/249 0.35 [ 0.15, 0.81 ]
Zongo 2005 BFA 0/261 3/260 0.14 [ 0.01, 2.74 ]
Subtotal (95% CI) 661 670 0.43 [ 0.25, 0.75 ]
Total events: 16 (AL6), 39 (AQ+SP)
Heterogeneity: Chi2 = 1.53, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.96 (P = 0.0031)
3 Gametocyte carriage day 7
Faye 2003 SEN 9/149 19/161 0.51 [ 0.24, 1.10 ]
Fanello 2004 RWA 2/251 19/249 0.10 [ 0.02, 0.44 ]
Zongo 2005 BFA 0/261 3/260 0.14 [ 0.01, 2.74 ]
Dorsey 2006 UGA 5/102 13/105 0.40 [ 0.15, 1.07 ]
Subtotal (95% CI) 763 775 0.32 [ 0.18, 0.54 ]
Total events: 16 (AL6), 54 (AQ+SP)
Heterogeneity: Chi2 = 4.28, df = 3 (P = 0.23); I2 =30%
Test for overall effect: Z = 4.24 (P = 0.000022)
4 Gametocyte carriage day 14
Faye 2003 SEN 4/149 0/161 9.72 [ 0.53, 179.02 ]
Fanello 2004 RWA 2/251 9/249 0.22 [ 0.05, 1.01 ]
Zongo 2005 BFA 0/261 2/260 0.20 [ 0.01, 4.13 ]
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Study or subgroup AL6 AQ+SP Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dorsey 2006 UGA 2/100 8/105 0.26 [ 0.06, 1.21 ]
Subtotal (95% CI) 761 775 0.46 [ 0.21, 1.01 ]
Total events: 8 (AL6), 19 (AQ+SP)
Heterogeneity: Chi2 = 5.94, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 1.94 (P = 0.052)
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Analysis 11.6. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine,
Outcome 6 Gametocyte development (in those negative at baseline).
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 6 Gametocyte development (in those negative at baseline)
Study or subgroup AL6 AQ+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zongo 2007 BFA 3/188 10/183 100.0 % 0.29 [ 0.08, 1.04 ]
Total (95% CI) 188 183 100.0 % 0.29 [ 0.08, 1.04 ]
Total events: 3 (AL6), 10 (AQ+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.058)
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Analysis 11.7. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine,
Outcome 7 Anaemia.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 7 Anaemia
Study or subgroup AL6 AQ+SP Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean haemoglobin (g/dl) at baseline
Zongo 2005 BFA 261 9.3 (2.3) 260 9.9 (2.3) -0.60 [ -0.99, -0.21 ]
Zongo 2007 BFA 188 10.2 (2) 184 10.3 (2.3) -0.10 [ -0.54, 0.34 ]
2 Mean change in haemoglobin (g/dl) from baseline to Day 28
Zongo 2005 BFA 261 1.18 (0.19) 260 1.01 (0.2) 0.17 [ 0.14, 0.20 ]
3 Mean haemoglobin (g/dl) at Day 42 or last day of follow up.
Zongo 2007 BFA 188 11.3 (1.6) 184 11.8 (1.4) -0.50 [ -0.81, -0.19 ]
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Analysis 11.8. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine,
Outcome 8 Serious adverse events (including deaths).
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 8 Serious adverse events (including deaths)
Study or subgroup AL6 AQ+SP Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Faye 2003 SEN 0/149 0/161 0.0 [ 0.0, 0.0 ]
Mutabingwa 2004 TZA 1/519 1/507 0.98 [ 0.06, 15.58 ]
Zongo 2005 BFA 1/261 1/260 1.00 [ 0.06, 15.84 ]
Dorsey 2006 UGA 14/202 16/253 1.10 [ 0.55, 2.19 ]
Zongo 2007 BFA 0/188 0/184 0.0 [ 0.0, 0.0 ]
Total (95% CI) 1319 1365 1.08 [ 0.56, 2.08 ]
Total events: 16 (AL6), 18 (AQ+SP)
Heterogeneity: Chi2 = 0.01, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
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Analysis 11.9. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine,
Outcome 9 Early vomiting.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 9 Early vomiting
Study or subgroup AL6 AQ+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zongo 2005 BFA 7/261 5/260 71.2 % 1.39 [ 0.45, 4.34 ]
Zongo 2007 BFA 3/188 2/184 28.8 % 1.47 [ 0.25, 8.68 ]
Total (95% CI) 449 444 100.0 % 1.42 [ 0.54, 3.68 ]
Total events: 10 (AL6), 7 (AQ+SP)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
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Analysis 12.1. Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine-pyrimethamine,
Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome: 1 Total Failure (P. falciparum) Day 28 PCR unadjusted
Study or subgroup AS+AQ AS+SP Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Africa
Guthmann 2003 AGO 6/84 3/84 2.00 [ 0.52, 7.73 ]
Hamour 2003 SDN 29/80 27/79 1.06 [ 0.70, 1.62 ]
Van den Broek 2004 ZAR 31/97 21/85 1.29 [ 0.81, 2.07 ]
Djimde 2004 MLI 44/235 10/232 4.34 [ 2.24, 8.42 ]
Bonnet 2004 GIN 6/107 9/106 0.66 [ 0.24, 1.79 ]
Swarthout 2004 ZAR 14/83 28/81 0.49 [ 0.28, 0.86 ]
Kayentao 2006 MLI 58/131 12/130 4.80 [ 2.71, 8.50 ]
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Analysis 12.2. Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine-pyrimethamine,
Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome: 2 Total Failure (P. falciparum) Day 28 PCR adjusted
Study or subgroup AS+AQ AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Guthmann 2003 AGO 1/79 1/82 3.1 % 1.04 [ 0.07, 16.31 ]
Hamour 2003 SDN 4/55 5/57 15.5 % 0.83 [ 0.23, 2.93 ]
Van den Broek 2004 ZAR 1/67 7/71 21.5 % 0.15 [ 0.02, 1.20 ]
Swarthout 2004 ZAR 5/74 13/66 43.5 % 0.34 [ 0.13, 0.91 ]
Bonnet 2004 GIN 1/102 1/98 3.2 % 0.96 [ 0.06, 15.15 ]
Djimde 2004 MLI 1/235 1/232 3.2 % 0.99 [ 0.06, 15.69 ]
Kayentao 2006 MLI 6/79 4/122 9.9 % 2.32 [ 0.67, 7.95 ]
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Analysis 12.3. Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine-pyrimethamine,
Outcome 3 Gametocyte carriage.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome: 3 Gametocyte carriage
Study or subgroup AS+AQ AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Gametocyte carriage day 0
Hamour 2003 SDN 4/80 4/81 8.7 % 1.01 [ 0.26, 3.91 ]
Swarthout 2004 ZAR 11/90 12/89 27.1 % 0.91 [ 0.42, 1.95 ]
Van den Broek 2004 ZAR 23/101 24/91 64.2 % 0.86 [ 0.53, 1.42 ]
Subtotal (95% CI) 271 261 100.0 % 0.89 [ 0.60, 1.32 ]
Total events: 38 (AS+AQ), 40 (AS+SP)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
2 Gametocyte carriage day 3
Van den Broek 2004 ZAR 36/99 36/88 75.0 % 0.89 [ 0.62, 1.28 ]
Swarthout 2004 ZAR 16/89 16/87 25.0 % 0.98 [ 0.52, 1.83 ]
Subtotal (95% CI) 188 175 100.0 % 0.91 [ 0.67, 1.25 ]
Total events: 52 (AS+AQ), 52 (AS+SP)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
3 Gametocyte carriage day 7
Van den Broek 2004 ZAR 30/98 31/89 78.9 % 0.88 [ 0.58, 1.33 ]
Swarthout 2004 ZAR 13/87 9/89 21.1 % 1.48 [ 0.67, 3.28 ]
Subtotal (95% CI) 185 178 100.0 % 1.02 [ 0.64, 1.61 ]
Total events: 43 (AS+AQ), 40 (AS+SP)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.31, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 0.07 (P = 0.95)
4 Gametocyte carriage day 14
Hamour 2003 SDN 3/80 4/79 16.0 % 0.74 [ 0.17, 3.20 ]
Swarthout 2004 ZAR 7/87 1/86 8.0 % 6.92 [ 0.87, 55.06 ]
Van den Broek 2004 ZAR 12/99 18/89 76.0 % 0.60 [ 0.31, 1.17 ]
Subtotal (95% CI) 266 254 100.0 % 1.08 [ 0.32, 3.73 ]
Total events: 22 (AS+AQ), 23 (AS+SP)
Heterogeneity: Tau2 = 0.72; Chi2 = 5.14, df = 2 (P = 0.08); I2 =61%
Test for overall effect: Z = 0.13 (P = 0.90)
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Analysis 12.4. Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine-pyrimethamine,
Outcome 4 Proportion of participants with anaemia.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome: 4 Proportion of participants with anaemia
Study or subgroup AS+AQ AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At baseline
Guthmann 2003 AGO 80/97 81/90 45.1 % 0.92 [ 0.82, 1.03 ]
Kayentao 2006 MLI 93/133 102/132 54.9 % 0.90 [ 0.78, 1.05 ]
Subtotal (95% CI) 230 222 100.0 % 0.91 [ 0.83, 1.00 ]
Total events: 173 (AS+AQ), 183 (AS+SP)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.051)
2 At Day 28
Guthmann 2003 AGO 33/84 31/84 28.4 % 1.06 [ 0.72, 1.57 ]
Kayentao 2006 MLI 71/131 78/130 71.6 % 0.90 [ 0.73, 1.12 ]
Subtotal (95% CI) 215 214 100.0 % 0.95 [ 0.79, 1.14 ]
Total events: 104 (AS+AQ), 109 (AS+SP)
Heterogeneity: Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
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Analysis 12.5. Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine-pyrimethamine,
Outcome 5 Serious adverse events (including deaths).
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome: 5 Serious adverse events (including deaths)
Study or subgroup AS+AQ AS+SP Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hamour 2003 SDN 0/81 0/80 0.0 [ 0.0, 0.0 ]
Swarthout 2004 ZAR 0/90 0/90 0.0 [ 0.0, 0.0 ]
Djimde 2004 MLI 1/252 0/250 2.98 [ 0.12, 72.71 ]
Kayentao 2006 MLI 0/133 1/132 0.33 [ 0.01, 8.05 ]
Total (95% CI) 556 552 0.99 [ 0.14, 7.02 ]
Total events: 1 (AS+AQ), 1 (AS+SP)
Heterogeneity: Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
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Analysis 13.1. Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-
pyrimethamine, Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 1 Total Failure (P. falciparum) Day 28 PCR unadjusted
Study or subgroup AS+AQ AQ+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 East Africa
Staedke 2003 UGA 19/130 24/129 17.6 % 0.79 [ 0.45, 1.36 ]
Karema 2004 RWA 45/251 66/255 21.2 % 0.69 [ 0.49, 0.97 ]
Yeka 2004 UGA 350/706 315/701 23.9 % 1.10 [ 0.99, 1.23 ]
Mutabingwa 2004 TZA 193/472 282/463 23.7 % 0.67 [ 0.59, 0.77 ]
Dorsey 2006 UGA 7/105 25/105 13.6 % 0.28 [ 0.13, 0.62 ]
Subtotal (95% CI) 1664 1653 100.0 % 0.72 [ 0.51, 1.01 ]
Total events: 614 (AS+AQ), 712 (AQ+SP)
Heterogeneity: Tau2 = 0.11; Chi2 = 42.74, df = 4 (P<0.00001); I2 =91%
Test for overall effect: Z = 1.90 (P = 0.057)
2 West Africa
Faye 2003 SEN 9/349 2/156 40.1 % 2.01 [ 0.44, 9.20 ]
Kayentao 2006 MLI 58/131 3/130 59.9 % 19.19 [ 6.17, 59.68 ]
Subtotal (95% CI) 480 286 100.0 % 6.57 [ 0.68, 63.26 ]
Total events: 67 (AS+AQ), 5 (AQ+SP)
Heterogeneity: Tau2 = 2.21; Chi2 = 5.71, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 1.63 (P = 0.10)
3 Other
Menard 2006 MDG 12/76 4/79 100.0 % 3.12 [ 1.05, 9.25 ]
Subtotal (95% CI) 76 79 100.0 % 3.12 [ 1.05, 9.25 ]
Total events: 12 (AS+AQ), 4 (AQ+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.040)
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Analysis 13.2. Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-
pyrimethamine, Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 2 Total Failure (P. falciparum) Day 28 PCR adjusted
Study or subgroup AS+AQ AQ+SP Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 East Africa
Yeka 2004 UGA 49/405 79/465 0.71 [ 0.51, 0.99 ]
Karema 2004 RWA 16/222 38/227 0.43 [ 0.25, 0.75 ]
Dorsey 2006 UGA 2/100 16/96 0.12 [ 0.03, 0.51 ]
Subtotal (95% CI) 727 788 0.44 [ 0.22, 0.89 ]
Total events: 67 (AS+AQ), 133 (AQ+SP)
Heterogeneity: Tau2 = 0.25; Chi2 = 7.34, df = 2 (P = 0.03); I2 =73%
Test for overall effect: Z = 2.30 (P = 0.022)
2 West Africa
Faye 2003 SEN 0/340 0/154 0.0 [ 0.0, 0.0 ]
Kayentao 2006 MLI 6/79 1/128 9.72 [ 1.19, 79.26 ]
Subtotal (95% CI) 419 282 9.72 [ 1.19, 79.26 ]
Total events: 6 (AS+AQ), 1 (AQ+SP)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 2.12 (P = 0.034)
3 Other
Menard 2006 MDG 6/70 3/78 2.23 [ 0.58, 8.58 ]
Subtotal (95% CI) 70 78 2.23 [ 0.58, 8.58 ]
Total events: 6 (AS+AQ), 3 (AQ+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
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Analysis 13.3. Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-
pyrimethamine, Outcome 3 Gametocyte development.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 3 Gametocyte development
Study or subgroup AS+AQ AQ+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Staedke 2003 UGA 6/121 9/125 5.3 % 0.69 [ 0.25, 1.88 ]
Yeka 2004 UGA 104/551 158/557 94.7 % 0.67 [ 0.54, 0.83 ]
Total (95% CI) 672 682 100.0 % 0.67 [ 0.54, 0.82 ]
Total events: 110 (AS+AQ), 167 (AQ+SP)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 3.73 (P = 0.00019)
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Analysis 13.4. Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-
pyrimethamine, Outcome 4 Gametocyte carriage.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 4 Gametocyte carriage
Study or subgroup AS+AQ AQ+SP Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Gametocyte carriage day 0
Faye 2003 SEN 0/360 5/161 0.04 [ 0.00, 0.73 ]
Dorsey 2006 UGA 16/111 12/111 1.33 [ 0.66, 2.69 ]
Menard 2006 MDG 3/83 2/83 1.50 [ 0.26, 8.75 ]
Subtotal (95% CI) 554 355 0.69 [ 0.13, 3.59 ]
Total events: 19 (AS+AQ), 19 (AQ+SP)
Heterogeneity: Tau2 = 1.36; Chi2 = 5.97, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Gametocyte carriage day 3
Faye 2003 SEN 0/360 16/161 0.01 [ 0.00, 0.23 ]
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(. . . Continued)
Study or subgroup AS+AQ AQ+SP Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Subtotal (95% CI) 360 161 0.01 [ 0.00, 0.23 ]
Total events: 0 (AS+AQ), 16 (AQ+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 3.00 (P = 0.0027)
3 Gametocyte carriage day 7
Faye 2003 SEN 0/360 19/161 0.01 [ 0.00, 0.19 ]
Dorsey 2006 UGA 11/111 13/105 0.80 [ 0.38, 1.71 ]
Menard 2006 MDG 2/80 3/80 0.67 [ 0.11, 3.88 ]
Subtotal (95% CI) 551 346 0.25 [ 0.02, 2.69 ]
Total events: 13 (AS+AQ), 35 (AQ+SP)
Heterogeneity: Tau2 = 3.61; Chi2 = 12.43, df = 2 (P = 0.002); I2 =84%
Test for overall effect: Z = 1.15 (P = 0.25)
4 Gametocyte carriage day 14
Faye 2003 SEN 0/360 0/161 0.0 [ 0.0, 0.0 ]
Dorsey 2006 UGA 7/109 8/105 0.84 [ 0.32, 2.24 ]
Menard 2006 MDG 1/79 5/80 0.20 [ 0.02, 1.69 ]
Subtotal (95% CI) 548 346 0.57 [ 0.16, 2.02 ]
Total events: 8 (AS+AQ), 13 (AQ+SP)
Heterogeneity: Tau2 = 0.33; Chi2 = 1.47, df = 1 (P = 0.23); I2 =32%
Test for overall effect: Z = 0.88 (P = 0.38)
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Analysis 13.5. Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-
pyrimethamine, Outcome 5 Anaemia.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 5 Anaemia
Study or subgroup AS+AQ AQ+SP Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean haemoglobin (g/dl) at baseline
Yeka 2004 UGA 194 9.1 (1.9) 181 8.9 (1.8) 0.20 [ -0.17, 0.57 ]
Mutabingwa 2004 TZA 515 9 (1.7) 507 9 (1.7) 0.0 [ -0.21, 0.21 ]
Yeka 2004 UGA 174 9.4 (1.7) 180 9.2 (1.7) 0.20 [ -0.15, 0.55 ]
Yeka 2004 UGA 174 9.2 (1.9) 183 9.4 (1.9) -0.20 [ -0.59, 0.19 ]
Yeka 2004 UGA 189 10.7 (2.2) 186 10.4 (2.3) 0.30 [ -0.16, 0.76 ]
Dorsey 2006 UGA 232 11.5 (1.4) 253 11.6 (1.3) -0.10 [ -0.34, 0.14 ]
Kayentao 2006 MLI 133 9.83 (1.8) 132 9.98 (1.59) -0.15 [ -0.56, 0.26 ]
2 Mean change in haemoglobin (g/dl) from baseline to day 14
Dorsey 2006 UGA 232 -0.03 (1.1) 253 0.16 (1.03) -0.19 [ -0.38, 0.00 ]
3 Mean change in haemoglobin (g/dl) from baseline to Day 28
Yeka 2004 UGA 174 1.44 (1.67) 180 1.44 (1.6) 0.0 [ -0.34, 0.34 ]
Yeka 2004 UGA 189 0.95 (1.91) 186 1.15 (1.93) -0.20 [ -0.59, 0.19 ]
Yeka 2004 UGA 194 1.14 (1.48) 181 1.58 (1.55) -0.44 [ -0.75, -0.13 ]
Yeka 2004 UGA 174 1.76 (1.55) 183 1.77 (1.79) -0.01 [ -0.36, 0.34 ]
Mutabingwa 2004 TZA 491 0.58 (1.4) 476 0.54 (1.4) 0.04 [ -0.14, 0.22 ]
4 Mean haemoglobin (g/dl) at Day 28
Kayentao 2006 MLI 105 10.78 (1.49) 130 11.05 (1.52) -0.27 [ -0.66, 0.12 ]
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Analysis 13.6. Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-
pyrimethamine, Outcome 6 Serious adverse events (including deaths).
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 6 Serious adverse events (including deaths)
Study or subgroup AS+AQ AQ+SP Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Staedke 2003 UGA 1/134 6/134 0.17 [ 0.02, 1.37 ]
Faye 2003 SEN 0/360 0/161 0.0 [ 0.0, 0.0 ]
Mutabingwa 2004 TZA 0/515 1/519 0.34 [ 0.01, 8.23 ]
Yeka 2004 UGA 4/731 12/730 0.33 [ 0.11, 1.03 ]
Dorsey 2006 UGA 15/232 16/253 1.02 [ 0.52, 2.02 ]
Kayentao 2006 MLI 0/133 0/132 0.0 [ 0.0, 0.0 ]
Menard 2006 MDG 0/83 0/83 0.0 [ 0.0, 0.0 ]
Total (95% CI) 2188 2012 0.61 [ 0.36, 1.03 ]
Total events: 20 (AS+AQ), 35 (AQ+SP)
Heterogeneity: Chi2 = 4.92, df = 3 (P = 0.18); I2 =39%
Test for overall effect: Z = 1.84 (P = 0.065)
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Analysis 14.1. Comparison 14 Dihydroartemisinin-piperaquine dose analysis: 3 dose vs 4 dose regimen,
Outcome 1 Total Failure PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 14 Dihydroartemisinin-piperaquine dose analysis: 3 dose vs 4 dose regimen
Outcome: 1 Total Failure PCR unadjusted
Study or subgroup DHA-P (4 doses) DHA-P (3 doses) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 63
Ashley 2004 THA 18/155 11/163 100.0 % 1.72 [ 0.84, 3.53 ]
Total (95% CI) 155 163 100.0 % 1.72 [ 0.84, 3.53 ]
Total events: 18 (DHA-P (4 doses)), 11 (DHA-P (3 doses))
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
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Analysis 14.2. Comparison 14 Dihydroartemisinin-piperaquine dose analysis: 3 dose vs 4 dose regimen,
Outcome 2 Total Failure PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 14 Dihydroartemisinin-piperaquine dose analysis: 3 dose vs 4 dose regimen
Outcome: 2 Total Failure PCR adjusted
Study or subgroup DHA-P (4 doses) DHA-P (3 doses) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 63
Ashley 2004 THA 1/138 2/154 100.0 % 0.56 [ 0.05, 6.09 ]
Total (95% CI) 138 154 100.0 % 0.56 [ 0.05, 6.09 ]
Total events: 1 (DHA-P (4 doses)), 2 (DHA-P (3 doses))
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
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Analysis 15.1. Comparison 15 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus
mefloquine), Outcome 1 Total Failure Day 63 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 15 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus mefloquine)
Outcome: 1 Total Failure Day 63 PCR unadjusted
Study or subgroup DHA-P ASMQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 DHA-P 4 doses
Ashley 2003b THA 26/154 29/151 24.9 % 0.88 [ 0.54, 1.42 ]
Ashley 2004 THA 18/155 27/157 23.2 % 0.68 [ 0.39, 1.17 ]
Janssens 2003 KHM 18/195 22/207 22.4 % 0.87 [ 0.48, 1.57 ]
Subtotal (95% CI) 504 515 70.5 % 0.81 [ 0.59, 1.10 ]
Total events: 62 (DHA-P), 78 (ASMQ)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.17)
2 DHA-P 3 doses
Ashley 2004 THA 11/163 27/157 20.7 % 0.39 [ 0.20, 0.76 ]
Grande 2005 PER 12/219 2/226 8.7 % 6.19 [ 1.40, 27.35 ]
Subtotal (95% CI) 382 383 29.5 % 1.44 [ 0.09, 22.81 ]
Total events: 23 (DHA-P), 29 (ASMQ)
Heterogeneity: Tau2 = 3.64; Chi2 = 11.56, df = 1 (P = 0.00067); I2 =91%
Test for overall effect: Z = 0.26 (P = 0.80)
Total (95% CI) 886 898 100.0 % 0.83 [ 0.49, 1.38 ]
Total events: 85 (DHA-P), 107 (ASMQ)
Heterogeneity: Tau2 = 0.22; Chi2 = 12.26, df = 4 (P = 0.02); I2 =67%
Test for overall effect: Z = 0.72 (P = 0.47)
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Analysis 15.2. Comparison 15 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus
mefloquine), Outcome 2 Total Failure Day 63 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 15 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus mefloquine)
Outcome: 2 Total Failure Day 63 PCR adjusted
Study or subgroup DHA-P ASMQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 DHA-P 4 doses
Ashley 2003b THA 3/131 9/131 26.6 % 0.33 [ 0.09, 1.20 ]
Ashley 2004 THA 1/138 7/137 15.5 % 0.14 [ 0.02, 1.14 ]
Janssens 2003 KHM 4/181 5/190 26.4 % 0.84 [ 0.23, 3.08 ]
Subtotal (95% CI) 450 458 68.5 % 0.42 [ 0.17, 1.04 ]
Total events: 8 (DHA-P), 21 (ASMQ)
Heterogeneity: Tau2 = 0.09; Chi2 = 2.31, df = 2 (P = 0.31); I2 =13%
Test for overall effect: Z = 1.88 (P = 0.060)
2 DHA-P 3 doses
Ashley 2004 THA 2/154 7/137 22.1 % 0.25 [ 0.05, 1.20 ]
Grande 2005 PER 4/211 0/224 9.4 % 9.55 [ 0.52, 176.35 ]
Subtotal (95% CI) 365 361 31.5 % 1.27 [ 0.03, 48.28 ]
Total events: 6 (DHA-P), 7 (ASMQ)
Heterogeneity: Tau2 = 5.56; Chi2 = 4.91, df = 1 (P = 0.03); I2 =80%
Test for overall effect: Z = 0.13 (P = 0.90)
Total (95% CI) 815 819 100.0 % 0.48 [ 0.18, 1.31 ]
Total events: 14 (DHA-P), 28 (ASMQ)
Heterogeneity: Tau2 = 0.54; Chi2 = 7.08, df = 4 (P = 0.13); I2 =44%
Test for overall effect: Z = 1.44 (P = 0.15)
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Analysis 15.3. Comparison 15 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus
mefloquine), Outcome 3 Total Failure Day 42 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 15 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus mefloquine)
Outcome: 3 Total Failure Day 42 PCR unadjusted
Study or subgroup DHA-P ASMQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 DHA-P 4 doses
Ashley 2004 THA 10/155 19/157 22.7 % 0.53 [ 0.26, 1.11 ]
Janssens 2003 KHM 9/195 9/207 19.0 % 1.06 [ 0.43, 2.62 ]
Tran 2002 VNM 16/166 7/77 20.2 % 1.06 [ 0.45, 2.47 ]
Subtotal (95% CI) 516 441 62.0 % 0.80 [ 0.50, 1.28 ]
Total events: 35 (DHA-P), 35 (ASMQ)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.98, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
2 DHA-P 3 doses
Ashley 2004 THA 6/163 19/157 19.3 % 0.30 [ 0.12, 0.74 ]
Mayxay 2004 LAO 4/106 5/108 12.7 % 0.82 [ 0.23, 2.95 ]
Smithuis 2004 MMR 6/319 1/316 6.1 % 5.94 [ 0.72, 49.09 ]
Subtotal (95% CI) 588 581 38.0 % 0.88 [ 0.20, 3.81 ]
Total events: 16 (DHA-P), 25 (ASMQ)
Heterogeneity: Tau2 = 1.17; Chi2 = 7.05, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 0.17 (P = 0.86)
Total (95% CI) 1104 1022 100.0 % 0.77 [ 0.43, 1.35 ]
Total events: 51 (DHA-P), 60 (ASMQ)
Heterogeneity: Tau2 = 0.23; Chi2 = 9.63, df = 5 (P = 0.09); I2 =48%
Test for overall effect: Z = 0.92 (P = 0.36)
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Analysis 15.4. Comparison 15 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus
mefloquine), Outcome 4 Total Failure Day 42 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 15 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus mefloquine)
Outcome: 4 Total Failure Day 42 PCR adjusted
Study or subgroup DHA-P ASMQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 DHA-P 4 doses
Ashley 2004 THA 1/146 7/145 18.9 % 0.14 [ 0.02, 1.14 ]
Janssens 2003 KHM 3/189 2/200 22.9 % 1.59 [ 0.27, 9.39 ]
Tran 2002 VNM 2/152 1/71 15.7 % 0.93 [ 0.09, 10.13 ]
Subtotal (95% CI) 487 416 57.5 % 0.62 [ 0.14, 2.82 ]
Total events: 6 (DHA-P), 10 (ASMQ)
Heterogeneity: Tau2 = 0.69; Chi2 = 3.24, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.62 (P = 0.54)
2 DHA-P 3 doses
Ashley 2004 THA 1/158 7/145 18.9 % 0.13 [ 0.02, 1.05 ]
Mayxay 2004 LAO 1/103 1/104 12.7 % 1.01 [ 0.06, 15.93 ]
Smithuis 2004 MMR 2/315 0/315 10.9 % 5.00 [ 0.24, 103.73 ]
Subtotal (95% CI) 576 564 42.5 % 0.70 [ 0.08, 5.87 ]
Total events: 4 (DHA-P), 8 (ASMQ)
Heterogeneity: Tau2 = 1.80; Chi2 = 4.05, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 0.33 (P = 0.74)
Total (95% CI) 1063 980 100.0 % 0.62 [ 0.20, 1.91 ]
Total events: 10 (DHA-P), 18 (ASMQ)
Heterogeneity: Tau2 = 0.62; Chi2 = 7.30, df = 5 (P = 0.20); I2 =32%
Test for overall effect: Z = 0.84 (P = 0.40)
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Analysis 15.5. Comparison 15 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus
mefloquine), Outcome 5 Total Failure Day 28 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 15 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus mefloquine)
Outcome: 5 Total Failure Day 28 PCR unadjusted
Study or subgroup DHA-P ASMQ Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 DHA-P 4 doses
Ashley 2003a THA 1/59 0/59 3.00 [ 0.12, 72.18 ]
Ashley 2004 THA 2/155 13/157 0.16 [ 0.04, 0.68 ]
Janssens 2003 KHM 2/195 2/207 1.06 [ 0.15, 7.46 ]
Tran 2002 VNM 0/166 0/77 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 575 500 0.56 [ 0.10, 3.14 ]
Total events: 5 (DHA-P), 15 (ASMQ)
Heterogeneity: Tau2 = 1.18; Chi2 = 4.12, df = 2 (P = 0.13); I2 =52%
Test for overall effect: Z = 0.66 (P = 0.51)
2 DHA-P 3 doses
Ashley 2004 THA 3/163 13/157 0.22 [ 0.06, 0.77 ]
Smithuis 2004 MMR 6/319 0/316 12.88 [ 0.73, 227.64 ]
Tangpukdee 2005 THA 1/107 0/54 1.53 [ 0.06, 36.89 ]
Subtotal (95% CI) 589 527 1.29 [ 0.09, 18.93 ]
Total events: 10 (DHA-P), 13 (ASMQ)
Heterogeneity: Tau2 = 4.07; Chi2 = 7.57, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 0.19 (P = 0.85)
Total (95% CI) 1164 1027 0.74 [ 0.20, 2.65 ]
Total events: 15 (DHA-P), 28 (ASMQ)
Heterogeneity: Tau2 = 1.32; Chi2 = 11.38, df = 5 (P = 0.04); I2 =56%
Test for overall effect: Z = 0.47 (P = 0.64)
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Analysis 15.6. Comparison 15 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus
mefloquine), Outcome 6 Total Failure Day 28 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 15 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus mefloquine)
Outcome: 6 Total Failure Day 28 PCR adjusted
Study or subgroup DHA-P ASMQ Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 DHA-P 4 doses
Ashley 2003a THA 1/59 0/59 3.00 [ 0.12, 72.18 ]
Ashley 2004 THA 1/154 7/151 0.14 [ 0.02, 1.12 ]
Janssens 2003 KHM 2/195 1/206 2.11 [ 0.19, 23.11 ]
Tran 2002 VNM 0/166 0/77 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 574 493 0.79 [ 0.10, 6.11 ]
Total events: 4 (DHA-P), 8 (ASMQ)
Heterogeneity: Tau2 = 1.62; Chi2 = 3.99, df = 2 (P = 0.14); I2 =50%
Test for overall effect: Z = 0.22 (P = 0.82)
2 DHA-P 3 doses
Ashley 2004 THA 1/161 7/151 0.13 [ 0.02, 1.08 ]
Smithuis 2004 MMR 2/315 0/316 5.02 [ 0.24, 104.06 ]
Tangpukdee 2005 THA 1/107 0/54 1.53 [ 0.06, 36.89 ]
Subtotal (95% CI) 583 521 0.79 [ 0.08, 7.82 ]
Total events: 4 (DHA-P), 7 (ASMQ)
Heterogeneity: Tau2 = 2.15; Chi2 = 4.21, df = 2 (P = 0.12); I2 =52%
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 1157 1014 0.74 [ 0.19, 2.86 ]
Total events: 8 (DHA-P), 15 (ASMQ)
Heterogeneity: Tau2 = 1.09; Chi2 = 8.19, df = 5 (P = 0.15); I2 =39%
Test for overall effect: Z = 0.43 (P = 0.66)
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Analysis 16.1. Comparison 16 Artesunate Mefloquine dose analysis: FDC versus split dose regimen,
Outcome 1 Total Failure Day 63 PCR unadjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 16 Artesunate Mefloquine dose analysis: FDC versus split dose regimen
Outcome: 1 Total Failure Day 63 PCR unadjusted
Study or subgroup ASMQ FDC ASMQ Loose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ashley 2005 THA 55/212 59/211 100.0 % 0.93 [ 0.68, 1.27 ]
Total (95% CI) 212 211 100.0 % 0.93 [ 0.68, 1.27 ]
Total events: 55 (ASMQ FDC), 59 (ASMQ Loose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
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Analysis 16.2. Comparison 16 Artesunate Mefloquine dose analysis: FDC versus split dose regimen,
Outcome 2 Total Failure Day 63 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 16 Artesunate Mefloquine dose analysis: FDC versus split dose regimen
Outcome: 2 Total Failure Day 63 PCR adjusted
Study or subgroup ASMQ FDC ASMQ Loose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ashley 2005 THA 13/170 20/172 100.0 % 0.66 [ 0.34, 1.28 ]
Total (95% CI) 170 172 100.0 % 0.66 [ 0.34, 1.28 ]
Total events: 13 (ASMQ FDC), 20 (ASMQ Loose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
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Analysis 17.1. Comparison 17 Artesunate plus mefloquine dose analysis (versus Dihydroartemisinin-
piperaquine), Outcome 1 Total Failure Day 63 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 17 Artesunate plus mefloquine dose analysis (versus Dihydroartemisinin-piperaquine)
Outcome: 1 Total Failure Day 63 PCR adjusted
Study or subgroup ASMQ 8mg/kg/day DHA-P Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ashley 2003b THA 9/131 3/131 3.00 [ 0.83, 10.83 ]
Ashley 2004 THA 7/137 3/292 4.97 [ 1.31, 18.94 ]
Grande 2005 PER 0/224 4/211 0.10 [ 0.01, 1.93 ]
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Analysis 17.2. Comparison 17 Artesunate plus mefloquine dose analysis (versus Dihydroartemisinin-
piperaquine), Outcome 2 Total Failure Day 28 PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 17 Artesunate plus mefloquine dose analysis (versus Dihydroartemisinin-piperaquine)
Outcome: 2 Total Failure Day 28 PCR adjusted
Study or subgroup ASMQ 8mg/kg/day DHA-P Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ashley 2003a THA 1/59 0/59 43.0 % 3.00 [ 0.12, 72.18 ]
Tangpukdee 2005 THA 1/107 0/54 57.0 % 1.53 [ 0.06, 36.89 ]
Total (95% CI) 166 113 100.0 % 2.16 [ 0.23, 19.88 ]
Total events: 2 (ASMQ 8mg/kg/day), 0 (DHA-P)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
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Analysis 18.1. Comparison 18 How does Dihydroartemisinin-piperaquine perform?, Outcome 1
Effectiveness: Total Failure (P. falciparum) PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 18 How does Dihydroartemisinin-piperaquine perform?
Outcome: 1 Effectiveness: Total Failure (P. falciparum) PCR adjusted
Study or subgroup DHA-P Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Day 63: DHA-P vs Artesunate plus mefloquine
Ashley 2003b THA 3/131 9/131 31.2 % 0.33 [ 0.09, 1.20 ]
Janssens 2003 KHM 4/181 5/190 30.8 % 0.84 [ 0.23, 3.08 ]
Ashley 2004 THA 3/292 7/137 29.6 % 0.20 [ 0.05, 0.77 ]
Grande 2005 PER 4/211 0/224 8.4 % 9.55 [ 0.52, 176.35 ]
Subtotal (95% CI) 815 682 100.0 % 0.57 [ 0.17, 1.83 ]
Total events: 14 (DHA-P), 21 (Control)
Heterogeneity: Tau2 = 0.78; Chi2 = 6.94, df = 3 (P = 0.07); I2 =57%
Test for overall effect: Z = 0.95 (P = 0.34)
2 Day 42: DHA-P vs Artemether-lumefantrine
Ratcliff 2005 IDN 3/179 3/138 11.7 % 0.77 [ 0.16, 3.76 ]
Kamya 2006 UGA 13/130 28/117 31.8 % 0.42 [ 0.23, 0.77 ]
Karunajeewa 2007 PNG 12/77 5/74 21.3 % 2.31 [ 0.85, 6.23 ]
Zongo 2007 BFA 4/163 7/128 17.0 % 0.45 [ 0.13, 1.50 ]
Yeka 2007 UGA 4/190 10/141 18.2 % 0.30 [ 0.10, 0.93 ]
Subtotal (95% CI) 739 598 100.0 % 0.62 [ 0.29, 1.30 ]
Total events: 36 (DHA-P), 53 (Control)
Heterogeneity: Tau2 = 0.42; Chi2 = 10.17, df = 4 (P = 0.04); I2 =61%
Test for overall effect: Z = 1.26 (P = 0.21)
3 Day 28: DHA-P vs Artesunate plus amodiaquine
Karema 2004 RWA 10/236 16/222 78.2 % 0.59 [ 0.27, 1.27 ]
Hasugian 2005 IDN 1/90 6/81 21.8 % 0.15 [ 0.02, 1.22 ]
Subtotal (95% CI) 326 303 100.0 % 0.42 [ 0.13, 1.35 ]
Total events: 11 (DHA-P), 22 (Control)
Heterogeneity: Tau2 = 0.31; Chi2 = 1.47, df = 1 (P = 0.22); I2 =32%
Test for overall effect: Z = 1.46 (P = 0.15)
4 Day 42: DHA-P vs Artesunate plus sulfadoxine-pyrimethamine
Karunajeewa 2007 PNG 12/77 17/84 100.0 % 0.77 [ 0.39, 1.51 ]
Subtotal (95% CI) 77 84 100.0 % 0.77 [ 0.39, 1.51 ]
Total events: 12 (DHA-P), 17 (Control)
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(. . . Continued)
Study or subgroup DHA-P Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
5 Day 28: DHA-P vs Amodiaquine plus sulfadoxine-pyrimethamine
Karema 2004 RWA 10/236 38/227 63.8 % 0.25 [ 0.13, 0.50 ]
Zongo 2007 BFA 4/172 7/167 36.2 % 0.55 [ 0.17, 1.86 ]
Subtotal (95% CI) 408 394 100.0 % 0.32 [ 0.16, 0.64 ]
Total events: 14 (DHA-P), 45 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 1.24, df = 1 (P = 0.27); I2 =19%
Test for overall effect: Z = 3.23 (P = 0.0012)
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Analysis 19.1. Comparison 19 How does Artesunate plus mefloquine perform?, Outcome 1 Effectiveness:
Total Failure (P. falciparum) PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 19 How does Artesunate plus mefloquine perform?
Outcome: 1 Effectiveness: Total Failure (P. falciparum) PCR adjusted
Study or subgroup ASMQ Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Day 63: AS+MQ vs Dihydroartemisinin-piperaquine
Ashley 2003b THA 9/131 3/131 3.00 [ 0.83, 10.83 ]
Janssens 2003 KHM 5/190 4/181 1.19 [ 0.32, 4.36 ]
Ashley 2004 THA 7/137 3/292 4.97 [ 1.31, 18.94 ]
Grande 2005 PER 0/224 4/211 0.10 [ 0.01, 1.93 ]
Subtotal (95% CI) 682 815 1.77 [ 0.55, 5.72 ]
Total events: 21 (ASMQ), 14 (Control)
Heterogeneity: Tau2 = 0.78; Chi2 = 6.94, df = 3 (P = 0.07); I2 =57%
Test for overall effect: Z = 0.95 (P = 0.34)
2 Day 42: AS+MQ vs Artemether-lumefantrine
Hutagalung 2002 THA 9/212 3/201 2.84 [ 0.78, 10.36 ]
Van den Broek 2003a BGD 0/105 3/102 0.14 [ 0.01, 2.65 ]
Stohrer 2003 LAO 0/45 3/37 0.12 [ 0.01, 2.21 ]
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(. . . Continued)
Study or subgroup ASMQ Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Mayxay 2003 LAO 0/106 3/96 0.13 [ 0.01, 2.48 ]
Subtotal (95% CI) 468 436 0.38 [ 0.05, 2.84 ]
Total events: 9 (ASMQ), 12 (Control)
Heterogeneity: Tau2 = 2.64; Chi2 = 8.30, df = 3 (P = 0.04); I2 =64%
Test for overall effect: Z = 0.95 (P = 0.34)
3 Day 28: AS+MQ vs Artesunate plus amodiaquine
Faye 2003 SEN 0/142 0/340 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 142 340 0.0 [ 0.0, 0.0 ]
Total events: 0 (ASMQ), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
4 Day 28: AS+MQ vs Artesunate plus sulfadoxine-pyrimethamine
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (ASMQ), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Day 28: AS+MQ vs Amodiaquine plus sulfadoxine-pyrimethamine
Faye 2003 SEN 0/142 0/154 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 142 154 0.0 [ 0.0, 0.0 ]
Total events: 0 (ASMQ), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.005 0.1 1 10 200
Favours ASMQ Favours Control
212Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 20.1. Comparison 20 How does Artemether-lumefantrine perform?, Outcome 1 Effectiveness:
Total Failure (P. falciparum) Day PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 20 How does Artemether-lumefantrine perform?
Outcome: 1 Effectiveness: Total Failure (P. falciparum) Day PCR adjusted
Study or subgroup AL Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Day 42: AL vs Dihydroartemisinin-piperaquine
Ratcliff 2005 IDN 3/138 3/179 1.30 [ 0.27, 6.33 ]
Kamya 2006 UGA 28/117 13/130 2.39 [ 1.30, 4.40 ]
Yeka 2007 UGA 10/141 4/190 3.37 [ 1.08, 10.52 ]
Karunajeewa 2007 PNG 5/74 12/77 0.43 [ 0.16, 1.17 ]
Zongo 2007 BFA 7/128 4/163 2.23 [ 0.67, 7.45 ]
Subtotal (95% CI) 598 739 1.61 [ 0.77, 3.39 ]
Total events: 53 (AL), 36 (Control)
Heterogeneity: Tau2 = 0.42; Chi2 = 10.17, df = 4 (P = 0.04); I2 =61%
Test for overall effect: Z = 1.26 (P = 0.21)
2 Day 42: AL vs Artesunate plus mefloquine
Hutagalung 2002 THA 3/201 9/212 0.35 [ 0.10, 1.28 ]
Mayxay 2003 LAO 3/96 0/106 7.72 [ 0.40, 147.59 ]
Van den Broek 2003a BGD 3/102 0/105 7.20 [ 0.38, 137.74 ]
Stohrer 2003 LAO 3/37 0/45 8.47 [ 0.45, 158.99 ]
Subtotal (95% CI) 436 468 2.66 [ 0.35, 20.09 ]
Total events: 12 (AL), 9 (Control)
Heterogeneity: Tau2 = 2.64; Chi2 = 8.30, df = 3 (P = 0.04); I2 =64%
Test for overall effect: Z = 0.95 (P = 0.34)
3 Day 28: AL vs Artesunate plus amodiaquine
Faye 2003 SEN 0/147 0/340 0.0 [ 0.0, 0.0 ]
Guthmann 2004 AGO 0/59 0/60 0.0 [ 0.0, 0.0 ]
Falade 2005 NGA 0/59 0/56 0.0 [ 0.0, 0.0 ]
Bukirwa 2005 UGA 2/102 0/68 3.35 [ 0.16, 68.71 ]
Dorsey 2006 UGA 0/95 2/100 0.21 [ 0.01, 4.33 ]
Adjei 2006 GHA 4/101 2/104 2.06 [ 0.39, 11.00 ]
Owusu-Agyei 2006 GHA 12/122 7/136 1.91 [ 0.78, 4.70 ]
Kobbe 2007 GHA 12/92 7/88 1.64 [ 0.68, 3.97 ]
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Favours AL Favours Control
(Continued . . . )
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(. . . Continued)
Study or subgroup AL Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Subtotal (95% CI) 777 952 1.71 [ 0.97, 3.02 ]
Total events: 30 (AL), 18 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.16, df = 4 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.066)
4 Day 42: AL vs Artesunate plus sulfadoxine-pyrimethamine
Karunajeewa 2007 PNG 5/74 17/84 0.33 [ 0.13, 0.86 ]
Subtotal (95% CI) 74 84 0.33 [ 0.13, 0.86 ]
Total events: 5 (AL), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
5 Day 28: AL vs Amodiaquine plus sulfadoxine-pyrimethamine
Faye 2003 SEN 0/147 0/154 0.0 [ 0.0, 0.0 ]
Fanello 2004 RWA 8/218 51/209 0.15 [ 0.07, 0.31 ]
Zongo 2005 BFA 4/212 1/223 4.21 [ 0.47, 37.34 ]
Dorsey 2006 UGA 0/95 16/96 0.03 [ 0.00, 0.50 ]
Zongo 2007 BFA 6/148 7/167 0.97 [ 0.33, 2.81 ]
Subtotal (95% CI) 820 849 0.40 [ 0.08, 2.11 ]
Total events: 18 (AL), 75 (Control)
Heterogeneity: Tau2 = 2.11; Chi2 = 16.71, df = 3 (P = 0.00081); I2 =82%
Test for overall effect: Z = 1.07 (P = 0.28)
0.002 0.1 1 10 500
Favours AL Favours Control
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Analysis 21.1. Comparison 21 How does Artesunate plus amodiaquine perform?, Outcome 1 Effectiveness:
Total Failure (P. falciparum) PCR adjusted.
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 21 How does Artesunate plus amodiaquine perform?
Outcome: 1 Effectiveness: Total Failure (P. falciparum) PCR adjusted
Study or subgroup ASAQ Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Day 28: AS+AQ vs Dihydroartemisinin-piperaquine
Karema 2004 RWA 16/222 10/236 1.70 [ 0.79, 3.67 ]
Hasugian 2005 IDN 6/81 1/90 6.67 [ 0.82, 54.20 ]
Subtotal (95% CI) 303 326 2.36 [ 0.74, 7.54 ]
Total events: 22 (ASAQ), 11 (Control)
Heterogeneity: Tau2 = 0.31; Chi2 = 1.47, df = 1 (P = 0.22); I2 =32%
Test for overall effect: Z = 1.46 (P = 0.15)
2 Day 28: AS+AQ vs Artesunate plus mefloquine
Faye 2003 SEN 0/340 0/142 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 340 142 0.0 [ 0.0, 0.0 ]
Total events: 0 (ASAQ), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
3 Day 28: AS+AQ vs Artemether-lumefantrine
Faye 2003 SEN 0/340 0/147 0.0 [ 0.0, 0.0 ]
Guthmann 2004 AGO 0/60 0/59 0.0 [ 0.0, 0.0 ]
Falade 2005 NGA 0/56 0/59 0.0 [ 0.0, 0.0 ]
Bukirwa 2005 UGA 0/68 2/102 0.30 [ 0.01, 6.12 ]
Dorsey 2006 UGA 2/100 0/95 4.75 [ 0.23, 97.72 ]
Adjei 2006 GHA 2/104 4/101 0.49 [ 0.09, 2.59 ]
Owusu-Agyei 2006 GHA 7/136 12/122 0.52 [ 0.21, 1.29 ]
Kobbe 2007 GHA 7/88 12/92 0.61 [ 0.25, 1.48 ]
Subtotal (95% CI) 952 777 0.59 [ 0.33, 1.03 ]
Total events: 18 (ASAQ), 30 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.16, df = 4 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.066)
4 Day 28: AS+AQ vs Artesunate plus sulfadoxine-pyrimethamine
Hamour 2003 SDN 4/55 5/57 0.83 [ 0.23, 2.93 ]
Guthmann 2003 AGO 1/79 1/82 1.04 [ 0.07, 16.31 ]
0.005 0.1 1 10 200
Favours ASAQ Favours Control
(Continued . . . )
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(. . . Continued)
Study or subgroup ASAQ Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Bonnet 2004 GIN 1/102 1/98 0.96 [ 0.06, 15.15 ]
Swarthout 2004 ZAR 5/74 13/66 0.34 [ 0.13, 0.91 ]
Van den Broek 2004 ZAR 1/67 7/71 0.15 [ 0.02, 1.20 ]
Djimde 2004 MLI 1/235 1/232 0.99 [ 0.06, 15.69 ]
Kayentao 2006 MLI 6/79 4/122 2.32 [ 0.67, 7.95 ]
Subtotal (95% CI) 691 728 0.70 [ 0.34, 1.45 ]
Total events: 19 (ASAQ), 32 (Control)
Heterogeneity: Tau2 = 0.24; Chi2 = 8.08, df = 6 (P = 0.23); I2 =26%
Test for overall effect: Z = 0.95 (P = 0.34)
5 Day 28: AS+AQ vs Amodiaquine plus sulfadoxine-pyrimethamine
Faye 2003 SEN 0/340 0/154 0.0 [ 0.0, 0.0 ]
Karema 2004 RWA 16/222 38/227 0.43 [ 0.25, 0.75 ]
Yeka 2004 UGA 49/405 79/465 0.71 [ 0.51, 0.99 ]
Dorsey 2006 UGA 2/100 16/96 0.12 [ 0.03, 0.51 ]
Menard 2006 MDG 6/70 3/78 2.23 [ 0.58, 8.58 ]
Kayentao 2006 MLI 6/79 1/128 9.72 [ 1.19, 79.26 ]
Subtotal (95% CI) 1216 1148 0.74 [ 0.33, 1.63 ]
Total events: 79 (ASAQ), 137 (Control)
Heterogeneity: Tau2 = 0.51; Chi2 = 17.28, df = 4 (P = 0.002); I2 =77%
Test for overall effect: Z = 0.76 (P = 0.45)
0.005 0.1 1 10 200
Favours ASAQ Favours Control
A P P E N D I C E S
Appendix 1. Treatment comparisons eligible for review
Question Analysis Comparisons
1. How does dihydroartemisinin-piper-
aquine perform?
1 vs artesunate plus mefloquine
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2 vs artemether-lumefantrine (6 doses)
3 vs artesunate plus amodiaquine
4 vs artesunate plus sulfadoxine-pyrimethamine
5 vs amodiaquine plus sulfadoxine-pyrimethamine
2. How does artesunate plus mefloquine
perform?
1 vs dihydroartemisinin-piperaquine
6 vs artemether-lumefantrine (6 doses)
7 vs artesunate plus amodiaquine
- vs artesunate plus sulfadoxine-pyrimethamine
8 vs amodiaquine plus sulfadoxine-pyrimethamine
3. How does artemether-lumefantrine (6
doses) perform?
2 vs dihydroartemisinin-piperaquine
6 vs artesunate plus mefloquine
9 vs artesunate plus amodiaquine
10 vs artesunate plus sulfadoxine-pyrimethamine
11 vs amodiaquine plus sulfadoxine-pyrimethamine
4. How does artesunate plus amodiaquine
perform?
3 vs dihydroartemisinin-piperaquine
7 vs artesunate plus mefloquine
9 vs artemether-lumefantrine (6 doses)
12 vs artesunate plus sulfadoxine-pyrimethamine
13 vs amodiaquine plus sulfadoxine-pyrimethamine
Footnotes
aTo contribute to informed decision-making, the review is limited to artemisinin combination therapies (ACTs) for which co-formulated
products are currently available or shortly to be made available (trials using co-packaged or loose preparations of these same ACTs are
included).
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Appendix 2. Detailed search strategy
Search set CIDG SRa CENTRAL MEDLINEb EMBASEb LILACSb
1 malaria malaria malaria malaria malaria
2 arte* arte* arte* arte* arte*
3 dihydroarte* dihydroarte* dihydroarte* dihydroarte* dihydroarte*
4 amodiaq* amodiaq* amodiaq* amodiaq$ amodiaq$
5 lumefantrine lumefantrine lumefantrine lumefantrine lumefantrine
6 Coartem* Coartem* Coartem* Coartem$ Coartem$
7 mefloquine mefloquine mefloquine mefloquine mefloquine
8 2 or 3 2 or 3 2 or 3 2 or 3 2 or 3
9 4 or 5 or 6 or 7 4 or 5 or 6 or 7 4 or 5 or 6 or 7 4 or 5 or 6 or 7 4 or 5 or 6 or 7
10 1 and 8 and 9 1 and 8 and 9 1 and 8 and 9 1 and 8 and 9 1 and 8 and 9
11 - - Limit 10 to humans Limit 10 to human -
Footnotes
aCochrane Infectious Diseases Group Specialized Register.
bSearch terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Lefebvre
2008); upper case: MeSH or EMTREE heading; lower case: free text term.
Appendix 3. Primary outcome measure (Total Failure) and sensitivity analyses
Analysis Participants PCRb-unadjusted PCR-adjusted
Numerator Denominator Numerator Denominator
Primary analysis Exclusions after en-
rolment
Excludedc Excluded Excluded Excluded
Missing or indeter-
minate PCR
Included as failures Included Excluded Excluded
New infections Included as failures Included Excluded Excluded
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Sensitivity analysis
1d
As ’Primary analysis’
except: missing or
indeterminate PCR
- - Included as failures Included
Sensitivity analysis
2e
As ’Sensitivity anal-
ysis 1’ except: new
infections
- - Included as successes Included
Sensitivity analysis
3f
As ’Sensitivity anal-
ysis 2’ except: ex-
clusions after enrol-
ment
Included as failures Included Included as failures Included
Sensitivity analysis
4g
As ’Sensitivity anal-
ysis 2’ except: ex-
clusions after enrol-
ment
Included as
successes
Included Included as successes Included
Footnotes
aNote: participants who were found to not satisfy the inclusion criteria after randomization are removed from all calculations.
bPCR: polymerase chain reaction.
c’Excluded’ means removed from the calculation.
dTo re-classify all indeterminate or missing PCR results as treatment failures in the PCR-adjusted analysis.
eTo re-classify all PCR-confirmed new infections as treatment successes in the PCR-adjusted analysis. (This analysis may overestimate
efficacy as PCR is not wholly reliable and some recrudescences may be falsely classified as new infections. Also some participants may
have gone on to develop a recrudescence after the new infection.)
fTo re-classify all exclusions after enrolment (losses to follow up, withdrawn consent, other antimalarial use, or failure to complete
treatment) as treatment failures. For PCR-unadjusted total failure this represents a true worse-case scenario.
gTo re-classify all exclusions after enrolment (losses to follow up, withdrawn consent, other antimalarial use, or failure to complete
treatment) as treatment successes.
Appendix 4. Adverse event tables
Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine
Study ID Adverse event monitoring Blinding Summary of adverse event findings
Ashley 2003a THA
(134 participants)
Inpatient monitoring until day
28
FBC, U&E, LFT on days 0 and
7
Open label SAE: No serious adverse events observed
Biochemical: No evidence of toxicity observed
Other: No differences between the groups reported
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Ashley 2003b THA
(356 participants)
Daily review until parasites
cleared thenweekly until day 63
A subset of patients in the
DHA-P group had FBC, U&E
and LFT on days 0 and 7 and
ECGmonitoring before and af-
ter treatment
Open label SAE: No serious adverse events observed
GI: More abdominal pain reported with DHA-P
(P = 0.025) Nausea, vomiting, and diarrhoea not
significantly different
CNS: More sleep disturbance with AS+MQ (P =
0.008) Dizziness not significantly different
Biochemical: Some minor fluctuations in LFTs
CVS: No comment
Ashley 2004 THA
(499 participants)
Clinical examination, symp-
tom enquiry, and haematocrit
daily until parasites cleared then
weekly until day 63
Open label SAE: 4 serious events with AS+MQ (death, severe
anaemia, febrile convulsion, coagulopathy)and 11
with DHA-P (2 deaths, bacterial sepsis, febrile con-
vulsion, leptospirosis, haematemesis, nephritic syn-
drome, severe anaemia, respiratory infection, epi-
gastric pain and vomiting). All except the one case
of severe vomiting were judged to be unrelated or
unlikely to be due to the study treatment
GI: More diarrhoea with DHA-P (P = 0.026); nau-
sea, vomiting, and abdominal pain not significantly
different
CNS: No significant difference in dizziness or sleep
disturbance
Other: Urticaria occurred in 1 patient with DHA-
P but none with AS+MQ
Grande 2005 PER
(522 participants)
Clinical assessment daily until
day 3 then weekly until day 63
FBC, U&E, LFT, and PCV
days 0 and 7, PCV days 14 and
63
Open label SAE: 3 serious drug related events with AS+MQ re-
quiring stopping treatment (encephalopathy, anxi-
ety and arrhythmia, palpitations, and chest pain)
GI: More nausea and vomiting with AS+MQ in
adults (P = 0.02) but not significantly different in
children. Abdominal pain and anorexia not signifi-
cantly different
CNS: More insomnia, dizziness and anxiety with
ASMQ in adults (P = < 0.001) and more insomnia
and anxiety with AS+MQ in children (P = < 0.001,
0.02). More somnolence with DHA-P (P = 0.02)
Biochemical: No clinically significant abnormal re-
nal or liver test results
Janssens 2003 KHM
(464 participants)
Clinical examination and
symptom questionnaire days 0,
1, 2, 3. Only adverse events oc-
curring in these 3 days are re-
ported.
Open label SAE: No serious adverse events observed
GI: More nausea, vomiting, and anorexia with
AS+MQ, only vomiting was significant (P = 0.03)
CNS: More dizziness and sleep disturbance with
AS+MQ (P = 0.002, 0.03)
CVS: More palpitations with AS+MQ (P = 0.04)
Mayxay 2004 LAO
(220 participants)
Daily review until parasites
cleared thenweekly until day 42
Open label SAE: One neuropsychiatric reaction in AS+MQ
group
GI: More nausea and vomiting with AS+MQ (P =
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< 0.001, 0.02), abdominal pain and diarrhoea not
significantly different
CNS: More dizziness, sleep disturbance, night-
mares, headache and weakness with AS+MQ (P =
< 0.001, 0.02, 0.003, 0.001, 0.009)
CVS/RS: More palpitations and dyspnoea with
AS+MQ (P = 0.002, 0.04)
Smithuis 2004 MMR
(652 participants)
Symptom questionnaire at days
0, 1, 2, 3 and 7. Only adverse
events occurring in the first 7
days are reported.
Open label SAE: No serious adverse events reported in the first
7 days
GI: More nausea with AS+MQ but only significant
in the grouphaving supervised treatment (P =0.05),
diarrhoea, vomiting, and abdominal pain were not
significantly different
CNS:More dizziness with AS+MQ but only signif-
icant in the group having unsupervised treatment
(P = 0.03), no other symptoms reported
Tangpukdee 2005 THA
(180 participants)
Inpatient monitoring until day
28. Assessed using non-sugges-
tive questioning.
Open label SAE: No serious adverse events observed
Other: Reported as minor. No differences between
groups reported
Tran 2002 VNM
(243 participants)
Review at days 0, 2 and 7
LFTs on days 3, 7 and 28. Fur-
ther follow-up is unclear.
Open label SAE: 12 events (10 vomiting, 2 dizziness)described
as significant in AS+MQ group and none with
DHA-P (P = 0.002)
Biochemical: No significant differences
Other: All other adverse events described as minor
with no differences between groups reported
Dihydroartemisinin-piperaquine vs Artemether-lumefantrine
Study ID Adverse event monitoring Blinding Adverse events
Kamya 2006 UGA
(421 participants)
Assessed daily until day 3
then weekly until day 42.
A standardized history, physi-
cal exam, including neurolog-
ical assessment at each visit.
Haemoglobin was checked at
baseline and last day of follow
up.
Double-blind SAE: four with DHA-P, 2 with AL, all judged to
be unrelated to studymeds (3 febrile convulsions,
otitis media, asthma attack, pyomyositis)
GI: No difference in vomiting, diarrhoea, ab-
dominal pain, or anorexia
CNS: No differences presented
CVS/RS: No difference in cough
Karunajeewa 2007 PNG
(250 participants)
Standardized follow up on days
0, 1, 2, 3, 7, 14, 28, and 42. Ad-
Open label Overall comment: No treatment withdrawals
were attributable to adverse events related to a
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verse event monitoring not de-
scribed.
study drug
No other significant differences are noted be-
tween treatments
Mens 2007 KEN
(146 participants)
Adverse events were recorded
at each visit in the case record
form (days 0, 1, 2, 3, 7, 14, and
28). An adverse event defined
as any unfavourable and unin-
tended sign.
Open label SAE: 1 patient treated with DHA-P died on day
14. Assessed as unrelated to treatment.
GI: No difference in anorexia, abdominal pain,
diarrhoea, or vomiting
CVS/RS: No difference in cough
CNS: Weakness more common with AL6 (P =
0.035). No difference in headache.
Derm: No difference in pruritis
Ratcliff 2005 IDN
(774 participants)
Assessed daily until fever and
parasites cleared then weekly
until day 42. A symptom ques-
tionnaire and physical exam at
each visit. Haemoglobin was
checked at each visit.
Open label SAE: 1 death 60 days after treatment. Cause not
known
GI: Diarrhoea was more common with DHA-P
(P = 0.003). Nausea, vomiting, abdominal pain,
and anorexia not different
CNS: Headache and dizziness not significantly
different
CVS/RS: Palpitations and cough not different
Other: No difference in rash or myalgia
Yeka 2007 UGA
(414 participants)
Standardized history, physical
exam, and malaria film on days
0, 1, 2, 3, 7, 14, 21, 28, 35, and
42 and any other day they were
unwell
Assessed at each visit including
neurological examination. Ad-
verse events described as any
untoward medical occurrence.
Single Blind SAE: 2 with AL, 5 with DHA-P, all judged unre-
lated to study meds (2 convulsions, 2 pyomyosi-
tis, vomiting, severe anaemia, dehydration)
GI: Abdominal pain more common with AL (P
= 0.05). No difference in anorexia, vomiting or
diarrhoea.
RS/CVS: No difference in cough or coryza
CNS: No difference in malaise/weakness
Derm: No difference in pruritis
Overall comment:Most AEwere ofmild tomod-
erate severity and consistent with symptoms of
malaria
Zongo 2007 BFA
(375 participants)
Assessed daily until day 3
then weekly until day 42.
A standardized history and
physical exam at each visit.
Haemoglobin was checked at
baseline and last day of follow
up.
Open label SAE: None observed
GI: Less abdominal painwithDHA-P (P < 0.05),
vomiting, diarrhoea, and anorexia not different
CNS: Less headache with DHA-P (P < 0.05), no
difference in weakness
CVS/RS: No difference in cough
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Dihydroartemisinin-piperaquine vs Artemether plus amodiaquine
Study ID Adverse event monitoring Blinding Adverse events
Hasugian 2005 IDN
(334 participants)
Assessed at each follow-up visit
(daily until afebrile and clear
of parasites, then weekly to day
42)
An adverse event defined as a
symptom that developed after
starting treatment
Open label SAE: 3 with AS+AQ (2 vomiting, 1 ataxia), none
with DHA-P
GI: On days 1 and 2more nausea (P = 0.004), vom-
iting (P = 0.02), anorexia (P = 0.007) with AS+AQ
No further comment
Karema 2004 RWA
(504 participants)
Assessed at each follow-up visit
(days 0, 1, 2, 3, 7, 14, 21, and
28)
An adverse event defined as any
unfavourable and unintended
sign associated temporally with
the use of the drug administered
Differential WBC count (and
liver function tests at one site
only) assessed at days 0 and 14
Open label SAE: Not reported (one seizure with AS+AQ)
GI: More vomiting (P = 0.007) and anorexia (P =
0.005) with AS+AQ. No difference in abdominal
pain, diarrhoea, nausea
CNS: More fatigue with AS+AQ (P = 0.001). No
difference in seizures, headache, dizziness, drowsi-
ness
CVS/RS: No difference in cough, angina, oedema
Biochemical: No differences in mean PCV or mean
WBC. No hepatotoxicity observed (one site only)
Other: No difference in rash
Dihydroartemisinin-piperaquine vs artesunate plus sulfadoxine-pyrimethamine
Study ID Adverse event monitoring Blinding Adverse events
Karunajeewa 2007 PNG
(245 participants)
Adverse event monitoring not
described
Open label Overall comment: No treatment withdrawals were
attributable to adverse events related to a study drug
No other significant differences are noted between
treatments
Dihydroartemisinin-piperaquine vs amodiaquine plus sulfadoxine-pyrimethamine
Study ID Adverse event monitoring Blinding Adverse events
Karema 2004 RWA
(510 participants)
Assessed at each follow-up visit
(days 0, 1, 2, 3, 7, 14, 21, and
28)
Open label SAE: Not reported (1 seizure with AQ+SP)
GI: More vomiting (P = 0.007) and anorexia (P =
0.005) with AQ+SP. No difference in abdominal
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An adverse event defined as any
unfavourable and unintended
sign associated temporally with
the use of the drug administered
Differential WBC count (and
liver function tests at 1 site only)
assessed at days 0 and 14
pain, diarrhoea, nausea
CNS:More fatigue with AQSP (P = 0.001). No dif-
ference in seizures, headache, dizziness, drowsiness
CVS/RS: No difference in cough, angina, oedema
Biochemical: No differences in mean PCV or mean
WBC. No hepatotoxicity observed (one site only)
Other: No difference in rash
Zongo 2007 BFA
(371 participants)
A standardized history and ex-
amination on days 0, 1, 2, 3, 7,
14, 21, 28, 35, and 42
Adverse events defined as unto-
ward medical occurrences
Haemoglobin measured on
days 0 and 42 or day of clinical
failure
Open label SAE: No serious adverse events were observed
GI: Abdominal pain was more common with
AQ+SP (P < 0.05). No difference in vomiting, di-
arrhoea, or anorexia.
CNS: No difference in headache or weakness
CVS/RS: No difference in cough
Other: Pruritis more common with AQ+SP (P <
0.05)
Artesunate plus mefloquine vs Artemether-lumefantrine
Study ID Adverse event monitoring Blinding Adverse events
Faye 2003 SEN
(294 participants)
All side effects were monitored
actively (days 0, 1, 2, 7, 14, 21,
and 28) and passively during
the study
25%were randomly selected for
blood counts, liver and renal
function tests at days 0, 14, and
28
Open label SAE: No serious adverse events
Overall comment: The side effects observed with
each treatment combination were minor, mainly
gastralgia, dizziness, pruritis, asthenia, and vomit-
ing
Biochemical: No severe alterations in renal or hep-
atic function were observed
Hutagalung 2002 THA
(490 participants)
Routine follow up daily until
fever and parasites cleared then
weekly to day 42 or any other
day they became unwell
At each visit a questionnaire on
adverse events was completed
An adverse event defined as
symptoms or signs that were
not present on admission and
that developed after the start of
treatment
Open label SAE: None reported
Overall comment: Both treatment regimens were
well tolerated
Lefevre 1999 THA
(219 participants)
Routine follow up at days 1, 2,
3, 7, 14, 21, and 28.
Adverse events assessed at each
visit. ECGmonitoring and lab-
Open label SAE: No comment.
GI: Abdominal pain, nausea, vomiting, diar-
rhoea, anorexia, constipation 18.3% AL vs 21.8%
224Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
oratory tests (including FBC
liver and renal function tests) at
baseline and each day of follow-
up.
AS+MQ
CNS: Headache, dizziness, and sleep disorder-
27.4% AL vs 16.4% AS+MQ
CVS/RS: ECG2%of each group showedQTpro-
longation of potential relevance with no cardiac
complication
Haematological: Slight worsening of anaemia after
3 days in both groups
Biochemical: Liver function tests slightly abnor-
mal at baseline. All baseline parameters normal-
ized over the course of treatment. Renal function,
electrolytes, glucose. Protein, urine tests showed
no relevant changes after baseline in either group.
Other: Skin reactions 8 AL vs 2 AS+MQ
Mayxay 2003 LAO
(220 participants)
Routine follow up daily until
fever and parasites cleared then
weekly until day 42 or anytime
they felt unwell
Potential side effects were
recorded at each visit
Open label SAE: 3 serious neuropsychiatric events in AS+MQ
group
GI: Nausea and vomiting, abdominal pain, and
diarrhoea more common with AS+MQ (P < 0.05)
CNS: Weakness, dizziness, headache, confu-
sion, and irritable/angry all more common with
AS+MQ (P < 0.05). No difference in nightmares
and tinnitus.
CVS/RS: No difference in palpitations or dysp-
noea
Other:Nodifference in urticaria, herpes or blurred
vision
Sagara 2005b MLI
(270 participants)
Routine follow up on days 1, 2,
3, 7, 14, 21, and 28
Complete blood count, ALT
and creatinine on 20% of par-
ticipants on days 0 and 14
A serious adverse event was de-
fined according to the Interna-
tional Conference on Harmon-
isation
Open label SAE: Not mentioned
GI: Vomiting more common with AS+MQ (P =
0.04). No significant difference in abdominal pain
or diarrhoea.
CNS:No significant difference in headache, weak-
ness, dizziness (P = 0.06) or malaise
Dermatological: No significant difference in pru-
ritis or rash
Biochemical: States ’both treatments were similar
for laboratory adverse events’
Stohrer 2003 LAO
(108 participants)
Treatment emergent symptoms
and signs were recorded on days
0 to 3
Open label SAE: 1 AL: severe diarrhoea, 1 ASMQ heavy sleep
disorder and dizziness
GI: None of the patients in either arm vom-
ited within 1 hour of drug intake. No differences
in abdominal pain, nausea, vomiting, diarrhoea,
anorexia.
CNS: Headache, dizziness, weakness, sleep disor-
der: 14 AL vs 22 ASMQ no significant difference
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Van den Broek 2003a BGD
(242 participants)
Routine follow up on days 0, 1,
2, 3, 7, 14, 21, 28, 35, and 42
and any other day when feeling
ill
Possible side effects assessed at
each visit
Open label SAE: None observed
During the first 3 days headache, vomiting, nau-
sea, and dizziness were significantlymore common
with AS+MQ (P < 0.05)
Other complaints were: sleeplessness, pruritis/
rash, epigastric pain, sweating with AS+MQ;
blurred vision and anorexia with AL
Van Vugt 1998 THA
(200 participants)
Routine follow up daily until
fever and parasites cleared then
weekly to day 28
A questionnaire for adverse ef-
fects was completed at each
visit. Full neurological exami-
nation on days 0, 3, 7, and
28. Complete haematology and
biochemistry (at one centre) on
days 0, 3, 7, and 28.
Open label SAE: 1 with AL: coma lasting 4 days 12 days after
treatment, 1 with AS+MQ; generalized urticaria
on day 1
Vomiting ofmedication: 4/150AL vs 5/50ASMQ
(P = 0.045)
GI: Anorexia, vomiting, nausea, abdominal pain,
hepatomegaly less common with AL (12.7% AL
vs 26% AS+MQ, P = 0.043)
CVS: No electrocardiographic changes
CNS: CNS symptoms (dizziness, sleep disorder,
headache) less common with AL (6% AL vs 34%
AS+MQ, P < 0.0001). One case of tremor and 2
cases of numbness with AL.
Overall: Possible drug related adverse events less
common with AL (33/150 AL vs 23/50 ASMQ,
P = 0.002)
Artesunate plus mefloquine vs Artesunate plus amodiaquine
Study ID Adverse event monitoring Blinding Adverse events
Faye 2003 SEN
(505 participants)
All side effects were monitored
actively (days 0, 1, 2, 7, 14, 21,
and 28) and passively during
the study
25%were randomly selected for
blood counts, liver, and renal
function tests at days 0, 14, and
28
Open label SAE: No serious adverse events
Overall comment: The side effects observed with
each treatment combination were minor; mainly
gastralgia, dizziness, pruritis, asthenia, and vomit-
ing
Biochemical: No severe alterations in renal or hep-
atic function were observed
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Artesunate plus mefloquine vs Amodiquine plus sulfadoxine-pyrimethamine
Study ID Adverse event monitoring Blinding Adverse events
Faye 2003 SEN
(306 participants)
All side effects were monitored
actively (days 0, 1, 2, 7, 14, 21,
and 28) and passively during
the study
25%were randomly selected for
blood counts, liver, and renal
function tests at days 0, 14, and
28
Open label SAE: No serious adverse events
Overall comment: The side effects observed with
each treatment combination were minor, mainly
gastralgia, dizziness, pruritis, asthenia, and vomit-
ing
Biochemical: No severe alterations in renal or hep-
atic function were observed
Artemether-lumefantrine vs Artesunate plus amodiaquine
Study ID Adverse event monitoring Blinding Adverse events
Adjei 2006 GHA
(227 participants)
Assessed at each follow-up visit
(days 0, 1, 2, 3, 7, 14, and
28), including neurological as-
sessment
Audiological assessment on
days 0, 3, 7, and 28
Total and differential WBC
counts and liver enzymes on
days 0, 3, 7, 14, and 28
Single blind (outcome asses-
sors)
SAE: 1 patient treated with
AS+AQ had severe anaemia on
day 14
GI: No significant difference in
nausea and vomiting between
groups
CNS: No significant difference
in dizziness, fatigue, or excessive
sleepiness between groups.Nys-
tagmus was observed in 1 pa-
tient in each group, both cases
hadpotential explanations from
the past medical history. A pos-
itive Romberg’s test was ob-
served in 1 child treated with
AL, again with a possible alter-
native diagnosis.
Audiology: Hearing thresholds
were significantly elevated in
treated subjects as days 0, 3, 7,
and 28 but no differences be-
tween participants and controls
after 9 months
Haematologi-
cal: Themean neutrophil count
was lower than baseline in both
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groups throughout follow up
but there was no significant dif-
ference between groups. There
was no significant difference in
the incidence of neutropenia
between groups (14/111 AL vs
13/116)
Biochemical: No difference in
liver enzymes were observed be-
tween groups. Liver enzymes
were not observed to increase in
response to treatment.
Bukirwa 2005 UGA
(408 participants)
Assessed at each follow-up visit
(days 0, 1, 2, 3, 7, 14, and
28), including neurological as-
sessment
An adverse event defined as any
untoward medical occurrence
Single blind (outcome asses-
sors)
SAE: One serious adverse event
in each group (AL6 convul-
sion; AS+AQ pneumonia)both
judged unlikely to be related to
study meds
CNS:Noabnormalities in hear-
ing or fine finger dexterity
Overall com-
ment: Adverse events of at least
moderate severity: 125/202 AL
vs 136/201 ASAQ (P = 0.25)
Dorsey 2006 UGA
(434 participants)
Assessed at each follow-up visit
(days 0, 1, 2, 3, 7, 14, and 28)
An adverse event defined as any
untoward medical occurrence
Complete blood count and liver
enzymes on days 0 and 14
Single blind (outcome asses-
sors)
SAE: 29 serious adverse events
(14/202 AL vs 15/232 ASAQ).
Majority were seizures associ-
ated with fever. None consid-
ered probably or definitely re-
lated to study meds
GI: Anorexia more common
with ASAQ (P < 0.05). No sig-
nificant difference in abdomi-
nal pain, vomiting or diarrhoea
CVS/RS: No significant differ-
ence in cough
CNS: No other significant dif-
ferences in weakness
Biochemical: Elevated liver en-
zymes occurred in 7 patients,
all were attributed to other
causes (6 viral hepatitis and 1
Salmonella bacteraemia)
Other:No significant difference
in pruritis
Falade 2005 NGA
(132 participants)
Assessed at each visit (days 0 to
7, 14, 21, and 28)
Open label SAE: There were no serious ad-
verse events
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FBC, WBC and liver enzymes
on days 0, 7 and 28
An adverse event defined as not
present at enrolment but occur-
ring during follow -up
GI: No significant difference in
abdominal pain or vomiting
CVS/RS: No significant differ-
ence in cough or palpitations
Haem: A significant transient
decline in neutrophil counts be-
tween days 0 and 7 with AL
which recovered by day 28
Biochemical: No statistically
significant disturbance in blood
chemistry. The study drugs did
not adversely affect liver en-
zymes
Faye 2003 SEN
(509 participants)
All side effects were monitored
actively (days 0, 1, 2, 7, 14, 21,
and 28) and passively during
the study
25%were randomly selected for
blood counts, liver and renal
function tests at days 0, 14, and
28
Open label SAE: No serious adverse events
Overall comment: The side ef-
fects observed with each treat-
ment combination were mi-
nor, mainly gastralgia, dizzi-
ness, pruritis, asthenia, and
vomiting
Biochemical: No severe alter-
ations in renal or hepatic func-
tion were observed
Guthmann 2004 AGO
(134 participants)
Adverse event monitoring not
described
Unclear AE not reported
(2
patients excluded from AS+AQ
group for vomiting and 1 from
AL)
Kobbe 2007 GHA
(237 participants)
’The comparative tolerability
was assessed by the risk of oc-
currence of an adverse event’
For each adverse event causality
was assessed as recommended
by the WHO
Open label SAE: 2 SAE in each group, all
classified as unlikely to be re-
lated to the treatment (asthma
attack, febrile convulsion, en-
teritic bacterial infection, and
severe anaemia)
GI: No difference in GI symp-
toms including vomiting
CVS/RS: No difference in res-
piratory symptoms
Derm: No difference in derma-
tological symptoms
Koram 2003 GHA
(105 participants)
Adverse event monitoring not
described
Open label AE not reported
(3 patients with AS+AQ and 1
with ALwere withdrawn for ex-
cessive vomiting)
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Martensson 2003 TZA
(407 participants)
Possible adverse events recorded
at each visit (days 0, 1, 2, 3, 7,
14, 21, 28, 35, and 42)
Differential white cell counts at
days 0, 3, 7, 14, 21, and 28
An adverse event was defined
as any undesirable medical oc-
currence regardless of whether
it was related to the treatments
Unclear SAE: 9 severe adverse events
(2/200 AL vs 7/208 AS+AQ)
all associatedwith clinically sus-
pected severe malaria and not
attributed to study drugs
Haematological: No signifi-
cant differences in mean WBC
or neutrophil count between
groups
Overall comment: Both regi-
mens generally well tolerated
Mutabingwa 2004 TZA
(1034 participants)
Parents or guardians were asked
to report on side effects, tol-
erability and usefulness of the
treatment (days 0, 14, and 28)
Unclear SAE: 1 death in the group
treated with AL
No other reporting of AE
Van den Broek 2004 ZAR
(207 participants)
Possible side effects as passively
reported to the examiner were
recorded at each visit (days 0, 1,
2, 3, 7, 14, 21, and 28)
Open label SAE: No severe adverse events
judged to be related to the treat-
ment given
Overall comment: Common
complaints were vomiting, di-
arrhoea, abdominal pain, and
anorexia
The frequency of potential ad-
verse events was low (around
10%) and did not differ be-
tween groups. 1 case of urticaria
occurred with AS+AQ
Owusu-Agyei 2006 GHA
(355 participants)
Field workers visited their
homes to solicit adverse events
on days 0, 2, 3, 7, 14, and 28
Open label SAE: Not reported
GI: No significant difference
in diarrhoea, vomiting, nausea,
anorexia, abdominal pain
CNS: No significant difference
in difficulty sleeping
CVS/RS: No significant differ-
ence in cough, dyspnoea, palpi-
tation
Other: Body pain more com-
mon with AS+AQ. No differ-
ence in fever, runny nose, it-
ching, joint pain, ulcers, yellow
eyes
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Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine
Study ID Adverse event monitoring Blinding Adverse events
Bousema 2004 KEN
(249 participants)
Adverse event monitoring not
described
Single blind (outcome asses-
sors)
AE not reported
Karunajeewa 2007 PNG
(249 participants)
Adverse event monitoring not
described
Open label Overall comment: No treat-
ment withdrawals were at-
tributable to adverse events re-
lated to a study drug
No other significant differences
are noted between treatments
Mukhtar 2005 SDN
(160 participants)
Adverse event monitoring not
described
Unclear AE not reported
Van den Broek 2004 ZAR
(197 participants)
Possible side effects as passively
reported to the examiner were
recorded at each visit (days 0, 1,
2, 3, 7, 14, 21, and 28)
Open label SAE: No severe adverse events
judged to be related to the treat-
ment given
Overall comment: Common
complaints were vomiting, di-
arrhoea, abdominal pain and
anorexia
The frequency of potential ad-
verse events was low (around
10%) and did not differ be-
tween groups. 1 case of urticaria
occurred with AS+SP
Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine
Study ID Adverse event monitoring Blinding Adverse events
Dorsey 2006 UGA
(455 participants)
Assessed at each follow-up visit
(days 0, 1, 2, 3, 7, 14, and 28)
An adverse event defined as any
untoward medical occurrence
Complete blood count and liver
enzymes on days 0 and 14
Single blind (outcome asses-
sors)
SAE: 30 serious adverse events
(14/202 AL vs 16 AQ+SP).
Majority were seizures associ-
ated with fever. None consid-
ered probably or definitely re-
lated to study meds.
GI: Anorexia more common
with AQ+SP (P < 0.05). No
significant difference in abdom-
inal pain, vomiting, or diar-
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rhoea.
CVS/RS: No significant differ-
ence in cough
CNS:Weakness more common
with AQ+SP (P < 0.05). No
other significant differences.
Biochemical: Elevated liver en-
zymes occurred in 7 patients,
all were attributed to other
causes (6 viral hepatitis and 1
Salmonella bacteraemia)
Other:No significant difference
in pruritis
Fanello 2004 RWA
(500 participants)
All adverse events were recorded
on the clinical record form (days
7, 14, 21, and 28) and a causal-
ity assessment was made
PCV and WBC days 0 and 14
Open label SAE: No comment on serious
AE
Overall comment: 251 patients
reported one AE concomitant
with administration of the drug
with no differences between
groups. AE possibly or proba-
bly related to the study drugs
22/251 AL, 35/249 AQ+SP P =
0.06
Haem: Mean WBC count at
day 14 was similar in both
groups (data not shown).
Faye 2003 SEN
(310 participants)
All side effects were monitored
actively (days 0, 1, 2, 7, 14, 21,
and 28) and passively during
the study
25%were randomly selected for
blood counts, liver and renal
function tests at days 0, 14, and
28
Open label SAE: No serious adverse events
Overall comment: The side ef-
fects observed with each treat-
ment combination were mi-
nor, mainly gastralgia, dizzi-
ness, pruritis, asthenia, and
vomiting
Biochemical: No severe alter-
ations in renal or hepatic func-
tion were observed
Mutabingwa 2004 TZA
(1026 participants)
Parents or guardians were asked
to report on side effects, tol-
erability, and usefulness of the
treatment (days 0, 14, and 28)
Unclear SAE: 1 death in each group
No other reporting of AE
Zongo 2007 BFA
(372 participants)
Assessed at each visit (days 0, 1,
2, 3, 7, 14, 21, 28, 35, and 42)
Adverse events defined as any
untoward medical occurrence
Open label SAE: No serious adverse events
GI: No significant difference in
abdominal pain, vomiting, di-
arrhoea, or anorexia
CVS/RS: No significant differ-
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ence in cough
CNS: No significant difference
in headache or weakness.
Other: Pruritis more common
with AQ+SP (P < 0.05)
Zongo 2005 BFA
(521 participants)
Assessed at each visit (days 0, 1,
2, 3, 7, 14, 21, and 28)
Adverse events defined as any
untoward medical occurrence
Double blind SAE: 1 serious AE in each group
(severe anaemia)
GI: No significant difference in
abdominal pain, vomiting, di-
arrhoea, or anorexia
CVS/RS: No significant differ-
ence in cough or coryza
CNS: No significant difference
in headache or weakness
Other: Pruritis more common
with AQ+SP (P < 0.0001)
Artesunate plus amodiaquine vs Artesunate plus sulfadoxine-pyrimethamine
Study ID Adverse event monitoring Blinding Adverse events
Bonnet 2004 GIN
(220 participants)
Adverse event monitoring not
described
Open label AE not reported
Djimde 2004 MLI
( participants)
Haemoglobin, glucose, com-
plete blood count, liver en-
zymes, and creatinine were
measured on days 0, 7, 14, and
28
Single blind (details not given) SAE: One with AS+AQ.
Overall comment:
Adverse event distribution was
unremarkable.
Haematological: All treatment
decreased the prevalence of ab-
normal values of leucocytes and
platelets (figures not given)
Biochemical: At day 14 the
prevalence of grade 1 ALT toxi-
city was 9.7% AS+AQ vs 2.5%
AS+SP (figures not given).
These changes not thought to
be clinically significant.
Guthmann 2003 AGO
(187 participants)
Adverse event monitoring not
described
Open label AE not reported
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Hamour 2003 SDN
(161 participants)
Adverse event monitoring not
described
Open label SAE: No significant adverse
events
Overall comment: No signif-
icant adverse events were re-
ported
Kayentao 2006 MLI
(265 participants)
Adverse event monitoring not
described
Single blind One death occurred at day 7 af-
ter treatment with AS+SP. The
parasitaemia was reported as
cleared and cause of death un-
known.
Other AE not reported
Swarthout 2004 ZAR
(180 participants)
Parents and guardians were
asked about tolerability and po-
tential side effects of the drugs
(days 0, 1, 2, 3, 7, 14, 21, and
28)
Open label SAE: None reported
Overall comment: There were
no adverse side effects reported
by parents and both regimens
were well tolerated
Van den Broek 2004 ZAR
(192 participants)
Possible side effects as passively
reported to the examiner were
recorded at each visit (days 0, 1,
2, 3, 7, 14, 21, and 28)
Open label SAE: No severe adverse events
judged to be related to the treat-
ment given
Overall comment: Common
complaints were vomiting, di-
arrhoea, abdominal pain and
anorexia
The frequency of potential ad-
verse events was low (around
10%) and did not differ be-
tween groups. 1 case of urticaria
occurred with AS+SP.
Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Study ID Adverse event monitoring Blinding Adverse events
Dorsey 2006 UGA
(485 participants)
Assessed at each follow-up visit
(days 0, 1, 2, 3, 7, 14, and 28)
An adverse event defined as any
untoward medical occurrence
Complete blood count and liver
enzymes on days 0 and 14
Single blind (outcome asses-
sors)
SAE: 31 serious adverse events
(15/232 AS+AQ vs 16/253
AQSP). Majority were seizures
associated with fever. None
considered probably or defi-
nitely related to study meds.
GI: Anorexia more common
with AQ+SP (P < 0.05). No sig-
nificant difference in abdomi-
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nal pain, vomiting or diarrhoea.
CVS/RS: No significant differ-
ence in cough
CNS:Weakness more common
with AQ+SP (P < 0.05). No
other significant differences
Biochemical: Elevated liver en-
zymes occurred in 7 patients,
all were attributed to other
causes (6 viral hepatitis and 1
Salmonella bacteraemia)
Other:No significant difference
in pruritis
Faye 2003 SEN
(521 participants)
All side effects were monitored
actively (days 0, 1, 2, 7, 14, 21,
and 28) and passively during
the study
25%were randomly selected for
blood counts, liver and renal
function tests at days 0, 14, and
28
Open label SAE: No serious adverse events
Overall comment: The side ef-
fects observed with each treat-
ment combination were mi-
nor, mainly gastralgia, dizzi-
ness, pruritis, asthenia and
vomiting
Biochemical: No severe alter-
ations in renal or hepatic func-
tion were observed
Karema 2004 RWA
(510 participants)
Assessed at each follow-up visit
(days 0, 1, 2, 3, 7, 14, 21, and
28)
An adverse event defined as any
unfavourable and unintended
sign associated temporally with
the use of the drug administered
Differential WBC count (and
liver function tests at one site
only) assessed at days 0 and 14
Open label SAE: Not reported (one seizure
withAS+AQ, onewithAQ+SP)
GI: No differences in nausea,
vomiting, diarrhoea, abdomi-
nal pain, or anorexia
CVS/RS: No difference in
cough, angina, oedema
CNS: No difference in seizures,
headache, dizziness, drowsi-
ness, or fatigue
Biochemical: No differences in
mean PCV or mean WBC. No
hepatotoxicity observed (1 site
only)
Other: No difference in rash
Kayentao 2006 MLI
(265 participants)
Adverse event monitoring not
described
Single blind AE not reported
Menard 2006 MDG
(166 participants)
Adverse event monitoring not
described
Single blind (outcome asses-
sors)
SAE: ‘No severe side effects at-
tributable to the study medica-
tion’
No other reporting of AE
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Mutabingwa 2004 TZA
(1022 participants)
Parents or guardians were asked
to report on side effects, tol-
erability, and usefulness of the
treatment (days 0, 14, and 28)
Unclear SAE: 1 death in the AQ+SP
group died on the day of ran-
domization
No other reporting of AE
Staedke 2003 UGA
(268 participants)
Assessed at each visit with a
standardized history and ex-
amination. Neurological assess-
ment on days 0, 7, 14, and
28. CBC, creatine and alanine
transferase on days 0, 7, and 28.
Single blind (outcome asses-
sors)
SAE: 16 serious adverse
events (1/134 AS+AQ vs 6/134
AQ+SP
CNS: ‘No important neurolog-
ical events were seen’
Biochem: 1 severe anaemiawith
AS+AQ, 1 severe neutropenia
with AQ+SP, 1 elevated alanine
transaminase with AQ+SP
No other comment on adverse
events
Yeka 2004 UGA
(1461 participants)
Adverse event monitoring not
described
Single blind (outcome asses-
sors)
SAE: 4/731 AS+AQ vs 10/730
AQ+SP. 2 additional patients
died in the AQ+SP group
No other reporting of AE
Footnotes
AE = adverse event
DHA-P = dihydroartemisinin-piperaquine
AS = artesunate
MQ = mefloquine
AL = artemether-lumefantrine
AQ = amodiaquine
SP = sulfadoxine-pyrimethamine
SAE = serious adverse event
GI = gastrointestinal system
CVS = cardiovascular system
RS = respiratory system
CNS = central nervous system
ECG = electrocardiogram
QT = interval between the Q and T waves of an ECG
U&E = urea and electrolytes
FBC = full blood count
LFT = liver function tests
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PCR = polymerase chain reaction
PCV = packed cell volume
WBC = white blood cells
Appendix 5. Anaemia tables
Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine
Study ID Outcome measure and result Significance test
Ashley 2003b THA Median decrease in haematocrit by day 7:
DHA-P 6.3% (0% to 13.6%) vs AS+MQ
9.4% (2.6% to 14.3%)
Mean haematocrit weekly fromday 0 to 63:
Presented graphically
P = 0.21
Ashley 2004 THA Median change in haematocrit in each
group, each week, from day 0 to 63: ’a de-
crease in haematocrit in both groups be-
tween days 0 and 7 followed by recovery
in both groups’. Figures presented graphi-
cally.
Not reported
Janssens 2003 KHM Mean haematocrit at day 63: DHA-P
40.0% vs AS+MQ 40.2%
(No differences at baseline)
Not reported
Mayxay 2004 LAO Mean haematocrit following treatment
(days 7 to 42): ’did not significantly differ
between groups’. Figures not given.
Not significant P > 0.05
Smithuis 2004 MMR Mean haemoglobin at day 28 (supervized
treatment): DHA-P 10.4g/dl vs AS+MQ
10.5g/dl
Proportion anaemic (Hb < 10g/dl) on
day 28 (superviZed treatment): DHA-P
56/152 vs AS+MQ 59/156
(no differences at baseline)
P = 0.65
P = 0.85
Artesunate plus mefloquine vs Artemether-lumefantrine
Study ID Outcome measure and result Significance test between groups
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Faye 2003 SEN Proportion with anaemia (Hb < 12) on day
0: AS+MQ 15/24 (62.5%) vs AL6 24/35
(68.6%)
Proportion with anaemia (Hb < 12) on day
14: AS+MQ 17/24 (70.8%) vs AL6 24/35
(68.6%)
(On 25% randomly selected participants)
Not reported
Hutagalung 2002 THA Mean decrease in haematocrit by day 7:
AS+MQ 9.3% (SD 11.5%, 95% CI 7.7%
to 10.9%) vs AL6 6.7% (SD 11.4%, 95%
CI 5.1% to 8.3%)
P = 0.023
Lefevre 1999 THA Meanhaemoglobin onday 0: AS+MQ11.5
g/dl vs AL6 11.6 g/dl
Mean haemoglobin on day 29: AS+MQ
12.2 g/dl vs AL6 12.4 g/dl
Not reported
Mayxay 2003 LAO Mean haematocrit after treatment (day 7 to
42): Data presented graphically
P > 0.05
Van Vugt 1998 THA Proportion with anaemia (haematocrit <
30%) on day 0: AS+MQ 10% vs AL6 6%
Proportion with anaemia (haematocrit <
30%) on day 28: AS+MQ 2.4% vs AL6
2.3%
Not reported
Sagara 2005b MLI Proportion with anaemia (Hb < 10g/dl) on
day 0: AS+MQ 24/213 (11.3%) vs AL6
27/193 (14.0%)
Proportion with anaemia (Hb < 10g/dl) on
day 28: AS+MQ 10/213 (4.7%) vs AL6
10/193 (5.2%)
Not reported
Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Study ID Outcome measure and result Significance test between groups
Dorsey 2006 UGA Mean (SD) change in haemoglobin from
baseline to Day 14: AS+AQ -0.03 (1.10)
g/dl vs AQ+SP 0.16 (1.03) g/dl
Not reported
Faye 2003 SEN Proportion with anaemia (Hb < 12g/dl) on
day 0: AS+AQ 35/52 (68.6%) vs AQ+SP
19/27 (70.3%)
Not reported
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Proportion with anaemia (Hb < 12g/dl) on
day 14: AS+AQ 40/51 (80.4%) vs AQ+SP
21/27 (77.7%)
In random 25% or study population
Karema 2004 RWA Mean (SD) PCV at day 14: AS+AQ 34.0%
(3.7) vs AQ+SP 34.5 (3.7)
Not significant
P not given
Kayentao 2006 MLI Mean (SD) haemoglobin day 14: AS+AQ
10.17 (1.5) g/dl vs AQ+SP 10.43 (1.49)
g/dl
Mean (SD) haemoglobin day 28: AS+AQ
10.78 (1.49) g/dl vs AQ+SP 11.05 (1.52)
g/dl
Not significant (P value not given)
Not significant (P value not given)
Menard 2006 MDG Median (IQR) of individual increases in
Hb from baseline to day 28 (95% CI):
AS+AQ 1.1 g/dl (-2.6 to 5.2) vs AQ+SP
0.5 g/dl (-4.4 to 5.8)
Not significant
P not given
Mutabingwa 2004 TZA Mean (SD) change in haemoglobin from
baseline to Day 14: AS+AQ 0.58 (1.4) g/dl
vs AQ+SP 0.54 (1.4) g/dl
Not reported
Staedke 2003 UGA Median (SD not reported) change in
haemoglobin from baseline to day 28:
AS+AQ 1.9 g/dl vs AQ+SP 1.3 g/dl
P = 0.004
Yeka 2004 UGA Mean increase in haemoglobin by Day 28:
Jinja site: AS+AQ 0.95 (1.91) g/dl vs
AQ+SP 1.15 (1.93) g/dl
Arua site: AS+AQ 1.44 (1.67) g/dl vs
AQ+SP 1.44 (1.60) g/dl
Tororo site: AS+AQ 1.14 (1.48) g/dl vs
AQ+SP 1.58 (1.55) g/dl
Apac site: AS+AQ 1.76 (1.55) g/dl vs
AQ+SP 1.77 (1.79) g/dl
P > 0.05
P > 0.05
P < 0.05
P > 0.05
Footnotes
DHA-P = dihydroartemisinin-piperaquine
AS = artesunate
MQ = mefloquine
AL6 = artemether-lumefantrine
AQ = amodiaquine
SP = sulfadoxine-pyrimethamine
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Hb = haemoglobin
IQR = interquartile range
PCV = packed call volume
SD = standard deviation
Appendix 6. Summary of findings tables
Is Dihydroartemisinin-piperaquine as effective as Artesunate plus mefloquine for uncomplicated malaria?
Patient or population: Patients with uncomplicated malaria
Settings: Endemic areas worldwide
Intervention: Dihydroartemisinin-piperaquine
Comparison: Artesunate plus mefloquine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Artesunate plus
mefloquine
Dihy-
droartemisinin-
piperaquine
Efficacy: Total Fail-
ure (P. falciparum)
Day 63 PCR ad-
justed - Asia
46 per 1000 18 per 1000
(9 to 36)
RR 0.39
(0.19 to 0.79)
1062
(3)
⊕⊕⊕⊕
high1,2,3,4,5,6
Efficacy: Total Fail-
ure (P. falciparum)
Day 63 PCR unad-
justed - Asia
151 per 1000 110 per 1000
(82 to 148)
RR 0.73
(0.54 to 0.98)
1182
(3)
⊕⊕⊕⊕
high1,2,3,4,5,6
Efficacy: Total Fail-
ure (P. falciparum)
Day
63 PCR adjusted -
South America
0 per 1000 Not estimable RR 9.55
(0.52 to 176.35)
435
(1)
⊕
very low7,8,9,10
Efficacy: Total Fail-
ure (P. falciparum)
Day 63 PCR un-
adjusted - South
America
9 per 1000 56 per 1000
(13 to 246)
RR 6.19
(1.4 to 27.35)
445
(1)
⊕⊕⊕
moderate7,8,9,11
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(Continued)
Vivax efficacy: P.
vivax parasitaemia
by day 63
180 per 1000 200 per 1000
(164 to 241)
RR 1.11
(0.91 to 1.34)
1661
(4)
⊕⊕⊕
moderate
4,12,13,14,15
Transmis-
sion potential: Ga-
metocyte develop-
ment (in those neg-
ative at baseline)
9 per 1000 28 per 1000
(10 to 79)
RR 3.06
(1.13 to 8.83)
1234
(3)
⊕⊕⊕⊕
high4,11,13,16
Harms: Serious ad-
verse events (in-
cluding deaths)
7 per 1000 6 per 1000
(3 to 15)
RR 0.9
(0.38 to 2.15)
2617
(8)
⊕⊕
low4,10,13,17
Harms: Early vom-
iting
88 per 1000 79 per 1000
(61 to 102)
RR 0.90
(0.69 to 1.16)
2473
(7)
⊕⊕
low4,13,18,19
*The assumed risk is the mean risk from the studies included in this review, calculated as the number of patients in the control
groups with the event divided by the total number of patients in control groups. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Footnotes
1Data on treatment failure at days 42 and 28 were also available and no differences between the two drugs were shown.
2Ashley 2003b THA, Ashley 2004 THA and Janssens 2003 KHM.
3No serious limitations: Allocation concealment was judged to be at ’low risk of bias’ in two trials and ’unclear’ in one. Sensitivity
analysis only including trials with adequate concealment did not substantially change the result. Laboratory staff were blinded in two
of the trials.
4No serious inconsistency: Heterogeneity was low.
5No serious indirectness: Trials were conducted in Asia (Thailand and Cambodia) in areas of low and unstable transmission. Children
age < one year and pregnant or lactating women were excluded.
6 No serious imprecision: The 95%CI of the pooled estimate includes appreciable benefit withDHA-P over AS+MQandno appreciable
benefit.
7Grande 2005 PER.
8No serious limitations: Allocation concealment was assessed as ’low risk of bias’. No blinding was described in this trial.
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9Serious indirectness: Only one trial conducted in Peru in a low transmission setting. Children age < 5 years and pregnant and lactating
women were excluded.
10Very serious imprecision: The 95% CI of the pooled estimate is wide including appreciable benefit or harm with each drug over the
other. Both drugs performed very well and there were too few events to detect a difference between the two drugs.
11No serious imprecision: Both limits of the 95% CI suggest appreciable benefit with AS+MQ.
12Overall five trials assessed P. vivax response. No differences were shown in occurrence of vivax parasitaemia at any time point or
between those with or without vivax co-infection at baseline.
13No serious indirectness: Trials conducted in Asia and South America in low and unstable transmission areas.
14No serious limitations: Allocation concealment was assessed as ’low risk of bias’ in three out of four trials.
15Serious imprecision: The 95% CI of the pooled estimate includes appreciable benefit with AS+MQ over DHA-P and crosses the line
of no effect.
16No serious limitations: Allocation concealment was assessed as ’low risk of bias’ in all four trials.
17No serious limitations: Allocation concealment was judged to be at ’low risk of bias’ in five out of eight trials.
18Serious limitations: All trials were open label and judged to be at ’high risk of bias’ for blinding.
19Serious imprecision: The 95% CI of the pooled estimate includes appreciable benefit with DHA-P and crosses the line of no effect.
Is Dihydroartemisinin-piperaquine as effective as Artemether-lumefantrine for treating uncomplicated malaria?
Patient or population: Patients with uncomplicated malaria
Settings: Endemic areas worldwide
Intervention: Dihydroartemisinin-piperaquine
Comparison: Artemether-lumefantrine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Artemether- lume-
fantrine
Dihy-
droartemisinin-
piperaquine
Efficacy: Total Fail-
ure (P. falciparum)
Day 42 PCR ad-
justed - Africa
117 per 1000 46 per 1000
(28 to 75)
RR 0.39
(0.24 to 0.64)
869
(3)
⊕⊕⊕⊕
high1,2,3,4,5,6,7
Efficacy: Total Fail-
ure (P. falciparum)
Day 42 PCR unad-
justed - Africa
380 per 1000 167 per 1000
(76 to 361)
RR 0.44
(0.20 to 0.95)
1136
(3)
⊕⊕⊕
moderate2,3,4,6,8,9
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(Continued)
Efficacy: Total Fail-
ure (P. falciparum)
Day 42 PCR ad-
justed - Asia
22 per 1000 17 per 1000
(4 to 83)
RR 0.77
(0.16 to 3.76)
317
(1)
⊕
very low1,10,11,12,13
Efficacy: Total Fail-
ure (P. falciparum)
Day 42 PCR unad-
justed - Asia
161 per 1000 97 per 1000
(56 to 169)
RR 0.60
(0.35 to 1.05)
356
(1)
⊕⊕
low10,11,12,14
Vivax efficacy: P.
vivax parasitaemia
by D42
197 per 1000 63 per 1000
(47 to 85)
RR 0.32
(0.24 to 0.43)
1442
(4)
⊕⊕⊕⊕
high2,5,7,15,16
Transmis-
sion potential: Ga-
metocyte develop-
ment (in those neg-
ative at baseline)
- - - 1203
(4)
⊕
very low17,18,19
Harms: Serious ad-
verse events (in-
cluding deaths)
6 per 1000 10 per 1000
(4 to 27)
RR 1.71
(0.66 to 4.46)
2110
(5)
⊕⊕
low5,20,21
Harms: Early vom-
iting
23 per 1000 32 per 1000
(16 to 64)
RR 1.38
(0.68 to 2.78)
1147
(2)
⊕
very low5,21,22
*The assumed risk is the mean risk from the studies included in this review, calculated as the number of patients in the control
groups with the event divided by the total number of patients in control groups. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
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Footnotes
1Please note that due to its longer half-life, PCR adjusted treatment failure with DHA-P may be underestimated at this time point.
2Data are also available for treatment failure at day 28 but provide no further useful information.
3Kamya 2006 UGA, Yeka 2007 UGA and Zongo 2007 BFA.
4No serious limitations: Allocation concealment was assessed as ’low risk of bias’ in all trials. Laboratory staff were blinded in two trials.
5No serious inconsistency: Heterogeneity was low.
6No serious indirectness: Trials were conducted in Africa (Uganda and Burkina Faso) in areas of high and moderate transmission.
Children aged < six months and pregnant or lactating women were excluded.
7No serious imprecision: Both limits of the 95% CI of the pooled estimate imply appreciable benefit with DHA-P.
8Serious inconsistency: Heterogeneity was high (I2 = 91%) reflecting differences in the magnitude of effect but not the direction.
9No serious imprecision: The 95% CI of the pooled estimate includes appreciable benefit and non-appreciable benefit with DHA-P
over AL6 but does not cross the line of no effect.
10Ratcliff 2005 IDN.
11Serious limitations: Allocation concealment was assessed as ’low risk of bias’ in this trial. At day 42 loss to follow-up was high: > 20%
in both groups.
12Serious indirectness: Only one trial from Asia.
13Serious imprecision: The 95% CI is very wide including appreciable benefit or harm with each drug over the other.
14No serious imprecision: The 95% CI includes appreciable benefit with DHA-P and crosses the line of no effect but does not include
appreciable benefit with AS+AQ.
15Allocation concealment was assessed as ’low risk of bias’ in three out of four trials. Laboratory staff were blinded in 4 trials.
16No serious indirectness: Although the strongest data are from Asia (Ratcliff 2005 IDN and Karunajeewa 2007 PNG) these are
consistent with the data from Africa.
17No serious limitations: Allocation concealment was assessed as ’low risk of bias’ in two out of four trials. Laboratory staff were blinded
in three trials.
18Very serious inconsistency: Heterogeneity was high (I2 = 76%) with two trials (Kamya 2006 UGA; Yeka 2007 UGA) favouring
DHA-P and two (Mens 2007 KEN; Zongo 2007 BFA) favouring AL6.
19Very serious imprecision: Data not pooled.
20No serious limitations: Allocation concealment was assessed as ’low risk of bias’ in four trials.
21Very serious imprecision: The 95% CI of the pooled estimate is wide including appreciable benefit and harm with each drug over
the other.
22Serious limitations: Allocation concealment was assessed as ’low risk of bias’ in both trials. Both trials were unblinded.
Is Dihydroartemisinin-piperaquine as effective as Artesunate plus amodiaquine for treating uncomplicated malaria?
Patient or population: Patients with uncomplicated malaria
Settings: Endemic areas worldwide
Intervention: Dihydroartemisinin-piperaquine
Comparison: Artesunate plus amodiaquine
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Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Artesunate plus
amodiaquine
Dihy-
droartemisinin-
piperaquine
Efficacy: Total Fail-
ure (P. falciparum)
Day 28 PCR ad-
justed
73 per 1000 34 per 1000
(17 to 69)
RR 0.47
(0.23 to 0.94)
629
(2)
⊕⊕⊕
moderate
1,2,3,4,5,6,7,8
Efficacy: Total Fail-
ure (P. falciparum)
Day 28 PCR unad-
justed
161 per 1000 85 per 1000
(56 to 130)
RR 0.53
(0.35 to 0.81)
679
(2)
⊕⊕⊕
moderate
2,3,4,5,6,7,8
Vivax efficacy: P.
vivax parasitaemia
by day 42
175 per 1000 44 per 1000
(16 to 130)
RR 0.25
(0.09 to 0.74)
170
(1)
⊕⊕⊕
moderate9,10,11
Transmission
potential: Gameto-
cyte carriage
- - - 881
(2)
-12
Harms: Serious ad-
verse events (in-
cluding deaths)
18 per 1000 3 per 1000
(0 to 49)
RR 0.14
(0.01 to 2.71)
334
(1)
⊕
very low9,10,13
Harms: Early vom-
iting
78 per 1000 41 per 1000
(17 to 101)
RR 0.53
(0.22 to 1.3)
334
(1)
⊕
very low10,13,14
*The assumed risk is the mean risk from the studies included in this review, calculated as the number of patients in the control
groups with the event divided by the total number of patients in control groups. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
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Footnotes
1Please note that due to its longer half-life, PCR adjusted treatment failure with DHA-P may be underestimated at this time point.
2One trial (Hasugian 2005 IDN) also reported outcomes at day 42 but losses to follow up were very high (> 20%) at this time point.
3Hasugian 2005 IDN and Karema 2004 RWA.
4No serious limitations: Allocation concealment was assessed as ’low risk of bias’ in one trial and ’unclear’ in one trial. Laboratory staff
were blinded in both trials.
5No serious inconsistency: Heterogeneity was low.
6One trial was conducted in Africa (Rwanda, transmission intensity not reported) and one in Asia (Indonesia, unstable transmission).
Children aged < one year and pregnant or lactating women were excluded.
7Serious indirectness: Due to variable resistance rates to amodiaquine extrapolation to other areas is likely to be unreliable.
8No serious imprecision: The 95% CI of the pooled estimate includes appreciable and non-appreciable benefit with DHA-P over
AS+AQ but does not cross the line of no effect.
9No serious limitations: Allocation concealment was assessed as ’low risk of bias’ in this trial (Hasugian 2005 IDN).
10Serious indirectness: Only one trial (Hasugian 2005 IDN) assessed this outcome.
11No serious imprecision: Both limits of the 95% CI imply appreciable benefit with DHA-P over AS+AQ.
12Both trials report no differences in gametocyte carriage but figures were not given.
13Very serious imprecision: The 95% CI includes appreciable benefit or harm with each drugs over the other.
14Serious limitations: This trial was open label.
Is Dihydroartemisinin-piperaquine superior to Artesunate plus sulfadoxine-pyrimethamine for treating uncomplicated
malaria?
Patient or population: Patients with uncomplicated malaria
Settings: Endemic areas excluding Southeast Asia
Intervention: Dihydroartemisinin-piperaquine
Comparison: Artesunate plus sulfadoxine-pyrimethamine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Artesunate plus
sulfadoxine-
pyrimethamine
Di-
hydroartemisinin -
piperaquine
Efficacy: Total Fail-
ure Day 42 PCR
adjusted
202 per 1000 156 per 1000
(79 to 305)
RR 0.77
(0.39 to 1.51)
161
(1)
⊕
very low1,2,3,4
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Efficacy: Total Fail-
ure Day 42 PCR
unadjusted
380 per 1000 391 per 1000
(281 to 551)
RR 1.03
(0.74 to 1.45)
215
(1)
⊕
very low1,2,3,4
Vivax efficacy: P.
vivax parasitaemia
Day 42
596 per 1000 268 per 1000
(191 to 387)
RR 0.45
(0.32 to 0.65)
194
(1)
⊕⊕
low1,2,3,5
Transmission
potential: Gameto-
cyte carriage
- - - 215
(1)
-6
Harms: Serious ad-
verse events (in-
cluding deaths)
- - - - Not reported
Harms: Early vom-
iting
- - - - Not reported
*The assumed risk is the mean risk from the studies included in this review, calculated as the number of patients in the control
groups with the event divided by the total number of patients in control groups. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Footnotes
1Karunajeewa 2007 PNG.
2Serious limitations: No allocation concealment was described. Laboratory staff were blinded to treatment allocation.
3Serious indirectness: Data only available from one country.
4Very serious imprecision: The 95% CI includes appreciable benefit and harm of one drug over the other.
5No serious imprecision: Both limits of the 95% CI suggest appreciable benefit with DHA-P.
6Karunajeewa 2007 PNG reports that there were no differences in gametocyte carriage but no figures were given.
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Is Dihydroartemisinin-piperaquine superior to Amodiaquine plus sulfadoxine-pyrimethamine for treating uncomplicated
malaria?
Patient or population: Patients with uncomplicated malaria
Settings: Africa
Intervention: Dihydroartemisinin-piperaquine
Comparison: Amodiaquine plus sulfadoxine-pyrimethamine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Amodiaquine plus
sulfadoxine-
pyrimethamine
Dihy-
droartemisinin-
piperaquine
Efficacy: Total Fail-
ure (P. falciparum)
Day 28 PCR ad-
justed
114 per 1000 34 per 1000
(19 to 62)
RR 0.3
(0.17 to 0.54)
802
(2)
⊕⊕⊕
moderate
1,2,3,4,5,6,7
Efficacy: Total Fail-
ure (P. falciparum)
Day 28 PCR unad-
justed
181 per 1000 67 per 1000
(45 to 100)
RR 0.37
(0.25 to 0.55)
848
(2)
⊕⊕⊕
moderate
1,2,3,4,5,6,7
Vivax efficacy: P.
vivax parasitaemia
- - - - Not reported
Transmis-
sion potential: Ga-
metocyte develop-
ment (in those neg-
ative at baseline)
55 per 1000 38 per 1000
(15 to 98)
RR 0.7
(0.27 to 1.79)
367
(1)
⊕
very low5,8,9
Harms: Serious ad-
verse events (in-
cluding deaths)
- - - 374
(1)
⊕
very low8,10,11
Harms: Early vom-
iting
- - - - Not reported12
*The assumed risk is the mean risk from the studies included in this review, calculated as the number of patients in the control
groups with the event divided by the total number of patients in control groups. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
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(Continued)
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Footnotes
1Please note that due to its longer half-life treatment failure due to DHA-P may be underestimated at this time point. One trial (Zongo
2007 BFA) also reported treatment failure at day 42 and did not show a difference.
2Karema 2004 RWA and Zongo 2007 BFA.
3No serious limitations: Allocation concealment was judged to be at ’low risk of bias’ in one trial and ’unclear’ in the other. Laboratory
staff were blinded to treatment allocation in one trial.
4No serious inconsistency: Heterogeneity was low.
5Serious indirectness: Due to variable resistance rates to AQ and SP, extrapolation of results to other areas is likely to be unreliable.
6Trials conducted in Rwanda (transmission not stated) and Burkina Faso (holoendemic). Children aged < 6 months and pregnant or
lactating women were excluded.
7No serious imprecision: Both limits of the 95% CI of the pooled estimate imply appreciable benefit with DHA-P over AQ+SP.
8No serious limitations: Allocation concealment was judged to be ’low risk of bias’ in this trial (Zongo 2007 BFA). This trial was
unblinded.
9Very serious imprecision: The 95% CI of the pooled estimate is wide including appreciable benefit or harm with each drug over the
other.
10Serious indirectness. Only one trial (Zongo 2007 BFA) reported this outcome.
11Very serious imprecision: No serious adverse events were recorded. It is unlikely that a trial of this size would detect rare but important
adverse events.
12One trial (Zongo 2007 BFA) reports vomiting medication on day 0 (as an exclusion criteria not an outcome) and found no difference.
Is Artesunate plus mefloquine superior to Artemether-lumefantrine for treating uncomplicated malaria?
Patient or population: Patients with uncomplicated malaria
Settings: Endemic areas worldwide
Intervention: Artesunate plus mefloquine
Comparison: Artemether-lumefantrine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
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(Continued)
Assumed risk Corresponding
risk
Artemether- lume-
fantrine
Artesunate plus
mefloquine
Efficacy: Total Fail-
ure (P. falciparum)
Day 42 PCR ad-
justed
28 per 1000 11 per 1000
(1 to 80)
RR 0.38
(0.05 to 2.84)
904
(4)
⊕
very low1,2,3,4,5,6
Efficacy: Total Fail-
ure (P. falciparum)
Day 42 PCR unad-
justed
149 per 1000 79 per 1000
(43 to 140)
RR 0.53
(0.29 to 0.94)
1000
(4)
⊕⊕
low1,2,3,4,5,7
Vivax efficacy: P.
vivax parasitaemia
by day 42
246 per 1000 74 per 1000
(52 to 101)
RR 0.3
(0.21 to 0.41)
1003
(4)
⊕⊕⊕⊕
high2,5,8,9
Transmission
potential: Gameto-
cyte carriage day
14
15 per 1000 6 per 1000
(1 to 31)
RR 0.41
(0.08 to 2.1)
536
(2)
⊕⊕
low8,10,11
Harms: Serious ad-
verse events (in-
cluding deaths)
2 per 1000 6 per 1000
(1 to 28)
RR 2.96
(0.64 to 13.76)
1773
(7)
⊕⊕
low8,11,12
Harms: Early vom-
iting
20 per 1000 21 per 1000
(11 to 42)
RR 1.07
(0.55 to 2.08)
1479
(6)
⊕
very low8,11,12,13
*The assumed risk is the mean risk from the studies included in this review, calculated as the number of patients in the control
groups with the event divided by the total number of patients in control groups. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
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Footnotes
1Data were also available for treatment failure at day 28 but these did not add any further information.
2Hutagalung 2002 THA, Mayxay 2003 LAO, Stohrer 2003 LAO, and Van den Broek 2003a BGD.
3Serious limitations: Allocation concealment was assessed as ’low risk of bias’ in 1 trial and ’unclear in 1. Sensitivity analysis removing
the trials with inadequate concealment substantially alters the result. In one trial (Hutagalung 2002 THA) a disproportionate number
of participants in the AL6 arm received additional antimalarials. Trials were unblinded.
4Serious inconsistency: There was moderate heterogeneity (PCR adjusted I2 = 64%, PCR unadjusted I2 = 54%) relating to one trial (
Hutagalung 2002 THA). Removal of this trial shifted the result significantly in favour of AS+MQ.
5No serious indirectness: Trials were conducted in Asia (Thailand, Laos, and Bangladesh) in areas of low and high transmission. Children
aged < one year and pregnant or lactating women were excluded.
6Very serious imprecision: The 95% CI of the pooled estimate is wide including appreciable benefit and harm with each drug over the
other. Both drugs performed very well in all four trials.
7No serious imprecision: The 95% CI of the pooled estimate includes appreciable benefit with AS+MQ but does not cross the line of
no effect.
8No serious inconsistency: Heterogeneity was low.
9No serious imprecision: Both limits of the 95% CI of the pooled estimate imply appreciable benefit with AS+MQ.
10Allocation concealment was assessed as at ’high risk of bias’ in both trials (Faye 2003 SEN, van den Broek2003a BGD). The number
of gametocyte carriers was generally low in both groups. One trial showed a statistical difference at day seven but not day three or 14.
11Very serious imprecision: The 95% CI of the pooled estimate are very wide including appreciable benefit or harm with both drugs.
12Allocation concealment was assessed as ’high risk of bias’ in three out of seven trials. Sensitivity analysis removing the trials without
adequate allocation concealment did not substantially alter the result.
13Serious limitations: All trials were open label.
Is Artesunate plus mefloquine superior to Artesunate plus amodiaquine for treating uncomplicated malaria?
Patient or population: Patients with uncomplicated malaria
Settings: Endemic areas worldwide
Intervention: Artesunate plus mefloquine
Comparison: Artesunate plus amodiaquine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Artesunate plus
amodiaquine
Artesunate plus
mefloquine
Efficacy: Total Fail-
ure (P. falciparum)
Day 28 PCR ad-
justed
- - - 482
(1)
⊕
very low1,2,3,4,5,6
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Efficacy: Total Fail-
ure (P. falciparum)
Day 28 PCR unad-
justed
26 per 1000 14 per 1000
(3 to 64)
RR 0.54
(0.12 to 2.46)
493
(1)
⊕
very low2,3,4,5,7
Vivax efficacy: P.
vivax parasitaemia
- - - - Not reported
Transmission
potential: Gameto-
cyte carriage day
14
- - - 505
(1)
⊕
very low2,3,4,5,7
Harms: Serious ad-
verse events (in-
cluding deaths)
- - - 505
(1)
⊕
very low2,3,4,5,9
Harms: Early vom-
iting
- - - - Not reported
*The assumed risk is the mean risk from the studies included in this review, calculated as the number of patients in the control
groups with the event divided by the total number of patients in control groups. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Footnotes
1Please note that due to its longer half-life treatment failure with AS+MQ may be underestimated at this time-point.
2Faye 2003 SEN.
3Serious limitations: Allocation concealment was assessed as ’high risk of bias’ and no blinding is described.
4Serious indirectness: Only one trial from Senegal reported this outcome. Extrapolation of this result to other countries is likely to be
unreliable.
5Children aged < one year and pregnant or lactating women were excluded.
6Very serious imprecision: There were no PCR adjusted treatment failures in either group.
7Very serious imprecision: The 95% CI is wide including appreciable benefit and harm with each drug over the other.
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8Very serious imprecision: There were no participants with detectable gametocytes in either arm. There were no significant differences
in gametocyte carriage at days three or seven.
9Very serious imprecision: No serious adverse events were recorded in this trial. A trial of this size would be unlikely to detect rare but
important adverse events.
Is Artesunate plus mefloquine superior to Amodiaquine plus sulfadoxine-pyrimethamine for treating uncomplicated malaria?
Patient or population: Patients with uncomplicated malaria
Settings: Africa
Intervention: Artesunate plus mefloquine
Comparison: Amodiaquine plus sulfadoxine-pyrimethamine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Amodiaquine plus
sulfadoxine-
pyrimethamine
Artesunate plus
mefloquine
Efficacy: Total Fail-
ure Day 28 PCR
adjusted
- - - 296
(1)
⊕
very low1,2,3,4,5,6
Efficacy: Total Fail-
ure Day 28 PCR
unadjusted
13 per 1000 14 per 1000
(2 to 99)
RR 1.08
(0.15 to 7.59)
300
(1)
⊕
very low2,3,4,5,7
Vivax efficacy: P.
vivax parasitaemia
- - - - Not reported
Transmission
potential: Gameto-
cyte carriage day 7
118 per 1000 4 per 1000
(0 to 55)
RR 0.03
(0 to 0.47)
306
(1)
⊕⊕
low2,3,4,5,8
Harms: Serious ad-
verse events (in-
cluding deaths)
- - - 306
(1)
⊕
very low2,3,4,5,9
Harms: Early vom-
iting
- - - - Not reported
*The assumed risk is the mean risk from the studies included in this review, calculated as the number of patients in the control
groups with the event divided by the total number of patients in control groups. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
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(Continued)
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Footnotes
1Please note that due to its longer half-life, treatment failure with AS+MQ may be underestimated at this timepoint.
2Faye 2003 SEN.
3Serious limitations: Allocation concealment was assessed as ’high risk of bias’ and no blinding is described.
4Serious indirectness: Only one trial from Senegal reported this outcome. Extrapolation of this result to other countries is likely to be
unreliable.
5Children aged < 1 year and pregnant or lactating women were excluded.
6Very serious imprecision: No PCR adjusted treatment failures were recorded in either treatment group.
7Very serious imprecision: The 95% CI is wide including appreciable benefit and harm with each drug over the other.
8No serious imprecision: Both limits of the 95% CI imply appreciable benefit with AS+MQ. At day 14 there were no participants with
detectable gametocytes in either group.
9Very serious imprecision: No serious adverse events were recorded in this trial. A trial of this size would be unlikely to detect rare but
important adverse events.
Is Artemether-lumefantrine superior to Artesunate plus amodiaquine for treating uncomplicated malaria?
Patient or population: Patients with uncomplicated malaria
Settings: Africa
Intervention: Artemether-lumefantrine
Comparison: Artesunate plus amodiaquine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Efficacy: Total Fail-
ure (P. falciparum)
Day 28 PCR ad-
justed
Artesunate plus
amodiaquine
Artemether-
lumefantrine
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(Continued)
Efficacy: Total Fail-
ure (P. falciparum)
Day 28 PCR ad-
justed
19 per 1000 31 per 1000
(18 to 55)
RR 1.65
(0.95 to 2.87)
1729
(8)
⊕⊕⊕
moderate1,2,3,4,5,6
Efficacy: Total Fail-
ure (P. falciparum)
Day 28 PCR unad-
justed
- - - 2617
(5)
⊕
very low2,5,7,8,9
Vivax efficacy: P.
vivax parasitaemia
- - - - Not reported10
Transmission
potential: Gameto-
cyte carriage day
14
- - - 718
(2)
⊕
very low11,12,13,14
Harms: Serious ad-
verse events (in-
cluding deaths)
13 per 1000 14 per 1000
(8 to 27)
RR 1.11
(0.59 to 2.08)
2617
(5)
⊕⊕
low3,4,5,15
Harms: Early vom-
iting
83 per 1000 72 per 1000
(49 to 109)
RR 0.87
(0.59 to 1.31)
1097
(5)
⊕
very low4,15,16
*The assumed risk is the mean risk from the studies included in this review, calculated as the number of patients in the control
groups with the event divided by the total number of patients in control groups. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Footnotes
1Please note that due to its long half-life PCR adjusted treatment failure with AL6 may be underestimated at this time point.
2Adjei 2006 GHA, Bukirwa 2005 UGA, Dorsey 2006 UGA, Falade 2005 NGA, Faye 2003 SEN, Guthmann 2004 AGO, Kobbe 2007
GHA and Owusu-Agyei 2006 GHA (and Mutabingwa 2004 TZA for PCR unadjusted only).
3No serious limitations: Allocation concealment was assessed as ’low risk of bias’ in four trials. Sensitivity analysis removing the trials
with inadequate allocation concealment did not substantially alter the result.
4No serious inconsistency: Heterogeneity was low.
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5No serious indirectness: Trials were conducted in a variety of African countries with variable transmission and resistance patterns.
Children aged < four months and pregnant or lactating women were excluded.
6Serious imprecision: The 95% CI of the pooled estimate includes appreciable benefit with ASAQ over AL6 and crosses the line of no
effect.
7No serious limitations: Allocation concealment was assessed as ’low risk of bias’ in five trials. Sensitivity analysis removing the trials
with inadequate allocation concealment did not substantially alter the result.
8Very serious inconsistency: Heterogeneity was high so data were not pooled. This heterogeneity seemed to be related to region
(with trials from East Africa favouring AL6 and trials from West Africa favouring ASAQ) and transmission intensity (with two trials
experiencing very high rates of new infections).
9Very serious imprecision: Data were not pooled due to heterogeneity. The effect estimate is likely to vary between settings.
10Only one trial reported P. vivax and there were too few events to draw a conclusion.
11Dorsey 2006 UGA had adequate allocation concealment and blinding. In Faye 2003 SEN no allocation concealment or blinding
was described.
12Very serious inconsistency: Heterogeneity was high so data were not pooled.
13Trials were conducted in Senegal (moderate transmission) and Uganda (mesoendemic).
14Very serious imprecision: The two trials reporting this outcome had very different results.
15Very serious imprecision: The 95% CI of the pooled estimate includes appreciable benefit and harm with each drug over the other.
16Serious limitations: Four out of five trials were unblinded.
Is Artemether-lumefantrine superior to Artesunate plus sulfadoxine-pyrimethamine for treating uncomplicated malaria?
Patient or population: Patients with uncomplicated malaria
Settings: Endemic areas worldwide
Intervention: Artemether-lumefantrine
Comparison: Artesunate plus sulfadoxine-pyrimethamine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Artesunate plus
sulfadoxine-
pyrimethamine
Artemether-
lumefantrine
Efficacy: Total Fail-
ure (P. falciparum)
Day 42 PCR ad-
justed
202 per 1000 67 per 1000
(26 to 174)
RR 0.33
(0.13 to 0.86)
158
(1)
⊕
very low1,2,3,4,5
Efficacy: Total Fail-
ure (P. falciparum)
Day 42 PCR unad-
380 per 1000 369 per 1000
(258 to 517)
RR 0.97
(0.68 to 1.36)
217
(1)
⊕
very low2,3,4,6
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(Continued)
justed
Vivax efficacy: P.
vivax parasitaemia
by Day 42
667 per 1000 700 per 1000
(507 to 954)
RR 1.05
(0.76 to 1.43)
72
(1)
⊕
very low2,3,7,8
Transmission
potential: Gameto-
cyte carriage
- - - 158
(1)
-9
Harms: Serious ad-
verse events (in-
cluding deaths)
- - - 197
(1)
⊕
very low10,11
Harms: Early vom-
iting
- - - - Not reported
*The assumed risk is the mean risk from the studies included in this review, calculated as the number of patients in the control
groups with the event divided by the total number of patients in control groups. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Footnotes
1Please note that due to its longer half-life, PCR adjusted treatment failure with AL6 may be underestimated at this time point.
2Karunajeewa 2007 PNG.
3Serious limitations: Allocation concealment was assessed as ’high risk of bias’ in this trial. Onlymicroscopists were blinded to treatment
allocation.
4Very serious indirectness: Data are only available from one country (Papua New Guinea). One other trial from Sudan with high risk
of bias (Mukhtar 2005 SDN) reports data for day 28 and did not find a difference.
5No serious imprecision: The 95% CI includes appreciable and non-appreciable benefit with AL6 over AS+SP but does not cross the
line of no effect.
6Very serious imprecision: The 95% CI is very wide including appreciable benefit and harm with each drug over the other.
7Serious indirectness: Data are only available from one country (Papua New Guinea). This outcome is for participants with P. vivax ±
P. falciparum at baseline.
8Serious imprecision: The 95% CI includes appreciable benefit with AS+SP and crosses the line of no effect.
9Karunajeewa 2007 PNG reports no differences in gametocyte carriage between the two groups during follow up (figures not given).
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10Very serious limitations: The only trial which reports this outcome (Van den Broek 2004 ZAR) was excluded from the primary
outcome due to baseline differences between groups.
11Very serious imprecision: There were no serious adverse events in this trial. Trials of this size would be unlikely to detect rare but
clinically important adverse events.
Is Artemether-lumefantrine superior to Amodiaquine plus sulfadoxine-pyrimethamine for treating uncomplicated malaria?
Patient or population: Patients with uncomplicated malaria
Settings: Africa
Intervention: Artemether-lumefantrine
Comparison: Amodiaquine plus sulfadoxine-pyrimethamine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Amodiaquine plus
sulfadoxine-
pyrimethamine
Artemether-
lumefantrine
Efficacy: Total Fail-
ure (P. falciparum)
Day 28 PCR ad-
justed - East Africa
220 per 1000 26 per 1000
(13 to 53)
RR 0.12
(0.06 to 0.24)
618
(2)
⊕⊕⊕
moderate
1,2,3,4,5,6,7,8
Efficacy: Total Fail-
ure (P. falciparum)
Day 28 PCR unad-
justed - East Africa
486 per 1000 170 per 1000
(146 to 199)
RR 0.35
(0.3 to 0.41)
1646
(3)
⊕⊕⊕
moderate
2,10,4,5,6,7,8,9
Efficacy: Total Fail-
ure (P. falciparum)
Day 28 PCR ad-
justed - West Africa
15 per 1000 21 per 1000
(8 to 52)
RR 1.39
(0.55 to 3.47)
1051
(3)
⊕
very low
1,3,4,5,6,11,12,13
Efficacy: Total Fail-
ure (P. falciparum)
Day 28 PCR unad-
justed - West Africa
43 per 1000 124 per 1000
(80 to 192)
RR 2.88
(1.86 to 4.47)
1130
(3)
⊕⊕⊕
moderate
3,5,6,11,12,14
Vivax efficacy: P.
vivax parasitaemia
- - - - Not reported15
Transmission
potential: Gameto-
cyte carriage day
14
25 per 1000 11 per 1000
(5 to 25)
RR 0.46
(0.21 to 1.01)
1536
(4)
⊕⊕
low16,17,18
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Harms: Serious ad-
verse events (in-
cluding deaths)
13 per 1000 14 per 1000
(7 to 27)
RR 1.08
(0.56 to 2.08)
2684
(5)
⊕⊕
low5,13,19
Harms: Early vom-
iting
- - - - Not reported20
*The assumed risk is the mean risk from the studies included in this review, calculated as the number of patients in the control
groups with the event divided by the total number of patients in control groups. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Footnotes
1Please note due to its longer half-life, treatment failure with AL6 may be underestimated at this time point.
2Dorsey 2006 UGA, Fanello 2004 RWA.
3No serious limitations: Allocation concealment was assessed as ’low risk of bias’ in one of the trials. Sensitivity analysis removing the
trials without adequate concealment did not substantially change the result.
4Only one trial had adequate blinding.
5No serious inconsistency: Heterogeneity was low.
6Serious indirectness: There is considerable variability in the efficacy of AQSP which makes extrapolation of results to other settings
unreliable.
7Trials were conducted in Uganda (mesoendemic), Rwanda (transmission not reported). Children aged < six months and pregnant or
lactating women were excluded.
8No serious imprecision: Both limits of the 95% CI of the pooled estimate imply appreciable benefit with AL6 over AQ+SP.
9No serious limitations: Allocation concealment was assessed as ’low risk of bias’ in two of the three trials. Sensitivity analysis removing
the trial with unclear concealment did not substantially change the result.
10and Mutabingwa 2004 TZA, Tanzania, very high transmission.
11Zongo 2005 BFA, Zongo 2007 BFA and Faye 2003 SEN.
12Trials conducted in Burkina Faso (holoendemic) and Senegal (moderate transmission). Children aged < six months and pregnant or
lactating women were excluded.
13Very serious imprecision: The 95% CI of the pooled estimate is wide including appreciable benefit and harm with each drug over
the other.
14No serious imprecision: Both limits of the 95% CI of the pooled estimate imply appreciable benefit with AQSP over AL6.
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15Only one trial reported on P. vivax and there were too few events to draw a conclusion.
16Data were also available for day seven where gametocyte carriage was significantly lower with AL6.
17Serious limitations: Only one of the four trials had adequate allocation concealment.
18Serious imprecision: The 95% CI of the pooled estimate includes appreciable benefit with AL6 and crosses the line of no effect.
19No serious limitations: Allocation concealment was assessed as ’low risk of bias’ in three trials.
20Two trials reported vomiting of medication on day 0 (as an exclusion criteria not an outcome) and found no difference.
Is Artesunate plus amodiaquine superior to Artesunate plus sulfadoxine-pyrimethamine for treating uncomplicated malaria?
Patient or population: Patients with uncomplicated malaria
Settings: Endemic areas worldwide
Intervention: Artesunate plus amodiaquine
Comparison: Artesunate plus sulfadoxine-pyrimethamine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Artesunate plus
sulfadoxine-
pyrimethamine
Artesunate plus
amodiaquine
Efficacy: Total Fail-
ure (P. falciparum)
Day 28 PCR ad-
justed
44 per 1000 28 per 1000
(16 to 48)
RR 0.64
(0.37 to 1.08)
1419
(7)
⊕⊕
low1,2,3,4,5
Efficacy: Total Fail-
ure (P. falciparum)
Day 28 PCR unad-
justed
- - - 1614
(7)
⊕
very low1,2,4,6,7
Vivax efficacy: P.
vivax parasitaemia
- - - - Not reported
Transmission
potential: Gameto-
cyte carriage day
14
91 per 1000 81 per 1000
(46 to 140)
RR 0.89
(0.51 to 1.54)
520
(3)
⊕
very low8,9,10,11
Harms: Serious ad-
verse events (in-
cluding deaths)
2 per 1000 2 per 1000
(0 to 14)
RR 0.99
(0.14 to 7.02)
1108
(4)
⊕
very low9,10,11
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(Continued)
Harms: Early vom-
iting
- - - - Not reported
*The assumed risk is the mean risk from the studies included in this review, calculated as the number of patients in the control
groups with the event divided by the total number of patients in control groups. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Footnotes
1Bonnet 2004 GIN; Djimde 2004 MLI; Guthmann 2003 AGO; Hamour 2003 SDN; Kayentao 2006 MLI; Swarthout 2004 ZAR;
Van den Broek 2004 ZAR.
2Serious limitations: Allocation concealment was assessed as ’low risk of bias’ in only one trial. Only one trial had adequate blinding of
laboratory staff.
3No serious inconsistency: Heterogeneity was low.
4Trials were conducted in a variety of African countries (Guinea, Mali, Angola, DRC) and transmission intensities in children aged 6
to 59 months.
5Serious imprecision: The 95% CI of the pooled estimate includes appreciable benefit with ASAQ and crosses the line of no effect.
6Very serious inconsistency: Heterogeneity was high (I2 = 88%) with some trials showing benefit with AS+AQ and some with AS+SP.
7Very serious imprecision: Data were not pooled due to high heterogeneity.
8No difference was shown in gametocyte carriage at day three or seven.
9Serious limitations: No trial adequately described an allocation concealment procedure.
10No serious inconsistency: Heterogeneity was low.
11Very serious imprecision: The 95% CI of the pooled estimate is wide including appreciable benefit or harm of each drug over the
other.
Is Artesunateplus amodiaquine superior toAmodiaquineplus sulfadoxine-pyrimethamine for treating uncomplicatedmalaria?
Patient or population: Patients with uncomplicated malaria
Settings: Africa
Intervention: Artesunate plus amodiaquine
Comparison: Amodiaquine plus sulfadoxine-pyrimethamine
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Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Amodiaquine plus
sulfadoxine-
pyrimethamine
Artesunate plus
amodiaquine
Efficacy: Total Fail-
ure (P. falciparum)
Day 28 PCR ad-
justed
- - - 2346
(6)
⊕
very low1,2,3,4,5
Efficacy: Total Fail-
ure (P. falciparum)
Day 28 PCR un ad-
justed-
- - - 4220
(8)
⊕
very low1,4,5,6,7,8
Vivax efficacy: P.
vivax parasitaemia
- - - - Not reported
Transmission
potential: Gameto-
cyte carriage day
14
38 per 1000 22 per 1000
(6 to 77)
RR 0.57
(0.16 to 2.02)
894
(3)
⊕
very low4,9,10,11,12
Harms: Serious ad-
verse events (in-
cluding deaths)
17 per 1000 1 per 1000
(6 to 18)
RR 0.61
(0.36 to 1.03)
4200
(7)
⊕⊕⊕
moderate13,14,15
Harms: Early vom-
iting
- - - - Not reported
*The assumed risk is the mean risk from the studies included in this review, calculated as the number of patients in the control
groups with the event divided by the total number of patients in control groups. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Footnotes
262Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1Dorsey 2006 UGA; Faye 2003 SEN; Karema 2004 RWA; Kayentao 2006 MLI; Menard 2006 MDG; Yeka 2004 UGA.
2No serious limitations: Allocation concealment was assessed as ’low risk of bias’ in two trials. Laboratory staff were blinded in 3 trials.
3Serious inconsistency: Substantial heterogeneity (I2 = 77%). In the three trials from east Africa AS+AQ tended to perform better that
AQ+SP, but AQ+SP still performed well elsewhere.
4Serious indirectness: Due to variability in resistance rates generalization of results is likely to be unreliable.
5Very serious imprecision: Data not pooled due to high heterogeneity. The magnitude of effect is likely to vary between settings.
6and Mutabingwa 2004 TZA and Staedke 2003 UGA.
7No serious limitations: Allocation concealment was assessed as ’low risk of bias’ in four trials. Laboratory staff were blinded in four
trials.
8Serious inconsistency: Substantial heterogeneity (I2 = 91%). In the five trials from east Africa AS+AQ tended to perform better than
AQ+SP, but AQ+SP still performed well elsewhere.
9Dorsey 2006 UGA; Faye 2003 SEN; Menard 2006 MDG.
10No serious limitations: Allocation concealment was assessed as ’low risk of bias’ in two trials.
11 Very serious imprecision: The 95% CI is very wide including appreciable benefit and harm or each drug over the other.
12Faye 2003 SEN found a significant reduction in gametocytaemia at day three with AS+AQ. Staedke 2003 UGA found a significant
reduction in gametocyte development with AS+AQ.
13No serious limitations.
14No serious inconsistency: Heterogeneity is low.
15Serious imprecision: The 95%CI of the pooled estimate includes appreciable benefit with AS+AQ over AQ+SP and crosses the line
of no effect.
WH A T ’ S N E W
Last assessed as up-to-date: 25 March 2009.
12 August 2009 Amended Tables for treatment comparisons, search strategy, primary outcomemeasures, adverse events, anaemia,
and summary of findings moved to appendices.
H I S T O R Y
Protocol first published: Issue 4, 2008
Review first published: Issue 3, 2009
263Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
All authors were involved in the conception and design of the protocol. Data extraction and assessment of risk of bias was performed
by David Sinclair and Babalwa Zani. David Sinclair, Piero Olliaro, and Paul Garner worked on the analysis of secondary outcomes.
Data input and analysis was conducted by David Sinclair with input from Piero Olliaro and Paul Garner and statistical advice from
Sarah Donegan. The text was drafted by David Sinclair with input from all other authors.
D E C L A R A T I O N S O F I N T E R E S T
None known.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Gametocyte clearance has been removed as a secondary outcome as the effect of ACTs on gametocytes is adequately assessed using the
remaining two outcomes.
The multiple treatment comparison methodology as described under ’data synthesis’ in the protocol was not used and this description
has been removed.
The clinical questions posed under ’quality of evidence’ were not stated in the protocol. These were added as currently relevant questions
regarding the use of ACTs.
We did not use funnel plots to assess for publication bias as there were too few trials under each comparison for meaningful analysis.
I N D E X T E R M S
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